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Abstracts 
This thesis describes the use of C(1) ammonium enolate chemistry with Lewis base isothiourea 
catalysis in Michael addition-lactonization/lactamization between 2-pyrrolyl acetic acid 
derivatives and various Michael acceptors. 
Chapter 2 proved the principle that amino esters protected as benzophenone Schiff base could 
be α-functionalized using Lewis base catalysis. 
Chapter 3 described the use of 2-pyrrolyl acetic acid in enantioselective Michael addition-
lactonization with CCl3 enone. After in situ ring-opening, a range of 30 diesters and diamides 
in up to 98% yield, >95:5 dr and >99:1 er. Further demonstration of the synthetic utility of 
these ring-opening derivatives was achieved with an intramolecular Friedel-Crafts acylation 
utilizing the electron-rich nature of pyrrole to afforded dihydroindolizinone derivatives in up 
to 90% yield with no erosion in stereoselectivity. 
Chapter 4 described the use of either α,β-unsaturated trifluoromethyl ketones or α-keto-β,γ-
unsaturated esters with 2-pyrrolyl acetic acid to synthesize tetrahydroindolizine derivatives in 
one-pot, with up to 98% yield, >95:5 dr and >99:1 er. 
Chapter 5 described the synthesis of dihydropyridinones from chalcone-derived N-Ts ketimine 
and unsaturated cyclic sulfonamide derived from saccharin in up to 97% yield, >95:5 dr 
and >99:1 er. 
Chapter 6 described the synthesis of tetrasubstituted pyridines using a variety of unsaturated 
ketimines bearing esters with DHPB catalyst in up to 66% yield. Further derivatization was 
demonstrated via transforming 2-pivaloyloxy group into 2-OTs group in a two-step process, 
enabling the Pd-catalyzed cross coupling and reduction. 
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Chapter 1: Introduction 
1.1. Organocatalysis Overview 
Catalysis is highly important throughout synthetic organic chemistry, ranging from the 
discovery of new reactions and processes to the large-scale production of complex organic 
molecules. Many chemists aim to develop chiral catalysts that can promote enantioselective 
transformations in order to prepare chiral molecules as a single enantiomer. An ideal catalyst 
should not contain any precious elements to avoid prohibitive cost and reduce resource 
depletion,1 as well as being both selective and recyclable. Moreover, it should enable reactions 
to be carried out using relatively simple operational procedures. Organocatalysts are small 
organic molecules that are capable of selectively promoting enantioselective transformations 
and are often inspired by enzymatic transformations. Most organocatalysts are generally 
bench-stable, and often use operationally simple procedures in reaction processes, avoiding 
the need for a strict inert atmosphere (glove-box chemistry) and other complex apparatus. 
Compared to metal catalysts, they are sometimes regarded as eco-friendly due to their 
relatively low toxicity to living creatures.1 From a synthetic viewpoint, an ideal catalyst should 
be relatively cheap to make in large quantities either from chiral pool reagents or through 
enantioselective transformations of starting materials. Enantioselective organocatalysis has 
become a fast-expanding field of study, as well as a powerful synthetic methodology which is 
complementary to metal-catalysis. The increasing focus on asymmetric organocatalytic 
transformations was triggered by a key report by MacMillan in 2000.2 A Diels-Alder reaction 
was achieved using chiral Lewis base organocatalysts to give products with excellent 
enantioselectivity, proceeding through an iminium ion intermediate (Scheme 1.1). The 
condensation between a secondary amine 5 and an α,β-unsaturated aldehyde 2 generates the 
activated iminium ion species 6 which has a lower energy LUMO compared with that of the 
corresponding α,β-unsaturated aldehyde 2. Reaction of 6 with cyclopentadiene 1 in a [4+2] 
cycloaddition furnished products 3 and 4 with good enantioselectivity.2 
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Scheme 1.1: MacMillan’s work on iminium ion catalysis 
The major defining feature of MacMillan’s work was the realization of the full potential of using 
small organic molecules to access novel activation modes which had previously not been 
widely applied in the organic synthesis community. This realization underlined the potential 
benefits of organocatalysts, hinting at a promising synthetic future for the use of 
organocatalysts to access complex molecules asymmetrically. Since the publication of 
MacMillan’s historic work, many advances have been made in developing organocatalysis 
across a range of four broad classes of organocatalysts: Brønsted acid catalysis, Lewis acid 
catalysis, Brønsted base catalysis and Lewis base catalysis. Selected examples of each type will 
be discussed herein. 
1.2. Brønsted acid catalysis 
Brønsted acid catalysts activate a carbon-heteroatom double bond such as a carbonyl or imine 
via partial or complete protonation. Thus, the LUMO energy of the substrate is lowered, 
rendering it more electrophilic.3 There are two distinct approaches for activation with 
Brønsted acid catalysts (Fig. 1.1). The first approach can be referred to as a general or neutral 
Brønsted acid catalysis, and relies on hydrogen bonding (H-bonding) between the substrates 
(H-bond acceptor) and the chiral catalysts (H-bond donor). Another approach generally utilizes 
the relative acidities between the substrates and the chiral catalysts to protonate the substrate, 
forming a tight ion-pair between the substrate and catalyst, which is recognized as specific or 
stronger Brønsted acid catalysis. The tight ion-pair is able to impart stereocontrol via the 
Chapter 1: Introduction 
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influence of the chiral backbone of the catalyst, guiding nucleophilic attack on the bound 
substrate. 
 
Fig. 1.1: General activation modes of Brønsted acid catalysis 
1.2.1. Neutral Brønsted acid catalysis 
H-bonding catalysis plays an important role in biological systems,4 especially in enzymatic 
reactions. Modern applications of neutral H-bonding catalysis in asymmetric synthesis have 
focused mainly on three types of catalysts, namely chiral ureas/thioureas 7, chiral diols 8 and 
BINOL derivatives 9 (Fig. 1.2). 
 
Fig. 1.2: Modern chiral H-bonding catalysts  
Pioneering work by Jacobsen and co-workers used chiral ureas and thioureas as H-bonding 
catalysts to build a compound library5 via enantioselective Strecker reactions. Further work 
showed that, starting from an allyl or benzyl imine 10, chiral thiourea 11 catalysed the 
formation of a cyanide-containing amide 12 with excellent yield and enantiomeric access 
(Scheme 1.2).6 Building upon these promising results, enantioselective additions to a range of 
functionally different electrophiles employing this catalytic strategy have been reported by 
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Jacobsen and co-workers, including asymmetric Mannich7 and aza-Baylis-Hilman reactions.8 
Other applications within this area includes the use of chiral diol derivative 8 in asymmetric 
Diels-Alder reaction by Rawal,9 and asymmetric variant of Morita-Baylis-Hillman reactions 
developed using BINOL derived H-bonding catalyst 9.10 
 
Scheme 1.2: Thiourea-catalyzed asymmetric Strecker reaction 
1.2.2. Stronger Brønsted acid catalysis 
Differing from neutral Brønsted acid catalysts, strong Brønsted acid catalysts can be fully 
deprotonated by a substrate, generating a tight ion pair with strong charge-controlled 
interactions (Fig. 1.1). Akiyama11 and Terada12 developed a range of BINOL-derived phosphoric 
acid catalysts 15 (Scheme 1.3). These catalysts are specially designed with rigid binaphthol 
backbones with tuneable R groups which can be used to optimize selectivity and reactivity. 
Well known examples of their use include Yamamoto’s Diels-Alder reaction13 between vinyl 
ketones and silyoxydienes, and Akiyama’s Mannich reaction (Scheme 1.3), in which amino 
esters 16 are generated from imines 13 and silyl enol ethers 14 with excellent 
enantioselectivity and in excellent yields.11 Based on theoretical calculations, a transition state 
is proposed, which features two key interactions between the imine and the deprotonated 
catalyst, resulting in overall Re-facial selectivity for the subsequent nucleophilic attack. 
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Scheme 1.3: Enantioselective Mannich reaction using stronger Brønsted acid catalysts 
1.3. Lewis acid catalysis 
Historically, metal-based Lewis acids have been extensively used in substrate activation, but 
some are associated with toxicity towards living creatures, harmful effects towards the 
environment and instability to air and moisture. Therefore, alternative novel organic Lewis 
acids have been developed in recent years. Normally a Lewis acid will accept an electron pair 
from the substrate to form a Lewis acid-substrate complex. If the Lewis acid is chiral, 
subsequent reactions can potentially generate enantioenriched product. Phase transfer 
catalysis (PTC) is an example of Lewis acid organocatalysis.14 Typically, a PTC system is designed 
to have two coexisting phases, one organic phase and one either aqueous or solid phase. Due 
to the biphasic nature of the system, it is often difficult to investigate mechanisms in detail. 
One mechanism proposed by Starks15 suggests that the phase-transfer catalyst (Q) moves 
between the aqueous phase and the organic phase, generating a hydroxide species (Q+HO-) in 
reaction with an organic phase insoluble base (MOH). The hydroxide species (Q+HO-) can then 
transfer to the organic phase where it can deprotonate an organic phase soluble nucleophile 
(NuH) to give a reactive carbanionic species (Q+Nuc-) (Fig. 1.3). The key to a successful PTC 
reaction is the generation of the tight ion pair Q+Nuc-, in which the chiral catalyst can influence 
the selectivity of the subsequent reactions, and result in an enantioselective transformation. 
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Fig. 1.3: General mechanism of phase-transfer catalysis 
One area of interest where chiral PTC has been widely applied is the synthesis of optically 
active α-amino acids using a prochiral glycine ester protected as a Schiff base. Using 
cinchonine-derived catalyst 18, Zhang and co-workers reported the asymmetric benzylation of 
tert-butyl glycine ester Schiff base 17 to synthesise phenylalanine derivative 19 with high 
enantioselectivity and in excellent yield (Scheme 1.4).16 A tight ion pair model has been 
proposed to account for the stereochemical rationale, where the enolate oxygen interacts 
closely with the ammonium catalyst 18 (Scheme 1.4).17 In addition to this, kinetic resolution 
of secondary alkyl halides,18 conjugate additions19 and Mannich reactions20 have also been 
investigated using similar cinchonine-derived catalysts. 
 
Scheme 1.4: Synthesis of optically active α-amino derivatives using chiral PTC 
1.4. Brønsted base catalysis 
Brønsted bases are characterised by their ability to deprotonate substrates and can be used 
to catalyse many carbon-carbon and carbon-heteroatom bond forming reactions. When a 
chiral base is used, generation of a tight ion pair between the deprotonated nucleophilic 
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species and the protonated chiral Brønsted base catalyst can introduce enantioselectivity. 
Catalysts usually include highly basic nitrogen-based functional groups which are easily 
accessible from chiral pool reagents. One state of the art example was reported by Lambert, 
using highly basic cyclopropenimine Brønsted base catalyst 22 in a Michael addition of 
deprotonated glycine ester Schiff base 20 into Michael acceptors 21. The observed high 
stereocontrol was proposed to arise through the lowest energy binding mode 24 between the 
catalyst and the enolate by computational calculations21 (Scheme 1.5). The relative ease of 
preparing catalyst 22 and the scalability of the reaction - up to 25 g scale (97% yield, 99% ee) 
- highlight the huge potential of chiral Brønsted base catalysts in asymmetric 
transformations.22  
 
Scheme 1.5: Michael addition involving cyclopropenimine as Brønsted base catalyst 
1.5. Lewis base catalysis 
Lewis base catalysis is one of the biggest areas of organocatalysis in terms of applications. In a 
simplified model, Lewis base catalysis can be defined as the donation of a lone pair of electrons 
to an electrophilic substrate, leading to a formal increase in the electron density on the 
activated substrate (Fig. 1.4).23 Subsequent transformations of the activated adduct form 
intermediates that can act as either electrophiles or nucleophiles. In the past decade many 
activation modes have been accessed using Lewis base catalysts and selected examples 
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focusing on nucleophilic enolate equivalents generated through secondary or tertiary amines 
will be briefly discussed herein. 
 
Fig. 1.4: General activation mode of Lewis base catalysis 
1.5.1. Enamine catalysis from secondary amines 
Enamine intermediates derived from chiral secondary amines and ketones or aldehydes react 
analogously to nucleophilic enolate equivalents. A higher energy HOMO makes them more 
reactive. One of the earliest examples of this type of catalysis appeared in 1971, when Hajos 
reported the enantio- and diastereoselective Hajos-Parrish-Eder-Sauer-Wiechert cyclization 
using proline as a catalyst.24 Intramolecular aldol reaction between triketone 25 and chiral 
proline catalyst 26 gave bicyclic product 27 with excellent stereoselectivity and in excellent 
yield (Scheme 1.6). It has been proposed that the transition state involved a six-membered 
ring structure 28 and that the stereoselectivity is directed by a H-bonding interaction between 
the carboxylic acid and the ketone moiety. 
 
Scheme 1.6: Hajos’ work on Hajos-Parrish-Eder-Sauer-Wiechert cyclisation 
It took modern chemists more than 30 years to begin to build on Hajos’ earlier discovery of 
asymmetric organocatalysis. In 2000, List published an asymmetric proline-catalyzed 
intermolecular aldol reaction between acetone and benzaldehydes. The reaction was 
postulated to proceed through a chair-like closed transition state 33 with H-bonding 
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controlling the selectivity, giving β-hydroxy ketones 32 in moderate to excellent yield and with 
good to high enantioselectivity (Scheme 1.7).25 
 
Scheme 1.7: Asymmetric aldol reaction 
Since List’s publication, further applications of enantioselective enamine catalysis have been 
documented, including Mannich reaction,26,27 α-oxygenation of aldehydes and ketones,28 α-
halogenation of aldehydes,29,30 conjugate additions31,32 and enamine alkylations.33 
1.5.2. Ammonium enolates from tertiary amines 
Ammonium enolates are a class of C-based nucleophilic species generated from chiral tertiary 
amine catalysts.34 Depending on the site of nucleophilic attack, C1-, C2- or C3-ammonium 
enolates can be produced and are classically accessed through reaction with ketenes 34, α-
halocarbonyls 35 and α,β-unsaturated carbonyls 36 respectively (Scheme 1.8). For the purpose 
of this thesis, C1-ammonium enolates will be selectively discussed thereafter. 
 
Scheme 1.8: C1, C2 and C3 ammonium enolates 
Historically, cinchona alkaloids, which were first isolated from bark, have represented an 
important class of tertiary amine catalysts to generate C1-ammonium enolates, due to their 
Lewis basic quinuclidine nitrogen atom presented in a chiral environment (Fig. 1.5). 
 
Fig. 1.5: Commonly encountered cinchona alkaloids 
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In 1982, Wynberg reported the use of catalytic tertiary amine cinchona alkaloid 39 in the 
enantioselective formation of β-lactone 40 via a C1-ammonium enolate.35 Highly reactive 
ketene 37 and trichloroacetaldehyde 38 starting materials were required to give the β-lactone 
40 in 95% yield and 98% ee (Scheme 1.9). 
 
Scheme 1.9: Synthesis of β-lactone by Wynberg 
Due to the significant limitations associated with the highly reactive ketenes generated either 
in situ or pre-formed, the C1-ammonium enolates have also been accessed from other bench 
stable precusors, such as acid chlorides, homoanhydrides and carboxylic acids. For example, 
Romo successfully demonstrated the use of simple keto-acid 41 as C1-ammonium enolate 
precursor in diastereo- and enantioselective cinchona-alkaloid catalyzed aldol lactonization 
reactions to access bicyclic β-lactones 44 in 54% yield, >19:1 dr and 92% ee via 45 (Scheme 
1.10).36 
 
Scheme 1.10: Keto-acids as C1-ammonium enolate precursors 
Acid chlorides have also been demonstrated as the C1-ammonium enolate precursors. As an 
example, in the report by Nelson, a Lewis acid co-catalyst was used to promote the aldol 
process between the Li ammonium enolate and an aldehyde in an intermolecular process via 
a proposed closed Zimmerman-Traxler transition state 50 (Scheme 1.11). The β-lactones 48 
could be obtained, under this protocol, in good yields and excellent diastereo- and 
enantioselectivity with a broad scope of aldehydes.37 
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Scheme 1.11: Acid chlorides in LiClO4 promoted aldol lactonization 
Application of ammonium enolates generated from cinchona alkaloids was extended further 
into formal [4+2] cycloaddition as a powerful strategy to construct 6-membered rings in a 
catalytic enantioselective fashion.38 For example, C1-ammonium enolates generated from 51 
in situ (via a ketene intermediate) can participate in enantioselective [4+2] cycloadditions with 
highly reactive substrates, such as o-quinone 53,39 o-quinone diimide 5440 and quinone imide 
5541 (Scheme 1.12). Excellent enantioselectivity and good yields were obtained, but the 
successful transformations were limited only to highly reactive cycloaddition partners. 
 
Scheme 1.12: C1-ammonium enolates in formal [4+2] cycloaddition 
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To overcome the requirement for highly reactive reaction partners in ammonium enolate 
chemistry, an intramolecular protocol was developed by Smith in 2013.42 Ozonolysis and 
subsequent Wittig reaction of alkene 56 furnished the enone acid 57. Treatment of enone acid 
57 with pivaloyl chloride to form a reactive anhydride intermediate, followed by chiral 
cinchona alkaloid derivative 49 furnished the Michael addition-lactonization product 57a in 
60% yield, moderate dr of 67:33 and an excellent 97% ee (Scheme 1.13). 
 
Scheme 1.13: Intramolecular formal [4+2] cycloaddition 
Enantioselective α-halogenation with a suitable electrophilic halogen source was also 
achieved using cinchona alkaloid derived catalysts 52. For example, Lectka reported the 
bromination of ammonium enolates (generated in situ from acid chloride 51, K2CO3 and 
benzoyl quinine 52 via a ketene intermediate) using polybrominated p-quinone 58. Up to 98% 
excellent ee and a good yield of up to 76% was achieved (Scheme 1.14).43 In this particular 
example, a turnover of the catalyst was achieved with the help of the aryloxide generated in 
situ from the brominating agent 58, unlike the previous catalyst turnover with tethered 
nucleophiles. Similarly, a chlorination procedure was also reported by the same group using a 
perchloroquinone derived reagent.44 
 
Scheme 1.14: α-bromination catalyzed by benzoyl quinine 
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1.6. Development of Lewis basic isothioureas in organocatalysis 
Isothioureas (ITUs) are nitrogen-based organocatalysts that show increasing popularity in the 
field of enantioselective catalysis. Their first appearance in asymmetric synthesis was in the 
kinetic resolution of secondary benzylic alcohols reported by Birman and co-workers in 2006.45 
Using chiral benzotetramisole 61 (BTM) as catalyst and isobutyric anhydride as acylating 
reagent, a maximum selectivity factor of 355 was achieved for the acylative kinetic resolution 
of secondary alcohols (Scheme 1.15). The reaction was proposed to proceed through a pre-TS 
assembly 64. A combination of a π-π stacking interaction and minimized steric interaction 
between the alcohol and acylating reagent are responsible for the selective acylation of 
racemic alcohol 60 to enantioenriched alcohol (S)-62 and ester (R)-63.45 
 
Scheme 1.15: Birman’s kinetic resolution of secondary alcohol 
Since Birman’s report, isothiourea catalyst 61 has been used to catalyze O-Si, C-N and C-C bond 
forming reactions, leading to the synthesis of complex molecules in high enantiopurity.46 
Multiple bond forming reactions have also been achieved via domino reactions and formal 
cycloadditions. New ITUs such as HBTM and its derivative, HyperBTM have been designed, and 
in many cases have enhanced catalytic reactivity and selectivity (Fig. 1.6). 
 
Fig. 1.6: Common isothiourea catalysts 
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Typically, ITUs can react with anhydrides, acyl halides, or aryl esters to access three main types 
of intermediates, namely acyl ammonium 65, ammonium enolate 66 and α,β-unsaturated acyl 
ammonium 67 (Scheme 1.16). The acyl ammonium species act as electrophiles and enable 
enantioselective acyl transfer, whilst C1-ammonium enolates are nucleophilic at the α-position. 
The α,β-unsaturated acyl ammonium can act as an Michael acceptor in conjugate additions, 
or a dienophile in hetero-Diels-Alder reactions.46 Within all three intermediates, a non-
covalent 1,5-S---O interaction is proposed to be responsible for locking the conformation of 
the carbonyl oxygen co-planar to sulfur,47 with the catalyst stereodirecting groups responsible 
for generating the facial selectivity. 
 
Scheme 1.16: Three main types of ITU-activated intermediates 
For the purpose of this thesis, C1-ammonium enolates derived from isothiourea catalysis will 
be the focus and selected examples will be discussed herein. 
1.6.1. Isothioureas in formal [4+2] cycloadditions 
Building upon previous work on using cinchona alkaloids to access enantioenriched 6-
membered lactones via formal [4+2] cycloaddition (Scheme 1.13), in 2011, Smith 
demonstrated intramolecular enantioselective formal [4+2] cycloadditions catalyzed by 
isothioureas. In this report, commercially available Lewis base catalyst tetramisole 
hydrochloride 70 was used to access the C1-ammonium enolate intermediate from enone acid 
68, following by Michael addition-lactonization to furnish the highly enantioenriched tricyclic 
lactone 69 in 81% yield, 99:1 dr and 95% ee (Scheme 1.17).48 
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Scheme 1.17: Intramolecular formal [4+2] cycloadditions 
A possible catalytic cycle was also proposed. Starting with the mixed anhydride 71 generated 
from enone acid 68, i-Pr2NEt and pivaloyl chloride, N-acylation with the isothiourea catalyst, 
followed by α-deprotonation, gives C1-ammonium enolate 73. Subsequent intramolecular 
Michael addition generates acyl ammonium intermediate 74 through a transition state 75 
where the two prochiral centres adopt an approximately staggered conformation to minimize 
unfavourable non-bonding interactions.48 Subsequent lactonization allows turnover of the 
catalyst while releasing the product 69 (Scheme 1.18). 
 
Scheme 1.18: Possible catalytic cycle for intramolecular formal [4+2] 
The corresponding intermolecular Michael addition-lactonization process has also been 
studied and developed extensively with isothiourea catalysis. A wide range of C1-ammonium 
enolate precursors with various aryl or alkenyl substituents (R1) have been reported, such as 
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carboxylic acids 76,49 aryl esters 77,50 homoanhydrides 7851 and acyl imidazoles 79.52 
Meanwhile, different Michael acceptors (80-85) have been employed to access 
enantioenriched δ-lactones48,51–54 or lactams,55,56 as well as their ring-opened derivatives 
(Scheme 1.19). 
 
Scheme 1.19: An overview of intermolecular formal [4+2] 
For example, in 2012, the isothiourea catalyzed intermolecular Michael addition-lactamization 
between carboxylic acids 86 and N-tosyl-α,β-unsaturated ketimines 87 was developed to 
access enantioenriched 6-membered lactams 88 in good diastereoselectivity and with 
excellent enantioselectivity (Scheme 1.20). The lactam products 88 undergo N- to C- sulfonyl 
photoisomerization to give 89 without erosion in diastereo- and enantioselectivity, or can be 
derivatized further into stereodefined trisubstituted piperidines 90.57 
 
Scheme 1.20: Synthesis of δ-lactams via intermolecular Michael addition-lactonization 
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This one-pot strategy was also applied in later work published by Smith in 2013. Starting from 
commercially available aryl acetic acids 91, in-situ activation followed by Michael addition-
lactonization with electron-deficient trifluoromethyl enones 92 afforded 6-membered 
lactones 94 with excellent diastereoselectivity and enantioselectivity (Scheme 1.21). Further 
derivatization afforded diverse building blocks 95 with trifluoromethyl stereogenic centres. A 
detailed mechanistic study, including the observation of a primary kinetic isotope effect (kH/kD 
= 3.8) is consistent with the rate determining step of this transformation being the α-
deprotonation of the acyl ammonium intermediate.49 
 
Scheme 1.21: Michael-lactonisation of trifluoromethylenones 
A similar mechanism, compared with the intramolecular version, was proposed. Formation of 
a mixed anhydride, N-acylation, deprotonation, Michael addition and lactonization furnished 
the lactone 94 with high level of stereocontrol (Scheme 1.22).48 A preferred transition state 98, 
analogous to Heathcock’s model,58 was proposed. The stabilizing no to σ*C-S interaction within 
the (Z)-ammonium enolate 96 positions both sulfur atom and the enolate oxygen coplanar.59 
The key to explain the observed stereoselectivity includes the isothiouronium heterocycle 99 
adopting a half-chair conformation, with minimization of 1,2-strain leading to the Ph group 
sitting in a pseudoaxial position with the i-Pr group pseudoequatorial. Several stabilizing  
non-classical C-H---O interactions between the catalyst backbone and the incoming Michael 
acceptors (NCH---O 2.09 Å, PhH-O 2.27 Å and i-PrH---O 2.16 Å) were identified, via 
computational study of the transition state structure 99, to impart the high stereoselectivity 
for the observed stereoisomer of the lactone 94.60 
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Scheme 1.22: Possible catalytic cycle for intermolecular formal [4+2] 
Instead of generating a carbon-carbon bond, isothiourea catalyzed asymmetric α-amination of 
carboxylic acids with N-aryl-N-aroyldiazenes 101 was also demonstrated. At low catalyst 
loading, this procedure gave either 1,3,4-oxadiazin-6-ones 102 in good yield and excellent 
enantioselectivity. Upon ring-opening and cleavage of the N-N bond using SmI2, 
enantioenriched α-amino acid derivatives 103 could be obtained in overall good yield with no 
erosion in the enantioselectivity (Scheme 1.23).61 
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Scheme 1.23: Isothiourea catalyzed asymmetric α-amination 
To avoid both the difficulties in removing the side product (mostly pivalic anhydride) generated 
using the in-situ activation strategy with pivaloyl chloride and i-Pr2NEt, as well as the use of 
excess reagents, pre-formed acyl transfer agents, such as homoanhydrides 78 and acyl 
imidazoles 79, have been used as the C1-ammonium enolate precursors instead of carboxylic 
acids. However, the first species formally require the use of two equivalents carboxylic acids, 
while the latter species require a high catalyst loading (20 mol%) and longer reaction times. 
Recently, the use of aryl esters as the bench-stable C1-ammonium enolate precursors in 
asymmetric Michael addition-lactonization reaction was developed. This strategy allows the 
use of electron-deficient aryl esters, such as 2,4,6-trichlorophenyl esters 104, with the HCl salt 
of the isothiourea catalyst 70, to access 6-membered lactones 105 and their ring-opening 
derivatives 106 in excellent yield, good diastereoselectivity and excellent enantioselectivity 
(Scheme 1.24).50 
 
Scheme 1.24: Bench-stable aryl esters in Michael addition-lactonization 
Besides commonly encountered C1-ammonium enolate precursors described above, the use 
of α-diazoketones 107 were also explored. In recent work published by Song, a sequential 
photoactivation/isothiourea catalyzed Michael addition-lactamization was developed 
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(Scheme 1.25). In the presence of isothiourea catalyst 109, light-induced Wolff rearrangement 
of α-diazoketones 107 afforded the corresponding disubstituted C1-ammonium enolates 112 
via ketenes 111. Subsequent Michael addition with auronederived α,β-unsaturated imines 
followed by lactamization afforded the tricyclic lactams 110 in excellent yield and with 
excellent diastereo- and enantioselectivity.62 By merging visible-light chemistry with 
isothiourea catalysis, this procedure solved the reactivity problems with disubstitution on 
traditional C1-ammonium enolate precursors 76-79, and enabled access to the 6-membered 
dihydropyridone 110 with quaternary stereocentre. 
 
Scheme 1.25: Michael addition-lactonization with α-diazoketones 
1.7. Aims and objectives 
This chapter highlights the importance of modern development of organocatalysis in synthetic 
organic chemistry. Among the four common types of organocatalysts, Lewis base 
organocatalysts have been extensively utilized to perform catalytic enantioselective 
transformations, such as ammonium enolate chemistry and formal [4+2] cycloadditions.46 
Despite all the efforts so far, the scope of this formal [4+2] cycloaddition process has been 
limited by the nature of the carbon-based substituents that could be installed on the 
ammonium enolate precursors, with aryl and alkenyl substituents extensively demonstrated 
in intermolecular processes at the onset of this thesis. Only the thiophenyl group has been 
successfully incorporated into ammonium enolate precursors to access dihydropyranone 115, 
but leads to a facile base-promoted elimination to afford trifluoromethyl substituted 2-
pyrones 116 in good to excellent yield (Scheme 1.26).63 
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Scheme 1.26: Incorporation of thiophenyl into formal [4+2] cycloaddition 
This thesis aims to broaden the scope of ITU-catalyzed enantioselective formal [4+2] 
cycloadditions by employing novel substituents onto ammonium enolate precursors. Efforts 
will focus on designing and evaluating nitrogen-based substituents to synthesize 
enantioenriched unnatural α-amino acid derivatives (Scheme 1.27), with subsequent 
derivatization using the chemistry of nitrogen-based substituents to afford synthetically useful 
building blocks. 
 
Scheme 1.27: Proposed formal [4+2] cycloaddition with nitrogen-based enolate precursors 
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Chapter 2: Glycine-derived Schiff bases in formal [4+2] cycloadditions 
2.1. Overview 
Unnatural α-amino acids are attracting more attention in modern drug design not only 
because of their biological activities, but also due to their role as probes in studying bioactive 
transformations of peptides, and the mechanisms underlying enzymatic transformations.1 
Examples of potential drug candidates containing unnatural α-amino acid groups include 
Atazanavir (a highly active azapeptide inhibitor of the HIV protease)2 and Tuftsin (a 
macrophage/microglial activator)3 (Fig. 2.1). 
 
Fig. 2.1: Structure of potential drug candidates 
The increasing demand for unnatural α-amino acids has made it necessary to develop new 
methodologies to access them particularly in enantio-pure form. Historically, glycine esters 
protected as benzophenone Schiff bases have frequently been used as equivalents of α-
anionic amino acids in asymmetric synthesis.4 The benzophenone-derived imines of glycine 
esters were first applied in the catalytic phase-transfer alkylations to make amino acid 
derivatives by O’Donnell in 1978.5 Since then, a wide variety of methods to access enantiopure 
α-amino acid derivatives have been developed using this class of substrates, including phase 
transfer catalyzed alkylations,6–8 Michael,9–14 aldol,15,16 and Mannich17–20 reactions (Scheme 
2.1). 
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Scheme 2.1: Reactions of Schiff base imine of glycine esters21 
Building upon the precedent for α-functionalization of Schiff base imines of glycine esters, this 
chapter will focus on expanding the reactivity to include isothiourea-catalyzed Michael 
addition-lactonization reactions between glycine aryl esters 117 and Michael acceptors 118 
(Scheme 2.2). 
 
Scheme 2.2: Isothiourea catalyzed formal [4+2] with Schiff base imines 
2.2. Choice and synthesis of enolate precursors 
As suggested by previous computational and mechanistic studies, the leaving group from 
ammonium enolate precursor not only initiates the catalytic cycle with Lewis base catalysis, 
but also deprotonates the N-acyl ammonium intermediate.22 In the case of acid-labile Schiff 
base imines, alternative ammonium enolate precursors other than carboxylic acids need to be 
considered. Historically, electron poor aryl esters have been successfully applied as effective 
acylating agents23 and been evaluated as C1-ammonium and azolium enolate precursors.24,25 
Following previous experience of using bench-stable aryl esters as C1-ammonium enolate 
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precursors (Scheme 1.24),26 both para-nitrophenol (PNP) and 2,4,6-trichlorophenol (TCP) 
esters were selected as potential substrates to be tested in catalytic transformations using 
Lewis basic isothioureas (Fig. 2.2).  
 
Fig. 2.2: Suggested glycine-derived Schiff base esters 
Initial attempts towards the synthesis of PNP ester benzophenone Schiff base using PNP 
bromoacetate 124 and benzophenone imine 123 under reflux conditions in MeCN gave full 
conversion to imine ester 121 (as determined by 1H NMR analysis of crude mixture). However, 
less than 10% yield was isolated after purification by flash column chromatography, with 
decomposition products benzophenone 125 and para-nitrophenol 126 isolated (Scheme 
2.3).27 Using eluents containing 1% Et3N as an additive still led to full decomposition of the 
product 121. This suggested that 121 is not only unstable under acidic conditions, but also 
potentially incompatible with the non-nucleophilic base triethylamine. With purification 
proving difficult, alternative routes to synthesize 121 were sought that would avoid flash 
chromatography. 
 
Scheme 2.3: Initial attempts on the synthesis of 121 
A successful procedure in synthesizing various aromatic Schiff base esters was reported by the 
Pan Group in 2014.28 This three-step procedure proceeds through initial DCC-mediated 
esterification of N-Boc-protected glycine 127, followed by Boc-deprotection using HCl to give 
glycine aryl esters 129 as their hydrochloride salts. Final transimination with benzophenone 
imine 123 affords the corresponding glycine aryl esters, which are readily separated from the 
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solid ammonium chloride side product via filtration (Scheme 2.4). Following this procedure, 
PNP ester Schiff base 121 was isolated, after trituration with ether to wash off any PNP and 
benzophenone impurities, as white needles in 48% yield over three steps. However, TCP ester 
Schiff base 122 has similar solubility in ether compared with benzophenone impurity, so had 
to be purified by column chromatography giving the product with 38% yield over three steps. 
 
Scheme 2.4: Improved synthetic procedure 
2.3. Formal [4+2] cycloadditions with α-keto-β,γ-unsaturated esters 
With the required substrates in hand, attention was turned to evaluating a model isothiourea-
catalyzed Michael addition-lactonization. α-Keto-β,γ-unsaturated ester was selected as a 
model Michael acceptor because it serves as a highly reactive electron deficient 4π system in 
formal [4+2] cycloadditions.29 It was synthesized in a simple two-step procedure, starting with 
the base-mediated aldol reaction between benzaldehyde and pyruvic acid 130 to afford 
potassium salt 131. Methylation with MeOH and acetyl chloride gave the desired ester 132 in 
35% yield over two-steps (Scheme 2.5). 
 
Scheme 2.5: Synthesis of Michael acceptors 132 
The formal [4+2] cycloadditions were then tested using keto-ester 132 and racemic ITU 
catalysts. An initial control experiment using i-Pr2NEt as base without any isothiourea catalyst 
showed no observable conversion, returning the PNP ester starting material 121 and the 
Michael acceptor 132 (Scheme 2.6 (a)). However, using 20 mol% tetramisole hydrochloride 
133 as the catalyst, PNP ester 121 was fully consumed within 24 hours, but the desired product 
134 could not be found upon 1H NMR analysis of the crude material. Instead, compound 135 
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was found to be the only product that was isolated in 60% yield (Scheme 2.6 (b)), suggesting 
complete elimination of the imine functionality from the proposed lactone product 134. 
 
Scheme 2.6: Initial proof of concept study 
A possible elimination pathway for the benzophenone imine is proposed, assuming initial 
Michael addition/lactonization of the ammonium enolate and enone to give 134 (Scheme 2.7). 
Deprotonation at C(4) leads to the intermediate 136, with subsequent elimination of the 
benzophenone imine generating the final product 135. The eliminated imine is further 
hydrolyzed to benzophenone and NH3 upon aqueous work-up. 
 
Scheme 2.7: Possible elimination pathway for the Schiff base imine 
Several attempts were made to avoid the formation of this elimination product (Table 2.1). 
Lower catalyst loading resulted in a decrease in the isolated yield of 135 (entry 1-2). Carrying 
out the reaction at −78 °C with 10 mol% catalyst loading did not prevent the elimination from 
happening, with 135 isolated in 45% yield (entry 3). Changing the catalyst from tetramisole 
hydrochloride 133 to either benzotetramisole, DHPB or HyperBTM still resulted in the isolation 
of 135 (entry 4-6). A final test reaction with TCP ester 122 and tetramisole hydrochloride 133 
also gave 135 in 38% yield (entry 7). 
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Entry Ar Temp. Catalyst (loading) Yield of 135* 
1 121 rt. 133 (10 mol%) 51% 
2 121 rt. 133 (5 mol%) 34% 
3 121 –78 °C 133 (10 mol%) 45% 
4 121 rt. 137 (10 mol%) 20% 
5 121 rt. 114 (10 mol%) 49% 
6 121 rt. 138 (10 mol%) 44% 
7 122 rt. 133 (10 mol%) 38% 
*Isolated yield. 
Table 2.1: Reaction condition screening of Michael acceptor 132 
2.4. Formal [4+2] cycloadditions with electron deficient ketones 
Given the potential problems observed in the elimination of the Schiff base lactone 134, we 
decided to investigate if reversing the position of the phenyl and ester functionalities would 
lead to different products (Scheme 2.8). Enone 139 is commercially available and has been 
successfully applied by Ye and co-workers in NHC-catalyzed formal [4+2] cycloadditions.30 
 
Scheme 2.8: Proposed Michael acceptor 
2.4.1. Reactivity with β-ester enone 
Under our catalytic conditions using 133, enone 139 did not lead to the formation of the 
desired Schiff base lactone 140 according to the 1H NMR analysis of the crude reaction mixture. 
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Instead, elimination of the imine was again observed, with substituted pyranone 141 isolated 
in 36% and 25% yield from PNP ester 121 and TCP ester 122 respectively (Scheme 2.9). 
 
Scheme 2.9: Test reactions with ketoenone 
In this case, an E1cB mechanism is proposed to explain the formation of 141, again assuming 
initial Michael addition-lactonization of the enolate and enone (Scheme 2.10). 
 
Scheme 2.10: Mechanistic explanations for the elimination process 
2.4.2. Reactivity with trifluoromethyl enones 
To reduce the risk of possible elimination, further studies used trifluoromethyl enones as these 
Michael acceptors have been successfully applied in a wide range of formal cycloadditions 
involving either ITU or NHC redox catalysis.31,32 CF3 enone Michael acceptor was synthesized 
via a one-step procedure published by Pedro.33 Reaction of commercially available α,β-
unsaturated methyl ester 143 with trifluoromethyltrimethylsilane, followed by acidic 
hydrolysis, gave the desired enone 144 in 47% yield (Scheme 2.11). 
 
Scheme 2.11: Synthesis of trifluoromethyl enone 
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2.4.2.1. Base-mediated Michael addition-lactonizations 
With the CF3 enone 144 in hand, the formal cycloadditions were attempted using racemic 
tetramisole hydrochloride catalyst 133 with PNP ester 121 (Table 2.2). At room temperature 
with 20 mol% catalyst loading and 2.5 equivalents of i-Pr2NEt, full consumption of the 
trifluoromethyl enone 144 was observed, and the desired lactone product 145 observed in 
52:48 dr (syn:anti) (determined by 1H NMR analysis of the crude material), although the 
isolated yield for the lactone 145 was only moderate (40%) (entry 1). No elimination product 
was identified in the crude reaction mixture, consistent with our hypothesis that switching to 
the trifluoromethyl group would prevent unwanted elimination. The catalytic reaction was 
then screened using different catalyst loadings at room temperature (15 mol% and 10 mol%) 
(entry 2-3). An overall incomplete conversion of CF3 enone was detected by TLC analysis of the 
reaction mixture after 24 h with lower catalyst loadings, giving isolated yields of 25% and 10% 
respectively. Meanwhile, consistently low diastereoselectivity (dr close to 50:50) was observed 
for the catalytic transformations performed at room temperature. To probe this, a control 
experiment in the absence of catalyst but using i-Pr2NEt was performed, showing about 30% 
conversion of enone 144 into the lactone product 145 with a dr. of 74:26 (syn:anti) and an 
isolated yield of 14% (entry 4). This is consistent with a base-mediated background reaction at 
room temperature in CH2Cl2 and may contribute to the observed low diastereoselectivity in 
entries 1-3. 
 
Entry Catalyst loading d.r. (syn:anti)* Yield** 
1 20 mol% 52:48 40% 
2 15 mol% 56:44 25% 
3 10 mol% 55:45 10% 
4 None 74:26 14% 
*Ratio determined from 1H NMR of crude reaction mixture **Yield refers to isolated yield of the combined 
diastereoisomers. 
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Table 2.2: Proof of concept study with CF3 enone 
The relative configuration of the [4+2] cycloaddition lactone product was assigned by 
comparing the observed coupling constants to those of similar δ-lactones 146 reported in the 
literature (Fig. 2.3). When the protons attached to C(3) and C(4) are syn- to each other, a 
literature coupling constant of 7.0 Hz was reported for syn-146,34 while a similar coupling 
constant of 5.4 Hz was observed for one of the diastereoisomers of 145; this was therefore 
assigned as the syn-diastereoisomer. Likewise, a coupling constant of 11.5 Hz was reported in 
the literature for anti-146,34 which is consistent with the observed coupling constant of 11.2 
Hz for the other diastereoisomer, assigned as anti-145. 
 
Fig. 2.3: Assigning the relative stereochemistry 
It was noticed that upon treating the crude with typical work-up procedure (0.1 M HCl or 
water), hydrolysis of the imine occurred, leading to the detection of benzophenone in the 
crude material. Benzophenone could also be released in the process of flash column 
chromatography, due to instability in the presence of slightly acidic silica gel. Both hydrolysis 
processes would give the lactone product 147 with a free amine group. The observed low 
isolation yield could be explained by 147 remaining either in the aqueous layer during work-
up, or on the silica gel during column chromatography (Scheme 2.12). 
 
Scheme 2.12: Possible explanation for low isolation yield 
To avoid the problem of hydrolyzing the imine motif in 145, the crude reaction mixture from 
entry 1 (Table 2.2) was quickly passed through a silica column after removing the solvent. The 
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filtrate showed a greatly reduced amount of benzophenone. Upon purification by column 
chromatography, a slightly improved isolated product yield of 52% was obtained. Encouraged 
by the improved result, this new procedure was used in all subsequent catalytic 
transformations below to record the isolated yield. In an attempt to improve 
diastereoselectivity, a solvent and catalyst screening were performed, and NMR yield (by using 
1,4-dinitrobenzene as the internal standard) was taken into consideration to avoid inaccurate 
results caused by decomposition during column chromatography (Table 2.3). 
Dichloromethane gave 60% NMR yield and low 52:48 dr with tetramisole 133 (entry 1). 
Changing the solvent from dichloromethane to either toluene or MeCN did not show any 
improvement in the diastereoselectivity, but the NMR yield dropped to 55% and 50% 
respectively (entry 2 and 3). An increased diastereoselectivity of 70:30 was noticed when 
changing the solvent to THF, but a poor NMR yield of 20% was observed (entry 4). With 
benzotetramisole 137 as the catalyst in CH2Cl2, NMR yield increased to 68%, but the 
diastereoselectivity remained similarly low (45:55) (entry 5). While HyperBTM 138 showed a 
reduced NMR yield of 45%, a slight increase in the dr to 66:34 was observed (entry 6). 
 
Entry Catalyst Solvent d.r. (syn:anti)* NMR Yield** 
1 133 CH2Cl2 52:48 60% 
2 133 Toluene 54:46 55% 
3 133 MeCN 57:43 50% 
4 133 THF 70:30 20% 
5 137 CH2Cl2 45:55 68% 
6 138 CH2Cl2 66:34 45% 
*Ratio determined from 1H NMR of reaction mixture. **Yield from 1H NMR using 1,4-dinitrobenzene as the 
internal standard. 
Table 2.3: Solvent and catalyst screening 
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Using benzotetramisole 137 in dichloromethane, the effect of the auxiliary base was explored 
(Table 2.4). When reducing the amount of i-Pr2NEt from 2.5 to 1.0 eq., NMR yield increased to 
78%, however the diastereoselectivity still remained the same at 48:52 (entry 2). 2,6-Lutidine 
gave a slight improvement in both diastereoselectivity to 38:62 and NMR yield to 77% (entry 
3). Satisfyingly, pyridine also gave the lactone 145 in 20:80 dr., together with an NMR yield of 
68% (entry 4).  
 
Entry Base Equivalents d.r. (syn:anti)* NMR Yield** 
1 i-Pr2NEt 2.5 45:55 68% 
2 i-Pr2NEt 1.0 48:52 78% 
3 2,6-lutidine 1.0 38:62 77% 
4 pyridine 1.0 20:80 68% 
*Ratio determined from 1H NMR of reaction mixture. **Yield from 1H NMR using 1,4-dinitrobenzene as the 
internal standard. 
Table 2.4: Base Optimization  
Trichlorophenyl ester 122 was also tested using 1 equivalent i-Pr2NEt and 20 mol% 
benzotetramisole catalyst 137. A good NMR yield of 50%, but poor diastereoselectivity of 
53:47 was observed (Scheme 2.13). 
 
Scheme 2.13: Reactivity with trichlorophenly ester 122 
With the racemic reaction giving a good NMR yield albeit with a variable degree of 
diastereoselectivity, the enantioselectivity of this reaction was explored. At room temperature 
with 1 equivalent of 2,6-lutidine as a base, high NMR yield of 74% was obtained along with a 
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moderate dr of 38:62 but a poor er of 48:52 (Table 2.5, entry 1). Pyridine gave similar 
diastereoselectivity of 20:80 dr, 66% NMR yield and similar er of 54:46 (entry 2). Similar to 
pyridine and lutidine, 2.5 equivalents of i-Pr2NEt also gave a poor enantioselectivity of 53:47 
er with a good NMR yield of 67% (entry 3). A significant increase in er for both 
diastereoisomers to 71:29 was observed when 1.0 equivalent of i-Pr2NEt was employed (entry 
4). Lowering the reaction temperature to 0 °C slightly improved the dr to 62:38 (entry 5). 
However, the NMR yield dropped to 60% and the er was maintained at 72:28. Further lowering 
the reaction temperature to –78 °C showed an improved er to 78:22 and an improved dr of 
75:25, but the NMR yield dropped significantly to 53% (entry 6). 
 
Entry Base (eq.) Temp. d.r. (syn:anti)* NMR Yield** 
er*** 
1 2,6-lutidine (1.0) rt. 38:62 74% (45%) 
48:52 (anti) 
48:52 (syn) 
2 Pyridine (1.0) rt. 20:80 66% (37%) 
49:51 (anti) 
54:46 (syn) 
3 i-Pr2NEt (2.5) rt. 45:55 67% (34%) 
53:47 (anti) 
53:47 (syn) 
4 i-Pr2NEt (1.0) rt. 48:52 78% (37%) 
71:29 (anti) 
73:27 (syn) 
5 i-Pr2NEt (1.0) 0 °C 62:38 60% (20%) 
72:28 (anti) 
72:28 (syn) 
6 i-Pr2NEt (1.0) –78 °C 75:25 53% (15%) 
75:25 (anti) 
78:22 (syn) 
*Ratio determined from 1H NMR of reaction mixture. **Yield from 1H NMR using 1,4-dinitrobenzene as the 
internal standard, isolated yield in parentheses. ***Determined from chiral HPLC analysis of a mixture of dr. 
Table 2.5: Screening on conditions with chiral catalyst 
2.4.2.2. Base-free Michael addition-lactonizations 
With the publication of a recent paper exploring the use of aryloxide as the base in C1-
ammonium enolate chemistry,35 the same idea was applied into the Michael addition-
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lactonization reactivity with substrate 121. At room temperature and using racemic BTM 137, 
polar aprotic solvents DMF, MeCN and isopropyl acetate gave nearly quantitative NMR yield 
with 1 equivalent aryl ester 121, but the diastereoselectivity was close to 50:50 (Table 2.6, 
entry 1-3). When switching to a relatively non-polar solvent CH2Cl2, a dr of 17:83 was observed 
for 145, favouring the anti-diastereomer (entry 4). To push the conversion, 2.0 equivalents of 
aryl ester 121 were employed, leading to an NMR yield of 75% and a similar 
diastereoselectivity of 15:85 (entry 6). 
 
Entry Eq. of 121 Solvent d.r. (syn:anti)* NMR Yield** 
1# 1.0 DMF 45:55 >99% 
2# 1.0 MeCN 53:47 >99% 
3# 1.0 Isopropyl acetate 51:49 97% 
4 1.0 CH2Cl2 17:83 55% 
5 1.5 CH2Cl2 13:87 63% 
6 2.0 CH2Cl2 15:85 75% 
*Ratio determined from 1H NMR of reaction mixture. **Yield from 1H NMR using 1,4-dinitrobenzene as the 
internal standard. #Reaction at 10 hours. 
Table 2.6: Optimizations with base-free process 
Next, the same base-free reactivity was investigated with TCP ester 122. Using 2 equivalents 
ester 122 and CH2Cl2 at room temperature, a much reduced reactivity of 43% NMR yield was 
observed with moderate dr (33:67) (Scheme 2.14), compared with the PNP ester under the 
same conditions (Table 2.6, entry 6). Therefore, the use of TCP ester was not evaluated further. 
 
Scheme 2.14: Base-free reaction with TCP ester 
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Following on the promising reactivity observed with the base-free process, the 
enantioselective was explored. At room temperature using CH2Cl2 as the solvent, a low 42:58 
er was observed for the major anti-diastereoisomer, while the minor syn-diastereoisomer was 
racemic (49:51 er) (Table 2.7, entry 1). Interestingly, when lowering the temperature to –10 °
C and –78 °C, the syn-diastereoisomer was favoured, and a dr of 60:40 and 66:34 was 
observed at –10 and –78 °C respectively (entry 2 and 3). Lowering the temperature resulted 
in no change in the er of syn-diastereoisomer (52:48), but an increase in the er of anti-
diastereoisomer to 34:66 (entry 2). As a comparison between different solvent systems, when 
the reaction is performed in the polar aprotic solvent DMF at low temperature of –40 °C, a 
poor diastereoselectivity of close to 50:50 was still observed, with a very promising NMR yield 
of 98% (entry 4). Interestingly, an enantioselectivity of 87:13 er was observed for the anti-
diastereoisomer, but a much lower er of 62:38 was noticed for the syn-diastereoisomer. 
 
Entry Solvent Temp. d.r. (syn:anti)* NMR Yield** er*** 
1 CH2Cl2 rt. 13:87 77% (40%) 
42:58 (anti) 
49:51 (syn) 
2 CH2Cl2 –10 °C 60:40 64% (33%) 
34:66 (anti) 
52:48 (syn) 
3 CH2Cl2 –78 °C 65:35 31% (10%) n/d. 
4# DMF –40 °C 53:47 98% (55%) 
87:13 (anti) 
62:38 (syn) 
*Ratio determined from 1H NMR of reaction mixture. **Yield from 1H NMR using 1,4-dinitrobenzene as the 
internal standard, isolated yield in parentheses. ***Determined from chiral HPLC analysis of reaction 
mixture. #Reaction with 1.0 eq. 121 and 10 mol% 146 after 16 h. 
Table 2.7: Enantioselectivity for base-free reactions 
In-situ derivatizations were investigated to facilitate the isolation of stable derivatives of the 
Michael addition-lactonization product 145. Unfortunately, no desired product was isolated 
following either hydrolysis of imine with citric acid or ring-opening of the lactone with MeOH. 
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The former resulted in the isolation of benzophenone as the only product, and the latter gave 
full decomposition of the desired lactone 145 without observing any benzophenone. 
2.4.2.3. Control reactions 
Analysis of all these results indicated that product diastereo- and enantioselectivity varied 
significantly with the reaction conditions, including solvent, temperature and base. The 
absolute configuration of the syn- and anti-diastereoisomers of the lactone 145 could not be 
unambiguously confirmed. Their configuration is arbitrarily assigned as direct analogy to the 
well-studied α-aryl acetic acid system using isothiourea catalysis could not be readily extended 
to the incorporation of the C(3)-imino group based upon these results.32 A simple 
epimerization study was carried out using isolated lactone product under basic conditions. 
Treatment of (±)-lactone product 145 (55:45 dr, syn:anti) with i-Pr2NEt in CDCl3 at rt gave a dr 
of 80:20 (syn:anti) after 5 h, suggesting that epimerization to favour the syn-diastereoisomer 
could occur at rt and this was favoured thermodynamically (Scheme 2.15). In situ 
epimerization may contribute to the varied results observed with this system.  
 
Scheme 2.15: Epimerization study 
  
Chapter 2: Glycine-derived Schiff base in formal [4+2] cycloaddition 
Page | 45  
2.5. Conclusions 
In this chapter, glycine derived Schiff base imines 121 and 122 were tested in isothiourea-
catalyzed Michael addition-lactonization with typical electron deficient Michael acceptors. The 
use of either a α-keto-β,γ-unsaturated ester 132 or a β-ester-α,β-unsaturated enone 139 led 
to the isolation of the elimination products (135 and 141) in 60% and 36% yield respectively 
(Scheme 2.16). 
 
Scheme 2.16: Results with 132 and 139 
The elimination could be prevented by replacing the ester group in 132 with a trifluoromethyl 
group 144. Initial screening on reaction conditions gave the lactone 145 in 75:25 dr (syn:anti), 
53% NMR yield and 78:22 er (syn-) using 1 equivalent i-Pr2NEt at –78 °C (Scheme 2.17). 
 
Scheme 2.17: Result with base-mediated reaction 
Additionally, a base-free protocol was developed in anhydrous DMF at –40 °C. Within 16 
hours, the lactone 145 was isolated in a moderate 55% yield (98% NMR yield), 53:47 dr 
(anti:syn) and good enantioselectivity of 87:13 er for the anti-diastereoisomer (Scheme 2.18). 
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Scheme 2.18: Base free enantioselective formal [4+2] cycloaddition 
One major drawback for this process was the difficulty associated with the isolation of the 
desired products and the inconsistent product dr and er. Therefore, the system has not been 
explored further. After proving the principle that amino esters could be α-functionalized using 
Lewis base catalysis, the attention was then turned into other stable nitrogen protection group 
of glycine esters. 
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Chapter 3: Formal [4+2] cycloadditions with trichloromethyl enones 
3.1. Overview 
Following the investigation of α-functionalization of Schiff-base imine protected glycine esters 
with isothiourea catalysis in Chapter 2, attention was turned to the use of more stable N-
substituents that could be incorporated into products. Recent work was published by Shiina 
using 2-(1H-pyrrol-1-yl)alkanoic acids 149 as α-amino acid equivalents in a BTM-catalysed 
dynamic kinetic resolution (DKR) to afford enantioenriched α-amino acid derivative 151 in 
good yield and with excellent enantioselectivity (Scheme 3.1).1  
 
Scheme 3.1: Lewis base catalysed DKR of pyrrolyl acid 149 
This N-bonded α-pyrrole substituent shares similar size and aromaticity with the 
corresponding α-aryl substituents that are well precedented in ammonium enolate chemistry 
promoted by isothiourea catalysis.2 Based on the previous methodologies developed within 
the Smith group (Scheme 1.21), it was proposed that pyrrole-substituted glycine would be a 
suitable substrate to begin our study into developing a heteroatom-linked substrate for 
enantioselective α-functionalization with isothiourea catalysis. Facile pyrrole preparation via a 
Clauson-Kaas synthesis3 and chemoselective late-stage pyrrole degradation by ozonolysis4,5 
make it an appealing protecting group (Scheme 3.2). 
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Scheme 3.2: Protection and deprotection of α-amino group 
3.2. Substrates synthesis 
Following a literature procedure by Taylor,6 a two-step synthesis of the model substrate 155 
was performed. Condensation of glycine ethyl ester hydrochloride 152 and 2,5-
dimethoxytetrahydofuran 153 afforded ethyl 2-(1H-pyrrol-1-yl)acetate 154 in 66% good yield. 
Subsequent alkaline hydrolysis with NaOH in THF and water gave the target 2-(1H-pyrrol-1-
yl)acetic acid 155 in 97% yield as a bench-stable white solid (Scheme 3.3). 
 
Scheme 3.3: Synthesis of pyrrole acetic acid 
In order to evaluate the behaviour of this 2-(1H-pyrrol-1-yl)acetic acid 155 in a model Michael 
addition-lactonization, trichloromethyl enone 158 was initially used. An established two-step 
synthetic procedure towards the enone 158 was used as a starting point for the investigations.7 
Beginning from cinnamyl aldehyde 156, trichloromethyl carbinol 157 was synthesized using 
trichloroacetic acid and sodium trichloroacetate in DMF. Purification by column 
chromatography gave allylic alcohol 157 in 87% yield. Swern oxidation gave the corresponding 
enone 158 in 95% isolated yield as a bench-stable solid (Scheme 3.4).8 
Chapter 3: Formal [4+2] cycloadditions with trichloromethyl enones 
Page | 51  
 
Scheme 3.4: Synthetic route towards trichloromethyl enone 158 
3.3. Evaluating the reactivity of 2-(1H-pyrrol-1-yl)acetic acid 
3.3.1. Reaction conditions optimization 
A mixed anhydride was generated in situ from 2-(1H-pyrrol-1-yl)acetic acid 155 and pivaloyl 
chloride, then BTM 146, i-Pr2NEt and Michael acceptor 158 were added. The reaction was 
stirred at room temperature in CH2Cl2 and monitored by TLC until complete consumption of 
the Michael acceptor was observed. Unfortunately, this reaction led to the exclusive formation 
of the pyranone 159, which was isolated in 50% yield (Scheme 3.5). 
 
Scheme 3.5: Initial reactivity test with trichloromethyl enone 158 
The unexpected formation of pyranone 159 was proposed to be a consequence of excess base 
in the reaction. Assuming the formation of the desired lactone 160, deprotonation at C(4), 
followed by loss of chloride generates intermediate 161. Isomerization of 161 would lead to 
the observed pyranone 159 (Scheme 3.6). A similar elimination process, where phenylacetic 
acid was used as the enolate precursor, had previously been reported by the Smith group in 
2014.7 
 
Scheme 3.6: Possible mechanistic explanation for pyranone formation 
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Using HyperBTM 93 as the isothiourea catalyst and performing the reaction at –40 °C allowed 
the first observation of the desired lactone 160 to be observed. 1H NMR analysis of the crude 
reaction mixture revealed 69% conversion of the trichloromethyl enone 158, along with a 
product distribution of 29:71 of lactone 160:pyranone 159 (Scheme 3.7). The lactone 160 was 
formed in a moderate 71:29 dr. 
 
Scheme 3.7: Observed formation of the desired lactone 160 
Further screening of reaction conditions at −40 °C showed that the nature of solvent had a 
significant impact on the product distribution. Both toluene and DMF led to preferential 
formation of the desired lactone product 160 to pyranone 159 in product ratios of 70:30 and 
85:15 respectively, but with much lower (37% and 40%) conversions of trichloromethyl enone 
158 (Table 3.1, entry 1 and 2). Ethyl acetate resulted in an 80% conversion of trichloromethyl 
enone 158 into an approximately 88:12 mixture of 160:159 within 48 hours, with 160 being 
formed in a promising dr of 89:11 (entry 3). In acetonitrile, lactone 160 was observed as the 
only product, giving a good dr (90:10) and almost quantitative conversion of the 
trichloromethyl enone 158 (entry 4). Screening of other isothiourea catalysts 146 and 70 
typically used in the Smith group resulted in lower reactivity of 30% and 49% conversion 
respectively. In both cases, lactone 160 was still observed as the only product, with high drs of 
92:8 and 94:6 respectively (entry 5 and 6). Attempted reduction of catalyst loading from 10 
mol% to 5 mol% showed minimal impact on the product distribution, but a slightly reduced 
conversion (95%) and diastereoselectivity (88:12) was observed (entry 7). A control reaction 
in the absence of the isothiourea catalyst did not lead to any conversion of 158 (entry 8). As a 
result, the conditions from entry 4 (10 mol% 93 in MeCN) were identified as the optimized 
conditions and used to explore the scope and limitations of this protocol. 
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Entry Cat. (mol%) Solvent Conv.a 160:159a 160 dra 
1 93 (10) PhMe 37% 70:30 80:20 
2 93 (10) DMF 40% 85:15 91:9 
3b 93 (10) EtOAc 80% 88:12 89:11 
4 93 (10) MeCN >99% 98:2 90:10 
5 146 (10) MeCN 30% 99:1 92:8 
6 70 (10) MeCN 49% 99:1 94:6 
7 93 (5) MeCN 95% 97:3 88:12 
8 - MeCN 0% n/a n/a 
a. Determined by 1H NMR analysis of crude reaction mixture. b. Reaction time of 48 h. 
Table 3.1: Reaction optimization using pyrrolylacetic acid 155 
Attempts to isolate lactone 160 by column chromatography or recrystallization were 
unsuccessful. It is proposed that during the process of chromatographic purification, lactone 
160 was ring-opened by water and subsequent CCl3 displacement released the corresponding 
diacid derivative 163 which could not be isolated (Scheme 3.8). 
 
Scheme 3.8: Proposed decomposition of lactone to dicarboxylic acid derivative  
3.3.2. In situ ring opening with nucleophiles 
To facilitate the isolation and study of unstable lactone 160, the crude Michael addition-
lactonization product was treated directly with a nucleophile to generate a more stable 
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derivative resulting from ring opening and CCl3 displacement. A similar procedure has 
previously been reported for the corresponding reaction from phenylacetic acid 164, leading  
to the isolation of the diester derivative 166 (Scheme 3.9).7 
 
Scheme 3.9: Previously established ring opening protocol 
Based upon this precedent and protocol, a range of nucleophiles were tested. Pyrrolylacetic 
acid 155 and trichloromethyl enone 158 gave, after ring opening with MeOH and DMAP at 
room temperature, the diester 167 as a mixture of separable diastereoisomers with a ratio of 
86:14 in 90% combined yield (Scheme 3.10). Chiral HPLC analysis showed that the major anti-
(2S,3S) diasteroisomer was formed in excellent 99:1 er, while the minor syn-(2R,3S) 
diastereoisomer was isolated in a slightly reduced 86:14 er. Amines could also be used as 
nucleophiles in the ring opening protocol to afford diamide derivatives. Ring opening and 
aminolysis using an excess of benzylamine gave the diamide product 168 in 92:8 dr, 70% yield 
and excellent er of >99:1. Secondary amines such as morpholine and pyrrolidine were also 
compatible with this protocol, resulting in the isolation of 169 and 170 in slightly reduced yield 
(55% and 50% respectively) and dr (87:13), but still excellent enantioselectivity of 99:1 er for 
the major diastereoisomer in both cases. However, the enantioselectivity of the minor 
diastereoisomer for the pyrrolidine ring-opening derivative 170 was reduced to 81:19 er. Due 
to the high diastereoselectivity, small scale and the polar nature of the benzylamine ring-
opening derivative 168, the minor diastereoisomer of 168 could not be successfully isolated 
to enable the determination of its enantiomeric ratio. 
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a. Yield referred to the combined isolated yield of separable mixture of diastereoisomers, unless otherwise 
stated. dr was determined from 1H NMR analysis of crude reaction mixture. er was determined from chiral 
HPLC analysis. b. Isolated yield of the major diastereoisomer in >95:5 dr. 
Scheme 3.10: Ring-opening and CCl3 displacementa 
3.3.3. Scope and limitations 
With reliable isolation of the derived products developed, the scope was explored by reacting 
pyrrolyl acetic acid 155 with a range of aryl, heteroaryl, alkenyl or alkyl substituted 
trichloromethyl enones (prepared from the reaction conditions outlined in Scheme 3.4) to 
investigate the effect of both electronics and sterics of the β-substituents on the catalytic 
system. Under the optimized conditions, Michael addition-lactonization and subsequent in-
situ nucleophilic ring opening and CCl3 displacement via either methanolysis or aminolysis 
(with benzylamine) afforded the corresponding stable diester or diamide derivatives (Scheme 
3.11). The transformation was well tolerated for a range of aryl trichloromethyl enones. With 
electron-donating methoxy substituents on the aryl ring, both MeOH and benzylamine 
derivatives 173-176 were formed in good yields (58%-90%) with excellent enantioselectivity 
for the major diastereoisomer (>99:1 er). A selection of electron-withdrawing substituents, 
such as 4-trifluoromethyl and nitro group on each ring positions, were well tolerated under 
both ring-opening protocols, giving derivatives 177-184 in similar stereoselectivity (87:13 
to >95:5 dr and up to >99:1 er for the major diastereoisomer) and yields (53%-85%) compared 
with electron-donating aryls. A range of halogen-substituted phenyl rings at either 4- or 2- 
position were also accommodated into the trichloromethylenone Michael acceptors, forming 
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ring-opening derivatives 185-192 in excellent yields of up to 92% and 99:1 er for the major 
diastereoisomer in each case. An extension of the reaction time from 24 hours to 40 hours 
was necessary for complete conversion when using 2-furyl substituted trichloromethyl enone, 
giving the products 193 and 194 in good yields (98% and 64%) and excellent (99:1 er) 
enantioselectivity. An alkenyl substituted trichloromethyl enone was also tested, with both the 
diester 195 and diamide 196 formed in good yield (61 and 60% respectively) and excellent 
enantioselectivity (>99:1 er) for the major diastereoisomer. For both diester 197 and diamide 
198, low dr (51:49 and 57:43) was observed when an alkyl substituent replaced the normal 
aromatic rings. The diester 197 was isolated in 94% yield but the enantiomers could not be 
separated by HPLC. The corresponding diamide 198 was isolated in a slightly lower yield of 
36%, albeit with excellent enantioselectivity (>99:1 er) for the major diastereoisomer and 
lower enantioselectivity (66:34 er) for the minor diastereoisomer. An interesting observation 
across all of these examples was that the BnNH2 quenched diamides were consistently 
observed with higher dr (typically >95:5) when compared with the diesters from alcoholysis 
(typically ca. 85:15 dr). This will be discussed further in later sections. 
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a. Isolated yields of major diastereoisomer unless otherwise stated. dr was determined by 1H NMR analysis of 
crude reaction mixture. er was determined by HPLC analysis. b. Combined isolated yield of separable mixture 
of diastereoisomers. c. Reaction at −40 °C for 40 h. 
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Scheme 3.11: Scope and limitationsa 
The protocol was also tolerated on gram scale (8 mmol 155), exemplified by diester 162 being 
isolated in 84% combined yield, 88:12 dr and 97:3 er for both diastereoisomers (Scheme 3.12). 
 
Scheme 3.12: Scale-up process 
3.3.4. Stereochemistry determination 
Single crystal x-ray analysis was performed on the major diastereoisomer of diester 193 
(Scheme 3.13),9 allowing the relative and absolute configuration for the major 
diastereoisomer to be determined, with the stereochemistry of all other ring-opening 
products assigned by analogy. The (2S,3R)-configuration within the major diastereoisomer 193 
is consistent with the stereochemical outcome previously observed using phenylacetic acid 
derived ammonium enolates in this process. This is consistent with the reaction of a (Z)-
ammonium enolate and enone 199 via a pre-transition state assembly that places the two pro-
stereogenic centres in a staggered array and orients the smallest C(3)-H substituent of the 
enone towards the catalyst, allowing for potential stabilization by non-classical C-H---O 
interaction between the acidic C-H of the catalyst and enone O.10 
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Scheme 3.13: Single crystal X-ray analysis and stereochemistry rationale 
3.3.5. Epimerization studies 
From analysing the scope, the BnNH2 quenched diamide products were consistently observed 
with higher dr (typically >95:5) compared with the corresponding diesters from alcoholysis 
(typically 85:15 dr). Moreover, in the diester series, the minor diastereoisomer was generally 
isolated with lower er compared with the corresponding major diastereoisomer. For example, 
alcoholysis with MeOH resulted in an 80:20 (185:200) mixture of diastereoisomers, with the 
major (2S,3S)-diastereoisomer 185 having 99:1 er, while the minor diastereoisomer 200 had a 
90:10 er (Scheme 3.14). 
 
Scheme 3.14: Observed inconsistent stereoselectivity 
To investigate the source of this inconsistency, a series of control experiments were performed, 
based on the hypothesis that the configuration at C(2) could be changed during methanolysis 
through epimerization. Isolated (2S,3S)-185 (>95:5 dr, 99:1 er) was treated with either 10 mol% 
HyperBTM 93 or typical conditions used for methanolysis (MeOH, 20 mol% DMAP) and 
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monitored using 1H NMR spectroscopic analysis. No trace of minor diastereoisomer (2R,3S)-
200 was detected in either case (Scheme 3.15(a)). Treatment of (2S,3S)-185 (>95:5 dr, 99:1 er) 
with DMAP (20 mol%) and i-Pr2NEt (10 eq.) in MeOH for 5 days led to a 29:71 185:200 ratio of 
diastereoisomers, both with er of 99:1 (Scheme 3.15(b)). Subjecting the isolated minor 
diastereoisomer (2R,3S)-200 (>95:5 dr, 90:10 er) to the same conditions gave a similar 22:78 
(185:200) ratio of diastereoisomers, both in the same 90:10 er (Scheme 3.15(c)). 
 
dr was determined by 1H NMR analysis of crude reaction mixture and er was determined by HPLC analysis. 
Scheme 3.15: Epimerization of diester products 
Single crystal X-ray analysis9 of the major product obtained from the epimerization of (2S,3S)-
185 (99:1 er) (Scheme 3.15(b)) enabled the relative and absolute configuration of 200 to be 
assigned unambiguously as (2R,3S)-200 (Scheme 3.16). 
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Scheme 3.16: Single crystal X-ray analysis of 200 
Comparison of the HPLC trace of (2R,3S)-200 used in single crystal X-ray analysis confirmed the 
(2R,3S) configuration of the minor diastereoisomer 200 from the catalytic reaction (Fig. 3.1). 
This suggested the presence of a base-mediated selective epimerization at either C(3) of the 
lactone or C(2) of the ring-opened intermediate/diester product. 
 
Fig. 3.1: Comparison in the HPLC traces 
Assuming the catalyst has good control over the configuration at C(3) of the initially formed 
product 160, lactone 201 was assumed as the minor diastereoisomer. MeOH ring opening 
would lead to the formation of the corresponding derivatives 167 and 202 (via the CCl3 ketone) 
(Scheme 3.17). Epimerization of 167 or 202 at C(2) would give 203 which is enantiomeric to 
204, potentially leading to the observed lower er (203:204) for the minor diastereoisomer. 
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Scheme 3.17: Explaining the lower er for minor diastereoisomer 
When treating the BnNH2 ring-opening diamide 186 under similar conditions, no 
epimerization was observed, consistent with the observed high dr for this series of products 
(Scheme 3.18). 
 
Scheme 3.18: Epimerization of diamide product 
3.3.6. Product derivatization 
The electron-rich nature of pyrrole was exploited in an intramolecular Friedel-Crafts acylation 
(Scheme 3.19).11 Treatment of isolated enantiopure 187 (>95:5 dr) with Lewis acid boron 
tribromide rapidly led to the formation of the corresponding acylation product 
dihydroindolizinone 206, which was isolated in 75% yield without erosion in either 
diastereoselectivity or enantioselectivity (>95:5 dr, 99:1 er). This Friedel-Crafts acylation 
protocol was compatible with diester substrates bearing aryl substituents with either electron-
donating (4-OMe) or electron-withdrawing (4-CF3 and 4-NO2) groups, and the products 207-
209 were isolated in high yield (70% to 88%), each as a single stereoisomer. Selective acylation 
of pyrrole was achieved in the presence of a 2-furyl substituent, with product 210 being 
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isolated in 86% yield as a single stereoisomer. A 4-Cl-aryl substituent was also well tolerated 
in the system, forming 211 in 90% yield as a single stereoisomer. Single crystal X-ray analysis9 
confirmed the relative and absolute configuration of the dihydroindolizinone 211, allowing the 
configuration of all other examples to be assigned by analogy. 
 
Yields referred to isolated yields. dr was determined by 1H NMR analysis of crude reaction mixture. er was 
determined by chiral HPLC analysis. 
Scheme 3.19: Synthesis of dihydroindolizinones 
3.4. Substituted pyrrole acetic acids 
Aiming to expand the scope of the Michael addition-lactonization protocol, 2,5-disubstituted 
pyrrole acetic acids were synthesized as potential precursors. Acid-catalyzed condensation of 
1,4-diketones 212 and 213 with glycine methyl ester in refluxing toluene in a sealed tube gave 
2,5-disubstituted pyrrole ester 215 and 216 in 70% and 55% yield respectively. Hydrolysis with 
LiOH in THF gave the corresponding diphenyl- and dimethyl substituted pyrrole acetic acid 218 
and 217 in 89% and 85% yield, respectively (Scheme 3.20).12 
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Scheme 3.20: Synthesis towards 2,5-disubstituted pyrrole acetic acid 
When 217 and 218 were subjected to the previously developed reaction conditions, >95% 
starting material was recovered in both cases even after long reaction time of 4 days (Table 
3.2, entry 1-2). Performing the reaction with 218 at room temperature did not provide any 
improvements in the conversion, with more than 90% starting material being recovered after 
48 h (entry 3). The general lack of conversion for this series of substrates was presumably due 
to increased steric bulk caused by the pyrrole ortho-substituents. 
 
Entry Acid Temp. Time Comments 
1 217 –40 °C 4 d >95% 158 recovereda 
2 218 –40 °C  4 d >95% 158 recovereda  
3 218 rt. 48 h 90% 158 recovereda  
a. Based upon the 158 recovered after chromatographic purification. 
Table 3.2: Test reactions with 2,5-disubstituted pyrrole acetic acid 
3.5. N-Heteroaryl acetic acids as enolate precursors 
With the substituted pyrrolyl acetic acids showing no conversion in Michael addition-
lactonization, attention turned to exploring the reactivity of other nitrogen linked α-heteroaryl 
acetic acids. Following procedures from the recent literature, both 2-indole acetic acid 223 
and 2-carbazole acetic acid 224 were synthesized by nucleophilic substitution of ethyl 
bromoacetate 220 with the requisite heteroaryl followed by hydrolysis (Scheme 3.21).13,14 
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Scheme 3.21: Preparation of N-heteroaryl acetic acids 
3.5.1. Reactivity with trichloromethyl enone 
Both isolated 2-indolyl and 2-carbazolyl acetic acids 223 and 224 were subjected to the 
previously developed reaction conditions with trichloromethyl enone. After 24 h, no 
conversion of the Michael acceptor was observed for 224 although in the case of 2-indolyl 
acetic acid 223, the desired lactone 225 was observed in a promising 90:10 dr via 1H NMR 
analysis of crude reaction mixture. Subsequent ring opening methanolysis afforded the diester 
products 226 and 227 in 63% combined yield, 80:20 dr and high er (95:5) for the major 
diastereoisomer 226 and 75:25 er for the minor (Table 3.3, entry 1). Increasing the 
trichloromethyl enone 158 stoichiometry to 1.2 and 1.5 equivalents gave the diesters 226 and 
227 in slightly increased combined yield of 83% and 87% respectively (entry 2-3), while both 
dr (80:20) and er (95:5 for 226 and 74:26 for 227) were consistent with before. Thus, the 
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Entry eq. of 158 dr of 225a dr (226:227)a 226 erb 227 erb Yieldc 
1 1.0 90:10 80:20 95:5 75:25 63% 
2 1.2 91:9 80:20 95:5 74:26 83% 
3 1.5 91:9 80:20 95:5 74:26 87% 
a. dr determined from 1H NMR analysis of crude reaction mixture. b. er determined from chiral HPLC analysis 
of isolated diastereoisomer (>95:5 dr). c. Combined isolated yield of separable mixture of diastereoisomers. 
Table 3.3: Optimization using 2-indolyl acetic acid 
Ring opening process with benzylamine gave diamide 228 in 64% yield and 97:3 er (Scheme 
3.22). This was slightly lower than the er observed using pyrrolyl acetic acid after aminolysis 
(>99:1 er). Unfortunately, the dr could not be clearly determined from the crude reaction 
mixture although 228 was isolated as a single diastereoisomer (>95:5 dr). 
 
Scheme 3.22: Aminolysis with 2-indolyl acetic acid substrate 
3.5.2. Exploring the synthetic utility of alcoholysis derivative 
By analogy to the pyrrole substituted diesters, intramolecular Friedel-Crafts acylation of indole 
ester 226 was proposed. A series of conditions were tested, including BBr3, BF3, BCl3 and AlCl3 
in CH2Cl2 or HFIP (Scheme 3.23).15–20 Unfortunately, under all the conditions tested, no 
cyclization was detected. Either the starting material was recovered, or a complex mixture was 
observed. A possible explanation was that the methyl ester is not a reactive enough acylating 
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group, particularly with indole substrates where typically an acyl halide, a carboxylic acid or a 
mixed anhydride was used as the acylating group.15–20 So this was not investigated further. 
 
Scheme 3.23: Attempted Friedel-Crafts acylation on indole 
3.6. Conclusions 
In this chapter, the successful application of 2-pyrrolyl acetic acid as a C1-ammonium enolate 
precursor in isothiourea catalyzed Michael addition-lactonization with a wide variety of α,β-
unsaturated trichloromethyl enones was demonstrated. The intermediate δ-lactone 160 could 
be readily ring opened by either alcoholysis or aminolysis to afford substituted pyrrole 
derivatives 229 with excellent diastereo- and enantioselectivity. These products could be 
further derivatized into substituted dihydroindolizinones 230 through intramolecular Friedel-
Crafts acylation (Scheme 3.24). 
 
Scheme 3.24: Michael addition-lactonization and derivatization 
2-Pyrrolyl acetic acids with o-substituents did not show any reactivity although 2-indolyl acetic 
acid 223 participated in the lactone formation, with ring-opening leading to diester 226 and 
diamide 228. Friedel-Crafts derivatization was unsuccessful (Scheme 3.25). 
 
Scheme 3.25: Results with 2-indolyl acetic acid 223 
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Chapter 4: One-pot synthesis of tetrahydroindolizine derivatives 
In this chapter, isothiourea-catalyzed Michael addition-lactonization using 2-pyrrolyl acetic 
acid 155 with trifluoromethyl enones 231 and α-keto-β,γ-unsaturated esters 232 was exploited 
as part of a one-pot process for the synthesis of 5,6,7,8-tetrahydroindolizine derivatives 234 
in high dr and er by ring-opening with a nucleophile (MeOH, morpholine or pyrrolidine, 
Scheme 4.1). 
Scheme 4.1: One-pot synthesis of 5,6,7,8-tetrahydroindolizines 
4.1. Overview 
The 5,6,7,8-tetrahydroindolizine structure is a commonly found core motif in many drug 
molecules.1 As a consequence the construction of this building block has attracted the 
attention of synthetic chemists. For example, tetrahydroindolizines are found as the core 
structure in the anticancer natural alkaloid Rhazinicine2 235 and the antimicrobial agent 
Polygonatine A 2363 (Fig. 4.1). CMV423 237, a tetrahydroindolizine derivative, was also 
developed as a treatment of human cytomegalovirus infections.4 
 
Fig. 4.1: Tetrahydroindolizines found in biologically important molecules 
5,6,7,8-Tetrahydroindolizine derivatives are usually synthesized from Brønsted acid or Lewis 
acid mediated Friedel-Crafts alkylation/acylation with pyrroles.5 However, this process is 
typically limited by the use of stoichiometric moisture sensitive Lewis acids. To overcome the 
problem of using a stoichiometric amount of reagent, several catalytic methods towards 
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tetrahydroindolizine have been developed.6–8 For example, a transition-metal catalyzed radical 
cyclization with pyrrole derivatives 238 containing epoxides to afford tetrahydroindolizines 
239 in good yields has been developed (Scheme 4.2).9 
 
Scheme 4.2: Ti-catalyzed synthesis of tetrahydroindolizines 
Following on from the stepwise Michael addition-lactonization and intramolecular Friedel-
Crafts acylation with trichloromethyl enone Michael acceptors and 2-pyrrolyl acetic acid 155 
detailed in Chapter 3, it was initially assumed that the same protocol could also be applied 
with trifluoromethyl enone Michael acceptor substrates to access tetrahydroindolizines, via 
ring-opening and subsequent intramolecular cyclization in a one-pot process. 
4.2. Proof of concept study 
Initial proof of concept studies began with the in situ activation of 2-pyrrolyl acetic acid 155 
using t-BuCOCl, followed by HyperBTM 93 catalyzed Michael addition-lactonization with 
trifluoromethyl enone Michael acceptor 144 in DMF. At room temperature, the reaction was 
monitored by TLC analysis, with full consumption of the starting material observed within 24 
hours. 1H NMR analysis of the crude material revealed the exclusive formation of the 
unexpected isomerized 5,6-dihydropyranone 240, rather than the expected product of 
catalysis, 3,4-dihydropyranone 241 (Scheme 4.3). Chromatographic purification allowed 240 
to be isolated in 97% yield with moderate enantioselectivity (80:20 er). 
 
Scheme 4.3: Unexpected formation of the isomerized product 
The formation of this enantioenriched isomerized product 5,6-dihydropyranone 240 had not 
been observed previously when aryl acetic acid derivatives had been used as the C1-
ammonium enolate precursor in this transformation.10 At this stage it was simply assumed that 
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240 was produced from the catalytically-generated 3,4-dihydropyranone 241 under the 
reaction conditions by isomerization. Attention subsequently focused on reaction optimization 
to favour formation of 3,4-dihydropyranone 241 and minimize the isomerization of 241 to 240. 
4.2.1. Reaction optimization 
Screening started by using different solvent/catalyst combinations at room temperature (Table 
4.1). In amide solvents (DMF and N,N-dimethylacetamide (DMA)), exclusive formation of the 
isomerization product 240 was found within 24 hours with all three isothiourea catalysts 70, 
146 and 93. Quantitative conversion of the starting Michael acceptor 144 was observed for 
each case, with 240 being isolated in excellent yields (95-97%) and good enantioselectivity 
(75:25 to 80:20 er) (entry 1-4). Another polar solvent, cyclohexanone, could also be used in 
the catalytic process, with full conversion of the Michael acceptor 144 into the isomerized 
product 240 using HyperBTM 93 (entry 5). When switching the solvent to 1,2-dichloroethane 
(DCE), the 5,6-dihydropyranone 240 was still the major product, however the desired catalytic 
product 3,4-dihydropyranone 241 and the β-lactone 242 were detected by 1H NMR analysis in 
a product distribution of 3:94:3 (241:240:242) (entry 6). For simplicity these product 
distributions take into account a mixture of diastereoisomers for both 241 (typically ca. 80:20) 
and 242 (typically >95:5). The use of MeCN as solvent resulted in full conversion of enone 144 
within 4 hours to give a 20:65:15 mixture of 241:240:242, with the 5,6-dihydropyranone 240 
still being formed as the major product (entry 7). Due to the difficulties associated with the 
isolation of the desired catalytic product 3,4-dihydropyranone 241 by chromatography, 
product ratios of the crude mixture, as well as conversion of starting material, were used to 
expedite optimization. The use of CH2Cl2, a common solvent used in Michael addition-
lactonization procedures, gave a product distribution of 20:30:50 (241:240:242) with the β-
lactone 242 obtained as the major product (entry 8). Other chlorinated solvents, such as CHCl3 
and CCl4, were also tested. Less than 5% conversion was found with CHCl3 (entry 9), while CCl4 
gave a good conversion of 95% into a product distribution of 57:26:17 (241:240:242) (entry 
10). Uncommon solvents dimethyl carbonate (DMC) and 2-methyl THF both gave 85% 
conversion of trifluoromethyl enone 144, with the 3,4-dihydropyranone 241 being observed 
as the major product in each case (65% and 69% product selectivity respectively) (entry 11 
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and 12). A similar product selectivity for 241 was observed when the reaction was conducted 
in tert-butylmethyl ether (MTBE), but a lower conversion of 63% was found (entry 13). A much 
improved product selectivity with more than 70% 3,4-dihydropyranone 241 was obtained with 
solvents toluene, 1,4-dioxane, Et2O, THF and EtOAc, with all solvents also providing good 
conversions (83-92%) (entry 14-18). The formation of the isomerized product 5,6-
dihydropyranone 240 could be completely suppressed when tert-amyl alcohol was used as the 
solvent, with 88% conversion of the Michael acceptor 144 to give a product ratio of 84:16 
(241:242) (entry 19). Finally, an excellent conversion of 98% was obtained using either 
cyclopentylmethyl ether (CPME) or isopropyl acetate (i-PrOAc) as the solvent, giving 85% and 
88% selectivity for 3,4-dihydropyranone 241 respectively, with only a trace (<5%) of isomerized 
product 240 detected by 1H NMR analysis of the crude reaction material (entry 20-21). 
 
Entry Cat. Solvent Time/ h Conv.a 
Product ratio 
241:240:242a,b 
1 70 DMF 24 100% 0:100 (95%, 20:80 er):0 
2 146 DMF 24 100% 0:100 (96%, 25:75 er):0 
3 93 DMF 24 100% 0:100 (97%, 80:20 er):0 
4 93 DMA 18 100% 0:100:0 
5 93 cyclohexanone 18 100% 0:100:0 
6 93 DCE 18 95% 3:94:3 
7 93 MeCN 4 100% 20:65:15 
8 93 CH2Cl2 18 100% 20:30:50 
9 93 CHCl3 18 <5% n/d. 
10c 93 CCl4 18 95% 57:26:17 
11 93 DMC 18 85% 65:10:24 
12 93 2-MeTHF 18 85% 69:16:15 
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13 93 MTBE 18 63% 65:5:30 
14 93 Toluene 18 92% 72:13:15 
15 93 1,4-dioxane 18 83% 77:3:20 
16 93 Et2O 18 90% 75:8:17 
17 93 THF 18 86% 76:11:14 
18 93 EtOAC 18 90% 75:18:7 
19 93 tert-Amyl alcohol 18 88% 84:0:16 
20c 93 CPME 18 97% 85:0:15 
21c 93 i-PrOAc 18 98% 88:5:7 
a. Determined by 1H NMR analysis of crude reaction mixture. b. Isolated yield and er for individual product in 
parenthesis. c. With 1.2 eq. acid 155. 
Table 4.1: Solvent optimization at room temperature 
During the optimization process some solvents, such as DMSO, 1,2-dimethoxyethane, HFIP 
and MeNO2, either show no conversion of the CF3 enone 144, or gave a complex mixture where 
no dihydropyranone 241 was detected by 1H NMR analysis of the crude material. 
Using a small solvent selection, the reaction was performed at a lower temperature in an 
attempt to improve product selectivity for 241, whilst maintaining high conversion (Table 4.2). 
In general, using HyperBTM as catalyst, at lower temperatures no isomerized product 5,6-
dihydropyranone 240 was detected by 1H NMR analysis, but formation of β-lactone 242 was 
still observed. In DMF at −60 °C, reduced conversion of 70% was observed, giving a product 
distribution of 86:14 (241:242), with no isomerized product 240 detected (entry 1). Inspired 
by this result, the reaction was performed at −60 °C and −78 °C in CH2Cl2, but unfortunately 
both conditions gave an approximate 50:50 ratio of 241:242 (entry 2 and 3). A promising 
product distribution of 85:15 (241:242), as well as quantitative conversion of the Michael 
acceptor 144 was observed with the reaction conducted in MeCN at −40 °C (entry 4). When 
either CPME or isopropyl acetate was used as solvent at −40 °C, quantitative conversion was 
observed, giving a product distribution of 84:16 and 90:10 (241:242) respectively (entry 5 and 
6). 
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Entry Solvent Temp./ °C Time/ h Conv.a 
Product ratio 
241:242a 
1 DMF −60 18 70% 86:14 
2 CH2Cl2 −60 15 95% 52:48 
3 CH2Cl2 −78 24 85% 56:44 
4b MeCN −40 20 99% 85:15 




−40 20 98% 90:10 
a. Determined by 1H NMR analysis of crude reaction mixture. b. With 1.2 eq. acid 155. 
Table 4.2: Screening of solvents at low temperatures 
4.2.2. Exploring the isomerization process 
To provide further insight into the proposed isomerization of 3,4-dihydropyranone 241 to 5,6-
dihydropyranone 240, and to probe the origin of the enantioenrichment of 5,6-
dihydropyranone 240, control reactions were conducted. Performing the Michael addition-
lactonization process at room temperature in isopropyl acetate allowed isolation of 3,4-
dihydropyranone 241 in 82:18 dr and a low isolated yield of 20% due to instability towards 
purification by column chromatography. Despite the low yield, the enantioenrichment of both 
the major and minor diastereoisomers could be determined as 95:5 er and 90:10 er, 
respectively (Scheme 4.4). 
 
Scheme 4.4: Isolation of 3,4-dihydropyranone 241 
A sample of the isolated 3,4-dihydropyranone 241 (94:6 dr, 95:5 ermajor, 90:10 erminor) was 
dissolved in DMF at room temperature, however no isomerization to 5,6-dihydropyranone 240 
was detected by TLC analysis after overnight stirring. Next, (2S,3R)-HyperBTM 93 (10 mol%) 
Chapter 4: One-pot synthesis of tetrahydroindolizine derivatives 
Page | 76  
and 5 eq. i-Pr2NEt were added, with formation of 5,6-dihydropyranone 240 in 55% isolated 
yield after 2 d (Scheme 4.5). HPLC analysis of 240 revealed an enantioselectivity of 80:20 er. 
 
Scheme 4.5: Isomerization of isolated xx in DMF 
The absolute configuration of the 5,6-dihydropyranone 240 has not been confirmed to date, 
as a suitable single crystal could not be obtained for X-ray analysis. However a tentative 
mechanism can be proposed to explain how this enantioenriched product may be obtained. 
Isomerization through initial deprotonation at C(4), followed by protonation at C(6) must be 
diastereoselective and controlled by the C(3)-stereocentre. Deprotonation at C(3) generates 
the conjugated system 245, followed by further protonation at C(5) to give the desired product 
(Scheme 4.6). 
 
Scheme 4.6: Proposed mechanism for isomerization and the origin of enantioselectivity 
4.2.3. β-lactone from [2+2] cycloaddition 
One of the interesting observations in this catalytic system was the observation of the β-
lactone which was presumably generated from a competing [2+2] cycloaddition. β-Lactone 
242 was isolated from the reaction performed in CH2Cl2 at −60 °C, in 40% yield as a single 
diastereoisomer (>95:5 dr, based on 1H and 19F NMR analysis) (Scheme 4.7). HPLC analysis 
revealed an excellent enantioselectivity of 96:4 er. The absolute and relative configuration of 
this β-lactone 242 was not unambiguously confirmed but assigned as (3S,4R) by analogy to 
the configuration of perfluoroalkyl substituted β-lactones formed through a related 
HyperBTM-catalyzed process.11 
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Scheme 4.7: Isolation of β-lactone 242 
As the β-lactone was only obtained during reaction optimization when certain solvents or low 
reaction temperatures were employed, it was hypothesized that the β-lactone may be either 
unstable, or further transformed under the reaction conditions. To investigate this possibility, 
an isolated sample of racemic β-lactone 242 was subjected to 4 eq. i-Pr2NEt and (2S,3R)-
HyperBTM (10 mol%) in DMF. Interestingly, transformation of the racemic β-lactone 242 into 
5,6-dihydropyranone 240 was observed within 3 days, with 240 isolated in 60% yield and with 
an enantioenrichment of 73:27 er (Scheme 4.8). This result could be explained by an 
isothiourea-mediated retro-formal [2+2] cycloaddition to reform the C(1)-ammonium enolate 
and CF3 enone Michael acceptor, which may then engage in a subsequent enantioselective 
Michael addition-lactonization to give 3,4-dihydropyranone, which following the isomerization 
described in the previous section, gives the enantioenriched 5,6-dihydropyranone 240. 
 
Scheme 4.8: Formation of the isomerized product from β-lactone 
4.2.4. Ring opening with nucleophiles 
With 3,4-dihydropyranone 241 being observed as the major product (>80% product selectivity) 
by 1H NMR analysis under several reaction conditions, in situ ring opening with a suitable 
nucleophile was investigated to facilitate the isolation of stable derivatives of the Michael 
addition-lactonization product 3,4-dihydropyranone 241. Only small quantities (typically <5%) 
of the β-lactone 242 could be isolated upon ring-opening and could not be fully characterised. 
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Ring-opening was initially explored by methanolysis with an excess of methanol and 20 mol% 
DMAP (Table 4.3). For the reactions conducted at room temperature in CPME, the initial 3,4-
dihydropyranone product 241 was formed in 81:19 dr. After in situ ring-opening with MeOH, 
the tetrahydroindolizine 246 was obtained in 88% yield, 75:25 dr, 93:7 er for the major 
diastereoisomer and 81:19 er for the minor diastereoisomer rather than the expected simple 
ring-opening product 247 (entry 1). Presumably, the ring-opening product 247 was initially 
formed, but underwent spontaneous cyclization to give the tetrahydroindolizine 246. A new 
stereocentre was generated at C(8) during the cyclization, but only two diastereoisomers were 
identified from both 1H and 19F NMR analysis. Switching the solvent to tert-amyl alcohol led to 
the formation of 241 in improved dr (87:13), however following addition of methanol a lower 
isolated yield (47%) of tetrahydroindolizine 246 was obtained, with reduced product er for 
both diastereoisomers to 60:40 (entry 2). In isopropyl acetate at room temperature, 3,4-
dihydropyranone 241 was formed in a dr of 82:18, with ring-opening with MeOH giving 
tetrahydroindolizine 246 in 88:12 dr, 71% yield, excellent er (97:3) for the major 
diastereoisomer, but lower er (68:32) for the minor diastereoisomer (entry 3). In MeCN at 
−40 °C, 241 was prepared in a good dr (87:13), giving tetrahydroindolizine 246 after ring-
opening in a moderate 60% yield, 81:19 dr but excellent er (98:2 and 97:3 for each 
diastereoisomer) (entry 4). Using CPME at −40 ° C provided 241 (81:19 dr), which 
subsequently gave tetrahydroindolizine 246 in high dr (88:12), 76% isolated yield and good er 
(94:6) for the major diastereoisomer (entry 5). The optimal conditions for the ring-opening 
process was found using isopropyl acetate as solvent at −40 °C, with tetrahydroindolizine 246 
obtained in high dr (91:9) and yield (83%), and consistently excellent er for both major and 
minor diastereoisomer (98:2 and 96:4) (entry 6). 
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er of 246c 












rt 18 82:18 71% 88:12 
97:3 (major) 
68:32 (minor) 
4 MeCN −40 °C 20 87:13 60% 81:19 
98:2 (major) 
97:3 (minor) 






−40 °C 20 82:18 83% 91:9 
98:2 (major) 
96:4 (minor) 
a. Determined by 1H and 19F NMR analysis of crude reaction mixture. b. Combined isolated yield of 246 as a 
mixture of diastereoisomers. c. Determined by chiral HPLC analysis of isolated product. d. With 1.0 eq. 155. 
Table 4.3: Optimization for ring-opening with MeOH 
In addition to methanolysis, secondary amines could also be applied as nucleophiles to provide 
tetrahydroindolizine products. After treating the reaction mixture at −40 °C in isopropyl 
acetate with an excess (300 eq.) of pyrrolidine, the cyclization product 248 was obtained in 
93:7 dr, 70% isolated yield and an excellent er (98:2) for the major diastereoisomer (Scheme 
4.9(i)). If less pyrrolidine (5 eq.) was used, a reduced isolated yield of 248 (50%) was observed 
due to the formation of unidentified side products. Morpholine was also successfully applied 
to give the cyclization product in 95:5 dr, 62% isolated yield and 97:3 er (Scheme 4.9(ii)). 
Compared to MeOH (£3 per 100 mL, Sigma-Aldrich), the secondary amines are significantly 
more expensive (£17.3 per 100 mL for morpholine and £33.5 per 100 mL for pyrrolidine, 
Sigma-Aldrich). Due to this price difference and the lower boiling point of MeOH, to simplify 
product isolation, subsequent studies on the scope of this transformation used methanol for 
the ring-opening step. 
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dr determined by 1H and 19F NMR analysis of crude reaction mixture, yield refers to the isolated yield in >95:5 
dr, er was determined by chiral HPLC analysis. 
Scheme 4.9: Ring opening with 2° amines 
4.2.5. Reaction scope 
The scope of this transformation was studied with different aryl/heteroaryl substituted 
trifluoromethyl enones, followed by methanolysis, to give a range of enantioenriched 
tetrahydroindolizine derivatives (Scheme 4.10). Incorporation of formally-electron 
withdrawing groups at the 4-position and 3-position of the -aryl ring of the CF3 enone Michael 
acceptor,12 tetrahydroindolizines 250, 251 and 252 were formed in good dr (87:13 to 90:10) 
and excellent er (96:4 to 98:2), however 251 was only obtained in low 40% yield. 
Trifluoromethyl enones bearing electron rich β-aryl rings (4-MeC6H4 or 4-OMeC6H4) were also 
tolerated, forming cyclization products 253 and 254 in 58% and 68% yield, moderate dr (80:20 
and 84:16) and excellent er for the major diastereoisomer in each case (98:2 and 99:1). With 
the incorporation of a 2-Me substituent on the -aryl ring of the CF3 enone, a significantly 
lower isolated yield of tetrahydroindolizine 255 (25%) was found, however excellent 
enantioselectivity for the major diastereoisomer (>99:1 er) was still observed. Electron neutral 
1-naphthyl and 2-naphthyl substituted CF3 enones were also tolerated, giving products 256 
and 257 in good yield (77% and 83%), good dr (80:20 and 85:15) and excellent er for the major 
diastereoisomer (both 98:2 er). Incorporation of a 2-furyl group at the β-position of the CF3 
Michael acceptor was also tolerated, giving cyclization product 258 in high 95% yield, good dr 
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a. Yield refers to isolated yield of major diastereoisomer (>95:5 dr) unless otherwise stated. dr determined by 
1H and 19F NMR analysis of crude reaction mixture following ring-opening, er determined by chiral HPLC 
analysis. b. Combined isolated yield as a mixture of diastereoisomers. 
Scheme 4.10: Scope using different trifluoromethyl enonesa 
The crystal structure of the enantioenriched major diastereoisomer of 254 was obtained by 
single crystal X-ray analysis,13 allowing determination of its absolute and relative configuration, 
with the configuration of the major diastereoisomer for all other cyclization products and 3,4-
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dihydropyranone 241 being assigned by analogy (Scheme 4.11). The configuration of the 
stereocentre at C(8), formed during the cyclization process, may be rationalised using a chair-
like Zimmerman–Traxler type transition state14 259 with the CF3 group in a pseudo-equatorial 
position. In solution, coupling constants analysis for the major diastereoisomer 246 showed: 
(i) C(5)H and C(6)H of 6.0 Hz (axial-equatorial coupling); (ii) C(6)H and C(7)Ha of 2.7 Hz (axial-
equatorial coupling); (iii) C(6)H and C(7)Hb of 13.6 Hz (trans-diaxial coupling). Based upon 
Karplus equation, the observed coupling constants are consistent with the half-chair structure 
determined by the X-ray single crystal analysis in the solid state.15 
 
Scheme 4.11: Determination of absolute configuration of 254, and proposed cyclization 
transition state 
Due to isolation difficulties, an enantioenriched sample of the minor diastereoisomer could 
not be isolated and crystallized to enable determination of its absolute or relative 
configuration. However analysis of the coupling constants for the minor diastereoisomer 
showed the coupling constant between C(5)H and C(6)H was 11.0 Hz, which can be assigned, 
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according to Karplus equation,15 as a trans-diaxial coupling. This is consistent with a change in 
the relative configuration between C(5) and C(6) for the two diastereoisomers. Assuming the 
configuration at C(5) is consistent with that observed within the major diastereoisomer, the 
configuration at C(6) is assigned as (R). No information on the relative configuration of C(8) 
was obtained from 1H NMR analysis of the minor diastereoisomer but it is assigned as (S)-
assuming a similar cyclisation transition state 262 (Scheme 4.12) 
 
Scheme 4.12: Coupling constant analysis and proposed transition state for the minor 
diastereoisomer 
4.3. The use of α-keto-β,γ-unsaturated esters in the synthesis of 
tetrahydroindolizine derivatives 
After the successful synthesis of tetrahydroindolizine derivatives using trifluoromethyl enone 
Michael acceptors, attention was turned to the use of an alternative electron-deficient 
Michael acceptor, α-keto-β,γ-unsaturated esters (Chapter 2). It was assumed that the α-keto 
ester group may also allow the one-pot synthesis of alternatively-functionalized 
tetrahydroindolizine derivatives. 
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4.3.1. Reaction conditions screening 
Initial studies were carried out in MeCN at room temperature using 10 mol% HyperBTM 93 
(Scheme 4.13). In contrast to the work using CF3 enones, no 3,4-dihydropyranone, 5,6-
dihydropyranone or β-lactone products were observed. Instead, a mixture of pyranone 264 
and diene 265 were identified by 1H NMR analysis of the crude material. Chromatographic 
purification allowed the isolation of the major pyranone 264 in 58% yield, while diene 265 was 
isolated in 18% yield as a mixture of stereoisomers in 88:12 ratio (not assigned by 1H NMR). 
 
Scheme 4.13: Observation of a mixture of two products at room temperature 
Although these products were unexpected, the origin of their generation can be proposed 
(Scheme 4.14). Assuming initial formation of Michael addition-lactonization product 3,4-
dihydropyranone 266, an oxidant, for example trace of oxygen dissolved in commercially 
available dry MeCN, may be responsible for oxidizing 266 into pyranone 264 (Scheme 4.14(a)). 
Formation of diene 265 is most likely to form following initial formation of a β-lactone 267, 
followed by entropy-driven elimination of CO2 (Scheme 4.14(b)). 
 
Scheme 4.14: Proposed formation of unexpected products 264 and 265 
To circumvent formation of these unwanted products, the reaction was performed at −40 °C 
in MeCN. At this temperature, pyranone 264 was not observed by 1H NMR analysis of the 
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crude mixture, and full consumption (within 24 hours) of 132 into a 91:9 mixture of the desired 
3,4-dihydropyranone 266 and diene 265 was found, with the 3,4-dihydropyranone 266 formed 
as a single diastereoisomer in >98:2 dr (Scheme 4.15). Other solvents were tested (CH2Cl2 and 
i-PrOAc), but neither of them provided any improvement compared to MeCN. 
 
Scheme 4.15: Reaction performed at −40 °C in MeCN 
Unfortunately, all attempts, including chromatography and recrystallization, to isolate the 3,4-
dihydropyranone 266 resulted in full decomposition. The unstable nature of this product 
suggested that a ring-opening procedure should be carried out to facilitate the isolation of a 
stable ring-opening derivative. 
4.3.2. Ring opening with MeOH 
As a starting point for the ring opening study, MeOH was selected as a nucleophile due to its 
readily accessibility and low boiling point. After treating the reaction mixture at −40 °C in 
MeCN with MeOH (2 mL) and DMAP (20 mol%), a mixture of several products was identified 
by 1H NMR analysis of the crude material (Scheme 4.16). Chromatographic purification 
allowed the isolation of the MeOH ring-opening derivative 268 from 3,4-dihydropyranone 266 
(70% yield, >95:5 dr and >99:1 er) as the major product. The high dr and excellent er observed 
for the major ring-opened product 268 suggested that the initial 3,4-dihydropyranone 266 
product was synthesized with an excellent level of both enantio- and diastereoselectivity . 
Inspired by this excellent degree of enantioselectivity, the use of secondary amines as ring-
opening nucleophiles was tested next. 
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Scheme 4.16: Exploring the ring opening with MeOH 
4.3.3. Ring-opening process with amines 
When employing an excess (300 eq.) of secondary amines morpholine or pyrrolidine for the 
ring-opening process, diamide products 269 and 270 were obtained in 70% and 74% isolated 
yield, and with excellent diastereoselectivity (>95:5 dr) and enantioselectivity (>99:1 er) 
(Scheme 4.17). Formation of these products can be explained through a sequential ring-
opening/amidation process. The absence of any tetrahydroindolizine products suggests that 
nucleophilic attack of the secondary amine on the α-ketoester to form the amide was much 
faster than the competing intramolecular cyclization process with pyrrole. In order to slow 
down this amide formation and provide an opportunity for cyclization to give the desired 
tetrahydroindolizine product, the use of fewer equivalents of amine was investigated for the 
ring opening process. 
 
Scheme 4.17: Formation of diamides with an excess of amines 
Reducing the equivalents of morpholine to 10 provided tetrahydroindolizine 271 in addition 
to diamide 269, with a product distribution of 62:38 (271:269) (Table 4.4, entry 1). The use of 
5 equivalents of morpholine provided improved selectivity for tetrahydroindolizine (86:14, 
271:269) and a slightly increased isolated yield of 64% (entry 2). The best results were 
obtained when 2 equivalents of morpholine were employed, giving exclusively the 
tetrahydroindolizine 271 in 75% isolated yield, >95:5 dr and >99:1 er (entry 3). 
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Entry Morpholine eq. 271:269a Isolated yield of 271b dr of 271a er of 271c 
1 10 62:38 42% >95:5 >99:1 
2 5 86:14 64% >95:5 >99:1 
3 2 100:0 75% >95:5 >99:1 
a. Determined by 1H NMR analysis of the crude reaction mixture. b. Isolated yield of xa as a single 
diastereoisomer (>95:5 dr). c. Determined by chiral HPLC analysis. 
Table 4.4: Optimization for the formation of tetrahydroindolizine product 
Using these optimal conditions, the same reaction was repeated and quenched with 2 
equivalents of pyrrolidine (Scheme 4.18). Tetrahydroindolizine 272 was formed exclusively in 
a similar isolated yield of 72%, and equally excellent >95:5 dr and >99:1 er. 
 
Scheme 4.18: Tetrahydroindolizine product formation with 2 eq. pyrrolidine 
4.3.4. Exploring the scope of α-keto-β,γ-unsaturated esters 
With the optimized conditions giving the desired tetrahydroindolizine product, the scope was 
further studied with different α-keto-β,γ-unsaturated esters, and employing morpholine (2 
equiv.) as the nucleophile in the ring-opening process (Scheme 4.19). In all cases the 
tetrahydroindolizine products were obtained with consistently excellent diastereo- and 
enantioselectivity (>95:5 dr and >99:1 er in each case). Both i-Pr ester and ethyl esters were 
tolerated, giving products 273 and 274 in good yield (64% and 55%). The use of electron-
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neutral 2-naphthyl substituted unsaturated keto ester gave tetrahydroindolizine 275 in a good 
yield of 79%, whilst incorporation of an electron-donating 4-Me substituent on phenyl ring of 
the unsaturated keto ester afforded tetrahydroindolizine 276 in an excellent yield of 95%. Due 
to the low solubility of 4-methoxyphenyl substituted keto ester in MeCN, the reaction was 
conducted in CH2Cl2, with the cyclization product 277 isolated in a slightly lower yield of 50%. 
Incorporation of formally electron-withdrawing 3-OMe or 4-CF3 substituent on the phenyl ring 
of unsaturated keto esters was also tolerated,12 giving the corresponding tetrahydroindolizine 
278 and 279 in 63% and 55% yield respectively. A range of keto ester Michael acceptors with 
a 2-, 3- or 4-Br substituent on the phenyl ring of the α-keto-β,γ-unsaturated esters gave 
products 280-282 in 58% to 98% isolated yield and excellent er. Finally, 2-furyl derived 
unsaturated keto ester afforded the cyclization product 283 in comparable 62% isolated yield. 
Attempts to obtain a crystal structure for the isolated tetrahydroindolizines were unsuccessful 
and so the relative  configuration was assigned based upon the observed average coupling 
constant of 6.1 Hz between C(5)-H and C(6)-H for the major diastereoisomer 271 (compared 
with the observed coupling constants of 11.0 Hz for the minor diastereoisomer within CF3 
containing tetrahydroindolizine) and the absolute configuration of all the isolated 
tetrahydroindolizines were assigned by analogy to the crystal structure obtained earlier when 
using CF3 enone Michael acceptors (Scheme 4.11). 
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a. Reaction in CH2Cl2. b. Yield refers to isolated yield as a single diastereoisomer of >95:5 dr, dr determined by 1H 
NMR analysis of the crude ring-opening mixture, er determined by chiral HPLC analysis. 
Scheme 4.19: Scope with α-keto-β,γ-unsaturated estersb 
During investigation of the substrate scope of this process, some limitations with respect to 
the α-keto-β,γ-unsaturated ester substrate were recognized (Scheme 4.20). With 4-NO2 
substituted substrate 284, full consumption of 284 into an unidentified complex mixture, 
which was deep blue in colour, was observed. Incorporation of an alkenyl substituent, or a 3-
pyridyl group at the γ-position of the α-keto-β,γ-unsaturated ester provided no formation of 
the desired dihydropyranone, which was attributed to the substrate’s low solubility in both 
CH2Cl2 and MeCN at −40 °C. Introduction of an extra substituent at the β-position of the 
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Michael acceptor was also investigated, however application of α-ketoesters resulted in the 
no product formation and only the return of starting materials. These final results are 
consistent with previous enantioselective isothiourea-catalyzed Michael addition-cyclization 
methodologies,16 in which, to date, the use of Michael acceptors bearing a substituent 
adjacent to the ketone/imine moiety have not been successfully applied. 
 
Scheme 4.20: Unsuccessful Michael acceptors 
4.3.5. Exploring the synthetic utility 
The synthetic utility of this cyclization product was explored next. Based on a number of 
literature precedents on related systems,17–19 the selective hydrogenation of 
tetrahydroindolizine 271 was tested. Unfortunately, under all the catalytic conditions tested 
so far using either PtO2 or Rh (entry 1-3), full consumption of starting material 271 was 
observed after overnight stirring to afford a complex mixture of unidentified products. A 
shorter reaction time, as well as lower pressure of hydrogen did not show any improvements. 
Purification by column chromatography was not successful for the isolation of any 
hydrogenation products (Table 4.5). 
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Entry Conditions Results 
1 PtO2 (25 mol%), AcOH, H2 balloon, rt., o/n. Complex mixture 
2 5% Rh on Al2O3 (5 w/w%), MeOH, rt., 5 atm H2, o/n. Complex mixture 
3 5% Rh on Al2O3 (5 w/w%), HFIP, rt., 5 atm H2, o/n. Complex mixture 
Table 4.5: Attempts on hydrogenation of tetrahydroindolizine 271 
4.4. Conclusions 
In conclusion, a one-pot isothiourea-catalyzed Michael addition/lactonization followed by in 
situ ring-opening with a nucleophile (MeOH or secondary amine) afforded highly 
enantioenriched tetrahydroindolizine products 234 bearing 3 stereogenic centres in up to 
98%, >95:5 dr and >99:1 er (Scheme 4.21). 25 Examples, with the incorporation of both 
electron-withdrawing and donating aryl ring, as well as heterocycles, were successfully 
synthesized. The absolute configuration of products in the CF3 enone series were confirmed 
by single crystal X-ray analysis. Unfortunately further derivatization through transition-metal 
catalyzed hydrogenation was not unsuccessful. 
 
Scheme 4.21: One-pot synthesis of tetrahydroindolizine 
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Chapter 5: Enantioselective synthesis of C(3)-pyrrolyl/C(8)-indolyl 
dihydropyridinones 
Having demonstrated the application of 2-pyrrolyl acetic acid 155 in Michael addition-
lactonization (Chapter 3 and 4), this chapter describes further organocatalytic formal [4+2] 
cycloadditions with 2-pyrrolyl and 2-indolyl acetic acids 233 as C1-ammonium enolate 
precursors. Interest will focus on the use of both acyclic α,β-unsaturated ketimines and cyclic 
sulfonamide derived α,β-unsaturated ketimines in isothiourea catalyzed Michael addition-
lactamization processes to access chromatographically stable dihydropyridinones 291 
(Scheme 5.1). 
 
Scheme 5.1: Isothiourea catalysed synthesis of dihydropyridinones 
5.1. Introduction 
In the area of natural products and bioactive small molecules, the dihydropyridinone motif is 
recognized as an important heterocyclic molecule containing a six membered ring with a cyclic 
amide.1,2 For example, the tetracyclic dihydropyridinone Finasteride 292 was used in the 
treatment of human hair loss,3 meanwhile the spiro-cyclic dihydropyridinone 293 showed its 
bioactivity in the antiproliferation of leukemia cell (Fig. 5.1).4 
 
Fig. 5.1: Commonly found bioactive small molecules containing dihydropyridinone 
Historically, one major synthetic approach towards these dihydropyridinone derivatives via 
[4+2] cycloaddition was the aza-Diels-Alder reaction through either a normal-electron demand 
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(involving nitrogen containing electron rich dienes and electron poor dienophiles) or an 
inverse-electron demand (involving nitrogen containing electron deficient dienes and electron 
rich dienophiles) pathway.5,6 Due to the high demand to access these dihydropyridinone 
derivatives in their enantioenriched form, approaches featuring the use of a compatible Lewis 
acid with chiral ligands have been developed.6–9 In addition, since the wide application of 
organocatalysis, several organocatalytic aza-Diels-Alder reaction have been developed,10–13 
with the most state-of-the-art NHC-catalyzed aza-Diels-Alder reaction being developed by 
Bode14 and Ye.15 In Bode’s procedure (Scheme 5.2(i)), enals 294 and α,β-unsaturated aldimines 
295 were reacted using NHC pre-catalyst 296 to form 297 in high yield and excellent 
stereoselectivity,14 while ketenes 298 and α,β-unsaturated ketimines 299 were employed in 
Ye’s work to obtain 301 in comparable yield and enantioselectivity (Scheme 5.2(ii)).15 
 
Scheme 5.2: NHC-catalysed enantioselective synthesis of dihydropyridinones 
In addition to acyclic α,β-unsaturated ketimines, cyclic sulfonamide core structures, commonly 
derived from the corresponding artificial sweetener saccharin 302, have been used by 
synthetic chemists to access dihydropyridinones and their derivatives.16,17 It is widely found in 
many biologically active drug molecules, such as Ampiroxicam 303,18 an example of anti-
inflammatory agent (Fig. 5.2). Another biologically active drug molecule Ipsapirone 304,19 
recognized for its application as a neuroprotectants, also consists of the core cyclic 
sulfonamide structure. 
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Fig. 5.2: Saccharin and its derivatives 
5.2. Previous work in the Smith Group 
Along with N-heterocyclic carbene catalysis, the use of C1-ammonium enolates have been 
demonstrated for the enantioselective Michael addition/lactamization to access of 
dihydropyridinones with α,β-unsaturated ketimines 306 as Michael acceptors (Scheme 1.20).20 
The same Michael addition-lactamization strategy with isothiourea catalysis could also be 
applied in the synthesis of polycyclic dihydropyridinones. Starting with saccharin-derived α,β-
unsaturated ketimines 306 and aryl/heteroaryl acetic acids 305, after in situ activation with 
pivaloyl chloride and i-Pr2NEt, cyclic dihydropyridinones 308 could be obtained in high dr 
(>95:5 dr), good yield (up to 99%) and excellent enantioselectivity (>99:1 er) (Scheme 5.3).21 
 
Scheme 5.3: Isothiourea catalyzed enantioselective synthesis of tricyclic 
dihydropyridinones 
Following these strategies, this chapter describes the use of acylic α,β-unsaturated ketimines 
and saccharin-derived α,β-unsaturated ketimines in Michael addition-lactamization with 
pyrrolyl 155 or indolyl acetic acid 223 (Scheme 5.4). 
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Scheme 5.4: Proposed isothiourea-catalyzed Michael addition-lactamization 
5.3. Substrate preparations 
α,β-Unsaturated ketimines 323-336 were prepared from the corresponding substituted 
chalcones 309-322 via condensation with p-toluenesulfonamide in the presence titanium 
tetrachloride (1 equiv.) and triethylamine (2 equiv.) (Scheme 5.5).20 Following 
chromatographic purification, ketimines were obtained in a range of yields between 41% to 
86% as bench stable solids. 1H NMR analysis of the isolated ketimine 323 indicated the 
presence of a single ketimine (E)-isomer, with proton chemical shifts showing a good 
correlation with the literature values.20 Considering the large C=N bond isomerization barrier 
of ca. 109 kJ/mol, the isomerization to another imine configuration was unlikely at room 
temperature.22 
 
Scheme 5.5: Preparation of α,β-unsaturated ketimines 
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Saccharin-derived Michael acceptors 339-343 were synthesized from saccharin via a two-step 
literature procedure,21 and was carried out by summer placement student Lucas Bacheley. 
Grignard addition between saccharin and MeMgBr afforded the intermediate imine 337 in 46% 
isolated yield. Subsequent aldol condensation between imine 337 and benzaldehyde 
derivatives gave the corresponding α,β-unsaturated ketimines 339-343 in good yield (up to 
67%) (Scheme 5.6). 
 
Scheme 5.6: Synthesis of saccharin-derived Michael acceptors 
5.4. Acyclic α,β-unsaturated ketimines as Michael acceptors 
5.4.1. Reaction conditions optimization 
Investigation began with using 2-pyrrolyl acetic acid 155 and acyclic α,β-unsaturated ketimine 
323 in the Michael addition-lactamization sequence (Table 5.1). Optimization studies used 
(2S,3R)-HyperBTM 93, as this catalyst had been found to be optimal for the reactions described 
in Chapter 3. Started with using DMF as the solvent at room temperature, the 
dihydropyridinone 344 could be furnished in 54% yield, excellent dr of 95:5 and moderate er 
of 78:22 (entry 1). Changing the solvent to THF led to a reduced isolated yield 35% after 72 h 
due to incomplete consumption of starting material as shown by 1H NMR analysis of the crude 
reaction mixture. 344 was isolated as a single diastereoisomer with moderate 68:32 er (entry 
2). Conducting the reaction in CH2Cl2 resulted in comparable er (79:21) to using DMF, but a 
low yield of 40% was obtained (entry 3). Switching to other ethereal solvents, such as CPME 
and MTBE did not show any improvements in the er and yield compared with entry 1-3, with 
MTBE showing only trace product formation (<5%) (entry 4-5). Using two equivalents of 
pyrrolyl acetic acid 155 led to a higher isolated yield in EtOAc, with the desired 
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dihydropyridinone 344 isolated in 85% yield and 77:23 er (entry 6). A slightly improved er of 
82:18 was observed using i-PrOAc as solvent, albeit with a lower isolated yield of 65% (entry 
7). Finally, the use of MeCN was found to be the optimal solvent, giving a balance between a 
high isolated yield (90%) and er (76:24) (entry 8). Unfortunately, the use of other isothiourea 
catalysts, such as (S)-tetramisole 70 or (S)-benzotetramisole 146, provided the 
dihydropyridinone 344 in lower yields (55% and 40%) and reduced enantioselectivity (62:38 
er) (entry 9-10). Without catalyst, no background reaction was observed in MeCN (entry 11). 
The er values reported here for Table 5.1 were obtained from HPLC traces of 344 prepared 
from a mixture of MeCN and isopropyl alcohol, making sure that all the material was fully 
dissolved. It was serendipitously observed that when preparing 344 from entry 8 in only 
isopropyl alcohol for HPLC analysis, a cloudy mixture was obtained, and the HPLC traces of the 
filtrate after removing the insoluble material revealed a manual enhancement of the er from 
76:24 to 97:3 (3S,4S:3R,4R). HPLC analysis of the insoluble material revealed a reduced er of 
45:55 (3S,4S:3R,4R). This process can be used to enhance product er but does not reflect the 
real er from the reaction mixture.  
 
Entry Solvent (conc.) Time/ h dra Yieldb erc 
1 DMF (0.1 M) 24 >95:5 54% 78:22 
2 THF (0.1 M) 72 >95:5 35% 68:32 
3 CH2Cl2 (0.1 M) 72 >95:5 40% 79:21 
4 CPME (0.1 M) 72 >95:5 44% 69:31 
5 MTBE (0.1 M) 72 n/d. <5% n/d. 
6d EtOAc (0.1 M) 72 >95:5 85% 77:23 
7d Isopropyl acetate (0.1 M) 72 >95:5 65% 82:18 
8d MeCN (0.05 M) 72 >95:5 90% 76:24e 
9f MeCN (0.05 M) 72 >95:5 55% 62:38 (ent.) 
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10g MeCN (0.05 M) 72 >95:5 40% 62:38 (ent.) 
11h MeCN (0.05 M) 72 n/d. <5% n/d. 
a. dr determined from 1H NMR analysis of crude reaction mixture. b. Isolated yield.c. er determined from 
HPLC analysis in ratio of (3S,4S):(3R,4R). d. 2.0 equivalents acid 155 used. e. 97:3 er obtained after preparing 
the HPLC samples in isopropyl alcohol. f. Reaction with catalyst 70 (10 mol%). g. Reaction with catalyst 146 
(10 mol%). h. Reaction without catalyst 93. CPME = cyclopentyl methyl ether, MTBE = methyl tert-butyl ether. 
Table 5.1: Solvent and catalyst optimization 
Screening of other reaction parameters, such as the reaction temperature and the order of 
addition, were performed next (Table 5.2). To remove the effect of moisture in the reaction 
system, the reaction was carried out under strictly anhydrous conditions with freshly distilled 
MeCN instead of using commercially available dry MeCN. In this case, dihydropyridinone 344 
was obtained in similar yield (92%) and er (78:22) (entry 1). Adding molecular sieves did not 
lead to an improvement in er, and the yield dropped slightly to 80% (entry 2). Lowering the 
reaction temperature to 0 °C resulted in a slightly increased er of 80:20, but a 96 h reaction 
time was required to obtain 344 in 85% yield (entry 3). Further improvements in the er to 
86:14 could be achieved with the reaction temperature decreased to −40 °C, however only 
50% isolated yield of 344 was obtained, with the low solubility of ketimine 323 at −40 °C 
potentially contributing to this low yield (entry 4). Dropwise addition of a premixed solution 
of ketimine 323 and HyperBTM 93 in THF (due to solubility) to a solution of the pre-formed 
mixed anhydride in MeCN (from 2-pyrrolyl acetic acid 155 and t-BuCOCl) at room temperature 
resulted in a higher isolated yield of 74%, but the er was still remained moderate (74:26) (entry 
5). 
 
Entry Temp. Time/ h Yielda drb erc 
1d rt 72 92% >95:5 78:22 
2d,e rt 72 80% >95:5 75:25 
3d 0 °C 96 85% >95:5 80:20 
4d −40 °C 100 50% >95:5 86:14 
5d,f rt 72 74% >95:5 74:26 
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a. Isolated yield. b. dr determined from 1H NMR analysis of crude reaction mixture.c. er determined from 
HPLC analysis in ratio of (3S,4S):(3R,4R). d. Reaction with MeCN freshly distilled from CaH2.e. Reaction with 
4Å molecular sieves. f. Pre-formed solution of ketimine 323 and HyperBTM 93 in dry THF added dropwise to a 
mixture of acid 155, t-BuCOCl and i-Pr2NEt in MeCN. 
Table 5.2: Optimization on reaction conditions 
5.4.2. Scope analysis 
With the optimized condition (Table 5.2, entry 1) in hand, subsequent studies focused on 
probing the generality of the Michael addition-lactamization process by initially varying the β-
aryl substituent within the ketimine substrate (Scheme 5.7). Under the developed reaction 
conditions, inductively electron withdrawing 4-Cl and 4-F substituents at the 4-position of the 
β-aryl ring were readily accommodated, afforded products 345 and 346 in good to excellent 
yield (95% and 60%), >95:5 dr and moderate er (83:17 and 76:24 respectively). An electron 
donating 4-OMe substituent was also tolerated, giving 347 as a single diastereoisomer in 67% 
yield with moderate enantioselectivity (77:23 er). The process also accommodated bulky β-
substituents, with 2-naphthyl, 1-naphthyl and biphenyl substituents giving products 348-350 
in up to 83% yield, consistently high dr (>95:5) and 78:22 to 85:15 er. The incorporation of an 
alkenyl substituent was not well tolerated, resulting in low isolated 40% yield due to the 
generation of several unidentified side products, as well as reduced dr (70:30) and er (66:34). 
Notably, ketimines substrates bearing strongly electron withdrawing 4-NO2 and 4-CF3 groups 
showed no formation of the desired Michael addition-lactamization product, with a complex 
mixture observed instead. 
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a. Combined yield of inseparable mixture of diastereoisomers. b. Isolated yield of >95:5 dr unless stated 
otherwise. dr was determined from 1H NMR of crude reaction mixture. er was determined from chiral HPLC. 
Scheme 5.7: Scope on varying the β-aryl substituents of the unsaturated ketiminesb 
Variation of the C(1) substituent within the α,β-unsaturated ketimine was also explored 
(Scheme 5.8). Electron-withdrawing halogen substituents at the 3- or 4-position in the C(1) 
aryl ring of the α,β-unsaturated ketimine were tolerated, giving 352 to 355 in good yields of 
up to 96% and up to 80:20 er. Incorporating electron donating 4-Me and 4-OMe substituents 
gave comparable results (60%-70% yields), >95:5 dr with again moderate er (75:25 and 72:28 
respectively). 
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Isolated yield of >95:5 dr unless stated otherwise. dr was determined from 1H NMR of crude reaction mixture. 
er was determined from chiral HPLC. 
Scheme 5.8: Scope on varying the C(1) substituents of the unsaturated ketimines 
Due to a general moderate level of enantioselectivity observed, the dihydropyridinone 
products were not derivatized further. The use of the cyclic saccharin-derived Michael 
acceptors was next investigated. 
5.5. Synthesis of dihydropyridinones using saccharin-derived ketimines 
5.5.1. Reaction optimization with 2-pyrrolyl acetic acid 
Initial experiments started with 1 equivalent of pyrrolyl acetic acid 155 and saccharin-derived 
α,β-unsaturated ketimine 339 at room temperature in DMF using DHPB 114 as the isothiourea 
catalyst. However, instead of isolating the Michael addition-lactamization product 358, the 
unexpected elimination of the pyrrole group was observed during the course of the reaction, 
leading to the isolation of pyridone 360 as the only product in 73% yield (Table 5.3, entry 1). 
Formation of this unexpected side-product may be explained by deprotonation of the second 
acidic proton at C(9) in dihydropyridinone 358, followed by elimination of pyrrole. Assuming 
the formation of trans-dihydropyridinone 358 with high diastereoselectivity, the syn- 
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relationship between the proton at C(9) and the eliminated pyrrole group indicated that the 
E1cB elimination pathway was the dominant mechanism.23 However, the existence of an 
epimerization at C(8) followed by E2 elimination could not be ruled out. Conducting the 
reaction in either dichloromethane or MeCN at room temperature using HyperBTM also led 
to the elimination product 360 being obtained in 40% and 65% yield respectively (entry 2-3). 
 
Entry Catalyst Solvent Yield of 360a 
1 144 DMF 73% 
2b 93 CH2Cl2 40% 
3b 93 MeCN 65% 
a. Isolated yield after column chromatography. b. With 2.0 equivalents of acid 155 and 0.05 M solvent. 
Table 5.3: Initial condition screenings 
The reaction was next performed at low temperature, as an alternative method to prevent 
elimination (Table 5.4). Performing the transformation in CH2Cl2 at −78 °C gave no conversion 
of the starting material while at −40 °C an unidentified complex mixture was observed (entry 
1-2). Switching the solvent to MeCN at −40 °C resulted in the isolation of the desired 
dihydropyridinone 358 in 44% yield within 72 hours, with excellent dr (>98:2) and er (99:1) 
(entry 3), with no elimination product 360 detected. An improvement in the isolated yield to 
70% after 48 hours was observed when the temperature was raised to −20 °C, with no erosion 
in enantio- and diastereoselectivity (>98:2 dr, 99:1 er) (entry 4). 
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Entry Solvent Temp./ °C Time/ h Yielda drb erc 
1 CH2Cl2 –78 24 0% n/a n/a 
2 CH2Cl2 –40 24 complex mixture n/a n/a 
3 MeCN –40 72 44% >98:2 99:1 
4 MeCN –20 48 70% >98:2 99:1 
a. Isolated yield. b. dr determined from 1H NMR of crude reaction mixture. c. er determined from HPLC 
analysis of isolated 358 (>95:5 dr). 
Table 5.4: Optimization on reaction temperatures with different solvents 
5.5.2. Substrate scope with 2-pyrrolyl acetic acid 
The scope of this transformation was next explored under the optimized condition (Scheme 
5.9). In general, changing the substituents on the β-aryl ring of saccharin derived α,β-
unsaturated ketimine to 4-Br, 4-OMe, 1-naphthyl or 2-furyl was well tolerated, and the 
corresponding dihydropyridinone 361-364 was afforded in 52-97% yield with consistently high 
dr (>95:5) and er (96:4 to 99:1). 
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Yield referred to isolated yield of >95:5 dr. dr was determined from 1H NMR analysis of crude reaction 
mixture. er was determined from chiral HPLC. 
Scheme 5.9: Substrate scope with 2-pyrrolyl acetic acid 
Single crystal x-ray analysis was performed on the major diastereoisomer of 362 (Fig. 5.3),24 
allowing the relative and absolute stereochemistry for the major diastereoisomer to be 
assigned as (8S,9S), with the stereochemistry of all other dihydropyridinones assigned by 
analogy. 
 
Fig. 5.3: Single crystal of 362 
5.5.3. Substrate scope with 2-indolyl acetic acid 
In collaboration with Lucas Bacheley, a summer placement student from France, the scope of 
this Michael addition-lactamization was explored further by employing 2-indolyl acetic acid 
223. Interestingly, in this case the use of either MeCN or CH2Cl2 as a solvent provided the 
expected dihydropyridinones at low temperature in a yield ranging from 26% to 77% (Scheme 
5.10). When using MeCN as solvent at –40 °C, dihydropyridinone 365 was obtained in 77% 
yield within 2 h, whilst a lower 48% yield was obtained in CH2Cl2 at –78 °C within 4 h. Both 
sets of reaction conditions gave 365 with excellent enantioselectivity (99:1 er) and high 
diastereoselectivity (>95:5 dr). Saccharin derived α,β-unsaturated ketimine with an electron-
withdrawing 4-Br substituent in the β-aryl ring was tested under both sets of reaction 
conditions (MeCN at – 40 °C and CH2Cl2 at –78 °C), with the former condition gave 366 in a 
low yield of 26% while the latter condition gave 366 in a moderate yield of 39%. Excellent dr 
(>95:5) and er (97:3 and 99:1 respectively) for 366 was observed. The reduced yield was 
ascribed to the observed formation (via 1H NMR analysis of the crude reaction mixture) of the 
corresponding indole elimination product after 48 h reaction time although this could not be 
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readily isolated. The incorporation of an electron-donating 4-OMe β-aryl resulted in the 
isolation of 367 in good yield in both MeCN and CH2Cl2 (62% and 60% respectively) with high 
dr (>95:5) and excellent er (95:5 and 96:4). With a 2-furyl substituent, dihydropyridinone 368 
was isolated in excellent dr and er (>95:5 dr, >99:1 er) using both MeCN (76% yield) and CH2Cl2 
(56% yield). Unfortunately, unlike the reaction with 2-pyrrolyl acetic acid 223, the 
incorporation of a 1-naphthyl group at the β- of the ketimine was not tolerated. In CH2Cl2, no 
conversion of the Michael acceptor into the corresponding dihydropyridinone 369 was 
observed by 1H NMR. In MeCN full conversion into 369 was observed but unfortunately 
attempted chromatographic purification was unsuccessful, potentially due to decomposition 
or elimination. In general, a shorter reaction time was required for the 2-indolyl system to 
prevent the indole elimination side reactivity which was not observed for 2-pyrrolyl system at 
low reaction temperatures. 
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a. Yield referred to isolated yield of >95:5 dr. dr was determined from 1H NMR analysis of crude reaction 
mixture. er was determined from chiral HPLC. b. Reaction after 48 h. 
Scheme 5.10: Substrate scope with 2-indolyl acetic acid (by Lucas Bacheley)a 
5.6. Exploring the elimination of pyrrole or indole to give pyridones  
The generality of the one-pot isothiourea-catalyzed Michael addition-
lactamization/elimination protocol as a new synthetic route towards fused pyridones was 
investigated. By repeating the Michael addition-lactamization protocol with 2-pyrrolyl acetic 
acid at room temperature, saccharin-derived Michael acceptors suggested the formation of 
the desired pyridones 370-372 upon 1H NMR analysis of the crude reaction mixture. 
Attempted chromatographic purification led to the decomposition of the product on the silica. 
Thus, a recrystallization was performed in Et2O/pentane solvent mixture, but resulted in very 
low isolated yields (between 15% and 20%) (Scheme 5.11), with 372 being isolated only using 
2-indolyl acetic acid 223. 
 
a. Isolation yield after recrystallization. b. Work by Lucas Bacheley with 1.5 eq. 2-indolyl acetic 223. 
Scheme 5.11: Formation of the elimination producta 
A control reaction was performed by taking the isolated dihydropyridinone 358 and treating 
with an excess of i-Pr2NEt in MeCN. The elimination product 360 could be obtained in 42% 
isolated yield (Scheme 5.12). A close examination of the 1H NMR spectra of the crude reaction 
product revealed the presence of the eliminated pyrrole group. This confirmed the previously 
proposed mechanistic explanation for the formation of 360 (Table 5.3), and potentially 
provided a more synthetically useful route to access the fused pyridone structure 360. 
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Scheme 5.12: Control experiment to obtain 360 
5.7. Conclusions 
In conclusion, this chapter has described the Michael addition-lactamization process between 
heterocyclic C1-ammonium enolate precursors, 2-pyrrolyl and 2-indolyl acetic acid, and α,β-
unsaturated ketimines to access core dihydropyridinone structural motifs enantioselectively. 
With chalcone-derived N-sulfonyl α,β-unsaturated ketimines as the Michael acceptors, yields 
of up to 96% were achieved under the optimized conditions with excellent diastereoselectivity 
(>95:5 dr) obtained in most cases (Scheme 5.13). Although several attempts have been made 
to improve the enantioselectivity, only moderate ers were obtained (between 62:38 to 85:15), 
possibly due to a base-mediated epimerization of the minor diastereoisomer into the minor 
enantiomer of the major diastereoisomer. 
 
Scheme 5.13: Synthesis of dihydropyridinones from chalcone derived ketimines 
Cyclic saccharin-derived α,β-unsaturated ketimine Michael acceptors were also demonstrated 
to be well tolerated in this process. The desired tricyclic dihydropyridinones could be obtained 
exclusively at low temperature with excellent diastereoselectivity and enantioselectivity (up 
to >95:5 dr and >99:1 er) using either 2-indolyl acetic acid 223 or 2-pyrrolyl acetic acid 155 
(Scheme 5.14). 
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Scheme 5.14: Isothiourea catalyzed enantioselective synthesis of tricyclic 
dihydropyridinones 
When the Michael addition reaction using saccharin-derived α,β-unsaturated ketimines was 
performed at room temperature, a facile elimination of the indole/pyrrole unit was observed 
to take place, allowing the isolation of a tricyclic pyridone. The relatively poor yields obtained 
were attributed to low chromatographic stability of the pyridone structure (Scheme 5.15). 
 
Scheme 5.15: Synthesis of tricyclic pyridone via elimination of pyrrole/indole 
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Chapter 6: One-pot synthesis of functionalized pyridines 
This chapter describes the unexpected discovery of a synthetic route to access 
tetrasubstituted pyridines. The initially generated anti-dihydropyridinone 375 from Michael 
addition-lactamization between 2-pyrrolyl 155 or 2-indolyl acetic acid 223 and α,β-
unsaturated ketimines, in the presence of pivaloyl chloride and i-Pr2NEt, is readily transformed 
in situ into tetrasubstituted pyridines 376 in up to 66% yield (Scheme 6.1). This unexpected 
result provides an one-pot organocatalytic protocol to access highly functionalized pyridine 
derivatives. 
 
Scheme 6.1: One-pot synthesis of functionalized pyridines 
6.1. Introduction 
Pyridines are generally recognized as a very important class of heterocycle that exist in the 
core of many drug molecules and agrochemical products (Figure 6.1).1–3 
 
Fig. 6.1: Biologically important molecules with core pyridine structures 
As a consequence, many synthetic methods have been developed to access these molecules 
efficiently.4 Historically, chemists used the condensation between carbonyl compounds and 
nitrogen containing molecules to obtain pyridines, including Hantzsch pyridine synthesis5 and 
Bohlmann-Rahtz pyridine synthesis (Scheme 6.2).6 
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Scheme 6.2: Examples of pyridine synthesis 
Besides condensation, cycloaddition chemistry is also recognized as an important strategy to 
construct pyridines. For example, the intramolecular hetero-Diels-Alder reaction between the 
electron rich azadiene and alkyne 377 afforded the intermediate 378, which following the 
elimination of MeOH provides pyridine 379 in good yield (Scheme 6.3).7 
 
Scheme 6.3: Cycloaddition in the synthesis of pyridine 
Pathways to pyridines involving the use of inverse electron demand hetero-Diels-Alder 
reaction followed by the release of nitrogen have also been developed. Using 1,2,4-triazine 
381 and a ketone 380, in the presence of a stoichiometric amount of pyrrolidine, the bicyclic 
intermediate 382 is generated. An entropy-favoured elimination of molecular nitrogen and 
pyrrolidine furnished the pyridine 383 in moderate to good yields (Scheme 6.4).8 
 
Scheme 6.4: Synthesis of pyridines via inverse electron demand Diels Alder 
With the growing interest in the area of catalysis, methods for the transition metal catalyzed 
synthesis of pyridines have been explored, including the ring-closing9–14 and cross 
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metathesis15,16 strategies developed by Donohoe. One representative example afforded 
pyridines 386 from saccharin-derived ketimines 384 and disubstituted alkynes 386 in excellent 
yields. An initial C-H activation and late-stage SO2 elimination was involved (Scheme 6.5).17 
 
Scheme 6.5: Transition metal catalyzed pyridine synthesis 
Highly substituted pyridines with 5 substituents have also been prepared by a formal 
dehydrative [4+2] cycloaddition using enamides 387 and alkynes 388 using Ru catalysis. The 
pentasubstituted pyridines could be isolated in excellent yields, with the scope of this process 
featuring a polycyclic and annulated examples (Scheme 6.6).18 
 
Scheme 6.6: Synthesis of pentasubstituted pyridines 
Apart from transition metal catalysis, organocatalytic approaches were also reported. In 2015, 
Lee developed an organocatalytic protocol using iminium ion catalysis. Condensation between 
enals 391 and catalytic proline 26 generates the iminium ion 393 which is then attacked by 
390 to afford the pyridines 392 in good to excellent yields (Scheme 6.7).19 
 
Scheme 6.7: Proline-catalyzed one-pot synthesis of pyridines 
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6.2. Previous work in the Smith Group 
N-Heterocycles have been prepared previously in the Smith group using isothiourea-catalyzed 
Michael addition-lactamization protocols. As previously described in Chapter 5, the synthesis 
of anti-dihydropyridinone was reported using aryl acetic acids and chalcone derived 
ketimines.20 Following this success, the scope of applicable Michael acceptors was expanded 
to β-ester/β-CF3 substituted α,β-unsaturated ketimines.21,22 When using aryl acetic acids as the 
C1-ammonium enolate precursors, dihydropyridinone products were isolated as the major 
product in each case.22 However, by switching to thiophenyl acetic acid 113 as the C1-
ammonium enolate precursor, pyridine products 395 were obtained in good to excellent yields 
with β-ester/β-CF3 substituted α,β-unsaturated ketimines (Scheme 6.8). It was proposed that 
following the Michael addition-lactamisation process to dihydropyridinone 396, elimination of 
PhSH affords pyridinone 397, which proceeded through a thermally promoted N- to O- sulfonyl 
migration to give the final pyridine product.21 
 
Scheme 6.8: Isothiourea catalysed one-pot synthesis of pyridines 
The method was later extended to provide access to tetrasubstituted pyridines, in a three-step 
procedure by employing α-ester-α,β-unsaturated ketimines as the Michael acceptors and α,α-
disubstituted (phenylthio)acetic acids as the C1-ammonium enolate precursors. The initially 
formed dihydropyridinone 400 was oxidized using m-CPBA to give the corresponding sulfoxide, 
which underwent spontaneous elimination (via E1 pathway) upon warming to room 
temperature.23,24 Subsequent thermally promoted N- to O- sulfonyl transfer was used to afford 
the desired functionalized pyridines 401 in moderate to good yields (Scheme 6.9).25 
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Scheme 6.9: Isothiourea catalyzed three-stage synthesis of tetrasubstituted pyridines 
During the investigation of using 2-pyrrolyl acetic acid 155 and β-ester substituted α,β-
unsaturated ketimine to synthesize 3,4-dihydropyridinones via Michael addition-lactamization, 
an unexpected pyridine formation was discovered. The observation of a sulfinic acid 
elimination, instead of a pyrrole elimination and N- to O- sulfonyl transfer, was significantly 
different to the previous work in the Smith group. 
6.3. Proof of concept study 
6.3.1. β-Ester-α,β-unsaturated N-tosyl ketimine 
Initial reactivity tests began with 2-pyrrolyl acetic acid 155 and N-tosyl protected β-ester-α,β-
unsaturated ketimine 402 with DHPB 114 as the catalyst. In either DMF or MeCN solvent at 
room temperature, full consumption of the ketimine 402 was observed within 72 h by 1H NMR 
analysis. Purification gave an inseparable 2:1 mixture of the 2-OPiv pyridine 403 and the 
dimerized sulfonyl species 404 (Scheme 6.10). The structure of 404 was assigned by direct 
comparison to the literature.26 
 
Scheme 6.10: Initial observation with ketimine xx and 2-pyrrolyl acetic acid 155 
The pyridine 403 was proposed to be generated from the corresponding 3,4-
dihydropyridinone 405 (Scheme 6.11) via an ionic pathway. Following Michael addition-
lactamization, deprotonation at C(4), promoted by delocalization of the resulting anion onto 
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the adjacent ester carbonyl, generated enolate 406. Sulfinate elimination (E1cb) led to the 
formation of 408. Subsequent deprotonation of the most acidic proton at C(3) of 408 gave 
hydroxypyridine 409 that was acylated with unreacted t-BuCOCl or (t-BuCO)2O to form the 
final tetrasubstituted pyridine 403. The eliminated sulfinate 407 was presumably oxidized by 
air to afford a sulfonyl radical 411 that dimerized readily to form the byproduct 404.26–29 
 
Scheme 6.11: Proposed mechanistic formation of pyridine 403 and 404 
6.3.2. α-Imino-β,γ-unsaturated ester 
One of the α-keto-β,γ-unsaturated ester substrates used in Chapter 4, was next converted to 
the corresponding N-tosyl ketimine 412 using a literature protocol with TsNH2, NEt3 and TiCl4.21 
Applying the ketimine derivative 412 in the catalytic reaction using DHPB 114 (10 mol%) at 
room temperature in MeCN gave a 1:1 mixture of 2-OPiv pyridine 413 and the 5,6-
dihydropyridinone 414 (Table 6.1, entry 1). Raising the temperature to 60 °C in MeCN 
afforded the pyridine 414 in 42% yield within 4 hours, giving an improved product ratio of 
65:35 (entry 2). Switching the solvent to EtOAc, isopropyl acetate or THF, and conducting the 
reaction at elevated temperature of 60 °C (entry 3-5) gave preferential formation of 5,6-
dihydropyridinone 414 rather than the desired 2-OPiv pyridine 413. 
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1 MeCN rt. 72 44:56 38% 
2 MeCN 60 °C 4 65:35 42% 
3 EtOAc 60 °C 16 22:78 n/d 
4 Isopropyl acetate 60 °C 16 17:83 n/d 
5 THF 60 °C 16 30:70 n/d 
a. Ratio determined from 1H NMR analysis of crude material. b. Isolation yield 
Table 6.1: Screening of solvents and temperatures 
The isomerized 5,6-dihydropyridinone 414 (Scheme 6.12) presumably arises from initially 
formed 3,4-dihydropyridinone 415, with deprotonation at C(4) giving enolate 416. Subsequent 
α-protonation, followed by tautomerization, affords 5,6-dihydropyridinone 414. 
 
Scheme 6.12: Proposed mechanistic pathways for the isomerization 
Conceivably 5,6-dihydropyridinone 414 could also be transformed into the final pyridine 
product 413 through an E1cb elimination of the sulfinic acid followed by tautomerization 
(Scheme 6.13). Therefore, depending on whether this pathway is operative under the reaction 
conditions would determine if 5,6-dihydropyridinone 414 should be considered as a reaction 
side-product, or an intermediate on the way to forming the final pyridine product 413. 
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Scheme 6.13: Proposed formation of pyridine 413 from 5,6-dihydropyridinone 414 
A control reaction was therefore performed by treating the isolated 414 with i-Pr2NEt, DHPB 
(10 mol%) and t-BuCOCl in MeCN at 60 °C. Less than 5% conversion to pyridine 413 was 
determined by 1H NMR analysis of the crude mixture, with more than 95% starting material 
being observed (Scheme 6.14a). This suggested that 5,6-dihydropyridinone 414 was a side 
product that could not be transformed into pyridine 413 under the standard reaction 
conditions. With a stronger base DBU (pKaH ~ 13.5 in H2O, cf. 10.9 for i-Pr2NEt in H2O), the final 
pyridine 413 could be isolated in 69% yield (Scheme 6.14b). This confirmed that DBU could 
effectively ‘switch on’ the pathway detailed in Scheme 6.13. It was then hypothesized that if 
DBU was used as the base in the catalytic reaction, more efficient access to the pyridine 413 
could be achieved, by promoting conversion of 5,6-dihydropyridinone 414 to pyridine 413. 
 
Scheme 6.14: Control reactions in product transformation 
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To test this hypothesis, using DBU in place of i-Pr2NEt led to an improved isolated yield of 52% 
for pyridine 413 (Scheme 6.15), with no 5,6-dihydropyridinone 414 detected by 1H NMR 
analysis. 
 
Scheme 6.15: DBU mediated pyridine synthesis 
As both the purification (α-imino group slowly hydrolysed under chromatographic conditions) 
and handling of the α-imino-β,γ-unsaturated ester 412 (a highly viscous yellow oil) was difficult, 
not all the “mass” of the substrate added was “pure” ketimine. Therefore, the calculated 
isolated yields underestimated the likely true yield of the reactions, and a better substrate, 
such as a bench-stable solid, was needed. 
6.3.3. Unsaturated ketimines with alternative N-sulfonyl substituents 
Different N-protected ketimines were synthesized from the corresponding sulfonamides 
(Scheme 6.16). Based on the proposed mechanism of pyridine formation (Scheme 6.13), it was 
rationalized that N-sulfonyl substituents bearing electron-withdrawing groups would be 
optimal to promote elimination of the sulfinic acid. Both 4-CF3 and 4-NO2 
benzenesulfonamides were subjected to the reaction conditions. However, with 4-CF3 
benzenesulfonamide, a full consumption of the α-keto-β,γ-unsaturated ester 132 into an 
unidentified complex mixture was observed, while no conversion of α-keto-β,γ-unsaturated 
ester 132 was observed with 4-NO2 benzenesulfonamide. Changing to electron-rich 2,4,6-
triisopropylbenzenesulfonamide (TIPBS) under the reaction conditions with α-keto-β,γ-
unsaturated ester 132 successfully afforded the α-imino-β,γ-unsaturated ester 424 in 75% 
yield after recrystallisation as a white crystalline solid. Meanwhile, β-ester-α,β-unsaturated 
ketimine 421 was synthesized from TIPBS and β-ester-α,β-unsaturated ketone 425 in 62% yield 
after recrystallisation as a white crystalline solid. 
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Scheme 6.16: Synthesis of unsaturated ketimines bearing different N- substituents 
Using ketimine 424 with 2 equivalents t-BuCOCl, 10 mol% DHPB and 4.5 equivalents i-Pr2NEt 
in DMF (0.1 M) at 60 °C, gave the pyridine 413 in 66% yield (Table 6.2) with no 5,6-
dihydropyridinone 426 detected in the crude reaction mixture. Switching the base from i-
Pr2NEt (4.5 eq.) to DBU (4.5 eq.) did not improve the isolated yield of pyridine 413 (50%) (entry 
1). Switching the solvent from DMF to either MeCN or THF at elevated temperature did not 
show improvements in the isolated yield (entry 2-3). Increasing the amount of activating agent 
t-BuCOCl from 2.0 eq. to 3.0 eq. afforded pyridine 413 only in 45% NMR yield (entry 3). 
 
Entry Variation from standard conditions Isolated yield / (NMR yielda) 
1 DBU (2.0 + 2.5 eq.) 50% / (-) 
2 THF (0.1 M), 60 °C, 18 h 30% / (-) 
3 MeCN (0.1 M), 50 °C, 18 h 43% / (-) 
4 t-BuCOCl (3 eq.), 50 °C, 24 h -/ 45% 
a. Calculated from crude 1H NMR of reaction mixture using 1,4-dinitrobenzene as the internal standard. 
Table 6.2: Optimizations with N-TIPBS ketimine 424 
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These conditions were used with β-ester-α,β-unsaturated ketimine 425, giving the pyridine 
403 in 64% isolated yield in MeCN, compared to 40% yield with DMF as the solvent (Scheme 
6.17). 
 
Scheme 6.17: Optimized conditions with β-ester-α,β-unsaturated ketimine 425 
6.4. Substrate scope of pyridine synthesis 
6.4.1. Scope study with β-ester-α,β-unsaturated ketimines 
With the established optimized conditions, the scope of this process was explored by varying 
the C(1) aryl ring on the β-ester-α,β-unsaturated ketimines (Scheme 6.18). With 2-pyrrolyl and 
2-indolyl acetic acid, C(1)-Phenyl substituted ketimine afforded the pyridines 403 and 427 in 
64% and 54% isolated yield respectively. Ketimines with electron-donating 4-OMe or 4-Me 
substituent on C(1) aryl ring were tolerated, afforded the corresponding pyridines 428 and 429 
in 38% and 58% yield with 2-pyrrolyl acetic acid. Installing electron-withdrawing 4-Cl group on 
C(1) aryl ring of the ketimine afforded the pyridine 430 in 62% yield with 2-pyrrolyl acetic acid. 
2-F substituted C(1) aryl ketimine was also tolerated, giving the corresponding pyridine 431 in 
similar 47% yield with 2-pyrrolyl acetic acid. 
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Scheme 6.18: Scope with β-ester-α,β-unsaturated ketimines 
An X-ray crystal structure was obtained for 403,30 despite the t-Bu group being disordered. This 
data provides confirmation of the products connectivity, demonstrating that the pivalate 
group is attached to oxygen, and not nitrogen (Fig. 6.2). 
 
Fig. 6.2: Crystal structure of 403 
6.4.2. Scope with α-imino-β,γ-unsaturated esters 
The scope was studied further with α-imino-β,γ-unsaturated esters (Scheme 6.19). Using both 
2-pyrrolyl and 2-indolyl acetic acids with γ-Ph-substituted imino ester, the corresponding 
pyridines 413 and 432 could be isolated in good yields of 66% and 47% respectively. An 
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electron-donating 4-Me substituent on the γ-aryl ring of imino ester was well tolerated, giving 
pyridine 433 in 59% yield with 2-pyrrolyl acetic acid while the pyridine product from 2-indolyl 
acetic acid could not be separated from the crude reaction mixture. Incorporation of a 
heteroaryl (2-furyl) group on the γ position of the imino ester resulted in pyridine 434 being 
isolated in 53% yield with 2-pyrrolyl acetic acid, however a complex mixture of starting 
material and several other species were identified by 1H NMR with 2-indolyl acetic acid and 
this was not pursued further. Finally, when a γ-alkenyl substituted imino ester was tested 
under the reactions, similar yields for pyridines 435 and 436 were obtained with both acids 
(57% and 55%). 
  
Scheme 6.19: Scope with α-imino-β,γ-unsaturated esters 
A crystal structure was also obtained for pyridine 413, providing further confirmation of the 
identity and connectivity present within these pyridine products (Fig. 6.3). 
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Fig. 6.3: Crystal structure of 413 
6.5. Product derivatization 
Initially, it was envisioned that, by selecting an appropriate transition metal catalyst, the 2-
pivaloyloxy pyridine could be directly functionalized via Suzuki-Miyaura cross coupling.31 
Following a literature procedure using NiCl2(PCy3)2 and phenyl boronic acid to functionalize 
aryl pivalates,32 the same catalytic system was tested with 2-pivalate pyridine 413. 
Unfortunately, only starting material was recovered and no cross-coupling product 437 was 
isolated (Scheme 6.20). 
 
Scheme 6.20: Attempts on cross coupling 
Since no other reported literature was found on the cross-coupling with a pivalate installed on 
the 2-position of the pyridine, attention turned to hydrolyzing the pivalate and transforming it 
into another leaving group suitable for the cross coupling. Inspired by literature 
procedures,33,34 the use of Lewis acids CuBr2 and AgOAc in the presence of a nucleophile was 
investigated (Scheme 6.21). Unfortunately, based on the inspection of the 1H NMR of the crude 
mixture, a complex mixture was identified with full consumption of starting pyridine 413. 
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Scheme 6.21: Attempts at hydrolysis of 413 
With the hydrolysis of 413 proving unsuccessful, nucleophilic aromatic substitution (SNAr) with 
morpholine was attempted as an alternative way to functionalize the pyridine.21 Using 10 
equivalents of morpholine as the nucleophile and NEt3 as the base in toluene, heating at reflux 
for 16 hours provided none of the expected SNAr product 440. Instead, the hydrolysis product, 
2-hydroxypyridine 439, was isolated in 58% yield (Scheme 6.22a), and the by-product N-
pivaloyl morpholine was detected by analyzing the 1H NMR of the crude reaction mixture. In 
the absence of morpholine, no conversion of 403 to the corresponding 2-hydroxypyridine 439 
was detected, consistent with morpholine acting as a nucleophile to remove the pivalate. 
Other nucleophiles, such as MeOH, returned only the starting material 403. The structure of 
439 was tentatively assigned to be the 2-hydroxypyridine rather than its 2-pyridone tautomer, 
as in solution only small energy differences between the two tautomers is excected (8.83 
kJ/mol, measured by IR spectroscopy).35,36 When pyridine 413, bearing the ester group at the 
C(6) position, was applied under the same conditions, hydrolysis and amidation of the C(6) 
ester was observed, giving amide 441 in 51% yield (Scheme 6.22b). The absence of SNAr 
product suggested that the pivalate carbonyl was relatively more electrophilic than the C(2) 
position on the pyridine. 
 
Scheme 6.22: Hydrolysis products from attempted SNAr reactions 
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After obtaining 2-hydroxypyridine 439, it was transformed into the 2-tosyl-pyridine 442, to 
investigate if the OTs group could be used for further derivatization (Scheme 6.23). Initially an 
attempted SNAr reaction with 2-OTs pyridine 442 and morpholine afforded a mixture of 
starting material and other products,37 with none of the desired product 440 able to be 
isolated. Mizoroki–Heck reaction using N-vinyl-acetamide 443 was next tested,38 however 
under these conditions none of the cross-coupling product 444 was observed, with only 
trisubstituted pyridine 445 and starting material 442 being isolated. Next, reduction of the 2-
OTs group was attempted using Pd(OAc)2 and formic acid.39 Trisubstituted pyridine 445 was 
isolated in 78% yield after 1 h. The success of this reduction indicated that the oxidative 
addition of Pd into 2-OTs group was happening, which was potentially useful for other 
derivatizations. Finally, Kumada cross-coupling40 using 4-methoxyphenylmagnesium bromide 
afforded the corresponding coupling product 446 in 20% yield, with the major side-product 
447, arising from addition of the Grignard reagent to the methyl ester, isolated in 54% yield. 
 
Scheme 6.23: Derivatization study 
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6.6. Conclusions 
In conclusion, a one-pot synthesis of tetrasubstituted pyridines has been developed. Using 
either 2-pyrrolyl or 2-indolyl acetic acid with N-TIPBS derived unsaturated ketimines 448 in 
MeCN or DMF at elevated temperature (50-60 °C), a range of 2-pivaloyloxy pyridines 449 were 
isolated in 30-66% yield (Scheme 6.24). The 2-pivaloyloxy substituent proved unreactive in 
model cross-coupling reactions, so attempts were made to deprotect the pivalate group. A 
two-step process with morpholine/TsCl afforded the corresponding 2-OTs pyridine 442. Cross-
coupling reactions and a reduction were tested, with Kumada coupling giving the coupling 
product in 20% yield, and Pd-catalysed reduction using formic acid affording the trisubstituted 
pyridine 445 in 78% yield. 
 
Scheme 6.24: One-pot synthesis of pyridines 
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Chapter 7: Conclusions and future work 
To conclude this thesis, N-substituted C(1)-ammonium enolate precursors, especially 2-
pyrrolyl and 2-indolyl acetic acid, have been successfully applied in isothiourea-catalyzed 
Michael addition-lactonization/lactamizations with a wide variety of Michael acceptors. 
Importantly, the installation of this N-linked substituents serves as a functional handle for 
further synthetic transformations. 
Firstly, the use of electron-deficient CCl3 Michael acceptors was demonstrated with 2-pyrrolyl 
acetic acid. Even through the intermediate 3,4-dihydropyranone generated as the catalysis 
product proved troublesome to purify due to chromatographic instability, in situ nucleophilic 
ring-opening facilitated the isolation of stable derivatives of this intermediate. CCl3 
displacement by nucleophiles allowed the isolation of stable ring-opening derivatives as a 
range of 30 diesters and diamides in up to 98% yield, >95:5 dr and >99:1 er. The substrate 
scope was examined by varying the β-substituent in CCl3 enone. Further demonstration of the 
synthetic utility of this ring-opening derivatives was achieved with an intramolecular Friedel-
Crafts acylation utilizing the electron-rich nature of pyrrole to afforded dihydroindolizinone 
derivatives in up to 90% yield with no erosion in stereoselectivity (Scheme 7.1). 
 
Scheme 7.1: Enantioselective Michael addition-lactonization with CCl3 Michael acceptors 
In the case of using either α,β-unsaturated trifluoromethyl ketones or α-keto-β,γ-unsaturated 
esters as the Michael acceptors, in situ nucleophilic ring-opening followed by spontaneous 
intramolecular cyclization with pyrrole afforded the corresponding tetrahydroindolizine 
derivatives in up to 98% yield, >95:5 dr and >99:1 er (Scheme 7.2). 
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Scheme 7.2: One-pot synthesis of enantioenriched tetrahydroindolizine derivatives 
Having shown that 2-pyrrolyl acetic acid is an effective C(1)-ammonium enolate precursor, its 
reaction with α,β-unsaturated ketimines was investigated next. With 2-pyrrolyl and 2-indolyl 
acetic acid, both chalcone-derived N-Ts ketimines and unsaturated cyclic sulfonamides derived 
from saccharin afforded a range of 23 chromatographic stable dihydropyridinones in up to 97% 
yield, >95:5 dr and >99:1 dr (Scheme 7.3).  
 
Scheme 7.3: Summary of isothiourea catalyzed synthesis of dihydropyridinones 
During the course of investigating a variety of α,β-unsaturated ketimines bearing esters, an 
unexpected elimination of the nitrogen-sulfonyl substituent was discovered, leading to the 
formation of tetrasubstituted pyridines in up to 66% yield with 2-indolyl and 2-pyrrolyl acetic 
acid (Scheme 7.4). Further derivatization via transforming the 2-pivaloyloxy group into 2-OTs 
group in a two-step process enabled Pd-catalyzed cross coupling and reduction. 
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Scheme 7.4: Synthesis of tetrasubstituted pyridines and further derivatization 
Inspired by the results outlined in this thesis, future work will likely focus on probing other 
heteroatom linked C(1)-ammonium enolate precursors, such as α-Si, O or B linked acids, with 
isothiourea catalysts and electron deficient Michael acceptors (Scheme 7.5). Further 
application of the methodologies described in the thesis to natural product synthesis will be 
investigated. 
 
Scheme 7.5: Overview of the future work envisaged in Si-linked C(1)-ammonium enolate 
precursors 
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Experimentals 
8.1. General Information 
Reactions involving moisture sensitive reagents were carried out in flame-dried glassware 
under an inert atmosphere (N2 or Ar) using standard vacuum line techniques. Anhydrous 
solvents (Et2O, CH2Cl2, THF and PhMe) were obtained after passing through an alumina column 
(Mbraun SPS-800). Petrol is defined as petroleum ether 40–60 °C. All other solvents and 
commercial reagents were used as received without further purification unless otherwise 
stated. 
Room temperature (rt) refers to 20–25 °C. Temperatures of 0 °C and –78 °C were obtained 
using ice/water and CO2 (s)/acetone baths, respectively. Temperatures of 0 °C to –78 °C for 
overnight reactions were obtained using an immersion cooler (HAAKE EK 90). Reaction 
involving heating were performed using DrySyn blocks and a contact thermocouple. 
Under reduced pressure refers to the use of either a Büchi Rotavapor R-200 with a Büchi V-
491 heating bath and Büchi V-800 vacuum controller, a Büchi Rotavapor R-210 with a Büchi V-
491 heating bath and Büchi V-850 vacuum controller, a Heidolph Laborota 4001 with vacuum 
controller, an IKA RV10 rotary evaporator with an IKA HB10 heating bath and ILMVAC vacuum 
controller, or an IKA RV10 rotary evaporator with a IKA HB10 heating bath and Vacuubrand 
CVC3000 vacuum controller. Rotary evaporator condensers are fitted to Julabo FL601 
Recirculating Coolers filled with ethylene glycol and set to –5 °C. 
Analytical thin layer chromatography was performed on pre-coated aluminium plates 
(Kieselgel 60 F254 silica) and visualisation was achieved using ultraviolet light (254 nm) and/or 
staining with aqueous KMnO4 solution followed by heating. Manual column chromatography 
was performed in glass columns fitted with porosity 3 sintered discs over Kieselgel 60 silica 
using the solvent system stated. 
Melting points were recorded on an Electrothermal 9100 melting point apparatus, (dec) refers 
to decomposition. 
Optical rotations were measured on a Perkin Elmer Precisely/Model-341 polarimeter 
operating at the sodium D line with a 100 mm path cell at 20 °C. 
Chapter 8: Experimentals 
Page | 136  
HPLC analyses were obtained on a Shimadzu HPLC consisting of a DGU-20A5 degassing unit, 
LC-20AT liquid chromatography pump, SIL-20AHT autosampler, CMB-20A communications bus 
module, SPD-M20A diode array detector and a CTO-20A column oven. Separation was 
achieved using either DAICEL CHIRALCEL OD-H and OJ-H columns or DAICEL CHIRALPAK AD-H, 
AS- H, IA and IB columns using the method stated. HPLC traces of enantiomerically enriched 
compounds were compared with authentic racemic spectra. 
Infrared spectra were recorded on a Shimadzu IRAffinity-1 Fourier transform IR 
spectrophotometer fitted with a Specac Quest ATR accessory (diamond puck). Spectra were 
recorded of either thin films or solids, with characteristic absorption wavenumbers (νmax ) 
reported in cm–1 . 
1H, 13C{1H}, 19F and 19F{1H} NMR spectra were acquired on either a Bruker AV300 with a BBFO 
probe (1H 300 MHz; 13C{1H} 75 MHz; 19F{1H} 282 MHz), a Bruker AV400 with a BBFO probe (1H 
400 MHz; 13C{1H} 101 MHz; 19F{1H} 377 MHz), a Bruker AVII 400 with a BBFO probe (1H 400 
MHz; 13C{1H} 101 MHz; 19F{1H} 376 MHz), a Bruker AVIII-HD 500 with a SmartProbe BBFO+ 
probe (1H 500 MHz; 13C{1 H} 126 MHz; 19F{1H} 470 MHz) or a Bruker AVIII 500 with a CryoProbe 
Prodigy BBO probe (1H 500 MHz; 13C{1H} 126 MHz; 19F 470 MHz) in the deuterated solvent 
stated. All chemical shifts are quoted in parts per million (ppm) relative to the residual solvent 
peak. All coupling constants, J, are quoted in Hz. Multiplicities are indicated as s (singlet), d 
(doublet), t (triplet), q (quartet), m (multiplet), and multiples thereof. The abbreviation Ar 
denotes aromatic and app denotes apparent. NMR peak assignments were confirmed using 
2D 1H correlated spectroscopy (COSY), 2D 1H-13C heteronuclear multiple-bond correlation 
spectroscopy (HMBC), and 2D 1H-13C heteronuclear single quantum coherence (HSQC) where 
necessary. 
Mass spectrometry (m/z) data were acquired by either electrospray ionisation (ESI), chemical 
ionisation (CI), electron impact (EI), atmospheric solids analysis probe (ASAP), atmospheric 
pressure chemical ionization (APCI) or nanospray ionisation (NSI) at either the University of St 
Andrews Mass Spectrometry Facility ([A] quoted) or at the EPSRC UK National Mass 
Spectrometry Facility at Swansea University ([A]+ or [A]– quoted). 
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8.2. Experimentals for Chapter 2 
8.2.1. General Procedures 
General procedure A: Synthesis of glycine-derived Schiff base esters 
 
To a round-bottom flask containing N-Boc glycine 127 (1.0 eq.), aromatic alcohol 450-451(1.0 
eq.), DCC (1.1 eq.) and DMAP (10 mol%) was added anhydrous CH2Cl2 (0.1 M) under Ar. The 
resulting mixture was stirred vigorously at room temperature for 24 h, before it was filtered 
through a Celite pad. The filtrate was collected, and HCl solution (2 M in Et2O, 4.0 eq.) was 
added to the filtrate. The mixture was stirred at rt. for further 4 hours. Solid 128 was collected 
through a sinter funnel and dried under vacuum. 
To a round-bottom flask charged with ammonium salt 129 from last step, anhydrous CH2Cl2 
(0.1 M) was added, followed by benzophenone imine 123 (1.0 eq.) under Ar. The mixture was 
allowed to stir vigorously at rt. for 24 h. Upon completion of the reaction, the mixture was 
filtered through a pad of Celite. The filtrate was collected and concentrated in vacuo. 
Purification via either trituration in Et2O or flash chromatography afforded the final product 
 
8.2.2. Substrate synthesis and characterization data 
4-Nitrophenyl 2-((diphenylmethylene)amino)acetate (121) 
 
Following general procedure A, N-Boc glycine 127 (2.63 g, 15 mmol, 1.0 eq.), 4-nitrophenol 
450 (2.09 g, 15 mmol, 1.0 eq.), DCC (3.41 g, 16.5 mmol, 1.1 eq), DMAP (183.3 mg, 1.5 mmol, 
Chapter 8: Experimentals 
Page | 138  
10 mol%) and benzophenone imine 123 (2.72 g, 15 mmol, 1.0 eq.) gave the titled compound 
121 (2.59 g, 48% yield over three-step), after trituration in Et2O, as white needles. mp 101-
103 °C; vmax (film, cm-1) 3076 (CH stretch), 1780 (ester C=O), 1624 (C=N), 1614 (C=C), 1522 (N-
O stretch); 1H NMR (400 MHz, CDCl3) δH: 4.49 (2H, s, CH2), 7.21–7.25 (2H, m, C(2)N=CArH), 
7.30–7.33 (2H, m, C(1)OArC(2,6)H), 7.35–7.39 (2H, m, C(2)N=CArH), 7.42–7.47 (1H, m, 
C(2)N=CArH), 7.50–7.54 (3H, m, C(2)N=CArH), 7.69–7.71 (2H, m, C(2)N=CArH), 8.25–8.29 (2H, 
m, C(1)OArC(3,5)H); 13C NMR (126 MHz, CDCl3) δC: 55.6 (CH2), 122.5 (C(1)OArC(2,6)H), 125.4 
(C(1)OArC(3,5)H), 127.7 (C(2)N=CArC), 128.4 (C(2)N=CArC), 129.0 (C(2)N=CArC), 129.1 
(C(2)N=CArC), 129.3 (C(2)N=CArC), 131.0 (C(2)N=CArC), 135.9 (C(2)N=CArC), 139.0 
(C(2)N=CArC), 145.5 (C(1)OArC(1)), 155.4 (C(1)OArC(4)), 168.4 (C(1)), 173.1 (C(2)N=C); HRMS 
(ESI+) C21H16O4N2Na [M+Na]+ found 383.0994, requires 383.1002 (-2.2 ppm). 
 
2,4,6-Trichlorophenyl 2-((diphenylmethylene)amino)acetate (122) 
 
Following general procedure A, N-Boc glycine (2.63 g, 15 mmol, 1.0 eq.), 2,4,6-trichlorophenol 
451 (2.96 g, 15 mmol, 1.0 eq.), DCC (3.41 g, 16.5 mmol, 1.1 eq.), DMAP (183.3 mg, 1.5 mmol, 
10 mol%) and benzophenone imine 123 (2.72 g, 15 mmol, 1.0 eq.) gave the titled compound 
122 (2.39 g, 38% yield over three-step), after flash column chromatography (10:90 
EtOAc:petrol, Rf 0.31), as white solids. mp. 79-83 °C; vmax (film, cm-1) 3080 (CH stretch), 1788 
(ester C=O), 1657 (C=N), 1624 (Ar C=C); 1H NMR (400 MHz, CDCl3) δH: 4.60 (2H, s, CH2), 7.24–
7.28 (2H, m, C(2)N=CArH), 7.36–7.40 (4H, m, C(2)N=CArH + C(1)OArC(3,5)H), 7.43–7.47 (1H, 
m, C(2)N=CArH), 7.50–7.56 (3H, m, C(2)N=CArH), 7.71–7.74 (2H, m, C(2)N=CArH); 13C NMR 
(126 MHz, CDCl3) δC: 54.9 (CH2), 127.8 (C(2)N=CArC), 128.2 (C(1)OArC(3)H), 128.3 
(C(1)OArC(3)H), 128.4 (C(2)N=CArC), 128.7 (C(2)N=CArC), 129.0 (C(2)N=CArC), 129.0 
(C(2)N=CArC), 129.2 (C(2)N=CArC), 129.7 (C(2)N=CArC), 130.2 (C(2)N=CArC), 130.9 
(C(2)N=CArC), 132.2 (C(2)N=CArC), 132.6 (C(2)N=CArC), 135.8 (C(1)OArC(1)), 139.1 
(C(1)OArC(2,6)), 142.9 (C(1)OArC(4)), 167.1 (C(1)), 173.4 (C(2)N=C); HRMS (ESI+) 
C21H14O2N35Cl3Na [M+Na]+ found 439.9973, requires 439.9982 (-2.1 ppm). 
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Methyl (E)-2-oxo-4-phenylbut-3-enoate (132) 
 
To a solution of pyruvic acid 130 (3.52 mL, 50 mmol, 1.0 eq.) and benzaldehyde (5.09 mL, 50 
mmol) in MeOH (5 mL) at 0 °C was added a solution of KOH (4.21 g, 75 mmol, 1.5 eq.) in 
MeOH (15 mL). The first 1 eq. of the KOH solution was added dropwise over 30 minutes. The 
last 0.5 eq. was added as one portion and the reaction mixture was stirred at 40 °C for 1 h 
followed by 0 °C for 16 h. The precipitate was collected by filtration, washed twice with cold 
MeOH, once with Et2O and dried under vacuum to furnish the potassium salt 131 (9.01 g, 84%) 
as a yellow solid. Spectroscopic data were in accordance with the literature.1 mp 248-249 °C 
{Lit.1 248 °C}; 1H NMR (400 MHz, D2O) δH: 6.82 (1H, d, J 16.5, C(3)H), 7.37–7.47 (3H, m, 
ArC(3,5)H and ArC(4)H), 7.60–7.66 (3H, m, ArC(2,6)H and C(4)H). 
Acetyl chloride (28.6 mL, 400 mmol, 11.5 eq.) was added to MeOH (200 mL) at 0 °C to 
generate HCl. Potassium salt 131 (7.48 g, 35.0 mmol, 1.0 eq.) was added and the mixture 
stirred at 0 °C for 30 min then warmed to rt for 2 h before heating at reflux for 16 h. 
Concentration in vacuo gave a sticky solid which was dissolved in H2O (50 mL) and extracted 
with CH2Cl2 (50 mL x 3). The combined organics were washed with saturated aq. NaHCO3 (25 
mL), H2O (25 mL) and brine (25 mL) before being dried with MgSO4. Concentration in vacuo 
afforded the crude reaction mixture which was purified by flash column chromatography 
(10:90 EtOAc:petrol) to afford 132 as a yellow solid (2.80 g, 42%). Spectroscopic data were in 
accordance with the literature.1 mp 68-70 °C (MeOH) {Lit.1 69-70 °C (MeOH)}; 1H NMR (400 
MHz, CDCl3) δH: 3.89 (3H, s, CH3), 7.34 (1H, d, J 16.1, C(3)H), 7.34–7.44 (3H, m, ArC(3,5)H and 
ArC(4)H), 7.56–7.61 (2H, m, ArC(2,6)H), 7.82 (1H, d, J 16.1, C(4)H). 
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(E)-1,1,1-Trifluoro-4-phenylbut-3-en-2-one (144) 
 
To a solution of methyl cinnamate 143 (2.0 g, 12.4 mmol, 1.0 eq.) in pentane (60 mL, 0.2 M) at 
room temperature under Ar was added trifluoromethyltrimethylsilane (2.28 mL, 15.4 mmol, 
1.25 eq). The mixture was cooled to 0 °C, before a 1 M solution of TBAF in THF (0.31 mL, 0.31 
mmol, 2.5 mol%) was added. The resulting mixture was warmed to room temperature and 
stirred for 18 h. Then, the solvent was removed in vacuo, and the residue was redissolved in 
THF (10 mL) and treated with 4 M aqueous HCl (10 mL). After stirring at rt. for another 10 h, 
the reaction mixture was diluted with Et2O (80 mL) and washed with brine (40 mL). The organic 
layer was dried over MgSO4, filtered and concentrated in vacuo to give the crude material. 
Purification by flash column chromatography (5:95 to 10:90 CH2Cl2:petrol) gave the titled 
compound 144 (1.17 g, 47%) as a light yellow. Spectroscopic data was in accordance with the 
literature.2 1H NMR (400 MHz, CDCl3) δH: 7.05 (1H, dq, J 16.0, 0.9, C(3)H), 7.41–7.58 (3H, m, 
ArH), 7.64–7.71 (2H, m, ArH), 8.00 (1H, d, J 16.0, C(4)H); 19F NMR (376 MHz, CDCl3) δF: -77.6 
(3F, s, CF3). 
 
Methyl 2-oxo-4-phenyl-2H-pyran-6-carboxylate (135) 
 
To a flame-dried Schlenk tube containing 4-nitrophenyl ester 121 (97.9 mg, 0.272 mmol, 1.0 
eq.), ketoester 132 (51.7 mg, 0.272 mmol, 1.0 eq.) and rac-tetramisoleHCl 133 (13.1 mg, 20 
mol%) under Ar, CH2Cl2 (2.7 mL, 0.1 M) was added followed by i-Pr2NEt (118 μL, 0.68 mmol, 
2.5 eq.). The resulting mixture was allowed to stir at room temperature for 24 h, and the 
progress of the reaction was monitored by TLC analysis. Upon complete consumption of the 
starting Michael acceptor, the reaction mixture was quenched with 0.1 M aqueous HCl (5 mL), 
extracted with CH2Cl2 (3 x 10 mL), dried over MgSO4 and concentrated in vacuo. Flash column 
chromatography (30:70 Et2O:petrol, Rf 0.37) gave the titled compound 135 as a light yellow 
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solid (37.6 mg, 60%). mp 89-91 °C; vmax (film, cm-1) 3061 (C-H), 2961 (C-H), 1742 (C=O ester), 
1709 (C=O); 1H NMR (500 MHz, CDCl3) δH: 3.97 (3H, s, CH3), 6.73 (1H, d, J 1.7, C(3)H), 7.47 (1H, 
d, J 1.7, C(5)H), 7.50–7.55 (3H, m, C(4)ArC(3,4,5)H), 7.62–7.65 (2H, m, C(4)ArC(2,6)H); 13C{1H} 
NMR (126 MHz, CDCl3) δC: 53.2 (CH3), 110.3 (C(5)H), 115.0 (C(3)H), 126.7 (C(4)ArC(2,6)H), 129.5 
(C(4)ArC(3,5)H), 131.3 (C(4)ArC(4)H), 134.4 (C(4)ArC(1)), 148.8 (C(4)), 153.5 (C(6)), 160.1 (C(2)), 
160.6 (C(6)CO2Me); HRMS (ESI+) C13H10O4Na [M+Na]+ found 253.0466, requires 253.0471 (-2.1 
ppm). 
 
Ethyl 2-oxo-6-phenyl-2H-pyran-4-carboxylate (141) 
 
To a flame-dried Schlenk tube containing 4-nitrophenyl ester 121 (103 mg, 0.285 mmol, 1.0 
eq.), β-ester enone 139 (58.2 mg, 0.285 mmol, 1.0 eq.) and rac-tetramisoleHCl 133 (6.91 mg, 
10 mol%) under Ar, CH2Cl2 (2.9 mL, 0.1 M) was added followed by i-Pr2NEt (123 μL, 0.712 mmol, 
2.5 eq.). The resulting mixture was allowed to stir at room temperature for 24 h, and the 
progress of the reaction was monitored by TLC analysis. Upon complete consumption of the 
starting Michael acceptor, the reaction mixture was quenched with 0.1 M aqueous HCl (5 mL), 
extracted with CH2Cl2 (3 x 10 mL), dried over MgSO4 and concentrated in vacuo. Flash column 
chromatography (30:70 Et2O:petrol, Rf 0.40) gave the titled compound 141 as a light yellow 
solid (23.6 mg, 36%). Spectroscopic data was in accordance with the literature.3 mp 73-74 °C; 
1H NMR (400 MHz, CDCl3) δH: 1.42 (3H, t, J 7.1, CH3), 4.42 (2H, q, J 7.1, CH2), 6.90 (1H, d, J 1.3, 
C(3)H), 7.12 (1H, d, J 1.3, C(5)H), 7.46–7.50 (3H, m, ArH), 7.86–7.90 (2H, m, ArH). 
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To a flame-dried Schlenk tube containing 4-nitrophenyl ester 121 (164 mg, 0.456 mmol, 1.0 
eq.), CF3 enone 144 (91.3 mg, 0.456 mmol, 1.0 eq.) and (S)-BTM 146 (23.0 mg, 20 mol%) under 
Ar, CH2Cl2 (4.6 mL, 0.1 M) was added. The resulting mixture was allowed to stir at rt for 24 h 
before it was concentrated in vacuo and then filtered directly through a short column of silica 
using CH2Cl2 eluent (ca. 20 mL). The filtrate was concentrated in vacuo to give the crude 
product (87:13 dr anti:syn) which was purified via flash column chromatography (30:70 
Et2O:petrol, Rf 0.33) to give the titled compound 145 as a light brown oil in >95:5 dr (77 mg, 
40%). Chiral HPLC analysis, Chiralpak OD-H (99:1 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 
30 °C) tR (major): 13.0 min, tR(minor): 7.7 min, 58:42 er; vmax (film, cm-1) 3061 (CH stretch), 
1717 (C=O), 1655 (C=N), 1597 (C=C), 1578 (C=C); 1H NMR (400 MHz, CDCl3) δH: 4.20 (1H, d, J 
11.2, C(3)H), 4.29–4.34 (1H, m, C(4)H), 6.02 (1H, d, J 2.3, C(5)H), 7.04–7.07 (2H, m, ArH), 7.31–
7.42 (11H, m, ArH), 7.53–7.55 (2H, m, ArH); 13C{1H} NMR (101 MHz, CDCl3) δC: 44.3 (C(4)H), 
65.4 (C(3)H), 110.1 (q, J 3.7, C(5)H), 119.9 (q, J 270.1, CF3), 127.4 (ArCH), 128.0 (ArCH), 128.1 
(ArCH), 128.2 (ArCH), 128.5 (ArCH), 128.7 (ArCH), 128.9 (ArCH), 129.0 (ArCH), 129.3 (ArCH), 
131.0 (ArCH), 135.0 (C(3)ArC(1)), 135.2 (NCAraC(1)), 135.6 (NCArbC(1)), 140.8 (q, J 38.2, C(6)), 
164.2 (C(2)), 173.8 (C=N); 19F NMR (376 MHz, CDCl3) δF: -72.1 (3F, s, CF3). Characterization was 
not carried out further due to product instability. 
Data for the minor diastereoisomer: Chiralc HPLC analysis, Chiralpak OD-H (99:1 hexane/i-
PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 22.2 min, tR(minor): 9.4 min, 51:49 er; 
1H NMR (400 MHz, CDCl3) δH: 3.94–3.98 (1H, m, C(4)H), 4.46 (1H, d, J 5.4, C(3)H), 6.17 (1H, d, 
J 3.8, C(5)H), 7.10–7.12 (2H, m, ArH), 7.31–7.42 (11H, m, ArH), 7.46–7.48 (2H, m, ArH); 13C{1H} 
NMR (101 MHz, CDCl3) δC (selected): 43.4 (C(4)), 63.4 (C(3)), 110.0 (q, J 3.7, C(5)), 164.4 (C(2)), 
173.2 (C=N);19F NMR (376 MHz, CDCl3) δF: -72.0 (3F, s, CF3). 
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8.3. Experimentals for Chapter 3 
8.3.1. General Procedures 
General Procedure A: Synthesis of trichloromethyl carbinols using trichloroacetate 
 
Trichloroacetic acid (1.5 equiv) and sodium trichloroacetate (1.5 equiv) were added to a 
solution of the appropriate aldehyde (1 equiv) in DMF (1.3 M) at 0 °C. The reaction was allowed 
to warm slowly to rt over 16 h before being diluted with water and extracted with EtOAc (×3). 
The combined organics were washed with water (×3) and NaHCO3, dried over MgSO4, filtered 
and concentrated under reduced pressure to give the crude product, which was purified by 
flash silica column chromatography. 
General Procedure B: Synthesis of tricchloromethyl carbinols using CHCl3 
 
A solution of KOH (1.0 equiv) in EtOH (4 mL) was added dropwise to a stirred solution of the 
appropriate aldehyde (1.0 equiv) and chloroform (2.2 equiv) in DMF (1.3 M) at 0 ℃. The 
solution turned deep red and was stirred at 0 ℃ for until complete by TLC analysis (ca. 30 
min to 1 h). The solution was acidified with 2 M HCl to pH 5-7 and extracted with EtOAc (×3). 
The combined organics were washed with water dried over Na2SO4, filtered and concentrated 
under reduced pressure to give the crude product, which was purified by flash silica column 
chromatography. 
General Procedure C: Synthesis of α,β-unsaturated trichloromethyl ketones 
 
A solution of DMSO (8 equiv) in anhydrous CH2Cl2 (4.4 M) was added dropwise to a solution of 
oxalyl chloride (4 equiv) in CH2Cl2 (0.25 M) at –78 °C. After 2 min, a solution of the appropriate 
alcohol (1 equiv) in CH2Cl2 (1.0 M) was added dropwise. After a further 15 min, Et3N (20 equiv) 
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was added dropwise and the reaction stirred for 0.5 h, allowing to warm to rt. The reaction 
mixture was then quenched with 2 M HCl and extracted with CH2Cl2 (×3). The combined 
organics were dried over MgSO4, filtered and concentrated under reduced pressure to give the 
crude product, which was purified by flash silica column chromatography. 
General Procedure D: Michael addition-lactonization with MeOH ring-opening 
 
2-(1H-Pyrrol-1-yl)acetic acid 155 (1 equiv.) was dissolved in anhydrous MeCN (0.1 M) under an 
atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (2 equiv) and pivaloyl chloride (2 equiv) 
were added. The reaction was stirred at 0 °C for 20 min before cooling to –40 °C. HyperBTM 
93 (10 mol%), the required α,β-unsaturated trichloromethyl ketone (1 equiv), and i-Pr2NEt (2.5 
equiv) were added sequentially and the reaction stirred at –40 °C for 24 h. Excess MeOH (equal 
volume) and DMAP (20 mol%) were added before the solution was warmed to rt and stirred 
for 24 h. The reaction was diluted with CH2Cl2 (equal volume) and washed with 1 M HCl (×2) 
and brine (×2) before being dried over MgSO4, filtered, and concentrated under reduced 
pressure to give the crude product, which was purified by flash silica column chromatography. 
General Procedure E: Michael addition-lactonization with BnNH2 ring-opening 
 
2-(1H-Pyrrol-1-yl)acetic acid 155 (1 equiv.) was dissolved in anhydrous MeCN (0.1 M) under an 
atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (2 equiv) and pivaloyl chloride (2 equiv) 
were added. The reaction was stirred at 0 °C for 20 min before cooling to –40 °C. HyperBTM 
93 (10 mol%), the required α,β-unsaturated trichloromethyl ketone (1 equiv), and i-Pr2NEt (2.5 
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equiv) were added sequentially and the reaction stirred at –40 °C for 24 h. Excess BnNH2 (equal 
volumes) was added before the solution was warmed to rt and stirred for 24 h. The reaction 
was diluted with EtOAc (8 volumes) and washed with 1 M HCl (×3), NaHCO3 (×3), and brine (×3) 
before being dried over MgSO4, filtered, and concentrated under reduced pressure. The crude 
product was purified by either trituration with Et2O or flash silica column chromatography. 
General Procedure F: Intramolecular Friedel-Crafts acylation 
 
The appropriate pyrrole diester (1 equiv) was dissolved in anhydrous CH2Cl2 (0.05 M) under an 
atmosphere of N2 and cooled to 0 °C before BBr3 (1.1 equiv) was added dropwise. The reaction 
was stirred at 0 °C for 40 min before being quenched by the careful addition of water (1 volume) 
followed by 2 M Na2CO3 (1 volume). The solution was extracted with CH2Cl2 (2 × 7 volumes) 
and the combined organics dried over MgSO4, filtered, and concentrated under reduced 
pressure. The crude product was purified by flash silica column chromatography. 
 
8.3.2. Starting materials synthesis 
Ethyl 2-(1H-pyrrol-1-yl)acetate (154) 
 
Glycine ethyl ester hydrochloride (2.50 g, 17.9 mmol) and NaOAc (2.45 g, 29.9 mmol) were 
suspended in H2O (12.5 mL) and AcOH (25 mL) before 2,5-dimethoxytetrahydrofuran (2.32 mL, 
17.9 mmol) was added. The reaction was heated at 100 °C for 4 h before being cooled to rt, 
poured into water (50 mL) and extracted with EtOAc (30 mL). The aqueous phase was 
neutralized with solid Na2CO3 and further extracted with EtOAc (2 × 30 mL). The combined 
organics were washed with water (50 mL), dried over MgSO4, filtered, and concentrated under 
reduced pressure. The crude material was purified by column chromatography (Petrol/EtOAc 
80:20, Rf 0.56) to give 154 (1.80 g, 66%) as a colourless oil. Spectroscopic data were in 
accordance with the literature.4 1H NMR (400 MHz, CDCl3) δH: 1.31 (3H, t, J 7.2, CH2CH3), 4.25 
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(2H, q, J 7.2, CH2CH3), 4.65 (2H, s, CH2), 6.23 (2H, t, J 2.1, ArC(3,4)H), 6.69 (2H, t, J 2.1, 
ArC(2,5)H). 
2-(1H-Pyrrol-1-yl)acetic acid (155) 
 
Ester 154 (1.80 g, 11.8 mmol) was dissoved in 1:1 THF/H2O (35 mL) and cooled to 0 °C before 
NaOH pellets (2.36 g, 59.0 mmol) were added. The reaction was stirred at 0 °C for 30 min 
before being washed with CH2Cl2 (40 mL). The aqueous phase was acidified with concentrated 
12 M HCl to ca. pH 1 and extracted with CH2Cl2 (3 × 40 mL) before being dried over MgSO4, 
filtered, and concentrated under reduced pressure to give 155 (1.43 g, 97%) as a white solid. 
Spectroscopic data were in accordance with the literature.4 mp 90-92 °C{Lit.5 84-87 °C}; 1H 




Following General Procedure A, cinnamyl aldehyde (5.03 mL, 40.0 mmol), Cl3CCO2H (9.80 g, 
60.0 mmol) and Cl3CCO2Na (11.1 g, 60 mmol) in DMF (30 mL) gave, after purification by column 
chromatography (Petrol/Et2O 90:10, Rf 0.24), 157 (8.80 g, 87%) as an orange oil. Spectroscopic 
data were in accordance with the literature.6 1H NMR (400 MHz, CDCl3) δH: 2.95 (1H, d, J 5.6, 
OH), 4.76–4.81 (1H, m, C(2)H), 6.38 (1H, dd, J 16.1, 6.1, C(3)H), 6.93 (1H, d, J 16.0, C(4)H), 7.28–
7.41 (3H, m, ArC(3,5)H and ArC(4)H), 7.45–7.49 (2H, m, ArC(2,6)H).  
(E)-1,1,1-Trichloro-4-phenylbut-3-en-2-one (158) 
 
Following General Procedure C, 157 (8.80 g, 35.0 mmol) in CH2Cl2 (35 mL), DMSO (19.1 mL, 
0.28 mol, 8 equiv) in CH2Cl2 (63 mL), oxalyl chloride (12.0 mL, 0.14 mol, 4 equiv) in CH2Cl2 (560 
mL) and Et3N (97.6 mL, 0.7 mol, 20 equiv) gave, after purification by column chromatography 
(Petrol/EtOAc 95:5, Rf 0.35), 158 (8.30 g, 95%) as a white solid. Spectroscopic data were in 
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accordance with the literature.6 mp 57–58 °C {Lit.6 56–58 °C}; 1H NMR (500 MHz, CDCl3) δH: 
7.37 (1H, d, J 15.7, C(3)H), 7.44–7.54 (3H, m, ArC(3,5)H and ArC(4)H), 7.64–7.72 (2H, m, 
ArC(2,6)H), 8.04 (1H, d, J 15.7, C(4)H). 
(E)-1,1,1-Trichloro-4-(4-methoxyphenyl)but-3-en-2-ol (452) 
 
Following General Procedure A, 4-methoxycinnamyl aldehyde (3.24 g, 20.0 mmol), Cl3CCO2H 
(4.90 g, 30.0 mmol) and Cl3CCO2Na (5.56 g, 30.0 mmol) in DMF (15 mL) gave, after purification 
by column chromatography (Petrol/Et2O 80:20, Rf 0.21), 452 (3.94 g, 14.0 mmol, 70%) as a 
white solid. Spectroscopic data were in accordance with the literature.6 mp 66 °C {Lit.6 66–
68 °C}; 1H NMR (400 MHz, CDCl3) δH: 2.98 (1H, d, J 5.8, OH), 3.85 (3H, s, OCH3), 4.71–4.81 (1H, 
m, C(2)H), 6.24 (1H, dd, J 15.8, 6.3, C(3)H), 6.86 (1H, d, J 16.0, C(4)H), 6.88–6.94 (2H, m, 
ArC(3,5)H), 7.38–7.43 (2H, m, ArC(2,6)H). 
(E)-1,1,1-Trichloro-4-(4-methoxyphenyl)but-3-en-2-one (453) 
 
Following General Procedure C, 452 (3.94 g, 14.0 mmol) in CH2Cl2 (14 mL), DMSO (7.96 mL, 
112 mmol, 8 equiv) in CH2Cl2 (25 mL), oxalyl chloride (4.80 mL, 56.0 mmol, 4 equiv) in CH2Cl2 
(224 mL) and Et3N (39.0 mL, 0.28 mol, 20 equiv) gave, after purification by column 
chromatography (Petrol/Et2O 80:20, Rf 0.65), 453 (3.21 g, 82%) as a light yellow solid. 
Spectroscopic data were in accordance with the literature.6 mp 99–101 °C {Lit.6 98–100 °C}; 1H 
NMR (500 MHz, CDCl3) δH: 3.90 (3H, s, OCH3), 6.94–7.01 (2H, m, ArC(3,5)H), 7.23 (1H, d, J 15.5, 
C(3)H), 7.61–7.67 (2H, m, ArC(2,6)H), 7.99 (1H, d, J 15.6, C(4)H).  
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(E)-1,1,1-Trichloro-4-(3-methoxyphenyl)but-3-en-2-ol (454) 
 
Following General Procedure B, 3-methoxycinnamyl aldehyde (1.64 g, 10.1 mmol), chloroform 
(1.78 mL, 22.2 mmol, 2.2 equiv) in DMF (8 mL) and KOH (567 mg, 10.1 mmol, 1.0 equiv) in 
EtOH (4 mL) gave, after purification by column chromatography (Petrol/Et2O 60:40, Rf 0.45), 
454 (1.93 g, 68%) as a light yellow oil. 1H NMR (500 MHz, CDCl3) δH: 2.93 (1H, d, J 5.8, OH), 
3.83 (3H, s, OCH3), 4.76 (1H, td, J 5.9, 1.3, C(2)H), 6.36 (1H, dd, J 15.9, 6.1, C(3)H), 6.85–6.90 
(2H, m, C(4)H and ArC(4)H), 6.97–6.98 (1H, m, ArC(2)H), 7.03–7.05 (1H, m, ArC(5)H), 7.27 (1H, 
t, J 7.9, ArC(6)H). The title compound was carried forward immediately without further 
characterisation due to instability. 
(E)-1,1,1-Trichloro-4-(3-methoxyphenyl)but-3-en-2-one (455) 
 
Following General Procedure C, 454 (1.93 g, 6.85 mmol) in CH2Cl2 (7 mL), DMSO (3.90 mL, 54.8 
mmol, 8 equiv) in CH2Cl2 (12 mL), oxalyl chloride (2.35 mL, 27.4 mmol, 4 equiv) in CH2Cl2 (110 
mL) and Et3N (19.1 mL, 137 mmol, 20 equiv) gave, after purification by column 
chromatography (Petrol/Et2O 90:10, Rf 0.31), 455 (1.63 g, 85%) as a white solid. mp 46–47 °C; 
νmax (film, cm–1) 2968 (C-H), 1709 (C=O), 1603 (C=C), 1580, 1248, 1105, 829; 1H NMR (500 MHz, 
CDCl3) δH: 3.89 (3H, s, OCH3), 7.05 (1H, dd, J 8.2, 2.5, ArC(4)H), 7.16 (1H, t, J 2.1, ArC(2)H), 7.27–
7.28 (1H, m, ArC(5)H), 7.34 (1H, d, J 15.6, C(3)H), 7.39 (1H, t, J 7.9, ArC(6)H), 8.00 (1H, d, J 15.6, 
C(4)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 55.6 (OCH3), 96.5 (C(1)), 114.0 (ArC(2)H), 116.2 
(C(3)H), 117.7 (ArC(4)H), 121.8 (ArC(5)H), 130.3 (ArC(6)H), 135.2 (ArC(1)), 149.8 (C(4)H), 160.1 
(ArC(3)), 180.2 (C(2)); HRMS (ASAP+) C11H10O235Cl3 [M+H]+ found 278.9745, requires 278.9746 
(–0.4 ppm). 
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(E)-1,1,1-Trichloro-4-(4-(trifluoromethyl)phenyl)but-3-en-2-ol (456) 
 
Following General Procedure A, 4-trifluoromethylcinnamyl aldehyde (1.98 g, 9.90 mmol), 
Cl3CCO2H (2.42 g, 14.9 mmol) and Cl3CCO2Na (2.75 g, 14.9 mmol) in DMF (20 mL) gave, after 
purification by column chromatography (Petrol/Et2O 60:40, Rf 0.42), 456 (1.74 g, 55%) as a 
yellow oil. Spectroscopic data were in accordance with the literature.7 1H NMR (400 MHz, CDCl3) 
δH: 3.03 (1H, d, J 5.6, OH), 4.83 (1H, t, J 5.4, C(2)H), 6.50 (1H, dd, J 15.9, 5.7, C(3)H), 6.98 (1H, 
d, J 16.0, C(4)H), 7.57 (2H, d, J 8.2, ArC(2,6)H), 7.64 (2H, d, J 8.0, ArC(3,5)H); 19F{1H} NMR (377 
MHz, CDCl3) δF: –62.7 (s, CF3).  
(E)-1,1,1-Trichloro-4-(4-(trifluoromethyl)phenyl)but-3-en-2-one (457) 
 
Following General Procedure C, 456 (1.74 g, 5.45 mmol) in CH2Cl2 (5 mL), DMSO (3.10 mL, 43.6 
mmol, 8 equiv) in CH2Cl2 (10 mL), oxalyl chloride (1.87 mL, 21.8 mmol, 4 equiv) in CH2Cl2 (87 
mL) and Et3N (15.2 mL, 109 mmol, 20 equiv) gave, after purification by column 
chromatography (Petrol/Et2O 90:10, Rf 0.45), 457 (1.25 g, 72%) as an orange solid. mp 70–
72 °C; νmax (film, cm–1) 1709 (C=O), 1614 (C=C), 1319, 1105, 1065; 1H NMR (500 MHz, CDCl3) δH: 
7.40 (1H, d, J 15.7, C(3)H), 7.70 (2H, d, J 8.3, ArC(3,5)H), 7.76 (2H, d, J 8.3, ArC(2,6)H), 8.01 (1H, 
d, J 15.7, C(4)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 96.2 (C(1)), 118.4 (C(3)H), 123.8 (q, J 272.5, 
CF3), 126.2 (q, J 3.8, ArC(3,5)H), 129.2 (ArC(2,6)H), 133.1 (q, J 32.8, ArC(4)), 137.1 (ArC(1)), 
147.6 (C(4)H), 179.8 (C(2)); 19F{1H} NMR (377 MHz, CDCl3) δF: –63.0 (s, CF3); HRMS (ASAP+) 
C11H7OF335Cl3 [M+H]+ found 316.9516, requires 316.9515 (+0.3 ppm). 
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(E)-1,1,1-Trichloro-4-(4-nitrophenyl)but-3-en-2-ol (458) 
 
Following General Procedure A, 4-nitrocinnamyl aldehyde (1.02 g, 5.76 mmol), Cl3CCO2H (1.41 
g, 8.64 mmol) and Cl3CCO2Na (1.60 g, 8.64 mmol) in DMF (40 mL) gave, after purification by 
column chromatography (Petrol/Et2O 70:30, Rf 0.22), 458 (1.08 g, 63%) as a light red solid. 
Spectroscopic data were in accordance with the literature.8 mp 140–141 °C {Lit.8 143 °C}; 1H 
NMR (400 MHz, CDCl3) δH: 3.62 (1H, d, J 5.6, OH), 4.85 (1H, td, J 5.5, 1.4, C(2)H), 6.60 (1H, dd, 
J 15.9, 5.5, C(3)H), 7.03 (1H, dd, J 15.9, 1.4, C(4)H), 7.57–7.65 (2H, m, ArC(2,6)H), 8.20–8.27 
(2H, m, ArC(3,5)H).  
(E)-1,1,1-Trichloro-4-(4-nitrophenyl)but-3-en-2-one (459) 
 
Following General Procedure C, 458 (1.08 g, 3.66 mmol) in CH2Cl2 (4 mL), DMSO (2.08 mL, 29.3 
mmol, 8 equiv) in CH2Cl2 (7 mL), oxalyl chloride (1.26 mL, 14.6 mmol, 4 equiv) in CH2Cl2 (58 mL) 
and Et3N (10.2 mL, 73.2 mmol, 20 equiv) gave, after purification by column chromatography 
(Petrol/Et2O 80:20, Rf 0.34), 459 (0.80 g, 74%) as a yellow solid. Spectroscopic data were in 
accordance with the literature.8 mp 155–157 °C {Lit.8 158–160 °C}; 1H NMR (500 MHz, CDCl3) 
δH: 7.47 (1H, d, J 15.7, C(3)H), 7.80–7.87 (2H, m, ArC(2,6)H), 8.04 (1H, d, J 15.8, C(4)H), 8.30–
8.36 (2H, m, ArC(3,5)H).  
(E)-1,1,1-Trichloro-4-(3-nitrophenyl)but-3-en-2-ol (460) 
 
Following General Procedure A, 3-nitrocinnamyl aldehyde (2.70 g, 15.3 mmol), Cl3CCO2H (3.74 
g, 23.0 mmol) and Cl3CCO2Na (4.24 g, 23.0 mmol) in DMF (40 mL) gave, after passing through 
a short pad of silica (eluent: CH2Cl2), 460 (2.72 g, 60% crude yield) as a yellow oil which was 
used directly in the next step. Characterization data: 1H NMR (500 MHz, CDCl3) δH: 3.25 (1H, d, 
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J 5.5, OH), 4.83 (1H, td, J 5.5, 1.4, C(2)H), 6.54 (1H, dd, J 15.9, 5.6, C(3)H), 7.00 (1H, dd, J 15.9, 
1.4, C(4)H), 7.54 (1H, t, J 8.0, ArC(5)H), 7.75–7.76 (1H, m, ArC(6)H), 8.16 (1H, ddd, J 8.2, 2.3, 
1.0, ArC(4)H), 8.30 (1H, t, J 2.0, ArC(2)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 82.8 (C(2)H), 102.5 
(C(1)), 121.7 (ArC(2)H), 123.3 (ArC(4)H), 126.0 (C(3)H), 129.9 (ArC(5)H), 132.9 (ArC(6)H), 134.2 
(C(4)H), 137.6 (ArC(1)), 149.2 (ArC(3)).  
(E)-1,1,1-Trichloro-4-(3-nitrophenyl)but-3-en-2-onze (461) 
 
Following General Procedure C, 460 (2.72 g, 9.18 mmol) in CH2Cl2 (9 mL), DMSO (5.22 mL, 73.4 
mmol, 8 equiv) in CH2Cl2 (17 mL), oxalyl chloride (3.15 mL, 36.7 mmol, 4 equiv) in CH2Cl2 (147 
mL) and Et3N (25.6 mL, 184 mmol, 20 equiv) gave, after purification by column 
chromatography (Petrol/Et2O 80:20, Rf 0.40), 461 (1.68 g, 62%) as a yellow solid. mp 138–
139 °C; νmax (film, cm–1) 1715 (C=O), 1609 (C=C), 1531 (N-O), 1344 (N-O); 1H NMR (500 MHz, 
CDCl3) δH: 7.45 (1H, d, J 15.7, C(3)H), 7.66 (1H, t, J 8.0, ArC(4)H), 7.95 (1H, d, J 7.7, ArC(6)H), 
8.03 (1H, d, J 15.7, C(4)H), 8.32 (1H, ddd, J 8.2, 2.2, 1.0, ArC(5)H), 8.51 (1H, t, J 2.0, ArC(2)H); 
13C{1H} NMR (126 MHz, CDCl3) δC: 96.1 (C(1)), 118.9 (C(3)H), 123.1 (ArC(2)H), 125.9 (ArC(5)H), 
130.4 (ArC(4)H), 134.7 (ArC(6)H), 135.5 (ArC(1)), 146.5 (C(4)H), 148.9 (ArC(3)), 179.6 (C(2)); 
HRMS (ASAP+) C10H7O3N35Cl3 [M+H]+ found 293.9488, requires 293.9492 (–1.4 ppm). 
(E)-1,1,1-Trichloro-4-(2-nitrophenyl)but-3-en-2-ol (462) 
 
Following General Procedure A, 2-nitrocinnamyl aldehyde (7.09 mL, 40.0 mmol), Cl3CCO2H 
(9.80 g, 60.0 mmol) and Cl3CCO2Na (11.1 g, 60.0 mmol) in DMF (100 mL) gave, after purification 
by column chromatography (Petrol/Et2O 70:30, Rf 0.25), 462 (3.56 g, 30%) as a white solid. 
Spectroscopic data were in accordance with the literature.6 mp 113–114 °C {Lit.6 114–116 °C}; 
1H NMR (500 MHz, CDCl3) δH: 3.10 (1H, d, J 5.7, OH), 4.86 (1H, app. t, J 5.8, C(2)H), 6.35 (1H, 
Chapter 8: Experimentals 
Page | 152  
dd, J 15.7, 5.8, C(3)H), 7.45 (1H, dd, J 15.7, 1.3, C(4)H), 7.48–7.54 (1H, m, ArC(4)H), 7.62–7.67 
(2H, m, ArC(5,6)H), 8.04 (1H, dt, J 8.2, 1.0, ArC(3)H).  
(E)-1,1,1-Trichloro-4-(2-nitrophenyl)but-3-en-2-one (463) 
 
Following General Procedure C, 462 (3.56 g, 12.0 mmol) in CH2Cl2 (12 mL), DMSO (6.82 mL, 
96.0 mmol, 8 equiv) in CH2Cl2 (22 mL), oxalyl chloride (4.12 mL, 48.0 mmol, 4 equiv) in CH2Cl2 
(192 mL) and Et3N (33.4 mL, 240 mmol, 20 equiv) gave, after purification by column 
chromatography (Petrol/Et2O 75:25, Rf 0.32), 463 (2.58 g, 73%) as a light yellow solid. 
Spectroscopic data were in accordance with the literature.6 mp 57–59 °C {Lit.6 56–58 °C}; 1H 
NMR (400 MHz, CDCl3) δH: 7.27 (1H, d, J 15.5, C(3)H), 7.61–7.70 (1H, m, ArC(4)H), 7.71–7.80 
(2H, m, ArC(5,6)H), 8.11–8.19 (1H, m, ArC(3)H), 8.47 (1H, d, J 15.5, C(4)H).  
(E)-1,1,1-Trichloro-4-(4-fluorophenyl)but-3-en-2-ol (464) 
 
As reported previously following General Procedure A,6 4-fluorocinnamaldehyde (5.00 g, 33.3 
mmol), DMF (30 mL), trichloroacetic acid (8.17 g, 50.0 mmol) and sodium trichloroacetate 
(9.27 g, 50.0 mmol) gave, after purification by column chromatography (Petrol/Et2O 85:15, Rf 
0.25), 464 (4.31 g, 48%) as an orange solid. Spectroscopic data were in accordance with the 
literature.6 mp 63–62 °C; {Lit.6 mp 60–62 °C}; 1H NMR (400 MHz, CDCl3) δH: 2.92 (1H, d, J 5.7, 
OH), 4.76 (1H, td, J 5.9, 1.3, C(2)H), 6.29 (1H, ddd, J 15.9, 6.1, 0.6, C(3)H), 6.87 (1H, d, J 15.9, 
C(4)H), 7.01–7.08 (2H, m, ArC(3,5)H), 7.38–7.46 (2H, m, ArC(2,6)H); 19F{1H} NMR (376 MHz, 
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(E)-1,1,1-Trichloro-4-(4-fluorophenyl)but-3-en-2-one (465) 
 
As reported previously following General Procedure C,6 464 (2.52 g, 9.34 mmol) in CH2Cl2 (10 
mL), DMSO (5.32 mL, 74.7 mmol) in CH2Cl2 (20 mL), oxalyl chloride (3.17 mL, 37.4 mmol) in 
CH2Cl2 (150 mL) and Et3N (26.1 mL, 187 mmol) gave, after purification by column 
chromatography (Petrol/Et2O 95:5, Rf 0.25), 465 (2.25 g, 90%) as a white solid. Spectroscopic 
data were in accordance with the literature.6 mp 60-62 °C; {Lit.6 mp 58–60 °C}; 1H NMR (500 
MHz, CDCl3) δH: 7.10–7.18 (2H, m, ArC(3,5)H), 7.26 (1H, d, J 15.6, C(3)H), 7.62–7.70 (2H, m, 
ArC(2,6)H), 7.97 (1H, d, J 15.6, C(4)H); 19F{1H} NMR (471 MHz, CDCl3) δF: –106.8 (ArC(4)F). 
(E)-1,1,1-Trichloro-4-(4-chlorophenyl)but-3-en-2-ol (466) 
 
Following General Procedure B, 4-chlorocinnamyl aldehyde (0.87 g, 5.21 mmol), chloroform 
(0.92 mL, 11.5 mmol, 2.2 equiv) in DMF (4 mL) and KOH (292 mg, 5.21 mmol, 1.0 equiv) in 
EtOH (4 mL) gave, after purification by column chromatography (Petrol/Et2O 80:20, Rf 0.41), 
466 (0.82 g, 55%) as a light-yellow oil. Spectroscopic data were in accordance with the 
literature.8 1H NMR (500 MHz, CDCl3) δH: 3.08 (1H, d, J 5.8, OH), 4.73 (1H, app. t, J 5.8, C(2)H), 
6.34 (1H, dd, J 15.8, 5.8, C(3)H), 6.91 (1H, d, J 15.8, C(4)H), 7.20–7.35 (2H, m, ArC(2,6)H), 7.38–
7.55 (2H, m, ArC(3,5)H).  
(E)-1,1,1-Trichloro-4-(4-chlorophenyl)but-3-en-2-one (467) 
 
Following General Procedure C, 466 (0.82 g, 2.87 mmol) in CH2Cl2 (3 mL), DMSO (1.63 mL, 23.0 
mmol, 8 equiv) in CH2Cl2 (5 mL), oxalyl chloride (0.98 mL, 11.5 mmol, 4 equiv) in CH2Cl2 (46 mL) 
and Et3N (8.0 mL, 57.4 mmol, 20 equiv) gave, after purification by column chromatography 
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accordance with the literature.8 mp 110–111 °C {Lit.8 108–110 °C}; 1H NMR (400 MHz, CDCl3) 
δH: 7.33 (1H, d, J 15.7, C(3)H), 7.42–7.47 (2H, m, ArC(2,6)H), 7.58–7.65 (2H, m, ArC(3,5)H), 7.97 
(1H, d, J 15.7, C(4)H).  
(E)-4-(4-Bromophenyl)-1,1,1-trichlorobut-3-en-2-ol (468) 
 
Following General Procedure B, 4-bromocinnamyl aldehyde (0.97 g, 4.61 mmol), chloroform 
(0.81 mL, 10.1 mmol, 2.2 equiv) in DMF (4 mL) and KOH (259 mg, 4.61 mmol, 1.0 equiv) in 
EtOH (4 mL) gave, after purification by column chromatography (Petrol/Et2O 80:20, Rf 0.37), 
468 (0.94 g, 62%) as a yellow solid. Spectroscopic data were in accordance with the literature.8 
mp 62–63 °C {Lit.8 63–65 °C}; 1H NMR (400 MHz, CDCl3) δH: 4.78 (1H, dd, J 6.0, 1.3, C(2)H), 6.39 
(1H, dd, J 15.9, 6.0, C(3)H), 6.87 (1H, d, J 15.9, C(4)H), 7.31–7.35 (2H, m, ArC(2,6)H), 7.48–7.52 
(2H, m, ArC(3,5)H).  
(E)-4-(4-Bromophenyl)-1,1,1-trichlorobut-3-en-2-one (469) 
 
Following General Procedure C, 468 (0.94 g, 2.86 mmol) in CH2Cl2 (3 mL), DMSO (1.63 mL, 22.9 
mmol, 8 equiv) in CH2Cl2 (5 mL), oxalyl chloride (0.98 mL, 11.4 mmol, 4 equiv) in CH2Cl2 (46 mL) 
and Et3N (8.0 mL, 57.2 mmol, 20 equiv) gave, after purification by column chromatography 
(Petrol/Et2O 90:10, Rf 0.41), 469 (0.69 g, 73%) as a white solid. Spectroscopic data were in 
accordance with the literature.8 mp 131–132 °C {Lit.8 133–135 °C}; 1H NMR (500 MHz, CDCl3) 
δH: 7.35 (1H, d, J 15.7, C(3)H), 7.51–7.57 (2H, m, ArC(2,6)H), 7.58–7.64 (2H, m, ArC(3,5)H), 7.96 
(1H, d, J 15.7, C(4)H). 
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(E)-4-(2-Bromophenyl)-1,1,1-trichlorobut-3-en-2-ol (470) 
 
Following General Procedure B, 2-bromocinnamyl aldehyde (1.46 g, 6.92 mmol), chloroform 
(1.22 mL, 15.2 mmol, 2.2 equiv) in DMF (5 mL) and KOH (299 mg, 6.92 mmol, 1.0 equiv) in 
EtOH (4 mL) gave, after purification by column chromatography (Petrol/Et2O 80:20, Rf 0.26), 
470 (1.28 g, 56%) as a white solid. 1H NMR (400 MHz, CDCl3) δH: 3.01 (1H, d, J 5.8, OH), 4.82 
(1H, t, J 5.2, C(2)H), 6.31 (1H, dd, J 15.8, 6.1, C(3)H), 7.14–7.19 (1H, m, ArC(4)H), 7.24–7.33 (2H, 
m, ArC(6)H and C(4)H), 7.54–7.59 (2H, m, ArC(3,5)H). The title compound was carried forward 
immediately without further characterisation due to instability. 
(E)-4-(2-Bromophenyl)-1,1,1-trichlorobut-3-en-2-one (471) 
 
Following General Procedure C, 470 (1.28 g, 3.87 mmol) in CH2Cl2 (4 mL), DMSO (2.20 mL, 31.0 
mmol, 8 equiv) in CH2Cl2 (7 mL), oxalyl chloride (1.33 mL, 15.5 mmol, 4 equiv) in CH2Cl2 (62 mL) 
and Et3N (10.8 mL, 77.4 mmol, 20 equiv) gave, after purification by column chromatography 
(Petrol/Et2O 95:5, Rf 0.33), 471 (1.03 g, 81%) as a light orange solid. mp 60–62 °C; νmax (film, 
cm–1) 1711 (C=O), 1603 (C=C), 1113; 1H NMR (500 MHz, CDCl3) δH: 7.28–7.32 (2H, m, ArC(3)H 
and C(3)H), 7.37–7.40 (1H, m, ArC(6)H), 7.67 (1H, dd, J 8.0, 1.3, ArC(4)H), 7.74 (1H, dd, J 7.8, 
1.7, ArC(5)H), 8.39 (1H, d, J 15.6, C(4)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 96.4 (C(1)), 118.6 
(C(3)H), 126.6 (ArC(1)), 128.0 (ArC(6)H), 128.4 (ArC(5)H), 132.6 (ArC(3)H), 133.9 (ArC(4)H), 
133.9 (ArC(2)), 147.8 (C(4)H), 179.6 (C(2)); HRMS (ASAP+) C10H7O79Br35Cl3 [M+H]+ found 
326.8750, requires 326.8746 (+1.2 ppm). 
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(E)-1,1,1-Trichloro-4-(furan-2-yl)but-3-en-2-ol (472) 
 
Following General Procedure A, 3-(furan-2-yl)acrylaldehyde (5.00 g, 40.9 mmol), Cl3CCO2H 
(10.1 g, 61.4 mmol) and Cl3CCO2Na (11.4 g, 61.4 mmol) in DMF (30 mL) gave, after purification 
by column chromatography (Petrol/Et2O 85:15, Rf 0.25), 472 (3.65 g, 37%) as a dark yellow oil. 
Spectroscopic data were in accordance with the literature.6 1H NMR (500 MHz, CDCl3) δH: 2.96 
(1H, d, J 5.9, OH), 4.77 (1H, td, J 5.8, 1.4, C(2)H), 6.35 (1H, dd, J 15.8, 5.8, C(3)H), 6.40 (1H, d, J 
3.3, ArC(3)H), 6.43 (1H, dd, J 3.4, 1.8, ArC(4)H), 6.74 (1H, dd, J 15.7, 1.4, C(4)H), 7.42 (1H, d, J 
1.8, ArC(5)H).  
(E)-1,1,1-Trichloro-4-(furan-2-yl)but-3-en-2-one (473) 
 
Following General Procedure C, 472 (3.65 g, 15.1 mmol) in CH2Cl2 (15 mL), DMSO (8.58 mL, 
121 mmol, 8 equiv) in CH2Cl2 (28 mL), oxalyl chloride (5.18 mL, 60.4 mmol, 4 equiv) in CH2Cl2 
(240 mL) and Et3N (42.1 mL, 302 mmol, 20 equiv) gave, after purification by column 
chromatography (Petrol/Et2O 90:10, Rf 0.35), 473 (1.12 g, 31%) as a light-yellow solid. 
Spectroscopic data were in accordance with the literature.6 mp 39–40 °C {Lit.6 40–42 °C}; 1H 
NMR (500 MHz, CDCl3) δH: 6.58 (1H, dd, J 3.5, 1.8, ArC(4)H), 6.86 (1H, d, J 3.4, ArC(3)H), 7.24 
(1H, d, J 15.3, C(3)H), 7.59–7.63 (1H, m, ArC(5)H), 7.75 (1H, d, J 15.3, C(4)H). 
(3E,5E)-1,1,1-Trichloro-6-phenylhexa-3,5-dien-2-ol (474) 
 
Following General Procedure B, (2E,4E)-5-phenylpenta-2,4-dienal (2.52 g, 15.9 mmol), 
chloroform (2.80 mL, 35.0 mmol, 2.2 equiv) in DMF (12 mL) and KOH (892 mg, 15.9 mmol, 1.0 
equiv) in EtOH (4 mL) gave, after purification by column chromatography (Petrol/EtOAc 90:10, 
Rf 0.23), 474 (2.47 g, 56%) as a yellow solid. Spectroscopic data were in accordance with the 
literature.8 mp 55–56 °C {Lit.8 57–59 °C}; 1H NMR (400 MHz, CDCl3) δH: 2.93 (1H, d, J 5.9, OH), 
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4.72 (1H, td, J 6.0, 1.1, C(2)H), 5.95–6.05 (1H, m, C(3)H), 6.66–6.80 (2H, m, C(4)H and C(5)H), 
6.80–6.94 (1H, m, C(6)H), 7.24–7.36 (1H, m, ArC(4)H), 7.32–7.45 (2H, m, ArC(2,6)H), 7.41–7.51 
(2H, m, ArC(3,5)H).  
(3E,5E)-1,1,1-Trichloro-6-phenylhexa-3,5-dien-2-one (475) 
 
Following General Procedure C, 474 (2.47 g, 8.90 mmol) in CH2Cl2 (9 mL), DMSO (5.06 mL, 71.2 
mmol, 8 equiv) in CH2Cl2 (16 mL), oxalyl chloride (3.05 mL, 35.6 mmol, 4 equiv) in CH2Cl2 (142 
mL) and Et3N (24.8 mL, 178 mmol, 20 equiv) gave, after purification by column 
chromatography (Petrol/Et2O 80:20, Rf 0.65), 475 (1.57 g, 64%) as a yellow needle. 
Spectroscopic data were in accordance with the literature.8 mp 36–37 °C {Lit.8 38–40 °C}; 1H 
NMR (400 MHz, CDCl3) δH: 6.90–6.97 (1H, m, C(3)H), 7.05 (1H, ddd, J 15.5, 10.6, 0.7, C(5)H), 
7.14 (1H, d, J 15.5, C(6)H), 7.38–7.45 (3H, m, ArC(4,2,6)H), 7.52–7.56 (2H, m, ArC(3,5)H), 7.80 
(1H, dd, J 14.9, 10.6, C(4)H).  
(E)-1,1,1-Trichloronon-3-en-2-ol (476) 
 
Following General Procedure A, (E)-oct-2-enal (2.50 mL, 19.8 mmol), Cl3CCO2H (4.88 g, 29.7 
mmol) and Cl3CCO2Na (5.55 g, 29.7 mmol) in DMF (15 mL) gave, after purification by column 
chromatography (Petrol/Et2O 95:5, Rf 0.21), 476 (2.04 g, 42%) as a yellow oil. Spectroscopic 
data were in accordance with the literature.6 1H NMR (400 MHz, CDCl3) δH: 0.86–0.97 (3H, m, 
CH3), 1.28–1.57 (6H, m, 3 × CH2), 2.09–2.21 (2H, m, C(5)H2), 2.77 (1H, d, J 5.9, OH), 4.54–4.57 
(1H, m, C(2)H), 5.67 (1H, ddt, J 15.4, 6.5, 1.5, C(3)H), 6.04 (1H, dtd, J 15.4, 6.8, 1.1, C(4)H).  
(E)-1,1,1-Trichloronon-3-en-2-one (477) 
 
Following General Procedure C, 476 (2.04 g, 8.32 mmol) in CH2Cl2 (8 mL), DMSO (4.73 mL, 66.6 
mmol, 8 equiv) in CH2Cl2 (15 mL), oxalyl chloride (2.85 mL, 33.3 mmol, 4 equiv) in CH2Cl2 (133 
mL) and Et3N (23.2 mL, 166 mmol, 20 equiv) gave, after purification by column 
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chromatography (Petrol/Et2O 98:2, Rf 0.40), 477 (1.74 g, 86%) as a colorless oil. Spectroscopic 
data were in accordance with the literature.6 1H NMR (400 MHz, CDCl3) δH: 0.90–0.96 (3H, m, 
CH3), 1.32–1.40 (4H, m, 2 × CH2), 1.50–1.57 (2H, m, C(6)H2), 2.34–2.40 (2H, m, C(5)H2), 6.76 
(1H, dt, J 15.3, 1.6, C(3)H), 7.38 (1H, dt, J 15.3, 7.0, C(4)H). 
Methyl 2-(2,5-dimethyl-1H-pyrrol-1-yl)acetate (215) 
 
Following the general procedure by Bard,24 a solution of hexane-2,5-dione (537 mg, 4.70 mmol, 
1.0 eq.), glycine methyl ester hydrochloride (886 mg, 7.05 mmol, 1.5 eq.) and p-TSA 
monohydrate (179 mg, 0.94 mmol, 20 mol%) in toluene (24 mL, 0.2 M) was refluxed for 2 days. 
The mixture was cooled and the toluene was concentrated under reduced pressure. The 
residue was diluted with EtOAc (20 mL) and H2O (20 mL). The two layers were separated and 
the aqueous layer was extracted with EtOAc (3 x 20 mL). The combined organic extracts were 
washed with 1 M aqueous NaOH (10 mL), H2O (10 mL) and brine (10 mL), dried with MgSO4 
and concentrated. The crude material was purified by flash column chromatography (10:90 
EtOAc:petrol, Rf 0.31) to give the titled compound 215 (550 mg, 70%) as a colourless oil. 
Spectroscopic data were in accordance with the literature.25 1H NMR (400 MHz, CDCl3) δH: 2.17 
(6H, s, C(2)ArC(2,5)CH3), 3.76 (3H, s, C(1)OCH3), 4.51 (2H, s, C(2)H2), 5.82 (2H, s, C(2)ArC(3,4)H). 
Methyl 2-(2,5-diphenyl-1H-pyrrol-1-yl)acetate (216) 
 
Following the general procedure by Bard,24 a solution of 1,4-diphenylbutane-1,4-dione (1.12 
g, 4.70 mmol, 1.0 eq.), glycine methyl ester hydrochloride (886 mg, 7.05 mmol, 1.5 eq.) and p-
TSA monohydrate (179 mg, 0.94 mmol, 20 mol%) in toluene (24 mL, 0.2 M) was refluxed for 2 
days. The mixture was cooled and the toluene was concentrated under reduced pressure. The 
residue was diluted with EtOAc (20 mL) and H2O (20 mL). The two layers were separated and 
the aqueous layer was extracted with EtOAc (3 x 20 mL). The combined organic extracts were 
washed with 1 M aqueous NaOH (10 mL), H2O (10 mL) and brine (10 mL), dried with MgSO4 
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and concentrated. The crude material was purified by flash column chromatography (10:90 
EtOAc:petrol) to give the titled compound 216 (753 mg, 55%) as a colourless oil. Spectroscopic 
data were in accordance with the literature.24 1H NMR (400 MHz, DMSO) δH: 3.50 (3H, s, 
C(1)OCH3), 4.65 (2H, s, C(2)H2), 6.22 (2H, s, C(2)ArC(3,4)H), 7.30–7.46 (10 H, m, ArH). 
2-(2,5-Dimethyl-1H-pyrrol-1-yl)acetic acid (217) 
 
Following the general procedure by Bard,24 A solution of methyl 2-(2,5-dimethyl-1H-pyrrol-1-
yl)acetate (215) (970 mg, 5.80 mmol, 1.0 eq.) and LiOH (14 mL, 1 M aqueous) in THF (25 mL) 
was stirred for 2 days until TLC analysis indicated a complete consumption of 215. The reaction 
mixture was quenched with H2O (20 mL) and acidified with 1 M aq. HCl to pH 2 and extracted 
with CH2Cl2 (10 mL x 3). The combined organic extract was dried with MgSO4 and concentrated 
under reduced pressure to afford a crude yellow oil. Acid/base extraction with conc. HCl and 
2 M aq. NaOH afforded the titled compound 217 as a red solid (755 mg, 85%). Spectroscopic 
data were in accordance with the literature.26 mp 134-135 °C {Lit.2 133-134 °C}; 1H NMR (400 
MHz, CDCl3) δH: 2.18 (6H, s, C(2)ArC(2,5)CH3), 4.55 (2H, s, C(2)H2), 5.84 (2H, s, C(2)ArC(3,4)H), 
8.65 (1H, br. s, COOH) 
2-(2,5-Diphenyl-1H-pyrrol-1-yl)acetic acid (218) 
 
Following the general procedure by Bard,24 A solution of methyl 2-(2,5-diphenyl-1H-pyrrol-1-
yl)acetate (216) (2.14 g, 7.35 mmol, 1.0 eq.) and LiOH (20 mL, 1 M aqueous) in THF (30 mL) 
was stirred for 2 days until TLC analysis indicated a complete consumption of 216. The reaction 
mixture was quenched with H2O (50 mL) and acidified with 1 M aq. HCl to pH 2 and extracted 
with CH2Cl2 (10 mL x 3). The combined organic extract was dried with MgSO4 and concentrated 
under reduced pressure to afford a crude white solid. Recrystallization in EtOAc/petrol 
afforded the titled compound 218 as a white solid (1.81 g, 89%). Spectroscopic data were in 
accordance with the literature.24 mp 195 °C {Lit.24 194-197 °C}; 1H NMR (400 MHz, CDCl3) δH: 
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4.66 (2H, s, C(2)H2), 6.34 (2H, s, C(2)ArC(3,4)H), 7.33–7.43 (10H, m, ArH). 
2-(1H-Indol-1-yl)acetic acid (223) 
 
Following the general procedure by Shen,27 to a solution of indole (1.17 g, 10.0 mmol, 1.0 eq.) 
in acetone (33 mL, 0.3 M) was added potassium carbonate (2.76 g, 20 mmol, 2.0 eq.) and ethyl 
bromoacetate (1.65 mL, 15 mmol, 1.5 eq.). The mixture was heated to reflux overnight and 
then the mixture was concentrated under reduced pressure. H2O (100 mL) was added to the 
residue and the resulting mixture was extracted with EtOAc (2 x 100 mL) and the combined 
organic layer was washed with 1 M aq. HCl (50 mL), saturated NaHCO3 (50 mL) and brine (2 x 
100 mL). Then the organic layer was dried over MgSO4, filtered and concentrated under 
reduced pressure to give the crude product as light brown oil that was used immediately in 
the next step. 
To a solution of the crude product obtained from next step (assuming quantitative yield, 10.0 
mmol) in 50 mL THF:EtOH:H2O mixed solvent system (2:2:1) was added NaOH (600 mg, 15 
mmol). The resulting mixture was stirred at room temperature overnight. Then the mixture 
was acidified with 1 M aq. HCl to pH 2 and extracted with EtOAc (3 x 50 mL). The combined 
organic layer was dried with MgSO4 before concentrated under reduced pressure to give the 
crude material which was basified with 2 M aq. NaOH to pH 11 and washed with CH2Cl2 (2 x 
30 mL). The aqueous phase was then extracted with CH2Cl2 (3 x 50 mL), dried and concentrated 
to give the titled compound 223 as a white solid (718 mg, 41% over two-step). Spectroscopic 
data were in accordance with the literature.28 mp 178 °C {Lit.28 175 °C}; 1H NMR (500 MHz, 
CDCl3) δH: 4.90 (2H, s, CH2), 6.58 (1H, d, J 3.2, indoleC(3)H), 7.08 (1H, d, J 3.2, indoleC(2)H), 
7.14 (1H, ddd, J 8.0, 5.5, 2.5, indoleCH), 7.22–7.25 (2H, m, indoleCH), 7.64 (1H, d, J 7.9, 
indoleCH). 
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2-(9H-Carbazol-9-yl)acetic acid (224) 
 
To a solution of carbazole (5.00 g, 30.0 mmol, 1.0 eq.) in DMF (100 mL, 0.3 M) was added ethyl 
bromoacetate (6.68 g, 40.0 mmol, 1.3 eq.). The mixture was stirred at 35 °C for 12 h, after 
which the mixture was poured into 200 mL H2O then filtered. The pH of the filtrate was 
adjusted to 1.0 with 2 M aq. HCl. Crude product was obtained by filtration of the resulting 
solid. After drying under vacuum, the crude solid was recrystallized in CH2Cl2/ethanol mixture 
to give the titled compound 224 as a white flake-like crystal (6.05 g, 89%). Spectroscopic data 
were in accordance with the literature.29 1H NMR (400 MHz, CDCl3) δH: 5.06 (2H, s, CH2), 7.24–
7.38 (4H, m, carbazoleCH), 7.46–7.52 (2H, m, carbazoleCH), 8.12 (2H, d, J 7.7, carbazoleCH). 
 
8.3.3. Michael Addition-lactonization compound data 
6-(Dichloromethyl)-4-phenyl-3-(1H-pyrrol-1-yl)-2H-pyran-2-one (158) 
 
2-(1H-Pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 equiv) was dissolved in anhydrous 
CH2Cl2 (0.1 M) under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (0.087 mL, 0.5 
mmol, 2 equiv) and pivaloyl chloride (0.062 mL, 0.5 mmol, 2 equiv) were added. The reaction 
was stirred at 0 °C for 20 min before warming up to rt. BTM 146 (6.3 mg, 10 mol%), 158 (62.4 
mg, 0.25 mmol, 1 equiv) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 equiv) were added sequentially 
and the reaction stirred at rt. for 24 h. Upon completion of the reaction (checked by TLC), it 
was diluted with CH2Cl2 (equal volume) and washed with 1 M HCl (×2) and brine (×2) before 
being dried over MgSO4, filtered, and concentrated under reduced pressure to give the crude 
product, which was purified by flash silica column chromatography (Petrol/EtOAc 90:10, Rf 
0.32), to give 159 (40.0 mg, 50%) as a brown oil. νmax (film, cm–1) 3105 (C-H), 3005 (C-H), 1713 
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(C=O), 1645, 1474, 1364, 903, 771; 1H NMR (500 MHz, CDCl3) δH: 6.18 (2H, t, J 2.2, C(3)Ar(3,4)H), 
6.41 (1H, s, CCl2H), 6.55 (2H, t, J 2.2, C(3)Ar(2,5)H), 6.77 (1H, s, C(5)H), 7.05–7.07 (2H, m, 
C(4)ArC(2,6)H), 7.32–7.40 (3H, m, C(4)ArC(3,4,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 64.9 
(CCl2), 106.6 (C(5)H), 110.4 (C(3)ArC(3,4)H), 121.9 (C(3)ArC(2,5)H), 124.1 (C(3)), 127.7 
(C(4)ArC(2,6)H), 129.1 (C(4)ArC(3,5)H), 130.4 (C(4)ArC(4)H), 134.0 (C(4)ArC(1)), 146.1 (C(4)), 
154.4 (C(6)), 158.7 (C(2)); HRMS (NSI+) C16H1235Cl2NO2 [M+H]+ found 320.0243, requires 
320.0240 (+1.1 ppm). 
 
Dimethyl (2S,3S)-3-phenyl-2-(1H-pyrrol-1-yl)pentanedioate (167) and dimethyl (2R,3S)-3-
phenyl-2-(1H-pyrrol-1-yl)pentanedioate (203) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 158 (62.4 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with MeOH (2.5 mL) and 
DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product (86:14 dr) that was purified by 
column chromatography (Petrol/EtOAc 90:10 to 85:15) to give:  
(2S,3S)-167 (58.3 mg, 77%) as a colourless oil. [α]D
20 − 35.8 (c 0.6 in CHCl3); Chiralpak OD-H 
(80:20 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 8.8 min, tR (minor): 6.6 
min, 99:1 er; νmax (film, cm–1) 2957 (C-H), 2918 (C-H), 1746 (C=O), 1720 (C=O); 1H NMR (500 
MHz, CDCl3) δH: 2.73 (1H, dd, J 16.0, 6.6, C(4)HAHB), 2.77 (1H, dd, J 16.0, 8.1, C(4)HAHB), 3.58 
(3H, s, C(5)COOCH3), 3.79 (3H, s, C(1)COOCH3), 3.94–3.99 (1H, m, C(3)H), 4.88 (1H, d, J 9.5, 
C(2)H), 5.99 (2H, t, J 2.2, C(2)Ar(3,4)H), 6.54 (2H, t, J 2.2, C(2)Ar(2,5)H), 7.03–7.07 (2H, m, 
C(3)ArC(2,6)H), 7.16–7.22 (3H, m, C(3)ArC(3,4,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 37.1 
(C(4)H2), 45.2 (C(3)H), 52.0 (C(5)COOCH3), 52.8 (C(1)COOCH3), 66.2 (C(2)H), 108.4 
(C(2)ArC(3,4)H), 120.8 (C(2)ArC(2,5)H), 127.6 (C(3)ArC(4)H), 127.9 (C(3)ArC(2,6)H), 128.5 
(C(3)ArC(3,5)H), 138.4 (C(3)ArC(1)), 170.0 (C(1)), 171.6 (C(5)); HRMS (NSI+) C17H20NO4 [M+H]+ 
found 302.1388, requires 302.1387 (+0.4 ppm). 
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(2R,3S)-203 (9.5 mg, 13%) as a light-yellow solid. mp 130–132 °C; [α]D
20 − 9.0 (c 0.1 in CHCl3); 
Chiral HPLC analysis, Chiralpak OJ-H (97.5:2.5 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 
30 °C) tR (major): 17.5 min, tR (minor): 23.4 min, 85:15 er; νmax (film, cm–1) 2957 (C-H), 1748 
(C=O), 1720 (C=O); 1H NMR (500 MHz, CDCl3) δH: 2.28 (1H, dd, J 15.9, 4.1, C(4)HAHB), 2.53 (1H, 
dd, J 15.9, 10.3, C(4)HAHB), 3.43 (3H, s, C(1)COOCH3), 3.46 (3H, s, C(5)COOCH3), 3.96 (1H, td, J 
10.8, 4.1, C(3)H), 4.77 (1H, d, J 11.3, C(2)H), 6.21 (2H, t, J 2.2, C(2)Ar(3,4)H), 6.89 (2H, t, J 2.1, 
C(2)Ar(2,5)H), 7.24–7.27 (3H, m, C(3)ArC(3,4,5)H), 7.30–7.33 (2H, m, C(3)ArC(2,6)H); 13C{1H} 
NMR (126 MHz, CDCl3) δC: 36.8 (C(4)H2), 45.7 (C(3)H), 51.8 (C(5)COOCH3), 52.4 (C(1)COOCH3), 
66.4 (C(2)H), 109.4 (C(2)ArC(3,4)H), 120.5 (C(2)ArC(2,5)H), 127.9 (C(3)ArC(4)H), 128.2 
(C(3)ArC(2,6)H), 128.9 (C(3)ArC(3,5)H), 138.4 (C(3)ArC(1)), 169.5 (C(1)), 171.7 (C(5)); HRMS 




Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 158 (62.4 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product (92:8 dr) that was was triturated in ether to give 168 (79.0 mg, 
70%) as a light yellow solid. mp 218–220 °C. [α]D
20 + 3.0 (c 0.19 in DMSO); Chiral HPLC analysis, 
Chiralpak AD-H (90: 10 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 28.0 min, 
tR (minor): 17.3 min, 99.8:0.2 er; νmax (film, cm-1) 3279 (N-H), 3088 (C-H), 3028 (C-H), 1639 (C=O); 
1H NMR (500 MHz, CDCl3) δH: 2.62–2.69 (2H, m, C(4)HAHB), 4.08 (1H, dt, J 9.4, 6.1, C(3)H), 4.27–
4.37 (2H, m, C(5)NHCH2Ph), 4.37–4.45 (2H, m, C(1)NHCH2Ph), 5.23 (1H, d, J 9.4, C(2)H), 5.67 
(1H, t, J 5.8, C(5)NH), 5.99 (2H, t, J 2.1, C(2)Ar(3,4)H), 6.58 (2H, t, J 2.2, C(2)Ar(2,5)H), 6.62 (1H, 
t, J 5.9, C(1)NH), 7.03–7.05 (2H, m, C(5)NHCH2ArC(2,6)H), 7.11–7.19 (7H, m, 
C(1)NHCH2ArC(3,4,5,6)H + C(5)NHCH2ArC(3,4,5)H), 7.23–7.30 (6H, m, C(3)ArC(2,3,4,5,6)H + 
C(1)NHCH2ArC(2)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 40.0 (C(4)H2), 43.7 (C(1)NHCH2 + 
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C(5)NHCH2), 45.0 (C(3)H), 66.0 (C(2)H), 108.9 (C(2)ArC(3,4)H), 120.9 (C(2)ArC(2,5)H), 127.4 
(C(3)ArC(2,6)H), 127.6 (C(3)ArC(3,5)H), 127.7 (C(3)ArC(4)H), 127.8 (C(1)NHCH2ArC(2,6)H + 
C(5)NHCH2ArC(2,6)H), 128.2 (C(1)NHCH2ArC(3,5)H + C(5)NHCH2ArC(3,5)H), 128.6 
(C(1)NHCH2ArC(4)H), 128.8 (C(5)NHCH2ArC(4)H), 137.8 (C(1)NHCH2ArC(1) + C(5)NHCH2ArC(1)), 
139.3 (C(3)ArC(1)), 169.8 (C(1)), 170.9 (C(5)); HRMS (NSI+) C29H30N3O2 [M+H]+ found 452.2330, 




Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 158 (62.4 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with morpholine (2.5 mL) 
at rt for 24 h gave crude product (87:13 dr) that was purified by column chromatography (60:40 
hexane/EtOAc) to give 169 (56.6 mg, 55%) as a white solid. mp 186–188 °C; [α]D
20 − 51.3 (c 
0.32 in CHCl3); Chiral HPLC analysis, Chiralpak AD-H (90:10 hexane/i-PrOH, flow rate 1 mLmin-
1, 211 nm, 30 °C) tR (major): 50.8 min, tR (minor): 23.4 min, 99:1 er; νmax (film, cm-1) 2955 (C-H), 
2851 (C-H), 1634 (C=O), 1614 (C=O); 1H NMR (500 MHz, CDCl3) δH: 2.72 (1H, dd, J 14.8, 6.8, 
C(4)HAHB), 2.85 (1H, dd, J 14.8, 5.7, C(4)HAHB), 3.13–3.18 (1H, m, C(1)NC(2)H), 3.24–3.28 (1H, 
m, C(1)NC(2)H), 3.34–3.39 (2H, m, C(1)NC(6)H), 3.43–3.69 (11H, m, C(1)NC(6)H + 
C(1)NC(3,5)H2 + C(5)NC(2,3,5,6)H2), 3.76–3.80 (1H, m, C(5)NC(2)H), 3.98 (1H, dt, J 9.4, 6.2, 
C(3)H), 5.46 (1H, d, J 9.5, C(2)H), 5.92 (2H, t, J 2.1, C(2)Ar(3,4)H), 6.48 (2H, t, J 2.1, C(2)Ar(2,5)H), 
7.08–7.10 (2H, m, C(3)ArC(2,6)H), 7.14–7.20 (3H, m, C(3)ArC(3,4,5)H); 13C{1H} NMR (126 MHz, 
CDCl3) δC: 35.7 (C(4)H2), 42.0 (C(1)NC(2)H2), 43.0 (C(5)NC(2)H2), 45.9 (C(3)H), 46.4 
(C(1)NC(6)H2), 46.6 (C(1)NC(6)H2), 61.0 (C(2)H), 66.5 (C(1)NC(3)H2), 66.6 (C(5)NC(3)H2), 66.8 
(C(1)NC(5)H2), 66.8 (C(5)NC(5)H2), 108.6 (C(2)ArC(3,4)H), 120.2 (C(2)ArC(2,5)H), 127.4 
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(C(3)ArC(4)H), 128.4 (C(3)ArC(2,6)H + C(3)ArC(3,5)H), 138.9 (C(3)ArC(1)), 167.4 (C(1)), 169.9 




Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 158 (62.4 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with pyrrolidine (2.5 mL) at 
rt for 24 h gave crude product (88:12 dr) that was purified by column chromatography (EtOAc, 
Rf 0.21) to give 170 (47.4 mg, 50%) as a white solid. mp 174–177 °C; [α]D
20 − 79.5 (c 0.41 in 
CHCl3); Chiral HPLC analysis, Chiralpak AS-H (95:5 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 
30 °C) tR (major): 20.6 min, tR (minor): 15.5 min, 99:1 er; νmax (film, cm-1) 2976 (C-H), 2870 (C-
H), 1637 (C=O), 1624 (C=O), 1443 (Ar); 1H NMR (500 MHz, CDCl3) δH: 1.64–1.91 (7H, m, 
C(1)NC(3,4)H2 + C(5)NC(3,4)H2), 1.92–2.00 (1H, m, C(1)NC(3)H), 2.69–2.74 (2H, m, C(4)H2), 
2.76–2.79 (1H, m, C(1)NC(2)H), 3.19–3.24 (1H, m, C(1)NC(2)H), 3.32–3.40 (3H, m, C(1)NC(5)H2 
+ C(5)NC(2)H), 3.41–3.46 (1H, m, C(5)NC(2)H), 3.50–3.55 (1H, m, C(5)NC(5)H), 3.89–3.94 (1H, 
m, C(5)NC(5)H), 4.01–4.05 (1H, m, C(3)H), 5.60 (1H, d, J 10.0, C(2)H), 5.89–5.90 (2H, m, 
C(2)Ar(3,4)H), 6.62–6.63 (2H, m, C(2)Ar(2,5)H), 7.11–7.17 (5H, m, C(3)ArCH); 13C{1H} NMR (126 
MHz, CDCl3) δC: 24.3 (C(5)NC(3)H2), 24.5 (C(1)NC(3)H2), 26.1 (C(5)NC(4)H2), 26.1 (C(1)NC(4)H2), 
37.6 (C(4)H2), 45.7 (C(3)H), 46.3 (C(5)NC(5)H2), 46.4 (C(1)NC(5)H2), 47.0 (C(5)NC(1)H2 + 
C(1)NC(1)H2), 62.4 (C(2)H), 107.9 (C(2)ArC(3,4)H), 120.5 (C(2)ArC(2,5)H), 127.1 (C(3)ArC(4)H), 
128.2 (C(3)ArC(2,6)H), 128.4 (C(3)ArC(3,5)H), 139.7 (C(3)ArC(1)), 167.5 (C(1)), 170.1 (C(5)); 
HRMS (NSI+) C23H30N3O2 [M+H]+ found 380.2328, requires 380.2333 (–1.2 ppm). 
Selected data for minor diastereoisomer: Chiral HPLC analysis, Chiralpak OD-H (90:10 
hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 20.5 min, tR (minor): 25.4 min, 
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81:19 er; 1H NMR (500 MHz, CDCl3) δH: 1.51–1.60 (1H, m, C(1)NC(3)H), 1.66–1.79 (7H, m, 
C(1)NC(3,4)H2 + C(5)NC(3,4)H2), 2.26–2.34 (2H, m, C(4)H2), 2.94–2.99 (1H, m, C(5)NC(5)H), 
3.06–3.15 (2H, m, C(1)NC(2)H + C(1)NC(2)H), 3.20–3.34 (5H, m, C(5)NC(5)H + C(1)NC(5)H2 + 
C(5)NC(2)H + C(5)NC(2)H), 4.10 (1H, ddd, J 11.4, 7.3, 4.8, C(3)H), 5.32 (1H, d, J 10.9, C(2)H), 
6.16 (2H, t, J 2.1, C(2)Ar(3,4)H), 7.01 (2H, t, J 2.2, C(2)Ar(2,5)H), 7.18–7.21 (1H, m, C(3)ArC(4)H), 
7.25–7.28 (2H, m, C(3)ArC(2,6)H), 7.35–7.37 (2H, m, C(3)ArC(3,4)H); 13C{1H} NMR (126 MHz, 
CDCl3) δC: 24.1 (C(5)NC(3)H2), 24.4 (C(1)NC(3)H2), 26.0 (C(5)NC(4)H2), 26.1 (C(1)NC(4)H2), 35.7 
(C(4)H2), 45.6 (C(1)NC(5)H2), 45.8 (C(5)NC(5)H2), 46.0 (C(3)H), 46.5 (C(5)NC(1)H2), 46.7 
(C(1)NC(1)H2), 63.1 (C(2)H), 108.5 (C(2)ArC(3,4)H), 120.9 (C(2)ArC(2,5)H), 127.2 (C(3)ArC(4)H), 
128.5 (C(3)ArC(2,6)H), 128.5 (C(3)ArC(3,5)H), 140.3 (C(3)ArC(1)), 167.1 (C(1)), 169.6 (C(5)). 
 
Dimethyl (2S,3S)-3-(4-methoxyphenyl)-2-(1H-pyrrol-1-yl)pentanedioate (173) and dimethyl 
(2R,3S)-3-(4-methoxyphenyl)-2-(1H-pyrrol-1-yl)pentanedioate (478) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 453 (69.9 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with MeOH (2.5 mL) and 
DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product (88:11 dr) that was purified by 
column chromatography (Petrol/EtOAc 90:10 to 85:15) to give:  
(2S,3S)-173 (65.4 mg, 79%) as a yellow oil. [α]D
20 − 20.0 (c 0.15 in CHCl3); Chiral HPLC analysis, 
Chiralpak AD-H (95:5 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 15.3 min, 
tR (minor): 13.7 min, 99.7:0.3 er; νmax (film, cm–1) 2999 (C-H), 2953 (C-H), 1740 (C=O), 1514 (Ar 
C=C); 1H NMR (500 MHz, CDCl3) δH: 2.66–2.74 (2H, m, C(4)HAHB), 3.58 (3H, s, C(5)COOCH3), 
3.74 (3H, s, OCH3), 3.76 (3H, s, C(1)COOCH3), 3.89–3.94 (1H, m, C(3)H), 4.84 (1H, d, J 9.2, C(2)H), 
6.00 (2H, t, J 2.2, C(2)Ar(3,4)H), 6.53 (2H, t, J 2.2, C(2)Ar(2,5)H), 6.71–6.74 (2H, m, 
C(3)ArC(3,5)H), 6.93–6.96 (2H, m, C(3)ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 37.2 
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(C(4)H2), 44.4 (C(3)H), 52.0 (C(5)COOCH3), 52.7 (C(1)COOCH3), 55.2 (OCH3), 66.3 (C(2)H), 108.4 
(C(2)ArC(3,4)H), 113.9 (C(3)ArC(3,5)H), 120.9 (C(2)ArC(2,5)H), 129.0 (C(3)ArC(2,6)H), 130.3 
(C(3)ArC(1)), 158.9 (C(3)ArC(4)), 170.1 (C(1)), 171.7 (C(5)); HRMS (ASAP+) C18H22NO5 [M+H]+ 
found 332.1496, requires 332.1498 (-0.6 ppm). 
(2R,3S)-478 (8.9 mg, 11%) as a white solid. mp 90–92 °C; [α]D
20 − 5.0 (c 0.15 in CHCl3); Chiral 
HPLC analysis, Chiralpak AD-H (97.5:2.5 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR 
(major,2R,3S): 23.1 min, tR (minor,2S,3R): 20.6 min, 85.5:14.5 er; νmax (film, cm–1) 2953 (C-H), 
1744 (C-H), 1516 (Ar);
 1H NMR (400 MHz, CDCl3) δH: 2.25 (1H, dd, J 15.8, 4.1, C(4)HAHB), 2.48 
(1H, dd, J 15.8, 10.4, C(4)HAHB), 3.46 (3H, s, C(1)COOCH3), 3.47 (3H, s, C(5)COOCH3), 3.79 (3H, 
s, OCH3), 3.88–3.93 (1H, m, C(3)H), 4.72 (1H, d, J 11.3, C(2)H), 6.20 (2H, t, J 2.2, C(2)Ar(3,4)H), 
6.83–6.86 (2H, m, C(3)ArC(3,5)H), 6.88 (2H, t, J 2.2, C(2)Ar(2,5)H), 7.16–7.19 (2H, m, 
C(3)ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 36.9 (C(4)H2), 44.9 (C(3)H), 51.8 
(C(5)COOCH3), 52.4 (C(1)COOCH3), 55.3 (O-CH3), 66.5 (C(2)H), 109.3 (C(2)ArC(3,4)H), 114.2 
(C(3)ArC(3,5)H), 120.5 (C(2)ArC(2,5)H), 129.3 (C(3)ArC(2,6)H), 130.2 (C(3)ArC(1)), 159.1 
(C(3)ArC(4)), 169.6 (C(1)), 171.8 (C(5)); HRMS (NSI+) C18H22NO5 [M+H]+ found 332.1495, 




Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 453 (69.9 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product (>95 : 5 dranti:syn) that was triturated in ether to give 174 (80.0 mg, 
67%) as a white solid. mp 194–195 °C. [α]D
20 + 3.2 (c 0.16 in DMSO); Chiral HPLC analysis, 
Chiralpak AD-H (90: 10 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 40.7 min, 
tR (minor): 28.4 min, >99.5:0.5 er; νmax (film, cm-1) 3289 (N-H), 3088 (C-H), 1639 (C=O); 1H NMR 
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(500 MHz, CDCl3) δH: 2.57–2.65 (2H, m, C(4)HAHB), 3.74 (3H, s, C(3)ArC(4)OCH3), 4.05 (1H, dt, J 
9.1, 6.3, C(3)H), 4.28–4.37 (2H, m, C(5)NHCH2Ph), 4.40 (2H, app. d, J 5.8, C(1)NHCH2Ph), 5.17 
(1H, d, J 9.1, C(2)H), 5.69 (1H, t, J 5.8, C(5)NH), 6.00 (2H, t, J 2.1, C(2)Ar(3,4)H), 6.56–6.58 (3H, 
m, C(2)Ar(2,5)H + C(1)NH), 6.68–6.71 (2H, m, C(3)ArC(3,5)H), 7.02–7.06 (4H, m, C(3)ArC(2,6)H 
+ C(1)NHCH2ArC(2,6)H), 7.13–7.16 (2H, m, C(5)NHCH2ArC(2,6)H), 7.22–7.30 (6H, m, 
C(1)NHCH2ArC(3,4,5)H + C(5)NHCH2ArC(3,4,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 40.1 
(C(4)H2), 43.7 (C(1)NHCH2 + C(5)NHCH2), 44.1 (C(3)H), 55.2 (C(3)ArC(4)OCH3), 66.2 (C(2)H), 
108.9 (C(2)ArC(3,4)H), 113.9 (C(3)ArC(3,5)H), 121.0 (C(2)ArC(2,5)H), 127.6 
(C(1)NHCH2ArC(2,6)H), 127.7 (C(5)NHCH2ArC(2,6)H), 127.8 (C(1)NHCH2ArC(3,4,5)H), 128.8 
(C(5)NHCH2ArC(3,4,5)H), 129.3 (C(3)ArC(2,6)H), 131.1 (C(3)ArC(1)), 137.8 (C(1)NHCH2ArC(1)), 
137.9 (C(5)NHCH2ArC(1)), 158.8 (C(3)ArC(4)), 169.9 (C(1)), 171.0 (C(5)); HRMS (NSI+) 
C30H32N3O3 [M+H]+ found 482.2430, requires 482.2438 (-1.7 ppm). 
 
Dimethyl (2S,3S)-3-(3-methoxyphenyl)-2-(1H-pyrrol-1-yl)pentanedioate (175) and dimethyl 
(2R,3S)-3-(3-methoxyphenyl)-2-(1H-pyrrol-1-yl)pentanedioate (479) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 455 (69.9 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with MeOH (2.5 mL) and 
DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product (77:23 dr) that was purified by 
column chromatography (Petrol/EtOAc 80:20) to give:  
(2S,3S)-175 (43.0 mg, 52%) as a colourless oil. [α]D
20 − 30.5  (c 0.2 in CHCl3); Chiral HPLC 
analysis, Chiralpak AD-H (95:5 hexane/i-PrOH, flow rate 1 mLmin-1, 254 nm, 30 °C) tR (major): 
13.4 min, tR (minor): 11.4 min, 98.5:1.5 er; νmax (film, cm–1) 2951 (C-H), 1728 (C=O);
 1H NMR 
(500 MHz, CDCl3) δH: 2.71 (1H, dd, J 16.0, 6.3, C(4)HAHB), 2.77 (1H, dd, J 16.0, 8.4, C(4)HAHB), 
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3.60 (3H, s, C(5)COOCH3), 3.70 (3H, s, OCH3), 3.76 (3H, s, C(1)COOCH3), 3.91–3.96 (1H, m, 
C(3)H), 4.84 (1H, d, J 9.4, C(2)H), 6.00 (2H, t, J 2.2, C(2)Ar(3,4)H), 6.52–6.53 (1H, m, 
C(3)ArC(2)H), 6.55 (2H, t, J 2.2, C(2)Ar(2,5)H), 6.65 (1H, app. d, J 7.7, C(3)ArC(4)H), 6.71 (1H, 
ddd, J 8.3, 2.6, 0.9, C(3)ArC(6)H), 7.11 (1H, t, J 7.9, C(3)ArC(5)H); 13C{1H} NMR (126 MHz, CDCl3) 
δC: 36.9 (C(4)H2), 45.1 (C(3)H), 52.0 (C(5)COOCH3), 52.7 (C(1)COOCH3), 55.3 (OCH3), 66.2 
(C(2)H), 108.5 (C(2)ArC(3,4)H), 113.1 (C(3)ArC(6)H), 113.8 (C(3)ArC(2)H), 120.0 (C(3)ArC(4)H), 
120.9 (C(2)ArC(2,5)H), 129.4 (C(3)ArC(5)H), 140.1 (C(3)ArC(1)), 159.5 (C(3)ArC(3)), 170.0 (C(1)), 
171.6 (C(5)); HRMS (NSI+) C18H22NO5 [M+H]+ found 332.1493, requires 332.1492 (+0.2 ppm). 
(2R,3S)-479 (12.8 mg, 15%) as a white solid. mp 76–78 °C; [α]D
20 − 6.0 (c 0.3 in CHCl3); Chiral 
HPLC analysis, Chiralpak AD-H (95:5 hexane/i-PrOH, flow rate 1 mLmin-1, 254 nm, 30 °C) tR 
(major): 12.7 min, tR (minor): 11.6 min, 82:18 er; νmax (film, cm–1) 2953 (C-H), 1740 (C=O); 1H 
NMR (500 MHz, CDCl3) δH: 2.27 (1H, dd, J 15.9, 4.2, C(4)HAHB), 2.52 (1H, dd, J 15.9, 10.2, 
C(4)HAHB), 3.47 (3H, s, C(1)COOCH3), 3.48 (3H, s, C(5)COOCH3), 3.79 (3H, s, OCH3), 3.91–3.96 
(1H, m, C(3)H), 4.76 (1H, d, J 11.2, C(2)H), 6.21 (2H, t, J 2.1, C(2)Ar(3,4)H), 6.77–6.81 (2H, m, 
C(3)ArC(2,4)H), 6.85 (1H, app. d, J 7.7, C(3)ArC(6)H), 6.87 (2H, t, J 2.2, C(2)Ar(2,5)H), 7.23 (1H, 
t, J 7.8, C(3)ArC(5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 36.7 (C(4)H2), 45.7 (C(3)H), 51.8 
(C(5)COOCH3), 52.5 (C(1)COOCH3), 55.4 (OCH3), 66.3 (C(2)H), 109.4 (C(2)ArC(3,4)H), 113.2 
(C(3)ArC(4)H), 114.0 (C(3)ArC(2)H), 120.4 (C(3)ArC(6)H), 120.6 (C(2)ArC(2,5)H), 129.9 
(C(3)ArC(5)H), 140.1 (C(3)ArC(1)), 159.8 (C(3)ArC(3)), 169.5 (C(1)), 171.7 (C(5)); HRMS (NSI+) 
C18H22NO5 [M+H]+ found 332.1493, requires 332.1492 (+0.2 ppm). 
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(2S,3S)-N1,N5-Dibenzyl-3-(3-methoxyphenyl)-2-(1H-pyrrol-1-yl)pentanediamide (176) 
 
Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 455 (69.9 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product (>95:5 dr) that was purified by column chromatography 
(hexane/EtOAc 50:50 to 40:60) to give 176 (69.8 mg, 58%) as a white solid. mp 158–160 °C; 
[α]D
20 + 4.2 (c 0.12 in DMSO); Chiral HPLC analysis, Chiralpak AD-H (90:10 hexane/i-PrOH, flow 
rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 23.5 min, tR (minor): 20.2 min, 99.5:0.5 er; νmax (film, 
cm-1) 3279 (N-H), 3088 (C-H), 2922 (C-H), 1639 (C=O); 1H NMR (500 MHz, CDCl3) δH: 2.64–2.71 
(2H, m, C(4)HAHB), 3.70 (3H, s, C(3)ArC(4)OCH3), 4.10 (1H, dt, J 9.3, 6.2, C(3)H), 4.32 (1H, dd, J 
14.8, 5.6, C(5)NHCHAHBPh), 4.37 (1H, dd, J 14.8, 5.8, C(5)NHCHAHBPh), 4.43 (2H, app d, J 5.9, 
C(1)NHCH2Ph), 5.22 (1H, d, J 9.3, C(2)H), 5.74 (1H, t, J 5.7, C(5)NH), 6.03 (2H, t, J 2.1, 
C(2)Ar(3,4)H), 6.61–6.64 (3H, m, C(2)Ar(2,5)H + C(1)NH), 6.70 (1H, t, J 2.1, C(3)ArC(2)H), 6.73–
6.75 (2H, m, C(3)ArC(4,6)H), 7.06–7.08 (2H, m, C(1)NHCH2ArC(2,6)H), 7.12 (1H, t, J 7.9, 
C(3)ArC(5)H), 7.17–7.18 (2H, m C(5)NHCH2ArC(2,6)H), 7.25–7.32 (6H, m 
C(1)NHCH2ArC(3,4,5)H + C(5)NHCH2ArC(3,4,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 39.9 
(C(4)H2), 43.7 (C(1)NHCH2), 43.7 (C(5)NHCH2), 44.8 (C(3)H), 55.2 (C(3)ArC(3)OCH3), 66.0 (C(2)H), 
108.9 (C(2)ArC(3,4)H), 112.9 (C(3)ArC(4)H), 114.0 (C(3)ArC(2)H), 120.4 (C(3)ArC(6)H), 120.9 
(C(2)ArC(2,5)H), 127.6 (C(5)NHCH2ArC(2,6)H), 127.6 (C(1)NHCH2ArC(2,6)H), 127.7 
(C(1)NHCH2ArC(3,4,5)H), 128.8 (C(5)NHCH2ArC(3,4,5)H), 129.5 (C(3)ArC(5)H), 137.8 
(C(5)NHCH2ArC(1)), 137.8 (C(1)NHCH2ArC(1)), 140.9 (C(3)ArC(1)), 159.6 (C(3)ArC(3)), 169.8 
(C(1)), 170.9 (C(5)); HRMS (NSI+) C30H32N3O3 [M+H]+ found 482.2430, requires 482.2438 (–1.7 
ppm). 
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Dimethyl (2S,3S)-2-(1H-pyrrol-1-yl)-3-(4-(trifluoromethyl)phenyl)pentanedioate (177) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 457 (79.4 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with MeOH (2.5 mL) and 
DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product (91:9 dr) that was purified by column 
chromatography (Petrol/EtOAc 90:10) to give: 
(2S,3S)-177 (60.9 mg, 66%) as a light yellow oil. [α]D
20 − 25.2 (c 0.29 in CHCl3); Chiral HPLC 
analysis, Chiralpak OD-H (95:5 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 
13.7 min, tR (minor): 11.0 min, 97:3 er; νmax (film, cm–1) 2957 (C-H), 1740 (C=O), 1325; 1H NMR 
(500 MHz, CDCl3) δH: 2.77 (2H, d, J 7.2, C(4)HAHB), 3.59 (3H, s, C(5)COOCH3), 3.77 (3H, s, 
C(1)COOCH3), 4.04 (1H, dt, J 9.5, 7.3, C(3)H), 4.86 (1H, d, J 9.6, C(2)H), 5.99 (2H, t, J 2.2, 
C(2)Ar(3,4)H), 6.52 (2H, t, J 2.1, C(2)Ar(2,5)H), 7.16 (2H, d, J 8.1, C(3)ArC(2,6)H), 7.45 (2H, d, J 
8.1, C(3)ArC(3,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 36.9 (C(4)H2), 45.0 (C(3)H), 52.1 
(C(5)COOCH3), 52.9 (C(1)COOCH3), 65.8 (C(2)H), 108.9 (C(2)ArC(3,4)H), 120.7 (C(2)ArC(2,5)H), 
124.1 (q, J 272.1, CF3), 125.4 (q, J 3.8, C(3)ArC(3,5)H), 128.4 (C(3)ArC(2,6)H), 129.8 (q, J 32.5, 
C(3)ArC(4)), 142.6 (C(3)ArC(1)), 169.6 (C(1)), 171.2 (C(5)); 19F NMR (471 MHz, CDCl3) δF: –62.6 
(s, CF3); HRMS (ASAP+) C18H19NO4F3 [M+H]+ found 370.1267, requires 370.1266 (+0.3 ppm); 
Selected data for minor diastereoisomer (2R,3S): 1H NMR (500 MHz, CDCl3) δH: 2.34 (1H, dd, J 
16.2, 4.0, C(4)HAHB), 2.55 (1H, dd, J 16.2, 10.3, C(4)HAHB), 3.49 (3H, s, C(1)COOCH3), 3.51 (3H, 
s, C(5)COOCH3), 4.06 (1H, td, J 10.7, 4.0, C(3)H), 4.82 (1H, d, J 11.2, C(2)H), 6.25 (2H, t, J 2.2, 
C(2)Ar(3,4)H), 6.89 (2H, t, J 2.2, C(2)Ar(2,5)H), 7.39–7.45 (2H, m, C(3)ArC(2,6)H), 7.58–7.65 (2H, 
m, C(3)ArC(3,5)H). 
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Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 457 (79.4 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product (> 95 : 5 dranti:syn) that was triturated in ether to give 178 (77.9 mg, 
60%) as a white solid. mp 204–205 °C; [α]D
20 − 1.5 (c 0.24 in DMSO); Chiral HPLC analysis, 
Chiralpak AD-H (90:10 hexane/i-PrOH, flow rate 1 mLmin-1, 220 nm, 30 °C) tR (major): 17.5 min, 
tR (minor): 14.3 min, 99.5:0.5 er; νmax (film, cm-1) 3294 (N-H), 3088 (C-H), 1639 (C=O), 1557; 1H 
NMR (500 MHz, DMSO) δH: 2.42 (1H, dd, J 14.1, 3.7, C(4)HAHB), 2.65 (1H, dd, J 14.1, 11.4, 
C(4)HAHB), 3.91 (1H, dd, J 15.5, 5.1, C(5)NHCHAHBPh), 4.03–4.08 (1H, m, C(3)H), 4.22–4.29 (2H, 
m, C(5)NHCHAHBPh + C(1)NHCHAHBPh), 4.40 (1H, dd, J 15.0, 5.9, C(1)NHCHAHBPh), 5.01 (1H, d, 
J 11.3, C(2)H), 5.78 (2H, t, J 2.2, C(2)Ar(3,4)H), 6.67–6.69 (4H, m, C(2)Ar(2,5)H + 
C(1)NHCH2ArC(2,6)H), 7.06–7.09 (2H, m, C(5)NHCH2ArC(2,6)H), 7.11–7.14 (1H, m, 
C(1)NHCH2ArC(4)H), 7.21–7.22 (2H, m C(5)NHCH2ArC(3,5)H), 7.23–7.27 (1H, m, 
C(5)NHCH2ArC(4)H), 7.29–7.32 (2H, m, C(1)NHCH2ArC(3,5)H), 7.35 (2H, app. d, J 8.0, 
C(3)ArC(2,6)H), 7.52 (2H, app. d, J 8.1, C(3)ArC(3,5)H), 8.28–8.30 (1H, m, C(5)NH), 8.91 (1H, t, 
J 5.8, C(1)NH); 13C{1H} NMR (126 MHz, DMSO) δC: 38.9 (C(4)H2), 42.1 (C(5)NHCH2), 42.8 
(C(1)NHCH2), 45.1 (C(3)H), 65.8 (C(2)H), 108.0 (C(2)ArC(3,4)H), 120.3 (C(2)ArC(2,5)H), 124.8 (q, 
J 271.9, C(3)ArC(4)CF3), 125.1 (d, J 4.2, C(3)ArC(3,5)H), 126.9 (C(1)NHCH2ArC(2,6)H), 127.0 
(C(1)NHCH2ArC(4)H), 127.5 (C(5)NHCH2ArC(4)H), 127.9 (C(5)NHCH2ArC(3,5)H), 128.3 
(C(5)NHCH2ArC(2,6)H), 128.9 (C(1)NHCH2ArC(3,5)H), 129.5 (C(3)ArC(2,6)H), 139.1 
(C(1)NHCH2ArC(1)), 139.6 (C(5)NHCH2ArC(1)), 145.0 (C(3)ArC(1)), 168.9 (C(1)), 169.6 (C(5)); 19F 
NMR (471 MHz, DMSO) δF: –60.7; HRMS (NSI+) C30H29N3O2F3 [M+H]+ found 520.2199, requires 
520.2206 (–1.4 ppm). 
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Dimethyl (2S,3S)-3-(4-nitrophenyl)-2-(1H-pyrrol-1-yl)pentanedioate (179) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 459 (73.6 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with MeOH (2.5 mL) and 
DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product (89:11 dr) that was purified by 
column chromatography (Petrol/EtOAc 85:15 to 75:25) to give: 
(2S,3S)-179 (70.1 mg, 81%) as a light yellow oil. [α]D
20 − 40.0 (c 0.11 in CHCl3); Chiral HPLC 
analysis, Chiralpak OD-H (95:5 hexane/i-PrOH, flow rate 1 mLmin-1, 220 nm, 30 °C) tR (major): 
40.3 min, tR (minor): 37.5 min, 98.5:1.5 er; νmax (film, cm–1) 2957 (C-H), 1736 (C=O), 1700 (C=O), 
1520 (N-O), 1344 (N-O); 1H NMR (500 MHz, CDCl3) δH: 2.75–2.84 (2H, m, C(4)HAHB), 3.58 (3H, 
s, C(5)COOCH3), 3.78 (3H, s, C(1)COOCH3), 4.07–4.12 (1H, m, C(3)H), 4.84 (1H, d, J 10.0, C(2)H), 
5.98 (2H, t, J 2.2, C(2)Ar(3,4)H), 6.51 (2H, t, J 2.2, C(2)Ar(2,5)H), 7.22–7.23 (2H, m, 
C(3)ArC(2,6)H), 8.04–8.05 (2H, m, C(3)ArC(3,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 36.9 
(C(4)H2), 45.1 (C(3)H), 52.2 (C(5)COOCH3), 53.1 (C(1)COOCH3), 65.6 (C(2)H), 109.2 
(C(2)ArC(3,4)H), 120.5 (C(2)ArC(2,5)H), 123.7 (C(3)ArC(3,5)H), 128.9 (C(3)ArC(2,6)H), 146.1 
(C(3)ArC(1)), 147.3 (C(3)ArC(4)), 169.4 (C(1)), 170.9 (C(5)); HRMS (NSI+) C17H19N2O6 [M+H]+ 
found 347.1242, requires 347.1238 (+1.3 ppm). 
Selected data for minor diastereoisomer (2R,3S): 1H NMR (500 MHz, CDCl3) δH: 2.36 (1H, dd, J 
16.4, 3.9, C(4)HAHB), 2.57 (1H, dd, J 16.4, 10.4, C(4)HAHB), 3.51 (3H, s, C(1)COOCH3), 3.52 (3H, 
s, C(5)COOCH3), 4.08–4.13 (1H, m, C(3)H), 4.85 (1H, d, J 11.0, C(2)H). 
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(2S,3S)-N1,N5-Dibenzyl-3-(4-nitrophenyl)-2-(1H-pyrrol-1-yl)pentanediamide (180) 
 
Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 459 (73.6 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product (>95:5 dr) that was purified by column chromatography 
(petrol/EtOAc 50:50 to 30:70) to give 180 (68.3 mg, 55%) as a light-brown solid. mp 182–184 °C; 
[α]D
20 − 9.5 (c 0.21 in DMSO); Chiral HPLC analysis, Chiralpak AD-H (90:10 hexane/i-PrOH, flow 
rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 59.9 min, tR (minor): 33.6 min, 98:2 er; νmax (film, cm-
1) 3327 (N-H), 3281 (N-H), 3088 (C-H), 1639 (C=O), 1522 (N-O), 1358 (N-O); 1H NMR (500 MHz, 
CDCl3) δH: 2.67 (1H, dd, J 14.9, 6.5, C(4)HAHB), 2.70 (1H, dd, J 15.1, 5.9, C(4)HAHB), 4.21 (1H, dt, 
J 9.3, 6.1, C(3)H), 4.33 (2H, app d, J 5.8, C(5)NHCH2Ph), 4.36–4.45 (2H, m, C(1)NHCH2Ph), 5.25 
(1H, d, J 9.4, C(2)H), 5.76 (1H, t, J 6.0, C(5)NH), 6.00 (2H, t, J 2.1, C(2)Ar(3,4)H), 6.46 (1H, t, J 
6.0, C(1)NH), 6.53 (2H, t, J 2.2, C(2)Ar(2,5)H), 7.08–7.10 (2H, m, C(1)NHCH2ArC(2,6)H), 7.15–
7.16 (2H, m, C(5)NHCH2ArC(2,6)H), 7.26–7.31 (8H, m, C(3)ArC(2,6)H + C(1)NHCH2ArC(3,4,5)H 
+ C(5)NHCH2ArC(3,4,5)H), 7.96–7.99 (2H, m, C(3)ArC(3,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 
39.2 (C(4)H2), 43.7 (C(1)NHCH2), 43.7 (C(5)NHCH2), 44.8 (C(3)H), 65.2 (C(2)H), 109.5 
(C(2)ArC(3,4)H), 120.6 (C(2)ArC(2,5)H), 123.5 (C(3)ArC(3,5)H), 127.5 (C(5)NHCH2ArC(2,6)H), 
127.7 (C(1)NHCH2ArC(2,6)H), 127.8 (C(5)NHCH2ArC(3,5)H), 127.8 (C(1)NHCH2ArC(3,5)H), 128.8 
(C(3)ArC(2,6)H), 129.2 (C(5)NHCH2ArC(4)H + C(1)NHCH2ArC(4)H), 137.4 (C(1)NHCH2ArC(1)), 
137.6 (C(5)NHCH2ArC(1)), 146.9 (C(3)ArC(4)), 147.0 (C(3)ArC(1)), 168.9 (C(1)), 169.9 (C(5)); 
HRMS (NSI+) C29H29N4O4 [M+H]+ found 497.2172, requires 497.2183 (–2.3 ppm). 
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Dimethyl (2S,3S)-3-(3-nitrophenyl)-2-(1H-pyrrol-1-yl)pentanedioate (181) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 461 (73.6 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with MeOH (2.5 mL) and 
DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product (87:13 dr) that was purified by 
column chromatography (Petrol/EtOAc 90:10 to 80:20) to give: 
(2S,3S)-181 (69.3 mg, 80%) as a yellow oil. [α]D
20 − 30.0 (c 0.05 in CHCl3); Chiral HPLC analysis, 
Chiralpak AD-H (97.5:2.5 hexane/i-PrOH, flow rate 1 mLmin-1, 254 nm, 30 °C) tR (major): 34.7 
min, tR (minor): 31.3 min, 96:4 er; νmax (film, cm–1) 2955 (C-H), 1732 (C=O), 1528; 1H NMR (500 
MHz, CDCl3) δH: 2.76–2.84 (2H, m, C(4)HAHB), 3.59 (3H, s, C(5)COOCH3), 3.80 (3H, s, 
C(1)COOCH3), 4.06–4.11 (1H, m, C(3)H), 4.84 (1H, d, J 9.9, C(2)H), 5.97 (2H, t, J 2.2, 
C(2)Ar(3,4)H), 6.51 (2H, t, J 2.1, C(2)Ar(2,5)H), 7.33–7.37 (2H, m, C(3)ArC(5,6)H), 7.95 (1H, app. 
s, C(3)ArC(2)H), 8.04 (1H, dt, J 7.4, 2.1, C(3)ArC(4)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 36.8 
(C(4)H2), 45.0 (C(3)H), 52.2 (C(5)COOCH3), 53.1 (C(1)COOCH3), 65.7 (C(2)), 109.2 
(C(2)ArC(3,4)H), 120.5 (C(2)ArC(2,5)H), 122.6 (C(3)ArC(2)H), 122.8 (C(3)ArC(4)H), 129.4 
(C(3)ArC(5)H), 134.6 (C(3)ArC(6)H), 140.6 (C(3)ArC(1)), 148.1 (C(3)ArC(3)), 169.4 (C(1)), 171.0 
(C(5)); HRMS (ASAP+) C17H19N2O6 [M+H]+ found 347.1244, requires 347.1243 (+0.3 ppm). 
Selected data for minor diastereoisomer (2R,3S): 1H NMR (500 MHz, CDCl3) δH: 2.37 (1H, dd, J 
16.4, 3.9, C(4)HAHB), 2.59 (1H, dd, J 16.4, 10.4, C(4)HAHB), 3.52 (6H, s, C(1)COOCH3 + 
C(5)COOCH3), 4.11 (1H, td, J 10.7, 3.8, C(3)H), 4.85 (1H, d, J 11.1, C(2)H), 6.26 (2H, t, J 2.1, 
C(2)Ar(3,4)H), 6.87 (1H, t, J 2.3, C(3)ArC(2)H), 6.88 (2H, t, J 2.1, C(2)Ar(2,5)H), 7.46–7.57 (1H, 
m, C(3)ArH), 7.62–7.68 (1H, m, C(3)ArH), 8.17 (1H, dt, J 5.3, 1.8, C(3)ArH). 
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(2S,3S)-N1,N5-Dibenzyl-3-(3-nitrophenyl)-2-(1H-pyrrol-1-yl)pentanediamide (182) 
 
Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 461 (73.6 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product (>95:5 dr) that was purified by column chromatography 
(hexane/EtOAc 50:50) to give 182 (74.4 mg, 60%) as a brown solid. mp 181–182 °C; [α]D
20 +
23.0 (c 0.10 in DMSO); Chiral HPLC analysis, Chiralpak AD-H (90:10 hexane/i-PrOH, flow rate 1 
mLmin-1, 220 nm, 30 °C) tR (major): 27.1 min, tR (minor): 21.7 min, 96.5:3.5 er; νmax (film, cm-1) 
3285 (N-H), 3090 (C-H), 1639 (C=O), 1525 (N-O), 1348 (N-O); 1H NMR (500 MHz, DMSO) δH: 
2.46–2.49 (1H, m, C(4)HAHB), 2.71 (1H, dd, J 14.2, 11.4, C(4)HAHB), 3.94 (1H, dd, J 15.4, 5.1, 
C(5)NHCHAHBPh), 4.12 (1H, td, J 11.4, 3.8, C(3)H), 4.23 (1H, dd, J 15.4, 6.9, C(5)NHCHAHBPh), 
4.30 (1H, dd, J 15.0, 5.5, C(1)NHCHAHBPh), 4.42 (1H, dd, J 15.0, 5.9, C(1)NHCHAHBPh), 5.08 (1H, 
d, J 11.2, C(2)H), 5.79 (2H, t, J 2.1, C(2)Ar(3,4)H), 6.70–6.71 (4H, m, C(2)Ar(2,5)H + 
C(1)NHCH2ArC(2,6)H), 7.08–7.14 (3H, m, C(1)NHCH2ArC(3,4,5)H), 7.23–7.25 (2H, m, 
C(5)NHCH2ArC(2,6)H), 7.26–7.28 (1H, m, C(5)NHCH2ArC(4)H), 7.31–7.34 (2H, m, 
C(5)NHCH2ArC(3,5)H), 7.43 (1H, t, J 7.8, C(3)ArC(5)H), 7.56–7.58 (1H, m, C(3)ArC(6)H), 8.02–
8.04 (2H, m, C(3)ArC(2,4)H), 8.36 (1H, t, J 6.1, C(5)NH), 8.90 (1H, t, J 5.8, C(1)NH); 13C{1H} NMR 
(126 MHz, DMSO) δC: 38.3 (C(4)H2), 41.6 (C(5)NHCH2), 42.4 (C(1)NHCH2), 44.6 (C(3)H), 65.2 
(C(2)H), 107.7 (C(2)ArC(3,4)H), 119.9 (C(2)ArC(2,5)H), 121.8 (C(3)ArC(2)H), 122.5 (C(3)ArC(4)H), 
126.5 (C(1)NHCH2ArC(2,6)H), 126.6 (C(1)NHCH2ArC(3,5)H), 127.1 (C(5)NHCH2ArC(4)H), 127.4 
(C(5)NHCH2ArC(2,6)H), 128.0 (C(1)NHCH2ArC(4)H), 128.4 (C(5)NHCH2ArC(3,5)H), 129.3 
(C(3)ArC(5)H), 135.5 (C(3)ArC(6)H), 138.6 (C(1)NHCH2ArC(1)), 139.1 (C(5)NHCH2ArC(1)), 142.1 
(C(3)ArC(1)), 147.3 (C(3)ArC(3)), 168.3 (C(1)), 169.1 (C(5)); HRMS (NSI+) C29H29N4O4 [M+H]+ 
found 497.2175, requires 497.2183 (-1.7 ppm). 
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Dimethyl (2S,3S)-3-(2-nitrophenyl)-2-(1H-pyrrol-1-yl)pentanedioate (183) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 463 (73.6 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with MeOH (2.5 mL) and 
DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product (88:12 dr) that was purified by 
column chromatography (Petrol/EtOAc 90:10 to 85:15) to give: 
(2S,3S)-183 (73.6 mg, 85%) as a light brown oil. [α]D
20 − 11.0  (c 0.4 in CHCl3); Chiral HPLC 
analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 
12.2 min, tR (minor): 9.8 min, 97.5:2.5 er; νmax (film, cm–1) 3013 (C-H), 2959 (C-H), 1742 (C=O), 
1728 (C=O), 1524, 1354; 1H NMR (500 MHz, CDCl3) δH: 2.87 (1H, dd, J 16.4, 6.0, C(4)HAHB), 2.90 
(1H, dd, J 16.4, 8.0, C(4)HAHB), 3.57 (3H, s, C(5)COOCH3), 3.74 (3H, s, C(1)COOCH3), 4.69 (1H, 
app. s, C(3)H), 5.18 (1H, d, J 9.1, C(2)H), 5.99 (2H, t, J 2.2, C(2)Ar(3,4)H), 6.66 (2H, t, J 2.2, 
C(2)Ar(2,5)H), 7.28–7.29 (1H, m, C(3)ArC(6)H), 7.31–7.34 (1H, m, C(3)ArC(4)H), 7.46 (1H, t, J 
7.6, C(3)ArC(5)H), 7.75 (1H, dd, J 8.2, 1.4, C(3)ArC(3)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 36.8 
(C(4)H2), 39.1 (C(3)H, broad), 52.1 (C(5)COOCH3), 53.0 (C(1)COOCH3), 64.4 (C(2)H), 109.1 
(C(2)ArC(3,4)H), 120.6 (C(2)ArC(2,5)H), 125.0 (C(3)ArC(3)H), 128.4 (C(3)ArC(4)H+C(3)ArC(6)H), 
132.7 (C(3)ArC(5)H), 132.9 (C(3)ArC(1)), 150.4 (C(3)ArC(2)), 169.4 (C(1)), 171.1 (C(5)); HRMS 
(ASAP+) C17H19N2O6 [M+H]+ found 347.1243, requires 347.1243 (0.0 ppm). 
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(2S,3S)-N1,N5-Dibenzyl-3-(2-nitrophenyl)-2-(1H-pyrrol-1-yl)pentanediamide (184)  
 
Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 463 (73.6 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product (>95:5 dr) that was triturated in ether to give 184 (65.7 mg, 53%) 
as a white solid. mp 219–220 °C (dec); [α]D
20 − 60.5 (c 0.22 in DMSO); Chiral HPLC analysis, 
Chiralpak IB (90:10 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 34.1 min, tR 
(minor): 21.6 min, >99.5:0.5 er; νmax (film, cm-1) 3289 (N-H), 3088 (C-H), 1645 (C=O), 1528 (N-
O), 1352 (N-O); 1H NMR (500 MHz, DMSO) δH: 2.51 (1H, overlapped with solvent signals, 
C(4)HAHB), 2.65–2.71 (1H, m, C(4)HAHB), 3.97 (1H, dd, J 15.5, 5.3, C(5)NHCHAHBPh), 4.16 (1H, 
dd, J 15.6, 6.3, C(5)NHCHAHBPh), 4.26 (1H, dd, J 15.3, 5.4, C(1)NHCHAHBPh), 4.38 (1H, dd, J 15.0, 
5.8, C(1)NHCHAHBPh), 4.71–4.76 (1H, m, C(3)H), 5.28 (1H, d, J 10.4, C(2)H), 5.80 (2H, app. s, 
C(2)Ar(3,4)H), 6.73 (2H, app. s, C(2)Ar(2,5)H), 6.82–6.83 (2H, m, C(1)NHCH2ArC(2,6)H), 7.18–
7.19 (5H, m, C(5)NHCH2ArC(2,6)H + C(1)NHCH2ArC(3,4,5)H), 7.23–7.31 (3H, m, 
C(5)NHCH2ArC(3,4,5)H), 7.38–7.41 (1H, m, C(3)ArC(4)H), 7.56 (2H, app. s, C(3)ArC(3,5)H), 7.74 
(1H, d, J 8.1, C(3)ArC(6)H), 8.28 (1H, app. s, C(5)NH), 8.92 (1H, app. s, C(1)NH); 13C{1H} NMR 
(126 MHz, DMSO) δC: 38.0 (C(3)H), 38.6 (C(4)H2), 41.7 (C(5)NHCH2), 42.4 (C(1)NHCH2), 64.1 
(C(2)H), 107.6 (C(2)ArC(3,4)H), 120.0 (C(2)ArC(2,5)H), 124.5 (C(3)ArC(6)H), 126.6 
(C(5)NHCH2ArC(2,6)H), 126.8 (C(1)NHCH2ArC(2,6)H), 127.0 (C(1)NHCH2ArC(3,5)H), 127.4 
(C(5)NHCH2ArC(3,5)H), 127.8 (C(3)ArC(4)H), 128.1 (C(1)NHCH2ArC(4)H), 128.4 
(C(5)NHCH2ArC(4)H), 128.7 (C(3)ArC(5)H), 132.7 (C(3)ArC(3)H), 133.9 (C(3)ArC(1)), 138.6 
(C(1)NHCH2ArC(1)), 139.1 (C(5)NHCH2ArC(1)), 150.4 (C(3)ArC(2)), 168.3 (C(1)), 169.1 (C(5)); 
HRMS (NSI+) C29H29N4O4 [M+H]+ found 497.2174, requires 497.2183 (–1.9 ppm). 
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Dimethyl (2S,3S)-3-(4-fluorophenyl)-2-(1H-pyrrol-1-yl)pentanedioate (185) and dimethyl 
(2R,3S)-3-(4-fluorophenyl)-2-(1H-pyrrol-1-yl)pentanedioate (200) and  
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 465 (66.9 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with MeOH (2.5 mL) and 
DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product (80:20 dr) that was purified by 
column chromatography (Petrol/EtOAc 90:10 to 85:15) to give: 
(2S,3S)-185 (58.7 mg, 74%) as a light yellow oil. [α]D
20 − 35.9 (c 1.65 in CHCl3); Chiral HPLC 
analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 
7.4 min, tR (minor): 6.7 min, 99:1 er; νmax (film, cm–1) 2955 (C-H), 1734 (C=O), 1510, 725; 1H 
NMR (500 MHz, CDCl3) δH: 2.68–2.75 (2H, m, C(4)HAHB), 3.58 (3H, s, C(5)COOCH3), 3.77 (3H, s, 
C(1)COOCH3), 3.95 (1H, dt, J 9.5, 7.4, C(3)H), 4.81 (1H, d, J 9.5, C(2)H), 5.99 (2H, t, J 2.2, 
C(2)Ar(3,4)H), 6.52 (2H, t, J 2.2, C(2)Ar(2,5)H), 6.86–6.90 (2H, m, C(3)ArC(2,6)H), 6.99–7.02 (2H, 
m, C(3)ArC(3,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 37.2 (C(4)H2), 44.6 (C(3)H), 52.0 
(C(5)COOCH3), 52.9 (C(1)COOCH3), 66.2 (C(2)H), 108.7 (C(2)ArC(3,4)H), 115.4 (d, 2JCF 21.4, 
C(3)ArC(3)H + C(3)ArC(5)H), 120.7 (C(2)ArC(2,5)H), 129.5 (d, 3JCF 8.1, C(3)ArC(2)H + 
C(3)ArC(6)H), 134.1 (d, 4JCF 3.2, C(3)ArC(1)), 162.1 (d, 1JCF 246.1, C(3)ArC(4)), 169.9 (C(1)), 171.5 
(C(5)); 19F{1H} NMR (377 MHz, CDCl3) δF: -114.7; HRMS (ASAP+) C17H19NO4F [M+H]+ found 
320.1298, requires 320.1298 (0.0 ppm). 
(2R,3S)-200 (14.7 mg, 18%) as a white solid. mp. 96–97 °C; [α]D
20 − 10.0 (c 0.2 in CHCl3); 
Chiral HPLC analysis, Chiralpak OJ-H (97.5:2.5 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 
30 °C) tR (major,2R,3S): 15.4 min, tR (minor,2S,3R): 23.2 min, 90:10 er; νmax (film, cm–1) 2949 (C-
H), 1728 (C=O), 727, 700; 1H NMR (500 MHz, CDCl3) δH: 2.27 (1H, dd, J 15.9, 4.1, C(4)HAHB), 
2.48 (1H, dd, J 16.0, 10.4, C(4)HAHB), 3.46 (3H, s, C(1)COOCH3)), 3.47 (3H, s, C(5)COOCH3)), 3.95 
(1H, td, J 10.8, 4.1, C(3)H), 4.73 (1H, d, J 11.3, C(2)H), 6.21 (2H, t, J 2.2, C(2)Ar(3,4)H), 6.87 (2H, 
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t, J 2.2, C(2)Ar(2,5)H), 6.99–7.03 (2H, m, C(3)ArC(2,6)H), 7.22–7.26 (2H, m, C(3)ArC(3,5)H); 
13C{1H} NMR (126 MHz, CDCl3) δC: 36.8 (C(4)H2), 45.0 (C(3)H), 51.8 (C(5)COOCH3), 52.5 
(C(1)COOCH3), 66.3 (C(2)H), 109.5 (C(2)ArC(3,4)H), 115.8 (d, 2JCF 21.6, C(3)ArC(3)H + 
C(3)ArC(5)H), 120.5 (C(2)ArC(2,5)H), 129.9 (d, 3JCF 8.1, C(3)ArC(2)H + C(3)ArC(6)H), 134.2 (d, 
4JCF 3.5, C(3)ArC(1)), 162.3 (d, 1JCF 246.2, C(3)ArC(4)), 169.4 (C(1)), 171.5 (C(5)); 19F NMR (471 





Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 467 (66.9 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product (95:5 dr) that was triturated in ether to give 186 (70.4 mg, 60%) 
as a white solid. mp 224–225 °C (dec); [α]D
20 + 3.6 (c 0.11 in DMSO); Chiral HPLC analysis, 
Chiralpak AD-H (90:10 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 28.9 min, 
tR (minor): 14.5 min, 99.9:0.1 er; νmax (film, cm-1) 3275 (N-H), 3034 (C-H), 1641 (C=O); 1H NMR 
(500 MHz, CDCl3) δH: 2.62 (2H, d, J 6.2, C(4)HAHB), 4.08 (1H, dt, J 9.3, 6.2, C(3)H), 4.29–4.37 (2H, 
m, C(5)NHCH2Ph), 4.38–4.44 (2H, m, C(1)NHCH2Ph), 5.18 (1H, d, J 9.2, C(2)H), 5.70 (1H, t, J 5.9, 
C(5)NH), 6.00 (2H, t, J 2.2, C(2)Ar(3,4)H), 6.51–6.55 (3H, m, C(2)Ar(3,4)H + C(1)NH), 6.82–6.87 
(2H, m, C(3)ArC(2,6)H), 7.05–7.10 (4H, m, C(3)ArC(3,5)H + C(1)NHCH2ArC(2,6)H), 7.14–7.16 
(2H, m, C(5)NHCH2ArC(2,6)H), 7.23–7.30 (6H, m, C(1)NHCH2ArC(3,4,5)H + 
C(5)NHCH2ArC(3,4,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 39.9 (C(4)H2), 43.7 (C(5)NHCH2 + 
C(1)NHCH2), 44.2 (C(3)H), 66.0 (C(2)H), 109.1 (C(2)ArC(3,4)H), 115.4 (d, 2JCF 21.6, C(3)ArC(3)H 
+ C(3)ArC(5)H), 120.9 (C(2)ArC(2,5)H), 127.7 (C(5)NHCH2ArC(2,6)H), 127.8 
(C(5)NHCH2ArC(3,4,5)H), 127.8 (C(1)NHCH2ArC(2,6)H), 128.8 (C(1)NHCH2ArC(3,4,5)H), 129.9 
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(d, 3JCF 8.0, C(3)ArC(2)H + C(3)ArC(6)H), 135.0 (d, 4JCF 3.5, C(3)ArC(1)), 137.7 (C(1)NHCH2ArC(1)), 
137.8 (C(5)NHCH2ArC(1)), 162.0 (d, 1JCF 246.0, C(3)ArC(4)), 169.6 (C(1)), 170.7 (C(5)); 19F NMR 
(471 MHz, CDCl3) δF: –115.0 (s, C(3)ArC(4)F); HRMS (NSI+) C29H29N3O2F [M+H]+ found 470.2235, 
requires 470.2238 (–0.7 ppm). 
 
Dimethyl (2S,3S)-3-(4-chlorophenyl)-2-(1H-pyrrol-1-yl)pentanedioate (187) and dimethyl 
(2R,3S)-3-(4-chlorophenyl)-2-(1H-pyrrol-1-yl)pentanedioate (480)  
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 467 (71.0 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with MeOH (2.5 mL) and 
DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product (87:13 dr) that was purified by 
column chromatography (Petrol/EtOAc 90:10 to 85:15) to give: 
(2S,3S)-187 (58.8 mg, 70%) as a colourless oil. [α]D
20 − 30.0  (c 0.25 in CHCl3); Chiral HPLC 
analysis, Chiralpak AD-H (99:1 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 
36.9 min, tR (minor): 32.2 min, 99:1 er; νmax (film, cm–1) 2999 (C-H), 2953 (C-H), 1732 (C=O); 1H 
NMR (500 MHz, CDCl3) δH: 2.68–2.74 (2H, m, C(4)HAHB), 3.58 (3H, s, C(5)COOCH3), 3.76 (3H, s, 
C(1)COOCH3), 3.94 (1H, dt, J 9.6, 7.4, C(3)H), 4.81 (1H, d, J 9.5, C(2)H), 6.00 (2H, t, J 2.2, 
C(2)Ar(3,4)H), 6.52 (2H, t, J 2.2, C(2)Ar(2,5)H), 6.96–6.98 (2H, m, C(3)ArC(2,6)H), 7.15–7.17 (2H, 
m, C(3)ArC(3,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 37.0 (C(4)H2), 44.6 (C(3)H), 52.1 
(C(5)COOCH3), 52.9 (C(1)COOCH3), 66.0 (C(2)H), 108.7 (C(2)ArC(3,4)H), 120.7 (C(2)ArC(2,5)H), 
128.7 (C(3)ArC(3,5)H), 129.3 (C(3)ArC(2,6)H), 133.4 (C(3)ArC(4)), 136.9 (C(3)ArC(1)), 169.8 
(C(1)), 171.4 (C(5)); HRMS (NSI+) C17H19NO435Cl [M+H]+ found 336.1001, requires 336.0997 
(+1.2 ppm). 
(2R,3S)-480 (8.9 mg, 11%) as a white solid. mp. 118–120 °C; [α]D
20 + 6.0 (c 0.1 in CHCl3); Chiral 
HPLC analysis, Chiralpak AD-H (97.5:2.5 hexane/i-PrOH, flow rate 1 mLmin-1, 220 nm, 30 °C) tR 
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(major): 20.8 min, tR (minor): 18.8 min, 95:5 er; νmax (film, cm–1) 2953 (C-H), 1740 (C=O);
 1H 
NMR (500 MHz, CDCl3) δH: 2.27 (1H, dd, J 16.0, 4.0, C(4)HAHB), 2.48 (1H, dd, J 16.0, 10.4, 
C(4)HAHB), 3.48 (6H, s, 2CH3), 3.94 (1H, td, J 10.8, 4.1, C(3)H), 4.74 (1H, d, J 11.2, C(2)H), 6.21 
(2H, t, J 2.1, C(2)Ar(3,4)H), 6.86 (2H, t, J 2.2, C(2)Ar(2,5)H), 7.19–7.21 (2H, m, C(3)ArC(2,6)H), 
7.27–7.31 (2H, m, C(3)ArC(3,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 36.6 (C(4)H2), 45.1 (C(3)H), 
51.9 (C(5)COOCH3), 52.6 (C(1)COOCH3), 66.1 (C(2)H), 109.6 (C(2)ArC(3,4)H), 120.5 
(C(2)ArC(2,5)H), 129.1 (C(3)ArC(3,5)H), 129.7 (C(3)ArC(2,4)H), 133.7 (C(3)ArC(4)), 137.0 
(C(3)ArC(1)), 169.3 (C(1)), 171.5 (C(5)); HRMS (ASAP+) C17H19NO435Cl [M+H]+ found 336.1005, 




Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 467 (71.0 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product (>95:5 dr) that was triturated in ether to give 188 (85.1 mg, 70%) 
as a white solid. mp 232–234 °C; [α]D
20 + 15.0  (c 0.10 in DMSO); Chiral HPLC analysis, 
Chiralpak AD-H (90:10 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 27.9 min, 
tR (minor): 20.1 min, 98.5:1.5 er; νmax (film, cm-1) 3273 (N-H), 3030 (C-H), 1639 (C=O); 1H NMR 
(500 MHz, DMSO) δH: 2.39 (1H, dd, J 13.9, 3.7, C(4)HAHB), 2.59 (1H, dd, J 13.9, 11.5, C(4)HAHB), 
3.89–3.97 (2H, m, C(3)H + C(5)NHCHAHBPh), 4.25–4.30 (2H, m, C(5)NHCHAHBPh + 
C(1)NHCHAHBPh), 4.40 (1H, dd, J 15.0, 5.9, C(1)NHCHAHBPh), 4.93 (1H, d, J 11.3, C(2)H), 5.79 
(2H, t, J 2.1, C(2)Ar(3,4)H), 6.65–6.67 (4H, m, C(2)Ar(2,5)H + C(1)NHCH2ArC(2,6)H), 7.11–7.16 
(5H, m, C(1)NHCH2ArC(3,5)H + C(5)NHCH2ArC(3,4,5)H), 7.20–7.23 (4H, m, C(3)ArC(2,6)H + 
C(5)NHCH2ArC(2,6)H), 7.24–7.27 (1H, m, C(1)NHCH2ArC(4)H), 7.30–7.33 (2H, m, 
C(3)ArC(3,5)H), 8.26–8.28 (1H, m, C(5)NH), 8.90 (1H, t, J 5.8, C(1)NH); 13C{1H} NMR (126 MHz, 
Chapter 8: Experimentals 
Page | 183  
DMSO) δC: 38.7 (C(4)H2), 41.6 (C(5)NHCH2), 42.3 (C(1)NHCH2), 44.3 (C(3)H), 65.6 (C(2)H), 107.5 
(C(2)ArC(3,4)H), 119.9 (C(2)ArC(2,5)H), 126.5 (C(5)NHCH2ArC(2,6)H), 126.5 
(C(1)NHCH2ArC(2,6)H), 127.1 (C(5)NHCH2ArC(3,5)H), 127.4 (C(3)ArC(2,6)H), 127.8 
(C(1)NHCH2ArC(3,5)H), 127.9 (C(5)NHCH2ArC(4)H), 128.4 (C(3)ArC(3,5)H), 130.1 
(C(1)NHCH2ArC(4)H), 131.2 (C(3)ArC(4)), 138.7 (C(1)NHCH2ArC(1)), 138.7 (C(3)ArC(1)) , 139.2 
(C(5)NHCH2ArC(1)), 168.7 (C(1)), 169.3 (C(5)); HRMS (NSI+) C29H29N3O235Cl [M+H]+ found 
486.1938, requires 486.1943 (–1.0 ppm). 
 
Dimethyl (2S,3S)-3-(4-bromophenyl)-2-(1H-pyrrol-1-yl)pentanedioate (189) and dimethyl 
(2R,3S)-3-(4-bromophenyl)-2-(1H-pyrrol-1-yl)pentanedioate (481) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 469 (82.1 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with MeOH (2.5 mL) and 
DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product (89:11 dr) that was purified by 
column chromatography (Petrol/EtOAc 90:10 to 85:15) to give: 
(2S,3S)-189 (62.6 mg, 66%) as a yellow oil. [α]D
20 − 27.7 (c 1.1 in CHCl3); Chiral HPLC analysis, 
Chiralpak OJ-H (97.5:2.5 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 28.8 
min, tR (minor): 51.9 min, 99.5:0.5 er; νmax (film, cm–1) 2953 (C-H), 1736 (C=O), 1489;
 1H NMR 
(500 MHz, CDCl3) δH: 2.71–2.72 (2H, m, C(4)HAHB), 3.59 (3H, s, C(5)COOCH3), 3.76 (3H, s, 
C(1)COOCH3), 3.94 (1H, dt, J 9.5, 7.3, C(3)H), 4.82 (1H, d, J 9.5, C(2)H), 6.00 (2H, t, J 2.2, 
C(2)Ar(3,4)H), 6.52 (2H, t, J 2.2, C(2)Ar(2,5)H), 6.90–6.93 (2H, m, C(3)ArC(2,6)H), 7.30–7.33 (2H, 
m, C(3)ArC(3,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 36.9 (C(4)H2), 44.7 (C(3)H), 52.1 
(C(5)COOCH3), 52.9 (C(1)COOCH3), 65.9 (C(2)H), 108.7 (C(2)ArC(3,4)H), 120.7 (C(2)ArC(2,5)H), 
121.6 (C(3)ArC(4)), 129.6 (C(3)ArC(2,6)H), 131.6 (C(3)ArC(3,5)H), 137.5 (C(3)ArC(1)), 169.7 
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(C(1)), 171.3 (C(5)); HRMS (ASAP+) C17H1979BrNO4 [M+H]+ found 380.0496, requires 380.0497 (-
0.3 ppm); 
(2R,3S)-481 (7.7 mg, 8%) as a light-yellow solid. mp 106–108 °C; [α]D
20 − 11.1 (c 0.15 in CHCl3); 
Chiral HPLC analysis, Chiralpak AD-H (97.5:2.5 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 
30 °C) tR (major): 24.2 min, tR (minor): 21.5 min, 92:8 er; νmax (film, cm–1) 2953 (C-H), 1732 (C=O), 
1487, 1435;
 1H NMR (400 MHz, CDCl3) δH: 2.26 (1H, dd, J 16.0, 4.1, C(4)HAHB), 2.48 (1H, dd, J 
16.0, 10.4, C(4)HAHB), 3.48 (3H, s, C(1)OOCH3), 3.48 (3H, s, C(5)OOCH3), 3.93 (1H, td, J 10.8, 4.1, 
C(3)H), 4.74 (1H, d, J 11.2, C(2)H), 6.21 (2H, t, J 2.2, C(2)Ar(3,4)H), 6.85 (2H, t, J 2.2, 
C(2)Ar(2,5)H), 7.13–7.16 (2H, m, C(3)ArC(2,6)H), 7.43–7.46 (2H, m, C(3)ArC(3,5)H); 13C{1H} 
NMR (126 MHz, CDCl3) δC: 36.5 (C(4)H2), 45.1 (C(3)H), 51.9 (C(5)COOCH3), 52.6 (C(1)COOCH3), 
66.0 (C(2)H), 109.6 (C(2)ArC(3,4)H), 120.5 (C(2)ArC(2,5)H), 121.9 (C(3)ArC(4)), 130.0 
(C(3)ArC(2,6)H), 132.0 (C(3)ArC(3,5)H), 137.6 (C(3)ArC(1)), 169.3 (C(1)), 171.5 (C(5)); HRMS 




Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 469 (82.1 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product (>95:5 dr) that was triturated in Et2O to give 190 (99.5 mg, 75%) 
as a white solid. mp 243–244 °C (dec); [α]D
20 − 5.2 (c 0.27 in DMSO); Chiral HPLC analysis, 
Chiralpak AD-H (90:10 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 28.3 min, 
tR (minor): 24.7 min, 99.5:0.5 er; νmax (film, cm-1) 3279 (N-H), 3090 (C-H), 1637 (C=O); 1H NMR 
(500 MHz, DMSO) δH: 2.38 (1H, dd, J 13.9, 3.7, C(4)HAHB), 2.58 (1H, dd, J 13.9, 11.6, C(4)HAHB), 
3.89–3.96 (2H, m, C(3)H + C(5)NHCHAHBPh), 4.25–4.31 (2H, m, C(5)NHCHAHBPh + 
C(1)NHCHAHBPh), 4.40 (1H, dd, J 15.0, 5.9, C(1)NHCHAHBPh), 4.94 (1H, d, J 11.3, C(2)H), 5.79 
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(2H, t, J 2.2, C(2)Ar(3,4)H), 6.65–6.68 (4H, m, C(2)Ar(2,5)H + C(1)NHCH2ArC(2,6)H), 7.07–7.10 
(2H, m, C(3)ArC(2,6)H), 7.14–7.16 (3H, m, C(1)NHCH2ArC(3,4,5)H), 7.21–7.23 (2H, m, 
C(5)NHCH2ArC(2,6)H), 7.24–7.27 (1H, m, C(5)NHCH2ArC(4)H), 7.30–7.33 (2H, m, 
C(5)NHCH2ArC(3,5)H), 7.34–7.36 (2H, m, C(3)ArC(3,5)H), 8.26–8.28 (1H, m, C(5)NH), 8.90 (1H, 
t, J 5.8, C(1)NH); 13C{1H} NMR (126 MHz, DMSO): 38.6 (C(4)H2), 41.6 (C(5)NHCH2), 42.3 
(C(1)NHCH2), 44.4 (C(3)H), 65.5 (C(2)H), 107.5 (C(2)ArC(3,4)H), 119.8 (C(2)ArC(2)H), 119.9 
(C(2)ArC(5)H), 126.5 (C(1)NHCH2ArC(4)H), 126.5 (C(1)NHCH2ArC(2,6)H), 127.1 
(C(5)NHCH2ArC(4)H), 127.4 (C(5)NHCH2ArC(2,6)H), 128.0 (C(1)NHCH2ArC(3,5)H), 128.4 
(C(5)NHCH2ArC(3,5)H), 130.5 (C(3)ArC(2,6)H), 130.8 (C(3)ArC(3,5)H), 138.7 (C(5)NHCH2ArC(1)), 
139.1 (C(1)NHCH2ArC(1) + C(3)ArC(1)), 139.2 (C(3)ArC(4)), 168.6 (C(1)), 169.3 (C(5)); HRMS 
(NSI+) C29H29N3O279Br [M+H]+ found 530.1435, requires 530.1438 (–0.5 ppm). 
 
Dimethyl (2S,3S)-3-(2-bromophenyl)-2-(1H-pyrrol-1-yl)pentanedioate (191) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 471 (82.1 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with MeOH (2.5 mL) and 
DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product (91:9 dr) that was purified by column 
chromatography (Petrol/EtOAc 90:10 to 80:20) to give: 
(2S,3S)-191 (61.8 mg, 65%) as a light-yellow oil. [α]D
20 − 23.2 (c 0.44 in CHCl3); Chiral HPLC 
analysis, Chiralpak OD-H (90:10 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 
16.5 min, tR (minor): 8.5 min, 98.5:1.5 er; νmax (film, cm–1) 2951 (C-H), 1734 (C=O), 1435;
 1H 
NMR (500 MHz, CDCl3) δH: 2.79–2.86 (2H, m, C(4)HAHB), 3.57 (3H, s, C(5)COOCH3), 3.73 (3H, s, 
C(1)COOCH3), 4.54 (1H, app. s, C(3)H), 5.12 (1H, app. s, C(2)H), 6.00 (2H, app. s, C(2)Ar(3,4)H), 
6.71 (2H, t, J 2.2, C(2)Ar(2,5)H), 7.01–7.05 (1H, m, C(3)ArC(4)H), 7.12–7.18 (2H, m, 
C(3)ArC(5,6)H), 7.46–7.48 (1H, m, C(3)ArC(3)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 36.4 (C(4)H2), 
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43.2 (C(3)H), 51.8 (C(5)COOCH3), 52.7 (C(1)COOCH3), 64.2 (C(2)H), 108.6 (C(2)ArC(3,4)H), 120.5 
(C(2)ArC(2,5)H), 127.4 (C(3)ArC(5,6)H), 127.7 (C(3)ArC(2)), 128.9 (C(3)ArC(4)H), 133.4 
(C(3)ArC(3)H), 137.4 (C(3)ArC(1)), 169.6 (C(1)), 171.2 (C(5)); HRMS (ASAP+) C17H19NO479Br 




Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 471 (82.1 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product (>95:5 dr) that was triturated in ether to give 192 (99.5 mg, 75%) 
as a white solid. mp 196–197 °C; [α]D
20 + 3.6 (c 0.28 in DMSO); Chiral HPLC analysis, Chiralpak 
AS-H (90:10 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 17.6 min, tR (minor): 
8.1 min, >99.5:0.5 er; νmax (film, cm-1) 3289 (N-H), 3061 (C-H), 1641 (C=O), 1557; 1H NMR (500 
MHz, DMSO) δH: 2.43–2.46 (1H, m, C(4)HAHB), 2.66–2.70 (1H, m, C(4)HAHB), 3.99 (1H, dd, J 15.4, 
5.4, C(5)NHCHAHBPh), 4.17–4.25 (2H, m, C(5)NHCHAHBPh + C(1)NHCHAHBPh), 4.38 (1H, dd, J 
15.1, 6.1, C(1)NHCHAHBPh), 4.44–4.47 (1H, m, C(3)H), 5.21 (1H, d, J 10.4, C(2)H), 5.80 (2H, app. 
s, C(2)Ar(3,4)H), 6.70 (2H, t, J 2.2, C(2)Ar(2,5)H), 6.77–6.79 (2H, m, C(1)NHCH2ArC(2,6)H), 7.07–
7.10 (1H, m, C(3)ArC(4)H), 7.13–7.17 (5H, m, C(5)NHCH2ArC(2,3,4,5,6)H), 7.22–7.29 (4H, m, 
C(3)ArC(5,6)H + C(1)NHCH2ArC(3,5)H), 7.40 (1H, d, J 7.7, C(1)NHCH2ArC(4)H), 7.44 (1H, dd, J 
8.0, 1.3, C(3)ArC(3)H), 8.25 (1H, t, J 6.0, C(5)NH), 8.92 (1H, app. s, C(1)NH); 13C{1H} NMR (126 
MHz, DMSO) δC: 37.9 (C(4)H2), 41.8 (C(5)NHCH2), 42.4 (C(1)NHCH2), 43.1 (C(3)H), 64.6 (C(2)H), 
107.5 (C(2)ArC(3,4)H), 120.0 (C(2)ArC(2,5)H), 125.8 (C(1)NHCH2ArC(2,6)H), 126.6 
(C(3)ArC(3)H), 126.8 (C(1)NHCH2ArC(3,5)H), 127.1 (C(3)ArC(4)H), 127.4 (C(3)ArC(5)H), 127.5 
(C(3)ArC(6)H), 128.2 (C(5)NHCH2ArC(2,6)H), 128.5 (C(5)NHCH2ArC(3,5)H), 128.5 
(C(5)NHCH2ArC(4)H + C(1)NHCH2ArC(4)H), 128.7 (C(3)ArC(1)), 132.8 (C(3)ArC(2)), 138.8 
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(C(1)NHCH2ArC(1)), 139.2 (C(5)NHCH2ArC(1)), 168.6 (C(1)), 169.3 (C(5)); HRMS (NSI+) 
C29H29N3O279Br [M+H]+ found 530.1431, requires 530.1438 (–1.3 ppm). 
 
Dimethyl (2S,3R)-3-(furan-2-yl)-2-(1H-pyrrol-1-yl)pentanedioate (193) and dimethyl 
(2R,3R)-3-(furan-2-yl)-2-(1H-pyrrol-1-yl)pentanedioate (482) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 473 (60.0 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 40 h. Ring-opening with MeOH (2.5 mL) and 
DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product (83:17 dr) that was purified by 
column chromatography (Petrol/EtOAc 90:10 to 85:15) to give: 
(2S,3R)-193 (59.2 mg, 81%) as a yellow solid. mp. 65–66 °C; [α]D
20 + 13.0  (c 0.1 in CHCl3); 
Chiral HPLC analysis, Chiralpak OJ-H (97.5:2.5 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 
30 °C) tR (major): 33.6 min, tR (minor): 46.9 min, 99:1 er; νmax (film, cm–1) 2953 (C-H), 1734 (C=O), 
1437; 1H NMR (500 MHz, CDCl3) δH: 2.53 (1H, dd, J 16.4, 7.0, C(4)HAHB), 2.74 (1H, dd, J 16.4, 
7.6, C(4)HAHB), 3.67 (3H, s, C(5)COOCH3), 3.79 (3H, s, C(1)COOCH3), 4.16 (1H, q, J 7.3, C(3)H), 
5.05 (1H, d, J 7.3, C(2)H), 5.94 (1H, dt, J 3.3, 0.8, C(3)ArC(3)H), 6.07 (2H, t, J 2.2, C(2)Ar(3,4)H), 
6.23 (1H, dd, J 3.3, 1.8, C(3)ArC(4)H), 6.44 (2H, t, J 2.2, C(2)Ar(2,5)H), 7.31 (1H, dd, J 1.9, 0.8, 
C(3)ArC(5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 34.3 (C(4)H2), 39.0 (C(3)H), 52.1 (C(5)COOCH3), 
52.8 (C(1)COOCH3), 63.9 (C(2)H), 108.3 (C(3)ArC(3)H), 108.6 (C(2)ArC(3,4)H), 110.6 
(C(3)ArC(4)H), 121.1 (C(2)ArC(2,5)H), 142.1 (C(3)ArC(5)H), 151.7 (C(3)ArC(2)), 169.8 (C(1)), 
171.7 (C(5)); HRMS (NSI+) C15H18NO5 [M+H]+ found 292.1181, requires 292.1179 (+0.5 ppm). 
(2R,3R)-482 (12.1 mg, 17%) as a yellow oil. [α]D
20 − 5.0 (c 0.2 in CHCl3); Chiral HPLC analysis, 
Chiralpak OJ-H (97.5: 2.5 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 21.7 
min, tR (minor): 40.6 min, 85:15 er; νmax (film, cm–1) 2953 (C-H), 1740 (C=O); 1H NMR (400 MHz, 
CDCl3) δH: 2.24 (1H, dd, J 16.0, 4.1, C(4)HAHB), 2.53 (1H, dd, J 16.0, 9.7, C(4)HAHB), 3.55 (3H, s, 
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C(5)COOCH3), 3.60 (3H, s, C(1)COOCH3), 4.06–4.11 (1H, m, C(3)H), 4.89 (1H, d, J 10.9, C(2)H), 
6.18 (1H, d, J 3.3, C(3)ArC(3)H), 6.19 (2H, t, J 2.1, C(2)Ar(3,4)H), 6.29 (1H, dd, J 3.2, 1.9, 
C(3)ArC(4)H), 6.82 (2H, t, J 2.2, C(2)Ar(2,5)H), 7.35–7.36 (1H, m, C(3)ArC(5)H); 13C{1H} NMR 
(126 MHz, CDCl3) δC: 34.4 (C(4)H2), 39.5 (C(3)H), 51.9 (C(5)COOCH3), 52.7 (C(1)COOCH3), 64.2 
(C(2)H), 108.1 (C(3)ArC(3)H), 109.5 (C(2)ArC(3,4)H), 110.6 (C(3)ArC(4)H), 120.5 (C(2)ArC(2,5)H), 
142.5 (C(3)ArC(5)H), 151.6 (C(3)ArC(2)), 169.7 (C(1)), 171.6 (C(5)); HRMS (NSI+) C15H18NO5 




Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 473 (60.0 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 40 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product (90:10 dr) that was purified by column chromatography 
(hexane/EtOAc 50:50) to give 194 (60.0 mg, 64%) as a white solid. mp 186–188 °C; [α]D
20 −
12.5 (c 0.16 in DMSO); Chiral HPLC analysis, Chiralpak AD-H (90:10 hexane/i-PrOH, flow rate 1 
mLmin-1, 211 nm, 30 °C) tR (major): 23.2 min, tR (minor): 19.0 min, 99.5:0.5 er; νmax (film, cm-1) 
3327 (N-H), 3275 (N-H), 3088 (C-H), 1643 (C=O), 1553; 1H NMR (500 MHz, CDCl3) δH: 2.48 (1H, 
dd, J 14.8, 6.9, C(4)HAHB), 2.65 (1H, dd, J 14.8, 6.8, C(4)HAHB), 4.30 (1H, dd, J 14.9, 5.3, 
C(1)NHCHAHBPh), 4.35 (2H, d, J 5.7, C(5)NHCH2Ph), 4.38–4.48 (2H, m, C(1)NHCHAHBPh + C(3)H), 
5.13 (1H, d, J 7.1, C(2)H), 5.91–5.95 (1H, m, C(5)NH), 5.99 (1H, d, J 3.2, C(3)ArC(3)H), 6.07 (2H, 
t, J 2.1, C(2)Ar(3,4)H), 6.23 (1H, dd, J 3.2, 1.8, C(3)ArC(4)H), 6.37–6.41 (3H, m, C(2)Ar(2,5)H + 
C(1)NH), 7.14–7.16 (4H, m, C(1)NHCH2ArC(2,6)H + C(5)NHCH2ArC(2,6)H), 7.21 (1H, dd, J 1.8, 
0.8, C(3)ArC(5)H), 7.22–7.32 (6H, m, C(1)NHCH2ArC(3,4,5)H + C(5)NHCH2ArC(3,4,5)H); 13C{1H} 
NMR (126 MHz, CDCl3) δC: 36.6 (C(4)H2), 38.4 (C(3)H), 43.6 (C(1)NHCH2), 43.7 (C(5)NHCH2), 
65.4 (C(2)H), 108.5 (C(3)ArC(3)H), 109.2 (C(2)ArC(3,4)H), 110.9 (C(3)ArC(4)H), 121.1 
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(C(2)ArC(2,5)H), 127.5 (C(1)NHCH2ArC(2,6)H), 127.6 (C(5)NHCH2ArC(2,6)H), 127.8 
(C(1)NHCH2ArC(4)H + C(5)NHCH2ArC(4)H), 128.7 (C(1)NHCH2ArC(3,5)H), 128.8 
(C(5)NHCH2ArC(3,5)H), 137.8 (C(1)NHCH2ArC(1)), 138.0 (C(5)NHCH2ArC(1)), 141.5 
(C(3)ArC(5)H), 152.4 (C(3)ArC(1)), 169.3 (C(1)), 170.5 (C(5)); HRMS (NSI+) C27H28N3O3 [M+H]+ 
found 442.2123, requires 442.2125 (–0.5 ppm). 
 
Dimethyl (2S,3S)-2-(1H-pyrrol-1-yl)-3-((E)-styryl)pentanedioate (195) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 475 (68.9 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with MeOH (2.5 mL) and 
DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product (85:15 dr) that was purified by 
column chromatography (Petrol/EtOAc 85:15) to give: 
(2S,3S)-195 (50.0 mg, 61%) as a yellow oil. [α]D
20 + 11.1 (c 0.67 in CHCl3); Chiral HPLC analysis, 
Chiralpak OJ-H (90:10 hexane/i-PrOH, flow rate 1 mLmin-1, 220 nm, 30 °C) tR (major): 27.5 min, 
tR (minor): 47.4 min, 99.5:0.5 er; νmax (film, cm–1) 2953 (C-H), 1732 (C=O), 1487 (C=C);
 1H NMR 
(500 MHz, CDCl3) δH: 2.41 (1H, dd, J 16.2, 6.8, C(4)HAHB), 2.48 (1H, dd, J 16.1, 7.0, C(4)HAHB), 
3.56–3.63 (1H, m, C(3)H), 3.71 (3H, s, C(5)COOCH3), 3.79 (3H, s, C(1)COOCH3), 4.97 (1H, d, J 
7.2, C(2)H), 5.97 (1H, dd, J 15.8, 8.8, ArCH=CH), 6.18 (2H, t, J 2.2, C(2)Ar(3,4)H), 6.41 (1H, d, J 
15.9, ArCH=CH), 6.77 (2H, t, J 2.2, C(2)Ar(2,5)H), 7.24–7.33 (5H, m, ArH); 13C{1H} NMR (126 
MHz, CDCl3) δC: 35.9 (C(4)H2), 42.7 (C(3)H), 52.0 (C(5)COOCH3), 52.7 (C(1)COOCH3), 64.7 (C(2)H), 
108.8 (C(2)ArC(3,4)H), 121.4 (C(2)ArC(2,5)H), 126.3 (ArCH=CH), 126.5 (ArC(2,6)H), 127.9 
(ArC(3,5)H), 128.6 (ArC(4)H), 133.5 (ArCH=CH), 136.8 (ArC(1)), 169.9 (C(1)), 172.0 (C(5)); HRMS 
(NSI+) C19H21NO4 [M+H]+ found 328.1548, requires 328.1543 (+1.4 ppm). 
Selected data for minor diastereoisomer (2R,3S): 1H NMR (500 MHz, CDCl3) δH: 2.22 (2H, dd, J 
6.3, 3.5, C(4)HAHB), 3.44–3.55 (1H, m, C(3)H), 3.62 (3H, s, C(5)COOCH3), 3.66 (3H, s, 
C(1)COOCH3), 4.75 (1H, d, J 10.8, C(2)H), 6.07 (1H, dd, J 15.8, 9.2, ArCH=CH), 6.22 (2H, t, J 2.1, 
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Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 475 (68.9 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product (>95:5 dr) that was purified by column chromatography 
(hexane/EtOAc 40:60) to give 196 (71.6 mg, 60%) as a white solid. mp 168–170 °C; [α]D
20 −
24.8 (c 0.21 in DMSO); Chiral HPLC analysis, Chiralpak AD-H (90:10 hexane/i-PrOH, flow rate 1 
mLmin-1, 254 nm, 30 °C) tR (major): 15.5 min, tR (minor): 19.7 min, >99.5:0.5 er; νmax (film, cm-
1) 3277 (N-H), 3059 (C-H), 3028 (C-H), 1672 (C=C), 1637 (C=O), 1541; 1H NMR (400 MHz, CDCl3) 
δH: 2.30 (1H, dd, J 14.7, 6.8, C(4)HAHB), 2.46 (1H, dd, J 14.7, 6.0, C(4)HAHB), 3.78–3.83 (1H, m, 
C(3)H), 4.34 (1H, dd, J 14.9, 5.7, C(1)NHCHAHBPh), 4.39–4.48 (2H, m, C(5)NHCH2Ph), 4.51 (1H, 
dd, J 14.9, 6.3, C(1)NHCHAHBPh), 5.07 (1H, d, J 7.0, C(2)H), 5.87 (1H, t, J 5.8, C(5)NH), 6.09 (1H, 
dd, J 16.0, 8.3, C(3)CH=CHPh), 6.16 (2H, t, J 2.2, C(2)Ar(3,4)H), 6.34 (1H, t, J 6.0, C(1)NH), 6.46 
(1H, d, J 15.9, C(3)CH=CHPh), 6.75 (2H, t, J 2.1, C(2)Ar(2,5)H), 7.16–7.19 (2H, m, 
C(3)CH=CHArC(2,6)H), 7.20–7.32 (13H, m, C(3)CH=CHArC(3,4,5)H + C(1)NHCH2ArCH + 
C(5)NHCH2ArCH); 13C{1H} NMR (126 MHz, CDCl3) δC: 38.3 (C(4)H2), 42.1 (C(3)H), 43.6 
(C(1)NHCH2), 43.7 (C(5)NHCH2), 65.8 (C(2)H), 109.5 (C(2)ArC(3,4)H), 121.4 (C(2)ArC(2,5)H), 
126.5 (ArCH), 127.2 (C(3)CH=CHPh), 127.6 (C(3)CH=CHArC(2,6)H), 127.7 (ArCH), 127.8 (ArCH), 
127.9 (ArCH), 128.7 (ArCH), 128.8 (ArCH), 128.9 (ArCH), 133.4 (C(3)CH=CHPh), 136.9 
(C(3)CH=CHArC(1)), 137.9 (C(1)NHCH2ArC(1)), 138.1 (C(5)NHCH2ArC(1)), 169.5 (C(1)), 170.7 
(C(5)); HRMS (NSI+) C31H32N3O2 [M+H]+ found 478.2482, requires 478.2489 (–1.5 ppm). 
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Dimethyl (2S,3R)-3-pentyl-2-(1H-pyrrol-1-yl)pentanedioate (197) and dimethyl (2R,3R)-3-
pentyl-2-(1H-pyrrol-1-yl)pentanedioate (483) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (33.4 mg, 0.267 mmol), i-
Pr2NEt (0.092 mL, 0.534 mmol), pivaloyl chloride (0.066 mL, 0.534 mmol) in MeCN (2.7 mL) at 
0 °C for 20 min followed by HyperBTM 93 (8.2 mg, 10 mol%), CCl3 enone 477 (65.0mg, 0.267 
mmol) and i-Pr2NEt (0.12 mL, 0.668 mmol) at –40 °C for 40 h. Ring-opening with MeOH (2.7 
mL) and DMAP (6.5 mg, 20 mol%) at rt for 24 h gave crude product (51:49 dr) that was purified 
by column chromatography (Petrol/EtOAc 90:10 to 85:15) to give: 
(2S,3R)-197 (37 mg, 47%) as a yellow oil. [α]D
20 − 6.4 (c 0.5 in CHCl3); νmax (film, cm–1) 2953 (C-
H), 2932 (C-H), 2859 (C-H), 1736 (C=O); 1H NMR (500 MHz, CDCl3) δH: 0.84 (3H, t, J 7.0, CH3), 
1.10–1.38 (8H, m, 4 × CH2), 2.26 (1H, dd, J 16.4, 6.9, C(4)HAHB), 2.39 (1H, dd, J 16.4, 5.4, 
C(4)HAHB), 2.62–2.69 (1H, m, C(3)H), 3.69 (3H, s, C(5)COOCH3), 3.73 (3H, s, C(1)COOCH3), 4.77 
(1H, d, J 8.7, C(2)H), 6.16 (2H, t, J 2.1, C(2)Ar(3,4)H), 6.73 (2H, t, J 2.2, C(2)Ar(2,5)H); 13C{1H} 
NMR (126 MHz, CDCl3) δC: 14.1 (CH3), 22.5 (CH2), 26.1 (CH2), 29.8 (CH2), 31.7 (CH2), 34.6 
(C(4)H2), 38.4 (C(3)H), 51.9 (C(5)COOCH3), 52.6 (C(1)COOCH3), 64.6 (C(2)H), 108.7 
(C(2)ArC(3,4)H), 121.0 (C(2)ArC(2,5)H), 170.7 (C(1)), 172.7 (C(5)); HRMS (NSI+) C16H26NO4 
[M+H]+ found 296.1859, requires 296.1856 (+0.9 ppm). 
(2R,3R)-483 (37 mg, 47%) as a yellow oil. [α]D
20 + 2.3 (c 0.13 in CHCl3); νmax (film, cm–1) 2953 
(C-H), 2930 (C-H), 2860 (C-H), 1736 (C=O); 1H NMR (500 MHz, CDCl3) δH: 0.88 (3H, t, J 6.9, CH3), 
1.20–1.39 (8H, m, 4 × CH2), 1.97 (1H, dd, J 16.2, 6.7, C(4)HAHB), 2.19 (1H, dd, J 16.2, 4.5, 
C(4)HAHB), 2.64–2.71 (1H, m, C(3)H), 3.61 (3H, s, C(5)COOCH3), 3.73 (3H, s, C(1)COOCH3), 4.67 
(1H, d, J 10.4, C(2)H), 6.15 (2H, t, J 2.1, C(2)Ar(3,4)H), 6.77 (2H, t, J 2.2, C(2)Ar(2,5)H); 13C{1H} 
NMR (126 MHz, CDCl3) δC: 14.1 (CH3), 22.6 (CH2), 26.1 (CH2), 30.5 (CH2), 31.9 (CH2), 33.4 
(C(4)H2), 38.9 (C(3)H), 51.7 (C(5)COOCH3), 52.6 (C(1)COOCH3), 64.7 (C(2)H), 108.9 
(C(2)ArC(3,4)H), 120.7 (C(2)ArC(2,5)H), 170.8 (C(1)), 172.6 (C(5)); HRMS (ASAP+) C16H26NO4 
[M+H]+ found 296.1859, requires 296.1862 (-1.0 ppm). 
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(2S,3R)-N1,N5-Dibenzyl-3-pentyl-2-(1H-pyrrol-1-yl)pentanediamide (198) and (2R,3R)-N1,N5-
dibenzyl-3-pentyl-2-(1H-pyrrol-1-yl)pentanediamide (484) 
 
Following General Procedure E, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol), i-
Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C 
for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 477 (60.9 mg, 0.25 mmol) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 40 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product (57:43 dr) that was triturated in ether to give the combined syn 
and anti diastereoisomers (70:30 dr) (40.1 mg, 36%) as a yellow solid. mp 133–134 °C; Chiral 
HPLC analysis, Chiralpak AD-H (97.5:2.5 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR 
(2S,3R-major): 75.5 min, tR (2R,3S-minor): 59.8 min, 99.5:0.5 er; tR (2R,3R-major): 107.3 min, 
tR (2S,3S-minor): 125.6 min, 66:34 er; νmax (film, cm-1) 3281 (N-H), 3088 (C-H), 2957 (C-H), 2932 
(C-H), 2859 (C-H), 1638 (C=O), 1553. 
(2S,3R)-198: 1H NMR (500 MHz, CDCl3) δH: 0.82 (3H, t, J 7.0, CH3), 1.09–1.47 (8H, m, 4 × CH2), 
2.19 (1H, dd, J 15.1, 6.3, C(4)HAHB), 2.36 (1H, dd, J 15.0, 4.2, C(4)HAHB), 2.61–2.67 (1H, m, 
C(3)H), 4.31–4.47 (4H, m, C(5)NHCH2Ph + C(1)NHCH2Ph), 4.84 (1H, d, J 9.2, C(2)H), 6.09–6.13 
(1H, m, C(1)NH), 6.16–6.17 (2H, t, J 1.9, C(2)Ar(3,4)H), 6.56 (1H, t, J 6.1, C(5)NH), 6.76 (2H, t, J 
2.2, C(2)Ar(2,5)H), 7.16–7.36 (10H, m, C(1)NHCH2ArCH + C(5)NHCH2ArCH); 13C{1H} NMR (126 
MHz, CDCl3) δC: 14.0 (CH3), 22.5 (CH2), 26.9 (CH2), 29.9 (CH2), 31.7 (CH2), 36.2 (C(4)H2), 38.8 
(C(3)H), 43.5 (C(1)NHCH2), 43.6 (C(5)NHCH2), 65.8 (C(2)H), 109.0 (C(2)ArC(3,4)H), 120.8 
(C(2)ArC(2,5)H), 127.5 (ArCH), 127.6 (ArCH), 127.8 (ArCH), 128.7 (ArCH), 128.8 (ArCH), 137.9 
(C(1)NHCH2ArC(1)), 138.1 (C(5)NHCH2ArC(1)), 170.4 (C(1)), 171.5 (C(5)). 
(2R,3R)-484: 1H NMR (500 MHz, CDCl3) δH: 0.86 (1H, t, J 6.9, CH3), 1.09–1.47 (8H, m, 4 × CH2), 
1.95 (1H, dd, J 14.7, 6.4, C(4)HAHB), 2.30 (1H, dd, J 14.7, 4.3, C(4)HAHB), 2.70–2.76 (1H, m, 
C(3)H), 4.31–4.47 (4H, m, C(5)NHCH2Ph + C(1)NHCH2Ph), 4.74 (1H, d, J 8.0, C(2)H), 5.97 (1H, t, 
J 5.8, C(1)NH), 6.09–6.13 (1H, m, C(5)NH), 6.16–6.17 (2H, t, J 1.9, C(2)Ar(3,4)H), 6.74 (2H, t, J 
2.2, C(2)Ar(2,5)H), 7.16–7.36 (10H, m, C(1)NHCH2ArCH + C(5)NHCH2ArCH); 13C{1H} NMR (126 
MHz, CDCl3) δC: 14.1 (CH3), 26.9 (CH2), 27.6 (CH2), 30.7 (CH2), 31.8 (CH2), 36.7 (C(4)H2), 39.2 
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(C(3)H), 43.5 (C(1)NHCH2), 43.6 (C(5)NHCH2), 65.7 (C(2)H), 109.2 (C(2)ArC(3,4)H), 120.9 
(C(2)ArC(2,5)H), 127.5 (ArCH), 127.6 (ArCH), 128.7 (ArCH), 128.8 (ArCH), 137.6 
(C(1)NHCH2ArC(1)), 138.3 (C(5)NHCH2ArC(1)), 170.0 (C(1)), 171.7 (C(5)); HRMS (NSI+) 
C28H36N3O2 [M+H]+ found 446.2798, requires 446.2802 (–0.9 ppm). 
 
Dimethyl (2S,3S)-2-(1H-indol-1-yl)-3-phenylpentanedioate (226) and dimethyl (2R,3S)-2-
(1H-indol-1-yl)-3-phenylpentanedioate (227) 
 
Following General Procedure D, 2-(1H-indol-1-yl)acetic acid 155 (43.8 mg, 0.25 mmol), i-Pr2NEt 
(0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C for 20 
min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 158 (74.9 mg, 0.3 mmol, 1.2 eq.) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with MeOH (2.5 mL) and 
DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product (80:20 dr) that was purified by 
column chromatography (Petrol/EtOAc 90:10 to 85:15) to give:  
(2S,3S)-226 (59.7 mg, 68%) as a light-yellow solid. mp 80–82 °C; [α]D
20 + 36.2 (c 0.6 in CHCl3); 
Chiralpak AD-H (95:5 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 16.2 min, 
tR (minor): 12.1 min, 95:5 er; νmax (film, cm–1) 3030 (C-H), 3007 (C-H), 2953 (C-H), 1732 (C=O); 
1H NMR (500 MHz, CDCl3) δH: 2.78–2.86 (2H, m, C(4)H2), 3.60 (3H, s, C(5)COOCH3), 3.73 (3H, s, 
C(1)COOCH3), 4.20–4.24 (1H, m, C(3)H), 5.42 (1H, d, J 9.1, C(2)H), 6.39 (1H, d, J 3.2, C(2)Ar(3)H), 
7.02–7.15 (8H, m, C(2)Ar(2,5,6)H + C(3)ArCH), 7.26–7.28 (1H, m, C(2)Ar(7)H), 7.50 (1H, dt, J 
7.8, 1.0, C(2)Ar(4)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 37.4 (C(4)H2), 44.1 (C(3)H), 52.0 
(C(5)COOCH3), 52.8 (C(1)COOCH3), 61.8 (C(2)H), 102.6 (C(2)ArC(3)H), 109.1 (C(2)ArC(7)H), 
119.9 (C(3)ArCH), 121.0 (C(2)ArC(4)H), 121.8 (C(3)ArCH), 126.9 (C(3)ArCH), 127.7 
(C(2)ArC(2)H), 128.0 (C(2)ArC(5)H), 128.3 (C(2)ArC(6)H), 128.5 (C(3)ArCH), 136.6 (C(2)ArC), 
138.4 (C(3)ArC(1)), 170.1 (C(1)), 171.8 (C(5)); HRMS (NSI+) C21H22NO4 [M+H]+ found 352.1543, 
requires 352.1543 (–0.1 ppm). 
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(2R,3S)-227 (13.2 mg, 15%) as a colourless oil. [α]D
20 + 8.2 (c 0.2 in CHCl3); Chiral HPLC analysis, 
Chiralpak AD-H (95:5 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 23.4 min, 
tR (minor): 15.2 min, 74:26 er; νmax (film, cm–1) 2988 (C-H), 1731 (C=O); 1H NMR (500 MHz, CDCl3) 
δH: 2.29 (1H, dd, J 16.0, 4.4, C(4)HAHB), 2.55 (1H, dd, J 16.0, 10.3, C(4)HAHB), 3.39 (3H, s, 
C(1)COOCH3), 3.41 (3H, s, C(5)COOCH3), 4.13–4.18 (1H, m, C(3)H), 5.24 (1H, d, J 11.3, C(2)H), 
6.64 (1H, d, J 3.3, C(2)Ar(3)H), 7.14–7.17 (1H, m, C(2)Ar(2)H), 7.25–7.31 (2H, m, C(2)Ar(5)H + 
C(3)ArCH), 7.35–7.37 (4H, m, C(3)ArCH), 7.48 (1H, d, J 8.3, C(2)Ar(6)H), 7.51 (1H, d, J 3.4, 
C(2)Ar(7)H), 7.64 (1H, dt, J 7.8, 0.9, C(2)Ar(4)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 36.8 (C(4)H2), 
45.0 (C(3)H), 51.6 (C(5)COOCH3), 52.3 (C(1)COOCH3), 62.2 (C(2)H), 103.8 (C(2)ArC(3)H), 109.2 
(C(2)ArC(7)H), 120.3 (C(3)ArCH), 121.2 (C(2)ArC(4)H), 122.24 (C(3)ArCH), 125.3 (C(3)ArCH), 
127.9 (C(2)ArC(2)H), 128.3 (C(2)ArC(5)H), 128.8 (C(2)ArC(6)H), 136.7 (C(2)ArC), 138.3 




Following General Procedure E, 2-(1H-indol-1-yl)acetic acid 155 (43.8 mg, 0.25 mmol), i-Pr2NEt 
(0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in MeCN (2.5 mL) at 0 °C for 20 
min followed by HyperBTM 93 (7.7 mg, 10 mol%), CCl3 enone 158 (74.9 mg, 0.3 mmol, 1.2 eq.) 
and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening with BnNH2 (2.5 mL) at rt 
for 24 h gave crude product that was triturated in ether to give 228 (80.3 mg, 64%) as a white 
solid. mp 189–190 °C. [α]D
20 + 7.9  (c 0.2 in DMSO); Chiral HPLC analysis, Chiralpak AD-H 
(80:20 hexane/i-PrOH, flow rate 1 mLmin-1, 220 nm, 30 °C) tR (major): 17.7 min, tR (minor): 8.5 
min, 97:3 er; νmax (film, cm-1) 3277 (N-H), 3086 (C-H), 3063 (C-H), 1672 (C=O), 1636 (C=O), 1557 
(Ar C=C), 1454 (Ar C=C); 1H NMR (500 MHz, DMSO) δH: 2.49 (1H, d, J 12.1, C(4)HAHB), 2.71 (1H, 
dd, J 13.8, 11.6, C(4)HAHB), 3.93 (1H, dd, J 15.6, 5.0, C(5)NHCHAHBPh), 4.16 (1H, td, J 11.4, 3.5, 
C(3)H), 4.24 (2H, td, J 15.4, 14.7, 6.1, C(1)NHCHAHBPh + C(5)NHCHAHBPh), 4.41 (1H, dd, J 15.0, 
6.0, C(1)NHCHAHBPh), 5.49 (1H, d, J 11.3, C(2)H), 6.29 (1H, d, J 3.3, C(2)Ar(3)H), 6.65–6.67 (2H, 
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m, C(1)NHCH2ArC(2,6)H), 6.90 (1H, t, J 7.4, C(2)Ar(2)H), 7.00–7.12 (7H, m, 
C(1)NHCH2ArC(3,4,5)H + C(2)Ar(4,5)H + C(5)NHCH2ArC(2,6)H), 7.19–7.30 (7H, m, 
C(5)NHCH2ArC(3,4,5)H + C(3)ArC(2,6,3,5)H), 7.36 (1H, d, J 7.8, C(3)ArC(4)H), 7.55 (1H, d, J 8.4, 
C(2)Ar(6)H), 7.59 (1H, d, J 3.4, C(2)Ar(7)H), 8.25–8.27 (1H, m, C(5)NH), 9.05 (1H, t, J 5.7, 
C(1)NH); 13C{1H} NMR (126 MHz, DMSO) δC: 40.0 (C(4)H2), 41.6 (C(5)NHCH2), 42.5 (C(1)NHCH2), 
44.2 (C(3)H), 61.9 (C(2)H), 101.3 (C(2)ArC(3)H), 109.7 (C(2)ArC(6)H), 119.0 (C(2)ArC(2)H), 120.1 
(C(2)ArC(5)H), 120.8 (C(2)ArC(7)H), 126.4 (C(2)ArC(4)H), 126.6 (C(3)ArC(4)H), 126.6 
(C(3)ArC(3,5)H), 126.7 (C(3)ArC(2,6)H), 127.1 (C(1)NHCH2ArC(2,6)H), 127.5 
(C(1)NHCH2ArC(4)H), 127.6 (C(1)NHCH2ArC(3,5)H), 127.8 (C(5)NHCH2ArC(4)H), 128.0 
(C(5)NHCH2ArC(3,5)H), 128.2 (C(5)NHCH2ArC(2)H), 128.4 (C(5)NHCH2ArC(6)H), 136.1 
(C(3)ArC(1)), 138.6 (C(2)ArC), 139.1 (C(1)NHCH2ArC(1)), 139.6 (C(5)NHCH2ArC(1)), 168.7 (C(1)), 
169.4 (C(5)); HRMS (NSI+) C33H32N3O2 [M+H]+ found 502.2484, requires 502.2489 (–1.0 ppm). 
 
8.3.4. Friedel-Crafts Acylation Compound Data 
Methyl (5S,6S)-8-oxo-6-phenyl-5,6,7,8-tetrahydroindolizine-5-carboxylate (206) 
 
Following General Procedure F, 167 (50.0 mg, 0.166 mmol), anhydrous CH2Cl2 (3.5 mL) and 
BBr3 (0.18 mL, 1.1 equiv, 1 M in CH2Cl2) gave, after flash column chromatography (petrol/EtOAc 
60:40, Rf 0.55), 206 (33.5 mg, 0.125 mmol, 75%) as a yellow solid. mp 109–110 °C. [α]D
20 +
347.7 (c 0.55 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 
1 mLmin-1, 211 nm, 30 °C) tR (major): 13.8 min, tR (minor): 29.8 min, >99.5 :0.5 er; νmax (film, 
cm-1) 3111 (C-H), 3057 (C-H), 2953 (C-H), 1736 (C=O), 1655 (C=O), 1533 (Ar); 1H NMR (500 MHz, 
CDCl3) δH: 2.80 (1H, dd, J 17.1, 4.0, C(7)HAHB), 3.45–3.48 (1H, m, C(7)HAHB), 3.51 (3H, s, OCH3), 
4.03 (1H, dt, J 13.7, 4.7, C(6)H), 5.11 (1H, d, J 5.4, C(5)H), 6.39 (1H, dd, J 4.1, 2.5, C(2)H), 6.91 
(1H, dd, J 2.5, 1.5, C(3)H), 7.15 (1H, dd, J 4.1, 1.5, C(1)H), 7.26–7.29 (2H, m, C(6)ArC(2,6)H), 
7.34–7.38 (1H, m, C(6)ArC(4)H), 7.40–7.43 (2H, m, C(6)ArC(3,5)H); 13C{1H} NMR (126 MHz, 
CDCl3) δC: 37.2 (C(7)H2), 42.8 (C(6)H), 52.4 (OCH3), 62.0 (C(5)H), 111.7 (C(2)H), 114.7 (C(1)H), 
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125.4 (C(3)H), 127.5 (C(6)ArC(2,6)H), 128.2 (C(6)ArC(4)H), 129.0 (C(6)ArC(3,5)H), 130.3 
(C(1)CN(4)), 137.1 (C(6)ArC(1)), 168.6 (C(5)C=OOMe), 186.3 (C(8)); HRMS (ASAP+) C16H16NO3 
[M+H]+ found 270.1136, requires 270.1130 (+2.2 ppm). 
 
Methyl (5S,6S)-6-(4-methoxyphenyl)-8-oxo-5,6,7,8-tetrahydroindolizine-5-carboxylate (207) 
 
Following General Procedure F, 173 (55.0 mg, 0.166 mmol), anhydrous CH2Cl2 (3.5 mL) and 
BBr3 (0.18 mL, 1.1 equiv, 1 M in CH2Cl2) gave, after flash column chromatography (petrol/EtOAc 
60:40, Rf 0.4), 207 (34.8 mg, 0.116 mmol, 70%) as a white solid. mp 121–122 °C. [α]D
20 +
295.0 (c 0.42 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 
1 mLmin-1, 220 nm, 30 °C) tR (major): 16.2 min, tR (minor): 26.7 min, 98:2 er; νmax (film, cm-1) 
3109 (C-H), 2953 (C-H), 1738 (C=O), 1655 (C=O), 1514 (Ar); 1H NMR (500 MHz, CDCl3) δH: 2.74 
(1H, dd, J 17.1, 4.0, C(7)HAHB), 3.40 (1H, dd, J 17.1, 13.7, C(7)HAHB), 3.50 (3H, s, C(5)C=OOCH3), 
3.81 (3H, s, C(6)ArC(4)OCH3), 3.95 (1H, dt, J 13.6, 4.7, C(6)H), 5.04 (1H, d, J 5.4, C(5)H), 6.35 
(1H, dd, J 4.1, 2.5, C(2)H), 6.87 (1H, dd, J 2.6, 1.5, C(3)H), 6.89–6.92 (2H, m, C(6)ArC(3,5)H), 
7.11 (1H, dd, J 4.1, 1.6, C(1)H), 7.15–7.18 (2H, m, C(6)ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) 
δC: 37.6 (C(7)H2), 42.2 (C(6)H), 52.5 (C(5)C=OOCH3), 55.4 (C(6)ArC(4)OCH3), 62.2 (C(5)H), 111.8 
(C(2)H), 114.4 (C(6)ArC(3,5)H), 114.7 (C(1)H), 125.5 (C(3)H), 128.6 (C(6)ArC(2,6)H), 129.1 
(C(6)ArC(1)), 130.4 (C(1)CN(4)), 159.4 (C(6)ArC(4)), 168.8 (C(5)C=OOMe), 186.5 (C(8)); HRMS 
(ASAP+) C17H18NO4 [M+H]+ found 300.1240, requires 300.1236 (+1.3 ppm). 
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Following General Procedure F, 177 (52.1 mg, 0.141 mmol), anhydrous CH2Cl2 (2.8 mL) and 
BBr3 (0.16 mL, 1.1 equiv, 1 M in CH2Cl2) gave, after flash column chromatography (petrol/EtOAc 
60:40, Rf 0.51), 208 (41.8 mg, 0.124 mmol, 88%) as a white crystalline solid. mp 136–138 °C. 
[α]D
20 + 257.2 (c 0.47 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (90:10 hexane/i-PrOH, 
flow rate 1 mLmin-1, 220 nm, 30 °C) tR (major): 29.7 min, tR (minor): 49.6 min, 97.5:2.5 er; νmax 
(film, cm-1) 3117 (C-H), 2957 (C-H), 1742 (C=O), 1661 (C=O), 1325; 1H NMR (500 MHz, CDCl3) 
δH: 2.79 (1H, ddd, J 17.0, 4.1, 0.7, C(7)HAHB), 3.44 (1H, dd, J 17.0, 13.5, C(7)HAHB), 3.50 (3H, s, 
C(5)C=OOCH3), 4.07 (1H, dt, J 13.5, 4.7, C(6)H), 5.11 (1H, d, J 5.2, C(5)H), 6.38 (1H, dd, J 4.1, 
2.5, C(2)H), 6.91 (1H, dd, J 2.5, 1.5, C(3)H), 7.14 (1H, dd, J 4.1, 1.5, C(1)H), 7.38–7.40 (2H, m, 
C(6)ArC(2,6)H), 7.65–7.66 (2H, m, C(6)ArC(3,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 37.2 
(C(7)H2), 42.7 (C(6)H), 52.7 (C(5)C=OOCH3), 61.7 (C(5)H), 112.0 (C(2)H), 115.2 (C(1)H), 124.0 (q, 
J 272.1, C(6)ArC(4)CF3), 125.8 (C(3)H), 126.0 (q, J 3.7, C(6)ArC(3,5)H), 128.1 (C(6)ArC(2,6)H), 
130.3 (C(6)ArC(1)), 130.6 (q, J 32.7, C(6)ArC(4)), 141.2 (C(1)CN(4)), 168.3 (C(5)C=OOMe), 185.5 
(C(8)); 19F NMR (471 MHz, CDCl3) δF: –62.7 (CF3); HRMS (ASAP+) C17H15NO3F3 [M+H]+ found 
338.1006, requires 338.1004 (+0.6 ppm). 
 
Methyl (5S,6S)-6-(4-nitrophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine-5-carboxylate (209) 
 
Following General Procedure F, 179 (65.3 mg, 0.189 mmol), anhydrous CH2Cl2 (3.8 mL) and 
BBr3 (0.21 mL, 1.1 equiv, 1 M in CH2Cl2) gave, after flash column chromatography (petrol/EtOAc 
60:40, Rf 0.34), 209 (47.4 mg, 0.151 mmol, 80%) as a white crystalline solid. mp 184–186 °C. 
[α]D
20 + 289.8 (c 0.44 in CHCl3); Chiral HPLC analysis, Chiralpak AD-H (80:20 hexane/i-PrOH, 
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flow rate 1 mLmin-1, 220 nm, 30 °C) tR (major): 24.9 min, tR (minor): 22.2 min, 98:2 er; νmax (film, 
cm-1) 3113 (C-H), 2955 (C-H), 1742 (C=O), 1661 (C=O), 1520 (N-O), 1348 (N-O); 1H NMR (500 
MHz, CDCl3) δH: 2.82 (1H, dd, J 16.9, 4.1, C(7)HAHB), 3.43 (1H, dd, J 16.9, 13.4, C(7)HAHB), 3.52 
(3H, s, C(5)C=OOCH3), 4.13 (1H, dt, J 13.4, 4.6, C(6)H), 5.13 (1H, d, J 5.2, C(5)H), 6.39 (1H, dd, J 
4.1, 2.5, C(2)H), 6.93 (1H, dd, J 2.6, 1.6, C(3)H), 7.15 (1H, dd, J 4.1, 1.5, C(1)H), 7.44–7.47 (2H, 
m, C(6)ArC(2,6)H), 8.25–8.27 (2H, m, C(6)ArC(3,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 37.2 
(C(7)H2), 42.7 (C(6)H), 52.8 (C(5)C=OOCH3), 61.4 (C(5)H), 112.1 (C(2)H), 115.4 (C(1)H), 124.3 
(C(6)ArC(3,5)H), 125.9 (C(3)H), 128.8 (C(6)ArC(2,6)H), 130.2 (C(1)CN(4)), 144.5 (C(6)ArC(1)), 
147.8 (C(6)ArC(4)), 168.1 (C(5)C=OOMe), 184.9 (C(8)); HRMS (ASAP+) C16H15N2O5 [M+H]+ found 
315.0982, requires 315.0981 (+1.3 ppm). 
 
Methyl (5S,6R)-6-(furan-2-yl)-8-oxo-5,6,7,8-tetrahydroindolizine-5-carboxylate (210) 
 
Following General Procedure F, 193 (50.5 mg, 0.173 mmol), anhydrous CH2Cl2 (3.5 mL) and 
BBr3 (0.19 mL, 1.1 equiv, 1 M in CH2Cl2) gave, after flash column chromatography (petrol/EtOAc 
60:40, Rf 0.55), 210 (33.6 mg, 0.130 mmol, 75%) as a yellow oil. [α]D
20 + 135.4 (c 0.13 in CHCl3); 
Chiral HPLC analysis, Chiralpak AD-H (95:5 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) 
tR (major): 33.3 min, tR (minor): 27.9 min, 98:2 er; νmax (film, cm-1) 3121 (C-H), 2955 (C-H), 1744 
(C=O), 1655 (C=O), 1535 (Ar); 1H NMR (500 MHz, CDCl3) δH: 2.84 (1H, dd, J 17.4, 4.4, C(7)HAHB), 
3.16 (1H, dd, J 17.4, 13.3, C(7)HAHB), 3.56 (3H, s, C(5)C=OOCH3), 4.07 (1H, dt, J 13.3, 4.7, C(6)H), 
5.28 (1H, d, J 5.3, C(5)H), 6.17–6.18 (1H, m, C(6)ArC(3)H), 6.35–6.36 (2H, m, C(6)ArC(4)H + 
C(2)H), 6.90 (1H, dd, J 2.5, 1.5, C(3)H), 7.12 (1H, dd, J 4.1, 1.5, C(1)H), 7.42–7.43 (1H, m, 
C(6)ArC(5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 36.2 (C(7)H2), 37.1 (C(6)H), 52.8 
(C(5)C=OOCH3), 59.8 (C(5)H), 107.2 (C(6)ArC(3)H), 110.6 (C(2)H), 111.9 (C(6)ArC(4)H), 115.1 
(C(1)H), 126.0 (C(3)H), 130.4 (C(1)CN(4)), 142.8 (C(6)ArC(5)H), 151.2 (C(6)ArC(2)), 168.5 
(C(5)C=OOMe), 185.2 (C(8)); HRMS (ASAP+) C14H14NO4 [M+H]+ found 260.0926, requires 
260.0923 (+1.2 ppm). 
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Methyl (5S,6S)-6-(4-chlorophenyl)-8-oxo-5,6,7,8-tetrahydroindolizine-5-carboxylate (211) 
 
Following General Procedure F, 187 (53.9 mg, 0.161 mmol), anhydrous CH2Cl2 (3.2 mL) and 
BBr3 (0.18 mL, 1.1 equiv, 1 M in CH2Cl2) gave, after flash column chromatography (petrol/EtOAc 
70:30, Rf 0.39), 211 (44.0 mg, 0.145 mmol, 90%) as a white solid. mp 150–152 °C. [α]D
20 +
332.0 (c 0.2 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 
mLmin-1, 211 nm, 30 °C) tR (major): 15.6 min, tR (minor): 26.9 min, 99:1 er; νmax (film, cm-1) 3121 
(C-H), 2955 (C-H), 1736 (C=O), 1655 (C=O), 1535 (Ar); 1H NMR (500 MHz, CDCl3) δH: 2.76 (1H, 
dd, J 17.0, 3.9, C(7)HAHB), 3.39 (1H, dd, J 17.0, 13.5, C(7)HAHB), 3.52 (3H, s, C(5)C=OOCH3), 3.98 
(1H, dt, J 13.6, 4.7, C(6)H), 5.06 (1H, d, J 5.3, C(5)H), 6.37 (1H, dd, J 4.1, 2.5, C(2)H), 6.89 (1H, 
dd, J 2.6, 1.5, C(3)H), 7.13 (1H, dd, J 4.1, 1.5, C(1)H), 7.18–7.21 (2H, m, C(6)ArC(2,6)H), 7.35–
7.38 (2H, m, C(6)ArC(3,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 37.4 (C(7)H2), 42.3 (C(6)H), 52.6 
(C(5)C=OOCH3), 61.8 (C(5)H), 111.9 (C(2)H), 115.0 (C(1)H), 125.6 (C(3)H), 129.0 (C(6)ArC(2,6)H), 
129.3 (C(6)ArC(3,5)H), 130.3 (C(1)CN(4)), 134.2 (C(6)ArC(4)), 135.7 (C(6)ArC(1)), 168.5 
(C(5)C=OOMe), 185.8 (C(8)); HRMS (NSI+) C16H15NO335Cl [M+H]+ found 304.0738, requires 
304.0735 (+1.0 ppm). 
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8.4. Experimentals for Chapter 4 
General Procedure A: Synthesis of α-keto-β,γ-unsaturated ester 
 
Following literature procedures,1 to a solution of pyruvic acid 130 (50 mmol, 1.0 eq.) and 
aromatic aldehyde (50 mmol, 1.0 eq.) in MeOH (5 mL) at 0 °C was added a solution of KOH 
(75 mmol, 1.5 eq.) in MeOH (15 mL). The first 1 eq. of the KOH solution was added dropwise 
over 30 minutes. The last 0.5 eq. was added as one portion and the reaction mixture was 
stirred at 40 °C for 1 h followed by 0 °C for 16 h. The precipitate was collected by filtration, 
washed twice with cold MeOH, once with Et2O and dried under vacuum to furnish the 
potassium salt that was used directly in the next step. 
Acetyl chloride (400 mmol, 11.5 eq.) was added to MeOH (200 mL) at 0 °C to generate HCl. 
Potassium salt obtained from last step was added and the mixture stirred at 0 °C for 30 min 
then warmed to rt for 2 h before heating at reflux for 16 h. Concentration in vacuo gave a sticky 
solid which was dissolved in H2O (50 mL) and extracted with CH2Cl2 (50 mL x 3). The combined 
organics were washed with saturated aq. NaHCO3 (25 mL), H2O (25 mL) and brine (25 mL) 
before being dried with MgSO4. Concentration in vacuo afforded the crude reaction mixture 
which was purified by flash column chromatography (EtOAc/petrol). 
All the rest of CF3 enone starting materials were kindly provided by colleague from Smith group 
and used as received. 
 
Isopropyl (E)-2-oxo-4-phenylbut-3-enoate (485) 
 
Following General Procedure A, the titled compound was obtained as a yellow oil (21% yield 
over two-step). Spectroscopy data were in accordance with the literature.1 1H NMR (400 MHz, 
CDCl3) δH: 1.41 (6H, d, J 6.1, CH3), 5.22 (1H, septet, J 6.1, CH), 7.34 (1H, d, J 16.2, C(3)H), 7.40–
7.52 (3H, m, ArCH), 7.62–7.69 (2H, m, ArCH), 7.82 (1H, d, J 16.1, C(4)H). 
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Ethyl (E)-2-oxo-4-phenylbut-3-enoate (486) 
 
Following General Procedure A, the titled compound was obtained as a yellow oil (25% yield 
over two-step). Spectroscopy data were in accordance with the literature.1 1H NMR (400 MHz, 
CDCl3) δH: 1.43 (3H, t, J 7.2, CH3), 4.42 (2H, q, J 7.1, CH2), 7.30 (1H, d, J 16.1, C(3)H), 7.38–7.46 
(3H, m, ArH), 7.62–7.69 (2H, m, ArH), 7.83 (1H, d, J 16.1, C(4)H). 
 
Methyl (E)-4-(naphthalen-2-yl)-2-oxobut-3-enoate (487) 
 
Following General Procedure A, the titled compound was obtained as a yellow solid (40% yield 
over two-step). Spectroscopy data were in accordance with the literature.1 mp 67-69 °C {Lit.1  
70-72 °C}; 1H NMR (400 MHz, CDCl3) δH: 4.01 (3H, s, CH3), 7.51 (1H, d, J 16.0, C(3)H), 7.52–7.61 
(2H, m, ArCH), 7.75–7.84 (1H, m, ArCH), 7.87–7.95 (3H, m, ArCH), 8.03–8.12 (2H, m, C(4)H and 
ArCH). 
 
Methyl (E)-2-oxo-4-(p-tolyl)but-3-enoate (488) 
 
Following General Procedure A, the titled compound was obtained as a yellow solid (41% yield 
over two-step). Spectroscopy data were in accordance with the literature.9 mp 80-81 °C {Lit.10  
70-72 °C}; 1H NMR (400 MHz, CDCl3) δH: 2.41 (3H, s, CH3), 3.94 (3H, s, OCH3), 7.22 (2H, d, J 7.8, 
ArCH), 7.32 (1H, d, J 16.1, C(3)H), 7.55 (2H, d, J 7.9, ArCH), 7.88 (1H, d, J 16.2, C(4)H). 
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Methyl (E)-4-(4-methoxyphenyl)-2-oxobut-3-enoate (489) 
 
Following General Procedure A, the titled compound was obtained as a yellow solid (25% yield 
over two-step). Spectroscopy data were in accordance with the literature.1 mp 84-86 °C {Lit.1   
86-88 °C}; 1H NMR (400 MHz, CDCl3) δH: 3.87 (3H, s, OCH3), 3.96 (3H, s, OCH3), 6.92–7.00 (2H, 
m, ArCH), 7.28 (1H, d, J 16.0, C(3)H), 7.58–7.64 (2H, m, ArCH), 7.88 (1H, d, J 16.0, C(4)H). 
 
Methyl (E)-4-(3-methoxyphenyl)-2-oxobut-3-enoate (490) 
 
Following General Procedure A, the titled compound was obtained as a yellow solid (25% yield 
over two-step). Spectroscopy data were in accordance with the literature.9 mp 83-84 °C {Lit.10   
100-102 °C}; 1H NMR (400 MHz, CDCl3) δH: 3.85 (3H, s, CH3), 3.93 (3H, s, CH3), 6.92–7.06 (1H, 
m, ArCH), 7.11–7.12 (1H, m, C(3)H), 7.19–7.23 (1H, m, ArCH), 7.26–7.36 (2H, m, ArCH), 7.82 
(1H, d, J 16.1, C(4)H). 
 
Methyl (E)-2-oxo-4-(4-(trifluoromethyl)phenyl)but-3-enoate (491) 
 
Following General Procedure A, the titled compound was obtained as a yellow solid (30% yield 
over two-step). Spectroscopy data were in accordance with the literature.11 mp 116-117 °C 
{Lit.11   122-123 °C}; 1H NMR (400 MHz, CDCl3) δH: 3.95 (3H, s, CH3), 7.37 (1H, d, J 16.2, C(3)H), 
7.71 (2H, d, J 8.1, C(4)ArC(2,6)H), 7.76 (2H, d, J 8.2, C(4)ArC(3,5)H), 7.89 (1H, d J 16.2, C(4)H). 
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Methyl (E)-4-(4-bromophenyl)-2-oxobut-3-enoate (492) 
 
Following General Procedure A, the titled compound was obtained as a yellow solid (28% yield 
over two-step). Spectroscopy data were in accordance with the literature.1 mp 115-116 °C {Lit.1 
116-118 °C}; 1H NMR (400 MHz, CDCl3) δH: 3.98 (3H, s, CH3), 7.42 (1H, d, J 15.9, C(3)H), 7.48–
7.54 (2H, m, ArCH), 7.55–7.64 (2H, m, ArCH), 7.81 (1H, d, J 15.9, C(4)H). 
 
Methyl (E)-4-(3-bromophenyl)-2-oxobut-3-enoate (493) 
 
Following General Procedure A, the titled compound was obtained as a yellow solid (34% yield 
over two-step). Spectroscopy data were in accordance with the literature.1 mp 103-104 °C {Lit.1 
96-98 °C}; 1H NMR (400 MHz, CDCl3) δH: 3.86 (3H, s, CH3), 7.22 (1H, t, J 8.0, ArCH), 7.29 (1H, d, 
J 16.1, C(3)H), 7.43–7.54 (2H, m, ArCH), 7.66–7.73 (2H, m, C(4)H and ArCH). 
 
Methyl (E)-4-(2-bromophenyl)-2-oxobut-3-enoate (494) 
 
Following General Procedure A, the titled compound was obtained as a yellow solid (26% yield 
over two-step). Spectroscopy data were in accordance with the literature.11 mp 50-52 °C {Lit.11   
54-57 °C}; 1H NMR (400 MHz, CDCl3) δH: 3.94 (3H, s, CH3), 7.28–7.40 (3H, m, C(3)H + ArCH), 
7.62–7.79 (2H, m, ArCH), 8.25 (1H, d, J 16.1, C(4)H). 
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Methyl (E)-4-(furan-2-yl)-2-oxobut-3-enoate (495) 
 
Following literature procedures,1 to a solution of pyruvic acid 130 (3.52 g, 50 mmol, 1.0 eq.) 
and furan-2-carbaldehyde (4.14 mL, 50 mmol, 1.0 eq.) in MeOH (5 mL) at 0 °C was added a 
solution of KOH (4.21 g, 75 mmol, 1.5 eq.) in MeOH (15 mL). The first 1 eq. of the KOH solution 
was added dropwise over 30 minutes. The last 0.5 eq. was added as one portion and the 
reaction mixture was stirred at 40 °C for 1 h followed by 0 °C for 16 h. The precipitate was 
collected by filtration, washed twice with cold MeOH, once with Et2O and dried under vacuum 
to furnish the crude potassium salt, which was then all dissolved in DMF (40 mL). Methyl iodide 
(3.4 mL, 55 mmol, 1.1 eq.) was added and the reaction mixture was heated at 75 °C for 4 h. 
Once the reaction mixture was cooled to room temperature, H2O (40 mL) was added and the 
organic layer was extracted with DCM (3 x 40 mL). The combined organic extracts were washed 
with H2O (3 x 30 mL) and brine (3 x 30 mL), dried, filtered and concentrated under reduced 
pressure. Chromatographic purification (15:85 EtOAc/petrol) gave the titled compound as a 
dark yellow solid (1.62 g, 18% over two-step). Spectroscopy data were in accordance with the 
literature.1 mp 51-53 °C; {Lit.1 56-58 °C}; 1H NMR (400 MHz, CDCl3) δH: 3.84 (3H, s, CH3), 6.47 
(1H, dd, J 3.5, 1.8, ArCH), 6.76 (1H, d, J 3.4, ArCH), 7.17 (1H, d, J 15.9, C(3)H), 7.48–7.53 (1H, 
m, ArCH), 7.58 (1H, d, J 16.0, C(4)H). 
 
General Procedure B: Enantioselective synthesis of tetrahydroindolizine 
 
2-(1H-Pyrrol-1-yl)acetic acid 155 (1.0-1.2 eq.) was dissolved in the solvent stated (0.1 M) under 
an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (2 eq.) and pivaloyl chloride (2 eq.) 
were added. The reaction was stirred at 0 °C for 20 min before cooling down to –40 °C. 
HyperBTM 93 (10 mol%), the required Michael acceptor (1 eq.), and i-Pr2NEt (2.5 eq.) were 
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added sequentially and the reaction stirred at –40 °C for the time stated. After that, the 
reaction was quenched with the nucleophile stated at –40 °C, and stirred at rt for 24 h before 
being concentrated under reduced pressure to give the crude product which was purified by 




2-(1H-Pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.) was dissolved in anhydrous DMF 
(0.1 M) under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (0.087 mL, 0.5 mmol, 2 
eq.) and pivaloyl chloride (0.062 mL, 0.5 mmol, 2 eq.) were added. The reaction was stirred at 
0 °C for 20 min before warming up to rt. HyperBTM 93 (7.7 mg, 10 mol%), CF3 enone 144 (50.0 
mg, 0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) were added sequentially and 
the reaction stirred at rt. for 24 h. Upon completion of the reaction (checked by TLC), it was 
diluted with CH2Cl2 (equal volume) and washed with 1 M HCl (×2) and brine (×2) before being 
dried over MgSO4, filtered, and concentrated under reduced pressure to give the crude 
product, which was purified by flash silica column chromatography (15:85 EtOAc/petrol, Rf 
0.33), to give the titled compound as a yellow solid (74.5 mg, 97%). mp 65–66 °C; Chiral HPLC 
analysis, Chiralpak OD-H (90:10 hexane/i-PrOH, flow rate 1 mLmin-1, 254 nm, 30 °C) tR (major): 
14.4 min, tR (minor): 10.1 min, 80:20 er; vmax (film, cm-1) 3102 (C-H stretch), 1728 (C=O stretch), 
1614; 1H NMR (400 MHz, CDCl3) δH: 3.16 (1H, dd, J 17.7, 4.3, C(5)HAHB), 3.35 (1H, dd, J 17.6, 
11.3, C(5)HAHB), 5.06 (1H, dqd, J 11.4, 5.6, 4.2, C(6)H), 6.19 (2H, t, J 2.2, C(3)Ar(3,4)H), 6.51 (2H, 
t, J 2.2, C(3)Ar(2,5)H), 6.98–7.02 (2H, m, C(4)ArC(2,6)H), 7.29–7.39 (3H, m, C(4)ArC(3,4,5)H);; 
13C{1H} NMR (101 MHz, CDCl3) δC: 28.2 (C(5)), 72.8 (q, 2JCF 34.4, C(6)), 110.1 (C(3)ArC(3,4)H), , 
122.0 (C(3)ArC(2,5)H), 122.5 (q, 1JCF 280.2, CF3), 125.2 (C(3)), 127.3 (C(4)ArC(2,6)H), 128.8 
(C(4)ArC(3,5)H), 130.4 (C(4)ArC(2,6)H), 134.3 (C(4)ArC(1)), 144.5 (C(4)), 159.8 (C(2)); 19F{1H} 
NMR (377 MHz, CDCl3) δF: -78.0 (CF3); HRMS (NSI+) C16H13F3NO2 [M+H]+ found 308.0894, 
requires 308.0893 (+0.4 ppm). 
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(3S,4S)-4-Phenyl-3-(1H-pyrrol-1-yl)-6-(trifluoromethyl)-3,4-dihydro-2H-pyran-2-one (241) 
 
2-(1H-Pyrrol-1-yl)acetic acid 155 (37.5 mg, 0.30 mmol, 1.2 eq.) was dissolved in i-PrOAc (0.1 
M) under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (0.087 mL, 0.5 mmol, 2 eq.) 
and pivaloyl chloride (0.062 mL, 0.5 mmol, 2 eq.) were added. The reaction was stirred at 0 °C 
for 20 min before warming up to rt. HyperBTM 93 (7.7 mg, 10 mol%), CF3 enone 144 (50.0 mg, 
0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) were added sequentially and the 
reaction stirred at rt. for 18 h. Then the mixture was concentrated under reduced pressure to 
give the crude product (82:18 dr) which was purified by flash silica column chromatography 
(5:95 Et2O/petrol) and recrystallization in hexane to give the titled compound as fine colourless 
needles (15.4 mg, 20%). mp 83–85 °C; Chiral HPLC analysis, Chiralpak AD-H (97.5:2.5 hexane/i-
PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 13.6 min, tR (minor): 19.1 min, 95:5 er; 
vmax (film, cm-1) 1782 (C=O), 1701; 1H NMR (400 MHz, CDCl3) δH: 4.28 (1H, dp, J 12.4, 2.8, C(4)H), 
4.88 (1H, d, J 12.4, C(3)H), 6.15 (2H, t, J 2.2, C(3)Ar(3,4)H), 6.18 (1H, dq, J 2.4, 0.8, C(5)H), 6.50 
(2H, t, J 2.1, C(3)Ar(2,5)H), 7.00–7.04 (2H, m, C(4)ArC(2,6)H), 7.28–7.33 (3H, m, 
C(4)ArC(3,4,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 44.6 (C(4)), 62.6 (C(3)), 109.8 
(C(3)ArC(2,5)H), 110.6 (d, 3JCF 3.4, C(5)), 118.2 (q, 1JCF 272.0, CF3), 120.2 (C(3)ArC(3,4)H), 127.1 
(C(4)ArC(2,6)H), 128.6 (C(4)ArC(3,5)H), 129.2 (C(4)ArC(4)H), 136.9 (C(4)ArC(1)), 140.7 (q, 2JCF 
38.9, C(6)), 163.1 (C(2)); 19F{1H} NMR (377 MHz, CDCl3) δF: -72.1 (CF3); HRMS (NSI+) C16H13F3NO2 
[M+H]+ found 308.0895, requires 308.0893 (+0.7 ppm); [α]D
20 not measured due to product 
instability. 
Selected data for minor diastereoisomer: Chiral HPLC analysis, Chiralpak AD-H (97.5:2.5 
hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 15.3 min, tR (minor): 22.3 min, 
90:10 er; 1H NMR (400 MHz, CDCl3) δH: 4.06–4.13 (1H, m, C(4)H), 5.49 (1H, d, J 7.3, C(3)H). 
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(3S,4R)-3-(1H-Pyrrol-1-yl)-4-((E)-styryl)-4-(trifluoromethyl)oxetan-2-one (242) 
 
2-(1H-Pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.) was dissolved in CH2Cl2 (0.1 M) 
under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (0.087 mL, 0.5 mmol, 2 eq.) and 
pivaloyl chloride (0.062 mL, 0.5 mmol, 2 eq.) were added. The reaction was stirred at 0 °C for 
20 min before cooling to –60 °C. HyperBTM 93 (7.7 mg, 10 mol%), CF3 enone 144 (50.0 mg, 
0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) were added sequentially and the 
reaction stirred at –60 °C for 15 h. Then the mixture was concentrated under reduced pressure 
to give the crude product (>95:5 dr) which was purified by flash silica column chromatography 
(10:90 Et2O/petrol) to give the titled compound as a colourless oil (30.7 mg, 40%). Chiral HPLC 
analysis, Chiralpak IB (99:1 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 9.6 
min, tR (minor): 8.8 min, 96:4 er; 1H NMR (500 MHz, CDCl3) δH: 5.69 (1H, d, J 16.2, PhCH=CH), 
6.09 (1H, s, C(3)H), 6.26 (2H, t, J 2.2, C(3)Ar(3,4)H), 6.65 (2H, t, J 2.1, C(3)Ar(2,5)H), 6.97 (1H, 
d, J 16.1, PhCH=CH), 7.25–7.27 (2H, m, ArC(2,6)H), 7.33–7.37 (3H, m, ArC(3,4,5)H); 13C{1H} 
NMR (126 MHz, CDCl3) δC: 70.5 (C(3)), 81.3 (q, 2JCF 33.5, C(4)), 111.2 (C(3)ArC(3,4)H), 113.1 
(PhCH=CH), 120.8 (C(3)ArC(2,5)H), 127.8 (q, 1JCF 271.6, CF3), 127.2 (PhC(2,6)H), 128.8 
(PhC(3,5)H), 129.5 (PhC(4)H), 134.4 (PhCH=CH), 139.0 (PhC(1)), 162.5 (C(2)); 19F NMR (471 
MHz, CDCl3) δF: -78.8 (CF3); HRMS (ASAP+) C16H13F3NO2 [M+H]+ found 308.0895, requires 
308.0898 (-1.0 ppm); [α]D





Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (30.0 mg, 0.24 mmol, 1.2 eq.), 
i-Pr2NEt (0.070 mL, 0.40 mmol), pivaloyl chloride (0.050 mL, 0.40 mmol) in i-PrOAc (2 mL) at 
0 °C for 20 min followed by HyperBTM 93 (6.2 mg, 10 mol%), CF3 enone 144 (40.0 mg, 0.20 
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mmol, 1.0 eq.) and i-Pr2NEt (0.089 mL, 0.5 mmol) at –40 °C for 20 h. Ring-opening with MeOH 
(2 mL) and DMAP (4.9 mg, 20 mol%) at rt for 24 h gave crude product (91:9 dr) that was 
purified by column chromatography (10:90 EtOAc/petrol) to give the combined 
diastereoisomers (90:10 dr) (56.0 mg, 83%) as a light yellow oil. vmax (film, cm-1) 3447 (br., O-
H), 2953 (C-H), 1740 (C=O); [α]D
20  + 158.8 (c 0.8 in CHCl3). 
Data for major diastereoisomer (5S,6S,8R)-246: Chiral HPLC analysis, Chiralpak AD-H (95:5 
hexane/i-PrOH, flow rate 1 mLmin-1, 220 nm, 30 °C) tR (major): 19.5 min, tR (minor): 28.4 min, 
98:2 er; 1H NMR (400 MHz, CDCl3) δH: 2.28 (1H, dd, J 13.6, 2.7, C(7)HAHB), 2.39–2.40 (1H, s, 
OH), 3.08 (1H, td, J 13.6, 1.9, C(7)HAHB), 3.42 (3H, s, OCH3), 4.07 (1H, ddd, J 13.6, 6.0, 2.7, 
C(6)H), 5.02 (1H, d, J 6.0, C(5)H), 6.29 (1H, dd, J 3.8, 2.8, C(2)H), 6.51 (1H, dp, J 3.4, 1.6, C(1)H), 
6.66 (1H, dd, J 2.8, 1.6, C(3)H), 7.27–7.30 (2H, m, C(6)ArC(2,6)H), 7.33–7.37 (1H, m, 
C(6)ArC(4)H), 7.38–7.42 (2H, m, C(6)ArC(3,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 28.7 (C(7)), 
37.8 (C(6)), 52.1 (OCH3), 62.2 (C(5)), 70.6 (q, 2JCF 30.5, C(8)), 107.7 (C(1)), 110.3 (C(2)), 121.3 
(C(3)), 125.4 (q, 1JCF 272.0, CF3), 125.8 (C(8a)), 127.6 (C(6)ArC(2,6)H), 128.0 (C(6)ArC(4)H), 
128.8 (C(6)ArC(3,5)H), 137.8 (C(6)ArC(1)), 169.3 (C(5)CO); 19F{1H} NMR (377 MHz, CDCl3) δF: -
80.6 (CF3); HRMS (ASAP+) C17H17F3NO3 [M+H]+ found 340.1161, requires 340.1161 (0.0 ppm). 
Selected data for minor diastereoisomer: Chiral HPLC analysis, Chiralpak AD-H (95:5 hexane:i-
PrOH, flow rate 1 mLmin-1, 220 nm, 30 °C) tR (major): 14.7 min, tR (minor): 24.8 min, 96:4 er; 
1H NMR (400 MHz, CDCl3) δH (selected): 3.64 (3H, s, OCH3), 3.91 (1H, td, J 11.1, 4.8, C(6)H), 






Following General Procedure A, 2-(1H-pyrrol-1-yl)acetic acid 155 (30.0 mg, 0.24 mmol, 1.2 eq.), 
i-Pr2NEt (0.070 mL, 0.40 mmol), pivaloyl chloride (0.050 mL, 0.40 mmol) in i-PrOAc (2 mL) at 
0 °C for 20 min followed by HyperBTM 93 (6.2 mg, 10 mol%), CF3 enone 144 (40.0 mg, 0.20 
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mmol, 1.0 eq.) and i-Pr2NEt (0.089 mL, 0.5 mmol) at –40 °C for 20 h. Ring-opening with 
pyrrolidine (300 eq.) at rt for 24 h gave crude product (93:7 dr) that was purified by column 
chromatography (30:70 EtOAc/petrol) to give the titled compound as a white solid (53.0 mg, 
70%). mp 170-172 °C; vmax (film, cm-1) 3318 (O-H), 2982 (C-H), 1636 (amide CO); [α]D
20  +
175.3 (c 0.6 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 
mLmin-1, 211 nm, 30 °C) tR (major): 7.7 min, tR (minor): 14.5 min, 98:2 er; 1H NMR (500 MHz, 
CDCl3) δH: 1.48–1.73 (4H, m, pyrrolidineCH), 2.11 (1H, dd, J 13.3, 2.8, C(7)H(A)H(B)), 2.15–2.21 
(1H, m, pyrrolidineCH), 2.36 (1H, s, OH), 3.19 (2H, ddt, J 14.3, 12.0, 6.7, pyrrolidineCH), 3.35–
3.41 (1H, m, pyrrolidineCH), 3.44 (1H, td, J 13.5, 1.5, C(7)H(A)H(B)), 4.01 (1H, ddd, J 13.5, 5.7, 
2.7, C(6)H), 5.12 (1H, d, J 5.7, C(5)H), 6.27 (1H, dd, J 3.8, 2.8, C(2)H), 6.46–6.51 (1H, m, C(1)H), 
6.54 (1H, dd, J 2.8, 1.6, C(3)H), 7.31–7.38 (5H, m, ArCH); 13C{1H} NMR (126 MHz, CDCl3) δC: 23.8 
(pyrrolidineCH), 26.0 (pyrrolidineCH), 29.3 (C(7)), 39.3 (C(6)), 45.8 (pyrrolidineCH), 46.3 
(pyrrolidineCH), 59.4 (C(5)), 70.8 (q, J 30.4, C(8)), 107.0 (app. d, J 2.7, C(1)), 110.0 (C(2)), 120.5 
(C(3)), 125.5 (q, J 284.3, CF3), 126.8 (C(8a)), 128.1 (ArCH), 128.4 (ArCH), 128.7 (ArCH), 138.3 
(C(6)ArC(1)), 166.3 (C(5)CO); 19F NMR (471 MHz, CDCl3) δF: -80.4 (CF3); HRMS (ESI+) 





Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (30.0 mg, 0.24 mmol, 1.2 eq.), 
i-Pr2NEt (0.070 mL, 0.40 mmol), pivaloyl chloride (0.050 mL, 0.40 mmol) in i-PrOAc (2 mL) at 
0 °C for 20 min followed by HyperBTM 93 (6.2 mg, 10 mol%), CF3 enone 144 (40.0 mg, 0.20 
mmol, 1.0 eq.) and i-Pr2NEt (0.089 mL, 0.5 mmol) at –40 °C for 20 h. Ring-opening with 
morpholine (300 eq.) at rt for 24 h gave crude product (95:5 dr) that was purified by column 
chromatography (30:70 EtOAc/petrol) to give the titled compound as a white solid (48.9 mg, 
62%). mp 174-175 °C; vmax (film, cm-1) 3391 (O-H), 2995 (C-H), 2873 (C-H), 1636 (amide C=O); 
[α]D
20  + 116.2 (c 3.0 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, 
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flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 18.5 min, tR (minor): 26.5 min, 97:3 er; 1H NMR 
(500 MHz, CDCl3) δH: 2.11 (1H, dd, J 13.3, 2.8, C(7)H(A)H(B)), 2.36 (1H, s, OH), 2.50 (2H, dddd, 
J 15.9, 9.4, 6.4, 3.0, morpholineCH), 3.14 (1H, ddd, J 13.0, 7.4, 3.1, morpholineCH), 3.27–3.39 
(4H, m, morpholineCH + C(7)H(A)H(B)), 3.44–3.53 (2H, m, morpholineCH), 4.02 (1H, ddd, J 13.5, 
5.9, 2.8, C(6)H), 5.33 (1H, d, J 5.9, C(5)H), 6.26 (1H, dd, J 3.8, 2.8, C(2)H), 6.46–6.48 (1H, m, 
C(1)H), 6.49 (1H, dd, J 2.8, 1.6, C(3)H), 7.31–7.41 (5H, m, C(6)ArCH); 13C{1H} NMR (126 MHz, 
CDCl3) δC: 29.1 (C(7)), 38.9 (C(6)), 42.1 (morpholineCH), 45.8 (morpholineCH), 56.2 (C(5)), 65.6 
(morpholineCH), 66.3 (morpholineCH), 70.7 (q, J 30.2, C(8)), 107.2 (app. d, J 2.7, C(1)), 110.2 
(C(2)), 120.3 (C(3)), 125.5 (q, J 284.2, CF3), 126.9 (C(8a)), 128.4 (C(6)ArCH), 128.5 (C(6)ArCH), 
129.1 (C(6)ArCH), 138.2 (C(6)ArC(1)), 166.6 (C(5)CO); 19F NMR (471 MHz, CDCl3) δF: -80.4 (CF3); 





Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (30.0 mg, 0.24 mmol, 1.2 eq.), 
i-Pr2NEt (0.070 mL, 0.40 mmol), pivaloyl chloride (0.050 mL, 0.40 mmol) in i-PrOAc (2 mL) at 
0 °C for 20 min followed by HyperBTM 93 (6.2 mg, 10 mol%), (E)-4-(4-bromophenyl)-1,1,1-
trifluorobut-3-en-2-one (55.8 mg, 0.20 mmol, 1.0 eq.) and i-Pr2NEt (0.089 mL, 0.5 mmol) at –
40 °C for 20 h. Ring-opening with MeOH (2 mL) and DMAP (4.9 mg, 20 mol%) at rt for 24 h 
gave crude product (90:10 dr) that was purified by column chromatography (15:85 to 20:80 
EtOAc/petrol) to give the titled compound as a light yellow oil (52.0 mg, 62%). vmax (film, cm-1) 
3433 (O-H stretch), 2953 (C-H stretch), 1740 (C=O), 1157; [α]D
20  + 117.3 (c 1.0 in CHCl3); 
Chiral HPLC analysis, Chiralpak AD-H (97.5: 2.5 hexane/i-PrOH, flow rate 1 mLmin-1, 220 nm, 
30 °C) tR (major): 52.0 min, tR (minor): 73.7 min, 97.5 : 2.5 er; 1H NMR (500 MHz, CDCl3) δH: 
2.22 (1H, dd, J 13.4, 2.7, C(7)H(a)H(b)), 2.41 (1H, s, J 1.8, OH), 3.01 (1H, td, J 13.5, 1.9, 
C(7)H(a)H(b)), 3.43 (3H, s, OCH3), 4.00 (1H, ddd, J 13.5, 6.0, 2.7, C(6)H), 4.96 (1H, d, J 6.0, C(5)H), 
6.27 (1H, dd, J 3.8, 2.8, C(2)H), 6.48 (1H, dt, J 3.6, 1.7, C(1)H), 6.64 (1H, dd, J 2.9, 1.6, C(3)H), 
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7.11–7.15 (2H, m, C(6)ArC(2,6)H), 7.48–7.52 (2H, m, C(6)ArC(3,5)H); 13C{1H} NMR (126 MHz, 
CDCl3) δC: 28.7 (C(7)), 37.4 (C(6)), 52.4 (OCH3), 62.0 (C(5)), 70.6 (q, J 30.6, C(8)), 107.9 (app. d, 
J 2.7, C(1)), 110.5 (C(2)), 121.4 (C(3)), 122.1 (C(6)ArC(4)), 125.4 (q, J 284.1, CF3), 125.7 (C(8a)), 
129.4 (C(6)ArC(2,6)H), 132.1 (C(6)ArC(3,5)H), 137.0 (C(6)ArC(1)), 169.2 (C(5)C=O); 19F NMR 
(471 MHz, CDCl3) δF: -80.6 (CF3); HRMS (ASAP+) C17H16F3NO379Br [M+H]+ found 418.0266, 





Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (30.0 mg, 0.24 mmol, 1.2 eq.), 
i-Pr2NEt (0.070 mL, 0.40 mmol), pivaloyl chloride (0.050 mL, 0.40 mmol) in i-PrOAc (2 mL) at 
0 °C for 20 min followed by HyperBTM 93 (6.2 mg, 10 mol%), (E)-1,1,1-trifluoro-4-(p-tolyl)but-
3-en-2-one (42.8 mg, 0.20 mmol, 1.0 eq.) and i-Pr2NEt (0.089 mL, 0.5 mmol) at –40 °C for 20 
h. Ring-opening with MeOH (2 mL) and DMAP (4.9 mg, 20 mol%) at rt for 24 h gave crude 
product (80:20 dr) that was purified by column chromatography (15:85 EtOAc/petrol) to give 
the titled compound as a light pink oil (41.0 mg, 58%). vmax (film, cm-1) 3458 (O-H stretch), 2953 
(C-H stretch), 1744 (C=O), 1161; [α]D
20  + 132.0  (c 0.4 in CHCl3); Chiral HPLC analysis, 
Chiralpak AD-H (97.5: 2.5 hexane/i-PrOH, flow rate 1 mLmin-1, 220 nm, 30 °C) tR (major): 38.7 
min, tR (minor): 59.7 min, 98 : 2 er; 1H NMR (500 MHz, CDCl3) δH: 2.23 (1H, dd, J 13.6, 2.8, 
C(7)H(a)H(b)), 2.34 (1H, d, J 1.9, OH), 2.35 (3H, s, CH3), 3.03 (1H, td, J 13.6, 1.9, C(7)H(a)H(b)), 
3.42 (3H, s, OCH3), 3.99 (1H, ddd, J 13.6, 6.0, 2.7, C(6)H), 4.97 (1H, d, J 6.0, C(5)H), 6.26 (1H, 
dd, J 3.8, 2.8, C(2)H), 6.48 (1H, dt, J 3.6, 1.7, C(1)H), 6.63 (1H, dd, J 2.9, 1.6, C(3)H), 7.10–7.20 
(4H, m, ArCH); 13C{1H} NMR (126 MHz, CDCl3) δC: 21.3 (CH3), 28.9 (C(7)), 37.6 (C(6)), 52.3 (OCH3), 
62.4 (C(5)), 70.7 (q, J 30.3, C(8)), 107.8 (C(1)), 110.4 (C(2)), 121.4 (C(3)), 125.5 (q, J 284.1, CF3), 
125.9 (C(8a)), 127.5 (C(6)ArC(3,5)H), 129.6 (C(6)ArC(2,6)H), 134.8 (C(6)ArC(4)), 137.8 
(C(6)ArC(1)), 169.5 (C(5)C=O); 19F NMR (471 MHz, CDCl3) δF: -80.6 (CF3); HRMS (ESI+) 
C18H18F3NO3Na [M+Na]+ found 376.1129, requires 376.1131 (-0.5 ppm). 
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Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (30.0 mg, 0.24 mmol, 1.2 eq.), 
i-Pr2NEt (0.070 mL, 0.40 mmol), pivaloyl chloride (0.050 mL, 0.40 mmol) in i-PrOAc (2 mL) at 
0 °C for 20 min followed by HyperBTM 93 (6.2 mg, 10 mol%), (E)-1,1,1-trifluoro-4-(4-
(trifluoromethyl)phenyl)but-3-en-2-one (53.6 mg, 0.20 mmol, 1.0 eq.) and i-Pr2NEt (0.089 mL, 
0.5 mmol) at –40 °C for 20 h. Ring-opening with MeOH (2 mL) and DMAP (4.9 mg, 20 mol%) at 
rt for 24 h gave crude product that was purified by column chromatography (15:85 
EtOAc/petrol) to give the titled compound as a light pink oil (33.0 mg, 40%). vmax (film, cm-1) 
3472 (O-H stretch), 2955 (C-H stretch), 1742 (C=O), 1325, 1161; [α]D
20  + 128.6 (c 0.5 in 
CHCl3); Chiral HPLC analysis, Chiralpak AD-H (97.5 : 2.5 hexane/IPA, flow rate 1 mLmin-1, 211 
nm, 30 °C) tR (major): 45.6 min, tR (minor): 62.9 min, 97 : 3 er; 1H NMR (500 MHz, CDCl3) δH: 
2.27 (1H, dd, J 13.5, 2.7, C(7)H(a)H(b)), 2.40 (1H, d, J 1.8, OH), 3.06 (1H, td, J 13.5, 1.9, 
C(7)H(a)H(b)), 3.41 (3H, s, OCH3), 4.11 (1H, ddd, J 13.5, 6.0, 2.6, C(6)H), 5.01 (1H, d, J 5.9, C(5)H), 
6.28 (1H, dd, J 3.8, 2.8, C(2)H), 6.49 (1H, dt, J 3.7, 1.7, C(1)H), 6.65 (1H, dd, J 2.8, 1.6, C(3)H), 
7.40 (2H, d, J 8.1, C(6)ArC(2,6)H), 7.64 (2H, d, J 8.1, C(6)ArC(3,5)H); 13C{1H} NMR (126 MHz, 
CDCl3) δC: 28.7 (C(7)), 37.8 (C(6)), 52.4 (OCH3), 61.9 (C(5)), 70.6 (q, J 30.8, C(8)), 108.0 (app. d, 
J 2.8, C(1)), 110.6 (C(2)), 121.5 (C(3)), 124.0 (q, J 272.1, C(6)ArC(4)CF3), 125.4 (q, J 284.1, 
C(8)CF3), 125.7 (C(8a)), 125.9 (q, J 3.7, C(6)ArC(3,5)H), 128.3 (C(6)ArC(2,6)H), 130.4 (q, J 32.6, 
C(6)ArC(4)), 142.0 (C(6)ArC(1)), 169.0 (C(5)C=O);19F NMR (471 MHz, CDCl3) δF: -80.6 (C(8)CF3), 
-62.6 (ArCF3); HRMS (ESI+) C18H15F6NO3Na [M+Na]+ found 430.0837, requires 430.0849 (-2.6 
ppm). 
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Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (30.0 mg, 0.24 mmol, 1.2 eq.), 
i-Pr2NEt (0.070 mL, 0.40 mmol), pivaloyl chloride (0.050 mL, 0.40 mmol) in i-PrOAc (2 mL) at 
0 °C for 20 min followed by HyperBTM 93 (6.2 mg, 10 mol%), (E)-1,1,1-trifluoro-4-(4-
methoxyphenyl)but-3-en-2-one (46.0 mg, 0.20 mmol, 1.0 eq.) and i-Pr2NEt (0.089 mL, 0.5 
mmol) at –40 °C for 20 h. Ring-opening with MeOH (2 mL) and DMAP (4.9 mg, 20 mol%) at rt 
for 24 h gave crude product (84:16 dr) that was purified by column chromatography (15:85 
EtOAc/petrol) to give the titled compound as a light orange solid (50.2 mg, 68%). mp 114-
116 °C; vmax (film, cm-1) 3460 (O-H stretch), 2953 (C-H stretch), 2814 (C-H stretch), 1744 (C=O), 
1514, 1259, 1160; [α]D
20  + 167.2  (c 0.5 in CHCl3); Chiral HPLC analysis, Chiralpak AD-H 
(97.5:2.5 hexane/IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 59.1 min, tR (minor): 104.6 
min, 99:1 er; 1H NMR (500 MHz, CDCl3) δH: 2.21 (1H, dd, J 13.6, 2.7, C(7)H(a)H(b)), 2.33 (1H, d, 
J 1.8, OH), 3.02 (1H, t, J 13.6, C(7)H(a)H(b)), 3.43 (3H, s, OCH3), 3.81 (3H, s, OCH3), 3.97 (1H, 
ddd, J 13.6, 6.0, 2.7, C(6)H), 4.95 (1H, d, J 6.0, C(5)H), 6.26 (1H, dd, J 3.8, 2.8, C(2)H), 6.47 (1H, 
dt, J 3.6, 1.7, C(1)H), 6.63 (1H, dd, J 2.8, 1.6, C(3)H), 6.82–6.97 (2H, m, C(6)ArC(3,5)H), 7.08–
7.22 (2H, m, C(6)ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 29.1 (C(7)), 37.1 (C(6)), 52.3 
(OCH3), 55.4 (OCH3), 62.4 (C(5)), 70.7 (q, J 30.3, C(8)), 107.8 (app. d, J 2.7, C(1)), 110.3 (C(2)), 
114.2 (C(6)ArC(3,5)H), 121.3 (C(3)), 125.5 (q, J 284.0, CF3), 125.8 (C(8a)), 128.7 (C(6)ArC(2,6)H), 
129.9 (C(6)ArC(1)), 159.2 (C(6)ArC(4)), 169.5 (C(5)CO); 19F NMR (471 MHz, CDCl3) δF: -80.6 (CF3); 
HRMS (NSI+) C18H19F3NO4 [M+H]+ found 370.1262, requires 370.1261 (+0.4 ppm). 
 
Selected data for the minor diastereoisomer: Chiral HPLC analysis, Chiralpak AD-H (97.5:2.5 
hexane/IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 37.2 min, tR (minor): 95.3 min, 95 : 
5 er; 1H NMR (500 MHz, CDCl3) δH: 2.24–2.37 (2H, m, C(7)H), 2.56 (1H, s, OH), 3.63 (3H, s, OCH3), 
3.83–3.89 (4H, m, OCH3 + C(6)H), 4.68 (1H, d, J 11.1, C(5)H), 6.25 (1H, dd, J 3.8, 2.9, C(2)H), 
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6.46 (1H, dt, J 3.7, 1.7, C(1)H), 6.57 (1H, dd, J 2.9, 1.6, C(3)H), 6.84–6.94 (2H, m, C(6)ArC(3,5)H), 
7.14–7.22 (2H, m, C(6)ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 35.1 (C(7)), 39.0 (C(6)), 
52.8 (OCH3), 55.4 (OCH3), 64.9 (C(5)), 70.3 (q, J 30.4, C(8)), 107.8 (C(1)), 110.1 (C(2)), 114.5 
(C(6)ArC(3,5)H), 120.9 (C(3)), 125.4 (q, J 284.2, CF3), 125.4 (C(8a)), 128.8 (C(6)ArC(2,6)H), 130.8 





Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (30.0 mg, 0.24 mmol, 1.2 eq.), 
i-Pr2NEt (0.070 mL, 0.40 mmol), pivaloyl chloride (0.050 mL, 0.40 mmol) in i-PrOAc (2 mL) at 
0 °C for 20 min followed by HyperBTM 93 (6.2 mg, 10 mol%), (E)-1,1,1-trifluoro-4-(furan-2-
yl)but-3-en-2-one (38.0 mg, 0.20 mmol, 1.0 eq.) and i-Pr2NEt (0.089 mL, 0.5 mmol) at –40 °C 
for 20 h. Ring-opening with MeOH (2 mL) and DMAP (4.9 mg, 20 mol%) at rt for 24 h gave 
crude product (77:23 dr) that was purified by column chromatography (20:80 EtOAc/petrol) 
to give the combined diastereoisomers (76:24 dr) (62.0 mg, 95%) as a light yellow oil. vmax (film, 
cm-1) 3456 (O-H stretch), 2957 (C-H stretch), 2361, 1746 (C=O), 1277, 1163; [α]D
20  + 81.5 (c 
2.2 in CHCl3). 
Data for major diastereoisomer (5S,6R,8R)-258: Chiral HPLC analysis, Chiralpak AD-H (97.5:2.5 
hexane/IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 40.4 min, tR (minor): 44.9 min, 97 : 
3 er; 1H NMR (500 MHz, CDCl3) δH: 2.31 (1H, dd, J 13.8, 2.9, C(7)H(a)H(b)), 2.38 (1H, s, OH), 
2.79 (1H, td, J 13.6, 1.7, C(7)H(a)H(b)), 3.50 (3H, s, OCH3), 4.05–4.11 (1H, m, C(6)H), 5.15 (1H, 
d, J 5.9, C(5)H), 6.19 (1H, dd, J 3.2, 0.9, C(6)ArH), 6.26 (1H, dd, J 3.9, 2.9, C(2)H), 6.35 (1H, dd, 
J 3.3, 1.9, C(6)ArH), 6.47 (1H, dt, J 3.7, 1.7, C(1)H), 6.65 (1H, dd, J 2.8, 1.6, C(3)H), 7.41–7.42 
(1H, m, C(6)ArH); 13C{1H} NMR (126 MHz, CDCl3) δC: 28.0 (C(7)), 32.5 (C(6)), 52.5 (OCH3), 59.9 
(C(5)), 70.2 (q, J 30.6, C(8)), 106.7 (C(6)ArCH), 107.1 (C(6)ArCH), 107.8 (d, J 2.4, C(1)), 110.4 
(C(2)), 121.6 (C(3)), 125.2 (q, J 284.2, CF3), 125.7 (C(8a)), 142.5 (C(6)ArCH), 151.8 (C(6)ArC), 
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169.2 (C(5)CO); 19F NMR (471 MHz, CDCl3) δF: -80.7 (CF3); HRMS (ESI+) C15H14F3NO4Na [M+Na]+ 
found 352.0763, requires 352.0767 (-1.2 ppm). 
Data for minor diastereoisomer: Chiral HPLC analysis, Chiralpak AD-H (97.5 : 2.5 hexane/IPA, 
flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 25.0 min, tR (minor): 31.8 min, 92 : 8 er; 1H NMR 
(500 MHz, CDCl3) δH (selected): 2.69 (1H, s, OH), 3.75 (3H, s, OCH3), 4.78 (1H, d, J 10.9, C(5)H), 
6.20–6.21 (1H, m, C(6)ArH), 6.23–6.25 (1H, m, C(2)H), 6.33 (1H, dd, J 3.3, 1.9, C(6)ArH), 6.43–
6.46 (1H, m, C(1)H), 6.59 (1H, dd, J 2.9, 1.5, C(3)H), 7.39 (1H, dd, J 1.8, 0.9, C(6)ArH); 19F NMR 





Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (30.0 mg, 0.24 mmol, 1.2 eq.), 
i-Pr2NEt (0.070 mL, 0.40 mmol), pivaloyl chloride (0.050 mL, 0.40 mmol) in i-PrOAc (2 mL) at 
0 °C for 20 min followed by HyperBTM 93 (6.2 mg, 10 mol%), (E)-1,1,1-trifluoro-4-(3-
methoxyphenyl)but-3-en-2-one (46.0 mg, 0.20 mmol, 1.0 eq.) and i-Pr2NEt (0.089 mL, 0.5 
mmol) at –40 °C for 20 h. Ring-opening with MeOH (2 mL) and DMAP (4.9 mg, 20 mol%) at rt 
for 24 h gave crude product (87:13 dr) that was purified by column chromatography (15:85 
EtOAc/petrol) to give the titled compound as a light yellow oil (40.0 mg, 54%); vmax (film, cm-1) 
3447 (O-H stretch), 2953 (C-H stretch), 2837 (C-H stretch), 1744 (C=O), 1165; [α]D
20  + 152.9 
(c 0.3 in CHCl3); Chiral HPLC analysis, Chiralpak IB (85:15 hexane/IPA, flow rate 1 mLmin-1, 211 
nm, 30 °C) tR (major): 9.0 min, tR (minor): 23.6 min, 96 : 4 er; 1H NMR (500 MHz, CDCl3) δH: 2.24 
(1H, dd, J 13.6, 2.7, C(7)H(a)H(b)), 2.46 (1H, s, OH), 3.02 (1H, t, J 13.5, C(7)H(a)H(b)), 3.43 (3H, 
s, OCH3), 3.82 (3H, s, OCH3), 4.00 (1H, ddd, J 13.5, 6.0, 2.7, C(6)H), 4.98 (1H, d, J 6.0, C(5)H), 
6.26 (1H, dd, J 3.8, 2.8, C(2)H), 6.47 (1H, dt, J 3.7, 1.7, C(1)H), 6.63 (1H, dd, J 2.9, 1.6, C(3)H), 
6.79 (1H, t, J 2.1, C(6)ArC(2)H), 6.81–6.88 (2H, m, C(6)ArC(4,6)H), 7.29 (1H, t, J 7.9, 
C(6)ArC(5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 28.8 (C(7)), 37.9 (C(6)), 52.3 (OCH3), 55.4 
(OCH3), 62.2 (C(5)), 70.6 (q, J 30.4, C(8)), 107.8 (d, J 2.8, C(1)), 110.4 (C(2)), 113.1 (C(6)ArCH), 
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113.8 (C(6)ArCH), 119.9 (C(6)ArCH), 121.3 (C(3)), 125.5 (q, J 284.0, CF3), 125.8 (C(8a)), 129.9 
(C(6)ArC(2)H), 139.5 (C(6)ArC(1)), 160.0 (C(6)ArC(3)), 169.4 (C(5)C=O); 19F NMR (471 MHz, 






Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (30.0 mg, 0.24 mmol, 1.2 eq.), 
i-Pr2NEt (0.070 mL, 0.40 mmol), pivaloyl chloride (0.050 mL, 0.40 mmol) in i-PrOAc (2 mL) at 
0 °C for 20 min followed by HyperBTM 93 (6.2 mg, 10 mol%), (E)-1,1,1-trifluoro-4-(naphthalen-
1-yl)but-3-en-2-one (50.0 mg, 0.20 mmol, 1.0 eq.) and i-Pr2NEt (0.089 mL, 0.5 mmol) at –40 °C 
for 20 h. Ring-opening with MeOH (2 mL) and DMAP (4.9 mg, 20 mol%) at rt for 24 h gave 
crude product (80:20 dr) that was purified by column chromatography (15:85 EtOAc/petrol) 
to give the titled compound as a light yellow oil (60.3 mg, 77%). vmax (film, cm-1) 3466 (O-H 
stretch), 2961 (C-H stretch), 1744 (C=O), 1163; [α]D
20  + 193.3 (c 2.9 in CHCl3); Chiral HPLC 
analysis, Chiralpak AD-H (97.5 : 2.5 hexane/IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 
52.9 min, tR (minor): 45.2 min, 98 : 2 er; 1H NMR (500 MHz, CDCl3) δH: 2.35 (1H, dd, J 13.3, 2.5, 
C(7)H(a)H(b)), 2.49 (1H, s, OH), 3.22–3.31 (4H, m, C(7)H(a)H(b) + OCH3), 4.89 (1H, ddd, J 13.2, 
5.9, 2.5, C(6)H), 5.27 (1H, d, J 5.8, C(5)H), 6.31 (1H, dd, J 3.9, 2.8, C(2)H), 6.54 (1H, dt, J 3.7, 1.7, 
C(1)H), 6.64 (1H, dd, J 2.8, 1.6, C(3)H), 7.32 (1H, d, J 7.2, C(6)ArCH), 7.45 (1H, dd, J 8.2, 7.2, 
C(6)ArCH), 7.56 (1H, ddd, J 8.0, 6.8, 1.2, C(6)ArCH), 7.61 (1H, ddd, J 8.4, 6.8, 1.5, C(6)ArCH), 
7.84 (1H, d, J 8.2, C(6)ArCH), 7.92–7.95 (1H, m, C(6)ArCH), 8.17 (1H, d, J 8.4, C(6)ArCH); 13C{1H} 
NMR (126 MHz, CDCl3) δC: 29.3 (C(7)), 33.2 (C(6)), 52.0 (OCH3), 61.0 (C(5)), 70.9 (q, J 30.2, C(8)), 
107.9 (d, J 2.9, C(1)), 110.5 (C(2)), 121.5 (C(3)), 122.3 (C(6)ArCH), 123.9 (C(6)ArCH), 125.3 
(C(6)ArCH), 125.6 (q, J 283.9, CF3), 126.0 (C(8a)), 126.1 (C(6)ArCH), 127.0 (C(6)ArCH), 128.8 
(C(6)ArCH), 129.5 (C(6)ArCH), 131.5 (C(6)ArC), 133.9 (C(6)ArC), 134.0 (C(6)ArC(1)), 169.3 
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(C(5)CO); 19F NMR (471 MHz, CDCl3) δF: -80.5 (CF3); HRMS (NSI+) C21H19F3NO3 [M+H]+ found 





Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (30.0 mg, 0.24 mmol, 1.2 eq.), 
i-Pr2NEt (0.070 mL, 0.40 mmol), pivaloyl chloride (0.050 mL, 0.40 mmol) in i-PrOAc (2 mL) at 
0 °C for 20 min followed by HyperBTM 93 (6.2 mg, 10 mol%), (E)-1,1,1-trifluoro-4-(o-tolyl)but-
3-en-2-one (42.8 mg, 0.20 mmol, 1.0 eq.) and i-Pr2NEt (0.089 mL, 0.5 mmol) at –40 °C for 20 
h. Ring-opening with MeOH (2 mL) and DMAP (4.9 mg, 20 mol%) at rt for 24 h gave crude 
product that was purified by column chromatography (15:85 EtOAc/petrol) to give the titled 
compound as a light pink oil (18.0 mg, 25%). vmax (film, cm-1) 3300 (O-H stretch), 2953 (C-H 
stretch), 1746 (C=O), 1152; [α]D
20  + 180.3 (c 0.3 in CHCl3); Chiral HPLC analysis, Chiralpak 
AD-H (97.5 : 2.5 hexane : IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 17.6 min, tR (minor): 
77.3 min, >99 : 1 er; 1H NMR (500 MHz, CDCl3) δH: 2.18 (1H, dd, J 13.5, 2.6, C(7)H(a)H(b)), 2.39 
(1H, d, J 1.8, OH), 2.47 (3H, s, CH3), 3.10 (1H, td, J 13.4, 1.9, C(7)H(a)H(b)), 3.37 (3H, s, OCH3), 
4.23 (1H, ddd, J 13.4, 6.0, 2.6, C(6)H), 4.98 (1H, d, J 5.9, C(5)H), 6.28 (1H, dd, J 3.8, 2.8, C(2)H), 
6.49 (1H, dt, J 3.6, 1.7, C(1)H), 6.63 (1H, dd, J 2.8, 1.6, C(3)H), 7.04–7.10 (1H, m, C(6)ArCH), 
7.17–7.25 (3H, m, C(6)ArCH); 13C{1H} NMR (126 MHz, CDCl3) δC: 19.5 (CH3), 29.2 (C(7)), 34.0 
(C(6)), 52.2 (OCH3), 60.1 (C(5)), 70.8 (q, J 30.3, C(8)), 107.7 (C(1)), 110.4 (C(2)), 121.4 (C(3)), 
125.5 (q, J 284.2, CF3), 125.9 (C(8a)), 126.0 (C(6)ArCH), 126.5 (C(6)ArCH), 127.9 (C(6)ArCH), 
131.0 (C(6)ArCH), 135.9 (C(6)ArC(2)), 136.4 (C(6)ArC(1)), 169.5 (C(5)CO); 19F NMR (471 MHz, 
CDCl3) δF: -80.6 (CF3); HRMS (ASAP+) C18H19F3NO3 [M+H]+ found 354.1315, requires 354.1317 
(-0.6 ppm). 
  
Chapter 8: Experimentals 




Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (30.0 mg, 0.24 mmol, 1.2 eq.), 
i-Pr2NEt (0.070 mL, 0.40 mmol), pivaloyl chloride (0.050 mL, 0.40 mmol) in i-PrOAc (2 mL) at 
0 °C for 20 min followed by HyperBTM 93 (6.2 mg, 10 mol%), (E)-1,1,1-trifluoro-4-(naphthalen-
2-yl)but-3-en-2-one (50.0 mg, 0.20 mmol, 1.0 eq.) and i-Pr2NEt (0.089 mL, 0.5 mmol) at –40 °C 
for 20 h. Ring-opening with MeOH (2 mL) and DMAP (4.9 mg, 20 mol%) at rt for 24 h gave 
crude product (85:15 dr) that was purified by column chromatography (20:80 EtOAc/petrol) 
to give the titled compound as a light yellow oil (65.0 mg, 83%). vmax (film, cm-1) 3472 (O-H 
stretch), 3055 (C-H stretch), 2903 (C-H stretch), 1742 (C=O), 1171; [α]D
20  + 118.9 (c 2.7 in 
CHCl3); Chiral HPLC analysis, Chiralpak AD-H (97.5:2.5 hexane/IPA, flow rate 1 mLmin-1, 254 nm, 
30 °C) tR (major): 69.1 min, tR (minor): 91.9 min, 98 : 2 er; 1H NMR (500 MHz, CDCl3) δH: 2.37 
(1H, dd, J 13.5, 2.7, C(7)H(a)H(b)), 2.40 (1H, d, J 1.8, OH), 3.19 (1H, td, J 13.5, 1.9, C(7)H(a)H(b)), 
3.31 (3H, s, OCH3), 4.20 (1H, ddd, J 13.5, 6.0, 2.7, C(6)H), 5.10 (1H, d, J 6.0, C(5)H), 6.29 (1H, 
dd, J 3.8, 2.8, C(2)H), 6.52 (1H, dt, J 3.6, 1.7, C(1)H), 6.66 (1H, dd, J 2.8, 1.6, C(3)H), 7.39 (1H, 
dd, J 8.5, 1.9, C(6)ArCH), 7.48–7.54 (2H, m, C(6)ArCH), 7.68–7.74 (1H, m, C(6)ArCH), 7.80–7.89 
(3H, m, C(6)ArCH); 13C{1H} NMR (126 MHz, CDCl3) δC: 28.9 (C(7)), 38.1 (C(6)), 52.3 (OCH3), 62.2 
(C(5)), 70.7 (q, J 30.3, C(8)), 107.9 (C(1)), 110.5 (C(2)), 121.4 (C(3)), 125.5 (q, J 280.9, CF3), 125.9 
(C(8a)), 125.9 (C(6)ArCH), 126.3 (C(6)ArCH), 126.4 (C(6)ArCH), 126.6 (C(6)ArCH), 127.8 
(C(6)ArCH), 128.0 (C(6)ArCH), 128.7 (C(6)ArCH), 133.0 (C(6)ArC), 133.5 (C(6)ArC), 135.4 
(C(6)ArC(1)), 169.4 (C(5)CO); 19F NMR (471 MHz, CDCl3) δF: -80.5 (CF3); HRMS (ASAP+) 
C21H19F3NO3 [M+H]+ found 390.1314, requires 390.1317 (-0.8 ppm). 
Selected data for minor diastereoisomer: Chiral HPLC analysis, Chiralpak AD-H (97.5 : 2.5 
hexane:IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 40.5 min, tR (minor): 75.5 min, 98 : 
2 er; 1H NMR (500 MHz, CDCl3) δH: 2.42–2.48 (2H, m, C(7)H2), 2.66 (1H, m, OH), 3.58 (3H, s, 
OCH3), 4.07 (1H, td, J 10.7, 5.8, C(6)H), 4.87 (1H, d, J 11.0, C(5)H), 6.28 (1H, dd, J 3.9, 2.9, C(2)H), 
6.50 (1H, dd, J 3.7, 1.8, C(1)H), 6.61 (1H, dd, J 2.9, 1.6, C(3)H), 7.39 (1H, dd, J 8.5, 1.9, C(6)ArCH), 
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7.47–7.53 (2H, m, C(6)ArCH), 7.75 (1H, d, J 1.8, C(6)ArCH), 7.78–7.86 (3H, m, C(6)ArCH); 13C{1H} 
NMR (126 MHz, CDCl3) δC (selected): 35.0 (C(7)), 39.9 (C(6)), 52.9 (OCH3), 64.4 (C(5)), 70.3 (d, 
J 30.5, C(8)), 107.9 (C(1)), 110.1 (C(2)), 121.0 (C(3)), 125.5 (C(8a)), 126.4 (C(6)ArCH), 126.6 
(C(6)ArCH), 127.0 (C(6)ArCH), 127.9 (C(6)ArCH), 128.0 (C(6)ArCH), 129.1 (C(6)ArCH), 133.1 
(C(6)ArC), 133.6 (C(6)ArC), 136.3 (C(6)ArC(1)), 170.5 (C(5)CO); 19F NMR (471 MHz, CDCl3) δF: -
80.2 (CF3) 
 
Methyl 2-oxo-4-phenyl-3-(1H-pyrrol-1-yl)-2H-pyran-6-carboxylate (264) 
 
2-(1H-Pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.) was dissolved in anhydrous 
MeCN (0.1 M) under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (0.087 mL, 0.5 
mmol, 2 eq.) and pivaloyl chloride (0.062 mL, 0.5 mmol, 2 eq.) were added. The reaction was 
stirred at 0 °C for 20 min before warming up to rt. HyperBTM 93 (7.7 mg, 10 mol%), α-keto-
β,γ-unsaturated ester 132 (47.6 mg, 0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 
eq.) were added sequentially and the reaction stirred at rt. for 24 h. Upon completion of the 
reaction (checked by TLC), the solvent was concentrated under reduced pressure and the 
crude was purified by flash silica column chromatography (15:85 EtOAc/petrol) to give the 
titled compound as a yellow oil (34.2 mg, 58%). vmax (film, cm-1) 3107 (C-H), 2955 (C-H), 1736 
(C=O), 1726 (C=O), 1643 (C=C), 1244; 1H NMR (500 MHz, CDCl3) δH: 4.00 (3H, s, CH3), 6.21 (2H, 
t, J 2.2, C(3)Ar(3,4)H), 6.59 (2H, t, J 2.2, C(3)Ar(2,5)H), 7.06–7.12 (2H, m, C(4)ArC(2,6)H), 7.34–
7.42 (4H, m, C(4)ArC(3,4,5)H + C(5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 53.3 (CH3), 110.5 
(C(3)ArC(3,4)H), 113.7 (C(5)H), 121.8 (C(3)ArC(2,5)H), 127.7 (C(4)ArC(2,6)H), 129.0 
(C(4)ArC(3,5)H), 130.3 (C(4)ArC(4)H), 133.7 (C(3)ArC(1)), 144.8 (C(4)), 145.7 (C(3)), 158.4 
(C(2)CO), 159.6 (C(6)CO2Me); HRMS (ESI+) C17H14NO4 [M+H]+ found 296.0918, requires 
296.0917 (+0.2 ppm). 
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Methyl (3E)-2-((1H-pyrrol-1-yl)methylene)-4-phenylbut-3-enoate (265) 
 
2-(1H-Pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.) was dissolved in anhydrous 
MeCN (0.1 M) under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (0.087 mL, 0.5 
mmol, 2 eq.) and pivaloyl chloride (0.062 mL, 0.5 mmol, 2 eq.) were added. The reaction was 
stirred at 0 °C for 20 min before warming up to rt. HyperBTM 93 (7.7 mg, 10 mol%), α-keto-
β,γ-unsaturated ester 132 (47.6 mg, 0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 
eq.) were added sequentially and the reaction stirred at rt. for 24 h. Upon completion of the 
reaction (checked by TLC), the solvent was concentrated under reduced pressure and the 
crude was purified by flash silica column chromatography (15:85 EtOAc/petrol) to give the 
titled compound as a colourless oil (11.4 mg, 18%, 88:12 mixture of stereoisomers). vmax (film, 
cm-1) 3026 (C-H stretch), 2951 (C-H stretch), 1713 (C=C), 1225; 1H NMR (500 MHz, CDCl3) δH: 
3.86 (3H, s, OCH3), 6.32 (2H, t, J 2.2, pyrroleC(3,4)H), 6.97 (1H, dd, J 16.4, 1.0, CH=CHPh), 7.05 
(2H, t, J 2.2, pyrroleC(2,5)H), 7.18 (1H, d, J 16.4, CH=CHPh), 7.27–7.30 (1H, ArH), 7.33–7.38 (2H, 
m, ArH), 7.45–7.49 (2H, m, ArH), 7.84 (1H, s, C(1)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 52.3 
(OCH3), 112.0 (pyrroleC(3,4)H), 115.6 (CH=CHPh), 120.0 (pyrroleC(2,5)H), 122.9 (CH=CHPh), 
126.8 (ArCH), 128.2 (ArCH), 128.9 (ArCH), 135.4 (C(1)), 136.2 (ArC(1)), 137.3 (C(2)), 167.7 
(CO2Me); HRMS (NSI+) C16H16NO2 [M+H]+ found 254.1177, requires 254.1176 (+0.6 ppm). 
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Dimethyl (4S,5S)-4-phenyl-2-(pivaloyloxy)-5-(1H-pyrrol-1-yl)hex-2-enedioate (268) 
 
Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 132 (47.6 mg, 0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. 
Ring-opening with MeOH (2 mL) and DMAP (6.1 mg, 20 mol%) at rt for 24 h gave crude product 
(>95:5 dr) that was purified by column chromatography (20:80 EtOAc/petrol) to give the titled 
compound as an off-white gum (72.4 mg, 70%). vmax (film, cm-1) 2980 (C-H stretch), 2968 (C-H 
stretch), 1740 (C=O), 1277, 1111; [α]D
20  + 83.1  (c 1.4 in CHCl3); Chiral HPLC analysis, 
Chiralpak AD-H (99:1 hexane/IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 15.4 min, tR 
(minor): 26.9 min, >99:1 er; 1H NMR (500 MHz, CDCl3) δH: 1.36 (9H, s, 3 x CH3), 3.74 (3H, s, 
OCH3), 3.76 (3H, s, OCH3), 4.41 (1H, t, J 10.4, C(4)H), 4.85 (1H, d, J 10.5, C(5)H), 5.98 (2H, t, J 
2.2, C(5)Ar(3,4)H), 6.58 (2H, t, J 2.2, C(5)Ar(2,5)H), 6.69 (1H, d, J 10.4, C(3)H), 6.99–7.06 (2H, 
m, C(4)ArC(2,6)H), 7.14–7.24 (3H, m, C(4)ArC(3,4,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 27.1 
(3 x CH3), 39.2 (3CH3C), 46.6 (C(4)), 52.7 (OCH3), 52.9 (OCH3), 66.1 (C(5)), 108.8 (C(5)ArC(3,4)H), 
120.5 (C(5)ArC(2,5)H), 127.1 (C(4)ArC(2,6)H), 127.8 (C(4)ArC(3,5)H), 127.9 (C(4)ArC(4)H), 
128.9 (C(2)), 137.0 (C(4)ArC(1)), 139.7 (C(3)H), 162.1 (C(6)OOMe), 169.3 (C(1)OOMe), 176.0 




Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
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mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 132 (47.6 mg, 0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. 
Ring-opening with morpholine (300 eq.) at rt for 24 h gave crude product (>95:5 dr) that was 
purified by column chromatography (30:70 EtOAc/petrol) to give the titled compound as a 
white solid (76.9 mg, 70%). mp 154–156 °C; [α]D
20  − 50.7  (c 1.1 in CHCl3); Chiral HPLC 
analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 
25.2 min, tR (minor): 33.3 min, >99:1 er; vmax (film, cm-1) 2967 (C-H), 2920 (C-H), 2857 (C-H), 
1713 (C=O), 1638 (amide C=O), 1441, 1271, 1113; 1H NMR (500 MHz, CDCl3) δH: 2.94 (1H, ddd, 
J 11.2, 7.8, 3.1, morpholineCH), 3.09 (2H, dd, J 5.7, 4.0, morpholineCH), 3.25–3.43 (7H, m, 
morpholineCH + C(3)H2), 3.46–3.73 (7H, m, morpholineCH), 3.89 (1H, ddd, J 13.4, 5.3, 3.0, 
morpholineCH), 4.11 (1H, td, J 9.7, 4.6, C(4)H), 4.80 (1H, d, J 10.0, C(5)H), 5.93 (2H, t, J 2.1, 
C(5)Ar(3,4)H), 6.36 (2H, t, J 2.1, C(5)Ar(2,5)H), 7.01–7.05 (2H, m, PhH), 7.14–7.20 (3H, m, PhH); 
13C{1H} NMR (126 MHz, CDCl3) δC: 41.9 (morpholineC), 42.7 (C(3)), 43.0 (morpholineC), 44.4 
(C(4)), 45.7 (morpholineC), 46.3 (morpholineC), 63.5 (C(5)), 66.2 (morpholineC), 66.5 
(morpholineC), 66.6 (morpholineC), 66.7 (morpholineC), 108.9 (C(5)ArC(3,4)H), 119.6 
(C(5)ArC(2,5)H), 127.4 (C(4)PhCH), 128.0 (C(4)PhCH), 128.5 (C(4)PhCH), 139.2 (C(4)PhC(1)), 
164.3 (C(6)), 166.4 (C(2)), 197.7 (C(1)); HRMS (ESI+) C24H29N3O5Na [M+Na]+ found 462.1988, 




Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 132 (47.6 mg, 0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. 
Ring-opening with pyrrolidine (300 eq.) at rt for 24 h gave crude product (>95:5 dr) that was 
purified by column chromatography (30:70 EtOAc/petrol) to give the titled compound as a 
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white solid (75.4 mg, 74%). mp 148–151 °C; [α]D
20  + 91.0  (c 1.5 in CHCl3); Chiral HPLC 
analysis, Chiralpak OD-H (90:10 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 
21.3 min, tR (minor): 27.8 min, >99:1 er; vmax (film, cm-1) 2974 (C-H), 2878 (C-H), 1715 (C=O), 
1638 (amide C=O), 1605 (C=O), 1447; 1H NMR (500 MHz, CDCl3) δH: 1.72–2.02 (8H, m, 
pyrrolidineCH), 3.18–3.34 (4H, m, C(3)H(a)H(b) + pyrrolidineCH), 3.39–3.60 (6H, m, 
C(3)H(a)H(b) + pyrrolidineCH), 4.10 (1H, td, J 10.2, 4.3, C(4)H), 4.72 (1H, d, J 10.4, C(5)H), 5.92 
(2H, t, J 2.1, C(5)Ar(3,4)H), 6.51 (2H, t, J 2.2, C(5)Ar(2,5)H), 7.05–7.08 (2H, m, C(6)ArC(2,6)H), 
7.11–7.18 (3H, m, C(6)ArC(3,4,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 23.5 (pyrrolidineC), 24.1 
(pyrrolidineC), 26.0 (pyrrolidineC), 26.3 (pyrrolidineC), 41.7 (C(3)), 44.5 (C(4)), 46.3 
(pyrrolidineC), 46.4 (pyrrolidineC), 46.4 (pyrrolidineC), 47.1 (pyrrolidineC), 65.6 (C(5)), 108.2 
(C(5)ArC(3,4)H), 120.1 (C(5)ArC(2,5)H), 127.0 (C(4)ArC(2,6)H), 128.0 (C(4)ArC(3,5)H), 128.3 
(C(4)ArC(4)H), 139.6 (C(4)ArC(1)), 162.2 (C(6)), 166.5 (C(2)), 197.7 (C(1)); HRMS (ESI+) 





Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 132 (47.6 mg, 0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. 
Ring-opening with morpholine (2 eq.) at rt for 24 h gave crude product (>95:5 dr) that was 
purified by column chromatography (30:70 EtOAc/petrol) to give the titled compound as a 
light yellow oil (72.1 mg, 75%). vmax (film, cm-1) 3399 (O-H stretch), 2961 (C-H), 2926 (C-H), 2857 
(C-H), 1732 (C=O), 1643 (amide C=O); [α]D
20  + 50.2 (c 2.4 in CHCl3); Chiral HPLC analysis, 
Chiralpak AD-H (80:20 hexane/IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 18.8 min, tR 
(minor): 31.9 min, >99.5 : 0.5 er; 1H NMR (500 MHz, CDCl3) δH: 2.02 (1H, dd, J 13.1, 2.6, 
C(7)H(a)H(b)), 2.46–2.57 (2H, m, morpholineCH), 3.16 (1H, ddd, J 13.7, 7.5, 3.1, 
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morpholineCH), 3.26–3.40 (3H, m, morpholineCH), 3.47–3.54 (2H, m, morpholineCH), 3.55 
(1H, d, J 1.3, OH), 3.73 (1H, td, J 13.3, 1.4, C(7)H(a)H(b)), 3.90 (3H, s, OCH3), 4.10 (1H, ddd, J 
13.5, 6.1, 2.6, C(6)H), 5.34 (1H, d, J 6.0, C(5)H), 6.10 (1H, dd, J 3.7, 1.6, C(2)H), 6.21 (1H, dd, J 
3.7, 2.8, C(1)H), 6.41 (1H, dd, J 2.8, 1.6, C(3)H), 7.31–7.39 (5H, m, C(6)ArCH); 13C{1H} NMR (126 
MHz, CDCl3) δC: 32.8 (C(7)), 39.5 (C(6)), 42.1 (morpholineC), 45.9 (morpholineC), 53.7 (OCH3), 
56.2 (C(5)), 65.8 (morpholineC), 66.4 (morpholineC), 71.2 (C(8)), 105.9 (C(2)), 110.1 (C(1)), 
119.5 (C(3)), 128.3 (C(6)ArCH), 128.8 (C(6)ArCH), 129.1 (C(6)ArCH), 130.3 (C(8a)), 138.9 
(C(6)ArC(1)), 167.2 (C(5)C=O), 175.1 (C(8)C=O); HRMS (NSI+) C21H25N2O5 [M+H]+ found 





Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 132 (47.6 mg, 0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. 
Ring-opening with pyrrolidine (2 eq.) at rt for 24 h gave crude product (>95:5 dr) that was 
purified by column chromatography (30:70 EtOAc/petrol) to give the titled compound as a 
light yellow oil (66.3 mg, 72%). vmax (film, cm-1) 3393 (O-H stretch), 2972 (C-H), 2951 (C-H), 1732 
(C=O), 1643 (amide C=O); [α]D
20  + 122.7 (c 1.8 in CHCl3); Chiral HPLC analysis, Chiralpak OD-
H (80: 20 hexane/IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 21.2 min, tR (minor): 29.3 
min, >99.5:0.5 er; 1H NMR (500 MHz, CDCl3) δH: 1.43–1.74 (4H, m, pyrrolidineCH), 1.99 (1H, 
dd, J 13.0, 2.5, C(7)H(a)H(b)), 2.22 (1H, ddd, J 9.5, 7.7, 5.2, pyrrolidineCH), 3.16 (2H, dt, J 12.1, 
7.0, pyrrolidineCH), 3.36 (1H, ddd, J 12.7, 7.5, 5.3, pyrrolidineCH), 3.55 (1H, s, OH), 3.78 (1H, t, 
J 13.3, C(7)H(a)H(b)), 3.88 (3H, s, OCH3), 4.07 (1H, ddd, J 13.5, 5.9, 2.6, C(6)H), 5.11 (1H, d, J 
5.9, C(5)H), 6.09 (1H, dd, J 3.7, 1.6, C(2)H), 6.20 (1H, dd, J 3.7, 2.8, C(1)H), 6.44 (1H, dd, J 2.8, 
1.6, C(3)H), 7.27–7.38 (5H, m, C(6)ArCH); 13C{1H} NMR (126 MHz, CDCl3) δC: 23.9 (pyrrolidineC), 
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26.1 (pyrrolidineC), 32.9 (C(7)), 39.8 (C(6)), 45.8 (pyrrolidineC), 46.4 (pyrrolidineC), 53.6 (OCH3), 
59.5 (C(5)), 71.2 (C(8)), 105.7 (C(2)), 109.9 (C(1)), 119.7 (C(3)), 128.0 (C(6)ArCH), 128.6 
(C(6)ArCH), 128.6 (C(6)ArCH), 130.2 (C(8a)), 139.0 (C(6)ArC(1)), 166.8 (C(5)C=O), 175.2 





Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 485 (54.6 mg, 0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. 
Ring-opening with morpholine (2 eq.) at rt for 24 h gave crude product (>95:5 dr) that was 
purified by column chromatography (30:70 EtOAc/petrol) to give the titled compound as a 
brown oil (66.0 mg, 64%). vmax (film, cm-1) 3414 (O-H stretch), 2974 (C-H), 2936 (C-H), 2922 (C-
H), 1713 (C=O), 1649 (amide C=O), 1234, 1111; [α]D
20  + 77.5 (c 1.0 in CHCl3); Chiral HPLC 
analysis, Chiralpak AD-H (90: 10 hexane : IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 
27.3 min, tR (minor): 56.9 min, >99.5:0.5 er; 1H NMR (400 MHz, CDCl3) δH: 1.33 (3H, d, J 6.2, 
CH3), 1.36 (3H, d, J 6.3, CH3), 1.98 (1H, dd, J 13.1, 2.6, C(7)H(a)H(b)), 2.51–2.58 (2H, m, 
morpholineCH), 3.16 (1H, ddd, J 12.7, 7.2, 3.1, morpholineCH), 3.23–3.40 (3H, m, 
morpholineCH), 3.46–3.54 (2H, m, morpholineCH), 3.61 (1H, s, OH), 3.70 (1H, t, J 13,3, 
C(7)H(a)H(b)), 4.12 (1H, ddd, J 13.2, 6.0, 2.4, C(6)H), 5.20 (1H, septet, J 6.3, iPr(CH)), 5.34 (1H, 
d, J 6.2, C(5)H), 6.08 (1H, dd, J 3.7, 1.6, C(2)H), 6.19 (1H, dd, J 3.7, 2.8, C(1)H), 6.40 (1H, dd, J 
2.8, 1.7, C(3)H), 7.29–7.43 (5H, m, C(6)ArCH); 13C{1H} NMR (101 MHz, CDCl3) δC: 21.5 (CH3), 
21.8 (CH3), 32.7 (C(7)), 39.4 (C(6)), 42.1 (morpholineC), 45.9 (morpholineC), 56.2 (C(5)), 65.8 
(morpholineC), 66.5 (morpholineC), 70.6 (iPr(CH)), 71.1 (C(8)), 105.6 (C(2)), 110.0 (C(1)), 119.4 
(C(3)), 128.2 (C(6)ArCH), 128.8 (C(6)ArCH), 129.0 (C(6)ArCH), 130.7 (C(8a)), 139.1 (C(6)ArC(1)), 
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167.3 (C(5)C=O), 173.7 (C(8)C=O); HRMS (ESI+) C23H28N2O5Na [M+Na]+ found 435.1882, 





Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 486 (0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening 
with morpholine (2 eq.) at rt for 24 h gave crude product (>95:5 dr) that was purified by column 
chromatography (20:80 EtOAc/petrol) to give the titled compound as a colourless oil (54.8 mg, 
55%). vmax (film, cm-1) 3420 (O-H stretch), 2978 (C-H), 2928 (C-H), 2859 (C-H), 1730 (C=O), 1649 
(amide C=O); [α]D
20  + 101.6 (c 1.2 in CHCl3); Chiral HPLC analysis, Chiralpak AD-H (90: 10 
hexane/IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 31.4 min, tR (minor): 63.7 
min, >99.5:0.5 er; 1H NMR (500 MHz, CDCl3) δH: 1.36 (3H, t, J 7.1, CH3), 2.01 (1H, dd, J 13.0, 2.6, 
C(7)H(a)H(b)), 2.51 (2H, ddt, J 10.2, 6.8, 3.4, morpholineCH), 3.17 (1H, ddd, J 13.8, 7.3, 3.1, 
morpholineCH), 3.26–3.39 (3H, m, morpholineCH), 3.45–3.53 (2H, m, morpholineCH), 3.57 
(1H, d, J 1.3, OH), 3.71 (1H, t, J 13.3, C(7)H(a)H(b)), 4.12 (1H, ddd, J 13.5, 6.1, 2.5, C(6)H), 4.37 
(2H, qd, J 7.1, 1.1, CH2), 5.34 (1H, d, J 6.1, C(5)H), 6.10 (1H, dd, J 3.7, 1.6, C(2)H), 6.20 (1H, dd, 
J 3.7, 2.8, C(1)H), 6.41 (1H, dd, J 2.8, 1.6, C(3)H), 7.29–7.40 (5H, m, C(6)ArCH); 13C{1H} NMR 
(126 MHz, CDCl3) δC: 14.3 (CH3), 32.8 (C(7)), 39.4 (C(6)), 42.1 (morpholineC), 45.9 
(morpholineC), 56.2 (C(5)), 62.8 (CH2), 65.8 (morpholineC), 66.5 (morpholineC), 71.1 (C(8)), 
105.8 (C(2)), 110.1(C(1)), 119.5 (C(3)), 128.3 (C(6)ArCH), 128.8 (C(6)ArCH), 129.1 (C(6)ArCH), 
130.5 (C(8a)), 139.0 (C(6)ArC(1)), 167.3 (C(5)C=O), 174.4 (C(8)C=O); HRMS (ESI+) C22H26N2O5Na 
[M+Na]+ found 421.1723, requires 421.1734 (-2.6 ppm). 
  
Chapter 8: Experimentals 




Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 487 (0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening 
with morpholine (2 eq.) at rt for 24 h gave crude product (>95:5 dr) that was purified by column 
chromatography (20:80 EtOAc/petrol) to give the titled compound as a colourless oil (85.8 mg, 
79%). vmax (film, cm-1) 3402 (O-H stretch), 3055 (C-H), 2955 (C-H), 2857 (C-H), 1719 (C=O), 1645 
(amide C=O); [α]D
20  + 75.6  (c 2.3 in CHCl3); Chiral HPLC analysis, Chiralpak IB (80 : 20 
hexane/IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 50.6 min, tR (minor): 65.4 
min, >99.5:0.5 er; 1H NMR (500 MHz, CDCl3) δH: 2.08–2.14 (2H, m, C(7)H(a)H(b) + 
morpholineCH), 2.39 (1H, ddd, J 13.0, 6.3, 3.0, morpholineCH), 3.03–3.14 (3H, m, 
morpholineCH), 3.30 (1H, ddd, J 12.4, 7.3, 2.4, morpholineCH), 3.36–3.49 (2H, m, 
morpholineCH), 3.61 (1H, d, J 1.3, OH), 3.85 (1H, td, J 13.3, 1.4, C(7)H(a)H(b)), 3.93 (3H, s, 
OCH3), 4.26 (1H, ddd, J 13.5, 6.0, 2.6, C(6)H), 5.43 (1H, d, J 6.0, C(5)H), 6.13 (1H, dd, J 3.7, 1.6, 
C(2)H), 6.23 (1H, dd, J 3.7, 2.7, C(1)H), 6.44 (1H, dd, J 2.8, 1.6, C(3)H), 7.41–7.55 (3H, m, 
C(6)ArCH), 7.76–7.88 (4H, m, C(6)ArCH); 13C{1H} NMR (126 MHz, CDCl3) δC: 33.0 (C(7)), 39.7 
(C(6)), 42.1 (morpholineC), 45.9 (morpholineC), 53.7 (OCH3), 56.3 (C(5)), 65.6 (morpholineC), 
66.3 (morpholineC), 71.2 (C(8)), 105.9 (C(2)), 110.1 (C(1)), 119.6 (C(3)), 126.6 (C(6)ArCH), 126.7 
(C(6)ArCH), 126.9 (C(6)ArCH), 127.4 (C(6)ArCH), 127.8 (C(6)ArCH), 127.9 (C(6)ArCH), 128.6 
(C(6)ArCH), 130.4 (C(8a)), 132.9 (C(6)ArC), 133.6 (C(6)ArC), 136.2 (C(6)ArC(1)), 167.2 (C(5)C=O), 
175.0 (C(8)C=O); HRMS (ESI+) C25H26N2O5Na [M+Na]+ found 457.1726, requires 457.1734 (-1.7 
ppm). 
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Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 488 (0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening 
with morpholine (2 eq.) at rt for 24 h gave crude product (>95:5 dr) that was purified by column 
chromatography (20:80 EtOAc/petrol) to give the titled compound as a light yellow oil (94.6 
mg, 95%); vmax (film, cm-1) 3410 (O-H stretch), 2955 (C-H), 2926 (C-H), 2859 (C-H), 1715 (C=O), 
1645 (amide C=O); [α]D
20  + 97.0 (c 2.1 in CHCl3); Chiral HPLC analysis, Chiralpak AD-H (90 : 
10 hexane/IPA, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 38.5 min, tR (minor): 55.0 
min, >99.5:0.5 er; 1H NMR (500 MHz, CDCl3) δH: 1.98 (1H, dd, J 13.1, 2.6, C(7)H(a)H(b)), 2.36 
(3H, s, CH3), 2.49–2.58 (2H, m, morpholineCH), 3.12–3.19 (1H, m, morpholineCH), 3.28–3.39 
(3H, m, morpholineCH), 3.45–3.53 (2H, m, morpholineCH), 3.55 (1H, s, OH), 3.68 (1H, td, J 13.3, 
1.3, C(7)H(a)H(b)), 3.89 (3H, s, OCH3), 4.05 (1H, ddd, J 13.6, 6.0, 2.6, C(6)H), 5.31 (1H, d, J 6.0, 
C(5)H), 6.09 (1H, dd, J 3.7, 1.6, C(2)H), 6.20 (1H, dd, J 3.7, 2.8, C(1)H), 6.41 (1H, dd, J 2.8, 1.6, 
C(3)H), 7.13–7.24 (4H, m, C(6)ArCH); 13C{1H} NMR (126 MHz, CDCl3) δC: 21.3 (CH3), 33.0 (C(7)), 
39.1 (C(6)), 42.1 (morpholineC), 45.9 (morpholineC), 53.7 (OCH3), 56.3 (C(5)), 65.8 
(morpholineC), 66.5 (morpholineC), 71.2 (C(8)), 105.8 (C(2)), 110.1 (C(1)), 119.5 (C(3)), 128.6 
(C(6)ArC(3,5)H), 129.6 (C(6)ArC(2,6)H), 130.3 (C(8a)), 135.8 (C(6)ArC(4)), 138.0 (C(6)ArC(1)), 
167.3 (C(5)C=O), 175.1 (C(8)C=O); HRMS (ESI+) C22H26N2O5Na [M+Na]+ found 421.1729, 
requires 421.1734 (-1.2 ppm). 
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Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous CH2Cl2 (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 489 (0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening 
with morpholine (2 eq.) at rt for 24 h gave crude product (>95:5 dr) that was purified by column 
chromatography (20:80 EtOAc/petrol) to give the titled compound as a light yellow oil (51.8 
mg, 50%). vmax (film, cm-1) 3406 (O-H stretch), 2959 (C-H), 2857 (C-H), 1732 (C=O), 1645 (amide 
C=O); [α]D
20  + 99.3 (c 1.7 in CHCl3); Chiral HPLC analysis, Chiralpak AD-H (90 : 10 hexane/IPA, 
flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 56.4 min, tR (minor): 80.8 min, >99.5:0.5 er; 1H 
NMR (500 MHz, CDCl3) δH: 1.94–1.99 (1H, m, C(7)H(a)H(b)), 2.54 (1H, ddd, J 13.2, 6.5, 3.0, 
morpholineCH), 2.68 (1H, ddd, J 11.5, 6.8, 3.0, morpholineCH), 3.17–3.23 (1H, m, 
morpholineCH), 3.32–3.45 (3H, m, morpholineCH), 3.47–3.56 (2H, m, morpholineCH), 3.57 
(1H, s, OH), 3.62–3.72 (1H, m, C(7)H(a)H(b)), 3.81 (3H, s, OCH3), 3.88 (3H, s, OCH3), 4.03 (1H, 
ddd, J 13.6, 6.0, 2.6, C(6)H), 5.31 (1H, d, J 6.1, C(5)H), 6.09 (1H, dd, J 3.7, 1.6, C(2)H), 6.19 (1H, 
dd, J 3.7, 2.7, C(1)H), 6.40 (1H, dd, J 2.8, 1.6, C(3)H), 6.84–6.90 (2H, m, C(6)ArC(3,5)H), 7.21–
7.25 (2H, m, C(6)ArC(2,4)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 33.0 (C(7)), 38.5 (C(6)), 42.0 
(morpholineC), 45.8 (morpholineC), 53.5 (OCH3), 55.4 (OCH3), 56.2 (C(5)), 65.8 (morpholineC), 
66.4 (morpholineC), 71.1 (C(8)), 105.7 (C(2)), 110.0 (C(1)), 114.2 (C(6)ArC(3,5)H), 119.4 (C(3)), 
129.6 (C(6)ArC(2,6)H), 130.2 (C(8a)), 130.7 (C(6)ArC(1)), 159.4 (C(6)ArC(4)), 167.3 (C(5)C=O), 
175.0 (C(8)C=O); HRMS (ESI+) C22H26N2O6Na [M+Na]+ found 437.1668, requires 437.1683 (-3.5 
ppm). 
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Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 490 (0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening 
with morpholine (2 eq.) at rt for 24 h gave crude product (>95:5 dr) that was purified by column 
chromatography (20:80 EtOAc/petrol) to give the titled compound as a light yellow oil (65.3 
mg, 63%). vmax (film, cm-1) 3416 (O-H stretch), 2955 (C-H), 2857 (C-H), 1732 (C=O), 1645 (amide 
C=O); [α]D
20  + 84.5 (c 1.3 in CHCl3); Chiral HPLC analysis, Chiralpak AD-H (90 : 10 hexane/IPA, 
flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 46.8 min, tR (minor): 68.2 min, >99.5:0.5 er; 1H 
NMR (500 MHz, CDCl3) δH: 2.01 (1H, dd, J 13.1, 2.6, C(7)H(a)H(b)), 2.56–2.64 (2H, m, 
morpholineCH), 3.17–3.22 (1H, m, morpholineCH), 3.29–3.37 (3H, m, morpholineCH), 3.51–
3.56 (3H, m, OH + morpholineCH), 3.68 (1H, td, J 13.3, 1.3, C(7)H(a)H(b)), 3.81 (3H, s, OCH3), 
3.90 (3H, s, OCH3), 4.07 (1H, ddd, J 13.5, 6.0, 2.6, C(6)H), 5.33 (1H, d, J 6.0, C(5)H), 6.09 (1H, 
dd, J 3.7, 1.6, C(2)H), 6.20 (1H, dd, J 3.7, 2.8, C(1)H), 6.41 (1H, dd, J 2.8, 1.6, C(3)H), 6.84–6.88 
(2H, m, C(6)ArC(4,5)H), 6.90–6.93 (1H, m, C(6)ArC(6)H), 7.27–7.31 (1H, m, C(6)ArC(2)H); 13C{1H} 
NMR (126 MHz, CDCl3) δC: 32.9 (C(7)), 39.6 (C(6)), 42.2 (morpholineC), 46.0 (morpholineC), 
53.7 (OCH3), 55.6 (OCH3), 56.1 (C(5)), 65.9 (morpholineC), 66.5 (morpholineC), 71.2 (C(8)), 
105.9 (C(2)), 110.1 (C(1)), 113.1 (C(6)ArCH), 114.8 (C(6)ArCH), 119.5 (C(3)), 121.0 (C(6)ArCH), 
130.0 (C(6)ArCH), 130.3 (C(8a)), 140.5 (C(6)ArC(1)), 160.2 (C(6)ArC(3)), 167.2 (C(5)C=O), 175.0 
(C(8)C=O); HRMS (ESI+) C22H26N2O6Na [M+Na]+ found 437.1670, requires 437.1683 (-3.0 ppm). 
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Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 491 (0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening 
with morpholine (2 eq.) at rt for 24 h gave crude product (>95:5 dr) that was purified by column 
chromatography (20:80 EtOAc/petrol) to give the titled compound as a light yellow oil (62.2 
mg, 55%). vmax (film, cm-1) 3387 (O-H stretch), 2961 (C-H), 2860 (C-H), 1732 (C=O), 1645 (amide 
C=O); [α]D
20  + 98.4 (c 1.1 in CHCl3); Chiral HPLC analysis, Chiralpak AD-H (90 : 10 hexane/IPA, 
flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 88.3 min, tR (minor): 134.8 min, >99:1 er; 1H 
NMR (500 MHz, CDCl3) δH: 2.00–2.04 (1H, m, C(7)H(a)H(b)), 2.51–2.63 (2H, m, morpholineCH), 
3.16–3.31 (2H, m, morpholineCH), 3.34–3.48 (3H, m, morpholineCH), 3.53 (1H, ddd, J 11.5, 
5.9, 3.3, morpholineCH), 3.58 (1H, s, OH), 3.78 (1H, t, J 13.2, C(7)H(a)H(b)), 3.91 (3H, s, OCH3), 
4.18 (1H, ddd, J 13.5, 6.0, 2.6, C(6)H), 5.35 (1H, d, J 6.0, C(5)H), 6.11 (1H, dd, J 3.8, 1.6, C(2)H), 
6.22 (1H, dd, J 3.7, 2.8, C(1)H), 6.42 (1H, dd, J 2.8, 1.6, C(3)H), 7.49 (2H, d, J 8.0, C(6)ArC(2,6)H), 
7.64 (2H, d, J 8.1, C(6)ArC(3,5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 32.6 (C(7)), 39.4 (C(6)), 
42.2 (morpholineC), 46.1 (morpholineC), 53.8 (OCH3), 55.7(C(5)), 65.8 (morpholineC), 66.5 
(morpholineC), 71.0 (C(8)), 106.1 (C(2)), 110.3 (C(1)), 119.6 (C(3)), 123.4 (q, J 272.0, CF3), 125.9 
(app. d, J 4.0, C(6)ArC(3,5)H), 129.2 (C(6)ArC(2,6)H), 130.1 (C(8a)), 130.7 (q, J 33.1, C(6)ArC(4)), 
143.1 (C(6)ArC(1)), 166.9 (C(5)C=O), 174.7 (C(8)C=O); 19F NMR (471 MHz, CDCl3) δF: -62.5 (CF3); 
HRMS (ESI+) C22H23N2O5F3Na [M+Na]+ found 475.1451, requires 475.1451 (-0.1 ppm). 
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Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 492 (0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening 
with morpholine (2 eq.) at rt for 24 h gave crude product (>95:5 dr) that was purified by column 
chromatography (20:80 EtOAc/petrol) to give the titled compound as a light yellow oil (69.5 
mg, 60%). vmax (film, cm-1) 3406 (O-H stretch), 2955 (C-H),2859 (C-H), 1734 (C=O), 1647 (amide 
C=O); [α]D
20  + 80.2 (c 1.4 in CHCl3); Chiral HPLC analysis, Chiralpak AD-H (80 : 20 hexane : IPA, 
flow rate 1 mLmin-1, 220 nm, 30 °C) tR (major): 41.5 min, tR (minor): 63.8 min, >99.5:0.5 er; 1H 
NMR (400 MHz, CDCl3) δH: 1.98 (1H, dd, J 13.0, 2.6, C(7)H(a)H(b)), 2.57 (1H, ddd, J 13.2, 6.5, 
3.0, morpholineCH), 2.74 (1H, ddd, J 11.5, 6.8, 3.0, morpholineCH), 3.22 (1H, ddd, J 13.1, 6.8, 
3.1, morpholineCH), 3.31–3.46 (4H, m, morpholineCH), 3.49–3.54 (1H, m, morpholineCH), 
3.55 (1H, d, J 1.4, OH), 3.69 (1H, td, J 13.3, 1.4, C(7)H(a)H(b)), 3.89 (3H, s, OCH3), 4.06 (1H, ddd, 
J 13.5, 6.0, 2.6, C(6)H), 5.32 (1H, d, J 6.0, C(5)H), 6.10 (1H, dd, J 3.7, 1.6, C(2)H), 6.20 (1H, dd, J 
3.7, 2.8, C(1)H), 6.41 (1H, dd, J 2.8, 1.6, C(3)H), 7.20–7.24 (2H, m, C(6)ArC(2,6)H), 7.48–7.53 
(2H, m, C(6)ArC(3,5)H); 13C{1H} NMR (101 MHz, CDCl3) δC: 32.8 (C(7)), 39.0 (C(6)), 42.2 
(morpholineC), 46.1 (morpholineC), 53.7 (OCH3), 55.8 (C(5)), 65.9 (morpholineC), 66.6 
(morpholineC), 71.0 (C(8)), 106.0 (C(2)), 110.3 (C(1)), 119.6 (C(3)), 122.2 (C(6)ArC(1)), 130.2 
(C(8a)), 130.4 (C(6)ArC(2,6)H), 132.1 (C(6)ArC(3,5)H), 138.0 (C(6)ArC(4)), 167.0 (C(5)C=O), 
174.8 (C(8)C=O); HRMS (ESI+) C21H23N2O579BrNa [M+Na]+ found 485.0675, requires 485.0683 (-
1.6 ppm). 
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Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 493 (0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening 
with morpholine (2 eq.) at rt for 24 h gave crude product (>95:5 dr) that was purified by column 
chromatography (20:80 EtOAc/petrol) to give the titled compound as a light yellow oil (113.5 
mg, 98%). vmax (film, cm-1) 3422 (O-H stretch), 2955 (C-H), 2855 (C-H), 1734 (C=O), 1647 (amide 
C=O); [α]D
20  + 72.3 (c 1.6 in CHCl3); Chiral HPLC analysis, Chiralpak AD-H (90 : 10 hexane/IPA, 
flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 63.3 min, tR (minor): 87.9 min, >99.5:0.5 er; 1H 
NMR (500 MHz, CDCl3) δH: 2.00 (1H, dd, J 13.0, 2.6, C(7)H(a)H(b)), 2.58 (1H, ddd, J 10.9, 7.5, 
3.0, morpholineCH), 2.64 (1H, ddd, J 13.1, 5.7, 3.0, morpholineCH), 3.22 (1H, ddd, J 13.1, 7.5, 
3.1, morpholineCH), 3.34 (2H, d, J 9.7, morpholineCH), 3.39 (1H, ddd, J 11.6, 5.7, 3.1, 
morpholineCH), 3.52–3.62 (3H, m, morpholineCH + OH), 3.69 (1H, td, J 13.3, 1.5, C(7)H(a)H(b)), 
3.90 (3H, s, OCH3), 4.08 (1H, ddd, J 13.5, 5.9, 2.6, C(6)H), 5.32 (1H, d, J 6.0, C(5)H), 6.10 (1H, 
dd, J 3.7, 1.6, C(2)H), 6.21 (1H, dd, J 3.7, 2.8, C(1)H), 6.41 (1H, dd, J 2.8, 1.6, C(3)H), 7.23–7.29 
(2H, m, C(6)ArCH), 7.48–7.50 (2H, m, C(6)ArCH); 13C{1H} NMR (126 MHz, CDCl3) δC: 32.7 (C(7)), 
39.3 (C(6)), 42.2 (morpholineC), 46.1 (morpholineC), 53.7 (OCH3), 55.9 (C(5)), 65.9 
(morpholineC), 66.6 (morpholineC), 71.0 (C(8)), 106.0 (C(2)), 110.2 (C(1)), 119.6 (C(3)), 123.2 
(C(6)ArC(1)), 127.6 (C(6)ArCH), 130.2 (C(8a)), 130.6 (C(6)ArCH), 131.4 (C(6)ArCH), 131.6 
(C(6)ArCH), 141.4 (C(6)ArC(3)), 166.9 (C(5)C=O), 174.8 (C(8)C=O); HRMS (ESI+) 
C21H23N2O579BrNa [M+Na]+ found 485.0684, requires 485.0683 (+0.3 ppm). 
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Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 494 (0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening 
with morpholine (2 eq.) at rt for 24 h gave crude product (>95:5 dr) that was purified by column 
chromatography (20:80 EtOAc/petrol) to give the titled compound as a light yellow oil (67.2 
mg, 58%). vmax (film, cm-1) 3424 (O-H stretch), 2959 (C-H), 2926 (C-H), 2859 (C-H), 1717 (C=O), 
1651 (amide C=O); [α]D
20  + 168.7 (c 1.4 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (90 : 
10 hexane/IPA, flow rate 1 mLmin-1, 220 nm, 30 °C) tR (major): 37.6 min, tR (minor): 58.4 
min, >99:1 er; 1H NMR (500 MHz, CDCl3) δH: 1.99 (1H, dd, J 12.9, 2.7, C(7)H(a)H(b)), 2.49 (1H, 
ddd, J 11.2, 7.7, 2.9, morpholineCH), 2.77 (1H, ddd, J 13.3, 5.7, 2.9, morpholineCH), 3.10–3.17 
(1H, m, morpholineCH), 3.21–3.33 (2H, m, morpholineCH), 3.37–3.44 (1H, m, morpholineCH), 
3.45–3.55 (3H, m, morpholineCH + OH), 3.78 (1H, t, J 13.2, 1.3, C(7)H(a)H(b)), 3.90 (3H, s, 
OCH3), 4.50 (1H, ddd, J 13.4, 6.0, 2.6, C(6)H), 5.59 (1H, d, J 5.9, C(5)H), 6.11 (1H, dd, J 3.7, 1.6, 
C(2)H), 6.21 (1H, dd, J 3.7, 2.8, C(1)H), 6.44 (1H, dd, J 2.8, 1.6, C(3)H), 7.19–7.24 (1H, m, 
C(6)ArCH), 7.32–7.35 (2H, m, C(6)ArCH), 7.61–7.65 (1H, m, C(6)ArCH); 13C{1H} NMR (126 MHz, 
CDCl3) δC: 32.7 (C(7)), 38.3 (C(6)), 42.2 (morpholineC), 46.0 (morpholineC), 53.1 (OCH3), 53.6 
(C(5)), 66.1 (morpholineC), 66.5 (morpholineC), 71.0 (C(8)), 105.9 (C(2)), 110.1 (C(1)), 119.8 
(C(3)), 125.8 (C(6)ArC(5)H), 128.3 (C(6)ArC(6)H), 129.7 (C(6)ArC(2)), 129.8 (C(6)ArC(4)H), 130.1 
(C(8a)), 133.2 (C(6)ArC(3)H), 138.0 (C(6)ArC(1)), 167.0 (C(5)C=O), 174.8 (C(8)C=O); HRMS (ESI+) 
C21H23N2O579BrNa [M+Na]+ found 485.0681, requires 485.0683 (-0.3 ppm). 
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Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol), pivaloyl chloride (0.062 mL, 0.5 mmol) in anhydrous MeCN (2.5 
mL) at 0 °C for 20 min followed by HyperBTM 93 (7.7 mg, 10 mol%), α-keto-β,γ-unsaturated 
ester 495 (0.25 mmol, 1 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol) at –40 °C for 24 h. Ring-opening 
with morpholine (2 eq.) at rt for 24 h gave crude product (>95:5 dr) that was purified by column 
chromatography (20:80 EtOAc/petrol) to give the titled compound as a light yellow oil (58.0 
mg, 62%). vmax (film, cm-1) 3410 (O-H stretch), 2955 (C-H), 2857 (C-H), 1734 (C=O), 1649 (amide 
C=O); [α]D
20  + 83.2 (c 1.3 in CHCl3); Chiral HPLC analysis, Chiralpak AD-H (90 : 10 hexane/IPA, 
flow rate 1 mLmin-1, 220 nm, 30 °C) tR (major): 89.3 min, tR (minor): 53.1 min, >99:1 er; 1H NMR 
(500 MHz, CDCl3) δH: 2.09 (1H, dd, J 13.2, 2.7, C(7)H(a)H(b)), 3.03 (1H, ddd, J 13.2, 6.6, 3.0, 
morpholineCH), 3.22 (1H, ddd, J 11.6, 6.7, 3.0, morpholineCH), 3.40–3.59 (8H, m, 
morpholineCH + C(7)H(a)H(b) + OH), 3.88 (3H, s, OCH3), 4.17 (1H, ddd, J 13.5, 6.0, 2.7, C(6)H), 
5.49 (1H, d, J 5.9, C(5)H), 6.10 (1H, dd, J 3.7, 1.6, C(2)H), 6.18–6.24 (2H, m, C(6)ArCH + C(1)H), 
6.39 (1H, dd, J 3.4, 1.9, C(6)ArCH), 6.44 (1H, dd, J 2.8, 1.6, C(3)H), 7.39–7.40 (1H, m, C(6)ArCH); 
13C{1H} NMR (126 MHz, CDCl3) δC: 31.6 (C(7)), 33.5 (C(6)), 42.4 (morpholineC), 45.9 
(morpholineC), 53.7 (OCH3), 54.6 (C(5)), 66.5 (morpholineC), 66.8 (morpholineC), 70.8 (C(8)), 
106.0 (C(2)), 107.5 (C(6)ArCH), 110.2 (C(1)), 111.2 (C(6)ArCH), 119.8 (C(3)), 130.3 (C(8a)), 142.1 
(C(6)ArCH), 153.2 (C(6)ArC(1)), 167.2 (C(5)C=O), 174.7 (C(8)C=O); HRMS (ESI+) C19H22N2O6Na 
[M+Na]+ found 397.1364, requires 397.1370 (-1.5 ppm). 
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8.5. Experimentals for Chapter 5 
General Procedure A: Synthesis of N-tosyl-α,β-unsaturated ketimines 
 
To a solution of the corresponding commercial available α,β-unsaturated ketone (1.0 eq.) in 
dry CH2Cl2 (0.5 M) was added p-toluenesulfonamide (1.0 eq.), NEt3 (2.0 eq.) and titanium 
tetrachloride (1.0 eq.) at 0 °C under an atmosphere of N2. The reaction mixture was refluxed 
for 16 h. Then it was cooled to rt and quenched with brine (20 mL). The aqueous phase was 
extracted with CH2Cl2 and the combined organic layers were dried with MgSO4 and 
concentrated under reduced pressure. Purification of the crude residue by flash silica column 
chromatography (EtOAc/petrol 20:80) and recrystallization in ca. 1:1 petrol:EtOAc gave the 




Following general procedure A: (E)-chalcone (2.08 g, 10.0 mmol, 1.0 eq.), TsNH2 (1.71 g, 10.0 
mmol, 1.0 eq.), Et3N (2.8 mL, 20.0 mmol, 2.0 eq.) and TiCl4 (1.1 mL, 10.0 mmol, 1.0 eq.) in 
CH2Cl2 (20 mL, 0.5 M) gave 323 as a light yellow solid (3.11 g, 86%). Spectroscopic data were 
in accordance with the literature.12 mp 118-121 °C {Lit.12 116-120 °C}; 1H NMR (500 MHz, CDCl3) 
δH: 2.45 (3H, s, CH3), 7.09 (1H, d, J 16.1, C(2)H), 7.34 (2H, d, J 7.9, ArH), 7.39–7.77 (10H, m, ArH 
+ C(3)H), 7.86–8.23 (3H, m, ArH). 
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N-((1E,2E)-3-(4-Chlorophenyl)-1-phenylallylidene)-4-methylbenzenesulfonamide (324) 
 
Following general procedure A: (E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one (2.43 g, 10.0 
mmol, 1.0 eq.), TsNH2 (1.71 g, 10.0 mmol, 1.0 eq.), Et3N (2.8 mL, 20.0 mmol, 2.0 eq.) and TiCl4 
(1.1 mL, 10.0 mmol, 1.0 eq.) in CH2Cl2 (20 mL, 0.5 M) gave 324 as a white solid (2.18 g, 55%). 
Spectroscopic data were in accordance with the literature.12 mp 105-106 °C {Lit.12 104-106 °C}; 
1H NMR (400 MHz, CDCl3) δH: 2.44 (3H, s, CH3), 7.01 (1H, d, J 16.1, C(2)H), 7.33–7.67 (11H, m, 




Following general procedure A: (E)-3-(4-fluorophenyl)-1-phenylprop-2-en-1-one (2.26 g, 10.0 
mmol, 1.0 eq.), TsNH2 (1.71 g, 10.0 mmol, 1.0 eq.), Et3N (2.8 mL, 20.0 mmol, 2.0 eq.) and TiCl4 
(1.1 mL, 10.0 mmol, 1.0 eq.) in CH2Cl2 (20 mL, 0.5 M) gave 325 as a white solid (1.78 g, 47%). 
Spectroscopic data were in accordance with the literature.13 mp 136-137 °C {Lit.13 138-139 °C}; 
1H NMR (500 MHz, CDCl3) δH: 2.43 (3H, s, CH3), 7.03 (1H, d, J 16.2, C(2)H), 7.11 (2H, t, J 8.4, 
ArH), 7.32 (2H, d, J 7.9, ArH), 7.44 (2H, t, J 7.7, ArH), 7.53–7.64 (5H, m, ArH+C(3)H), 7.92–8.01 




Following general procedure A: (E)-3-(4-methoxyphenyl)-1-phenylprop-2-en-1-one (2.38 g, 
10.0 mmol, 1.0 eq.), TsNH2 (1.71 g, 10.0 mmol, 1.0 eq.), Et3N (2.8 mL, 20.0 mmol, 2.0 eq.) and 
TiCl4 (1.1 mL, 10.0 mmol, 1.0 eq.) in CH2Cl2 (20 mL, 0.5 M) gave 326 as a yellow solid (1.78 g, 
80%). Spectroscopic data were in accordance with the literature.12 mp 55-57 °C; 1H NMR (400 
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MHz, CDCl3) δH: 3.85 (3H, s, OCH3), 6.90–6.94 (2H, m, ArH), 7.04 (1H, d, J 15.9, C(2)H), 7.31 (2H, 
d, J 8.0, ArH), 7.41–7.45 (2H, m, ArH), 7.50–7.55 (3H, m, ArH+C(3)H), 7.58–7.66 (2H, m, ArH), 




Following general procedure A: (E)-3-([1,1'-biphenyl]-4-yl)-1-phenylprop-2-en-1-one (2.84 g, 
10.0 mmol, 1.0 eq.), TsNH2 (1.71 g, 10.0 mmol, 1.0 eq.), Et3N (2.8 mL, 20.0 mmol, 2.0 eq.) and 
TiCl4 (1.1 mL, 10.0 mmol, 1.0 eq.) in CH2Cl2 (20 mL, 0.5 M) gave 327 as a yellow solid (2.32 g, 
53%). mp 56-58 °C; νmax (film, cm–1) 3057 (C-H), 3026 (C-H), 1612, 1597, 1530, 1514, 1310, 
1288; 1H NMR (500 MHz, CDCl3) δH: 2.43 (3H, s, OCH3), 7.11 (1H, d, J 16.0, C(2)H), 7.32 (2H, d, 
J 8.0, ArH), 7.37–7.41 (1H, m, ArH), 7.43–7.49 (4H, m, ArH), 7.53–7.58 (1H, m, ArH), 7.61–7.70 
(8H, m, ArH+C(3)H), 7.94 (2H, d, J 7.4, ArH), 8.08–8.19 (1H, m, ArH); 13C{1H} NMR (126 MHz, 
CDCl3) δC: 21.7 (CH3), 127.2 (ArCH), 127.4 (ArCH+C(2)H), 127.8 (ArCH), 128.2 (ArCH), 128.5 
(ArCH), 129.1 (ArCH), 129.5 (ArCH), 129.6 (ArCH), 133.7 (C), 140.1 (2xC), 143.6 (2xC), 144.0 (C), 
148.7 (C(3)H), 163.1 (C(1)); HRMS (ESI+) C28H23NO2SNa [M+Na]+ found 460.1335, requires 




Following general procedure A: (E)-3-(naphthalen-1-yl)-1-phenylprop-2-en-1-one (2.58 g, 10.0 
mmol, 1.0 eq.), TsNH2 (1.71 g, 10.0 mmol, 1.0 eq.), Et3N (2.8 mL, 20.0 mmol, 2.0 eq.) and TiCl4 
(1.1 mL, 10.0 mmol, 1.0 eq.) in CH2Cl2 (20 mL, 0.5 M) gave 328 as a yellow solid (2.67 g, 65%). 
mp 116-118 °C; νmax (film, cm–1) 3059 (C-H), 1595, 1578, 1524, 1506, 1298, 1285; 1H NMR (500 
MHz, CDCl3) δH: 2.43 (3H, s, OCH3), 7.33 (2H, d, J 8.0, ArH), 7.48–7.54 (4H, m, ArH+C(2)H), 7.55–
7.63 (2H, m, ArH), 7.75–8.02 (9H, m, ArH+C(3)H), 8.09–8.24 (1H, m, ArH); 13C{1H} NMR (126 
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MHz, CDCl3) δC: 21.7 (CH3), 123.0 (ArCH), 125.9 (ArCH), 126.3 (ArCH), 126.4 (ArCH), 127.2 
(ArCH), 127.4 (ArCH+C(2)H), 128.6 (ArCH), 129.1 (ArCH), 129.6 (ArCH), 131.5 (C), 131.6 (C), 
132.0 (C), 133.8 (C), 138.8 (C), 143.6 (C), 145.5 (C(3)H), 163.2 (C(1)); HRMS (ESI+) C26H22NO2S 




Following general procedure A: (E)-3-(naphthalen-2-yl)-1-phenylprop-2-en-1-one (2.58 g, 10.0 
mmol, 1.0 eq.), TsNH2 (1.71 g, 10.0 mmol, 1.0 eq.), Et3N (2.8 mL, 20.0 mmol, 2.0 eq.) and TiCl4 
(1.1 mL, 10.0 mmol, 1.0 eq.) in CH2Cl2 (20 mL, 0.5 M) gave 329 as a yellow solid (2.55 g, 62%). 
mp 122-124 °C; νmax (film, cm–1) 2972 (C-H), 2922 (C-H), 1611, 1595, 1528, 1314, 1285; 1H NMR 
(500 MHz, CDCl3) δH: 2.43 (3H, s, OCH3), 7.24 (1H, d, J 16.1, C(2)H), 7.32 (2H, d, J 8.0, ArH), 
7.44–7.59 (5H, m, ArH+C(3)H), 7.68 (2H, app. s, ArH), 7.78–7.97 (7H, m, ArH), 8.09–8.31 (1H, 
m, ArH); 13C{1H} NMR (126 MHz, CDCl3) δC: 21.7 (CH3), 124.0 (ArCH), 127.0 (ArCH), 127.4 
(ArCH+C(2)H), 127.9 (ArCH), 128.0 (ArCH), 128.5 (ArCH), 128.9 (ArCH), 129.1 (ArCH), 129.6 
(ArCH), 131.2 (C), 132.3 (C), 133.4 (C), 134.8 (C), 138.9 (C), 143.6 (C), 149.3 (C(3)H), 163.5 (C(1)); 




Following general procedure A: (2E,4E)-1,5-diphenylpenta-2,4-dien-1-one (2.34 g, 10.0 mmol, 
1.0 eq.), TsNH2 (1.71 g, 10.0 mmol, 1.0 eq.), Et3N (2.8 mL, 20.0 mmol, 2.0 eq.) and TiCl4 (1.1 
mL, 10.0 mmol, 1.0 eq.) in CH2Cl2 (20 mL, 0.5 M) gave 330 as a yellow solid (3.26 g, 84%). 
Spectroscopic data were in accordance with the literature.14 mp 144-145 °C {Lit.14 143-144 °C}; 
1H NMR (400 MHz, CDCl3) δH: 2.43 (3H, s, CH3), 6.86 (1H, d, J 15.4, C(5)H), 6.89–6.94 (1H, m, 
C(3)H), 7.10 (1H, dd, J 15.5, 10.9, C(4)H), 7.30–7.62 (13H, m, C(2)H+ArH), 7.92 (2H, d, J 7.9, 
ArH). 
Chapter 8: Experimentals 
Page | 240  
N-((1E,2E)-1-(4-Chlorophenyl)-3-phenylallylidene)-4-methylbenzenesulfonamide (331) 
 
Following general procedure A: (E)-1-(4-chlorophenyl)-3-phenylprop-2-en-1-one (2.43 g, 10.0 
mmol, 1.0 eq.), TsNH2 (1.71 g, 10.0 mmol, 1.0 eq.), Et3N (2.8 mL, 20.0 mmol, 2.0 eq.) and TiCl4 
(1.1 mL, 10.0 mmol, 1.0 eq.) in CH2Cl2 (20 mL, 0.5 M) gave 331 as a white solid (2.14 g, 54%). 
Spectroscopic data were in accordance with the literature.12 mp 102-103 °C {Lit.12 104-108 °C}; 
1H NMR (400 MHz, CDCl3) δH: 2.44 (3H, s, CH3), 7.04 (1H, d, J 16.1, C(2)H), 7.33 (2H, d, J 8.3, 




Following general procedure A: (E)-1-(4-fluorophenyl)-3-phenylprop-2-en-1-one (2.26 g, 10.0 
mmol, 1.0 eq.), TsNH2 (1.71 g, 10.0 mmol, 1.0 eq.), Et3N (2.8 mL, 20.0 mmol, 2.0 eq.) and TiCl4 
(1.1 mL, 10.0 mmol, 1.0 eq.) in CH2Cl2 (20 mL, 0.5 M) gave 332 as a white solid (1.59 g, 42%). 
Spectroscopic data were in accordance with the literature.13 mp 168-169 °C {Lit.13 173-174 °C}; 
1H NMR (500 MHz, CDCl3) δH: 2.43 (3H, s, CH3), 7.04 (1H, d, J 16.1, C(2)H), 7.08–7.17 (2H, m, 
ArH), 7.28–7.35 (2H, m, ArH), 7.37–7.48 (3H, m, ArH+C(3)H), 7.49–7.77 (4H, m, ArH), 7.92 (2H, 




Following general procedure A: (E)-1-(4-bromophenyl)-3-phenylprop-2-en-1-one (2.87 g, 10.0 
mmol, 1.0 eq.), TsNH2 (1.71 g, 10.0 mmol, 1.0 eq.), Et3N (2.8 mL, 20.0 mmol, 2.0 eq.) and TiCl4 
(1.1 mL, 10.0 mmol, 1.0 eq.) in CH2Cl2 (20 mL, 0.5 M) gave 333 as a white solid (2.64 g, 60%). 
mp 106-108 °C; νmax (film, cm–1) 3036 (C-H), 2988 (C-H), 2920 (C-H), 1612, 1589, 1576, 1533, 
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1447, 1285; 1H NMR (500 MHz, CDCl3) δH: 2.43 (3H, s, CH3), 7.04 (1H, d, J 16.0, C(2)H), 7.32 (2H, 
d, J 8.0, ArH), 7.39–7.46 (3H, m, ArH), 7.52–7.61 (6H, m, ArH+C(3)H), 7.91 (2H, d, J 7.1, ArH), 
8.00–8.17 (1H, m, ArH); 13C{1H} NMR (126 MHz, CDCl3) δC: 21.7 (CH3), 127.4 (ArCH), 128.9 
(C(2)H), 129.2 (ArCH), 129.6 (ArCH), 131.4 (ArCH), 131.8 (ArCH), 134.5 (2xC), 138.6 (2xC), 143.8 
(C), 149.0 (C(3)H), 162.1 (C(1)); HRMS (ESI+) C22H19NO2S79Br [M+H]+ found 440.0307, requires 




Following general procedure A: (E)-3-phenyl-1-(p-tolyl)prop-2-en-1-one (2.22 g, 10.0 mmol, 
1.0 eq.), TsNH2 (1.71 g, 10.0 mmol, 1.0 eq.), Et3N (2.8 mL, 20.0 mmol, 2.0 eq.) and TiCl4 (1.1 
mL, 10.0 mmol, 1.0 eq.) in CH2Cl2 (20 mL, 0.5 M) gave 334 as a light yellow solid (1.54 g, 41%). 
mp 108-110 °C; νmax (film, cm–1) 3049 (C-H), 1612, 1576, 1522, 1445, 1314, 1296, 1285; 1H NMR 
(500 MHz, CDCl3) δH: 2.42 (6H, s, 2xCH3), 7.07 (1H, d, J 16.0, C(2)H), 7.23–7.25 (2H, m, ArH), 
7.30–7.32 (2H, m, ArH), 7.40–7.43 (3H, m, ArH), 7.56–7.58 (4H, m, ArH+C(3)H), 7.92 (2H, d, J 
7.9, ArH), 7.98–8.07 (1H, m, ArH); 13C{1H} NMR (126 MHz, CDCl3) δC: 21.7 (CH3), 127.3 (ArCH), 
128.8 (C(2)H), 129.2 (ArCH), 129.2 (ArCH), 129.5 (ArCH), 131.1 (ArCH), 134.8 (2xC), 139.0 (C), 
143.5 (2xC), 148.4 (C(3)H), 162.4 (C(1)); HRMS (ESI+) C23H22NO2S [M+H]+ found 376.1359, 




Following general procedure A: (E)-1-(4-methoxyphenyl)-3-phenylprop-2-en-1-one (2.38 g, 
10.0 mmol, 1.0 eq.), TsNH2 (1.71 g, 10.0 mmol, 1.0 eq.), Et3N (2.8 mL, 20.0 mmol, 2.0 eq.) and 
TiCl4 (1.1 mL, 10.0 mmol, 1.0 eq.) in CH2Cl2 (20 mL, 0.5 M) gave 335 as a yellow solid (2.78 g, 
71%). Spectroscopic data were in accordance with the literature.12 mp 65-67 °C; 1H NMR (400 
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MHz, CDCl3) δH: 2.43 (3H, s, CH3), 3.89 (3H, s, OCH3), 6.95 (2H, d, J 8.8, ArH), 7.08 (1H, d, J 16.1, 
C(2)H), 7.33 (2H, d, J 8.7, ArH), 7.43–7.45 (3H, m, ArH+C(3)H), 7.55–7.61 (2H, m, ArH), 7.73 




Following general procedure A: (E)-1-(3-bromophenyl)-3-phenylprop-2-en-1-one (2.87 g, 10.0 
mmol, 1.0 eq.), TsNH2 (1.71 g, 10.0 mmol, 1.0 eq.), Et3N (2.8 mL, 20.0 mmol, 2.0 eq.) and TiCl4 
(1.1 mL, 10.0 mmol, 1.0 eq.) in CH2Cl2 (20 mL, 0.5 M) gave 336 as a white solid (1.94 g, 44%). 
mp 120-121 °C; νmax (film, cm–1) 3063 (C-H), 1607, 1574, 1533, 1310, 1290; 1H NMR (500 MHz, 
CDCl3) δH: 2.46 (3H, s, CH3), 7.07 (1H, d, J 16.0, C(2)H), 7.31–7.38 (3H, m, ArH), 7.42–7.50 (3H, 
m, ArH), 7.55–7.65 (3H, m, ArH+C(3)H), 7.67–7.71 (1H, m, ArH), 7.80 (1H, app. s, ArH), 7.94 
(2H, app. s, ArH), 8.06–8.19 (1H, m, ArH); 13C{1H} NMR (126 MHz, CDCl3) δC: 21.8 (CH3), 127.4 
(ArCH), 129.0 (ArCH), 129.3 (ArCH), 129.7 (C(2)H), 130.0 (ArCH), 131.5 (ArCH), 134.5 (2xC), 
138.5 (C), 143.9 (2xC), 149.3 (C(3)H), 163.4 (C(1)); HRMS (ESI+) C22H19NO2S79Br [M+H]+ found 
440.0306, requires 440.0314 (-1.9 ppm). 
 
3-Methylbenzo[d]isothiazole 1,1-dioxide (337) 
 
Following literature procedure,15 in a flame-dried flask, to a solution of saccharin (10.0 g, 54.6 
mmol, 1 eq.) in anhydrous THF (500 mL) at 0 °C was added methyl magnesium bromide (3.0 
M in Et2O, 36 mL, 109 mmol, 2 eq.) dropwise. The reaction was warmed to rt and stirred for 
16 hours before being quenched with sat. aq. NH4Cl, extracted with CH2Cl2 (3 x 200 mL). 
Combined organics were dried over MgSO4, filtered and concentrated under reduced pressure 
to give crude reaction product. The crude material was purified by trituration in CH2Cl2 to give 
a white solid (4.55 g, 46%). Spectroscopic data were in accordance with the literature.16 mp 
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221-223 °C {Lit.16 216-219 °C}; 1H NMR (500 MHz, CDCl3) δH: 2.68 (3H, s, CH3), 7.67–7.70 (1H, 
m, ArH), 7.73–7.78 (2H, m, ArH), 7.91–7.94 (1H, m, ArH). 
 
General Procedure B: Preparation of sulfonyl imine substrates 
 
Imine 337 (1.0 eq.) was dissolved in ethanol (0.3 M) and heated to 80 °C. The aldehyde (1.0 
eq.), acetic acid (10 mol%) and piperidine (10 mol%) were added. The reaction was stirred at 
80 °C for 3 hours then cooled to 0 °C and filtered. The solid was washed with cold ethanol to 
give the unsaturated ketimine, which was used without further purification. 
 
(E)-3-Styrylbenzo[d]isothiazole 1,1-dioxide (339) 
 
Imine 337 (3.0 g, 11.1 mmol, 1.0 eq.) was dissolved in ethanol (37 mL, 0.3 M) and heated to 
80 °C. Benzaldehyde (2.5 mL, 24.5 mmol, 2.2 eq.) and piperidine (25 drops) were added. The 
reaction was stirred at 80 °C for 30 minutes. Acetic acid (25 drops) was added and the reaction 
was stirred at 80 °C for 17 hours. The reaction was cooled to rt and filtered. The collected solid 
was then washed with petrol (50 mL) to give 339 as a yellow solid (2.00 g, 67%). Spectroscopic 
data were in accordance with the literature.17 mp 247 °C {Lit.17 244-246 °C}; 1H NMR (400 MHz, 
CDCl3) δH: 7.30 (1H, d, J 15.6, C(1’)H), 7.45–7.52 (3H, m, C(2’)ArCH+ArH), 7.68–7.73 (2H, m, 
C(2’)ArCH), 7.74–7.80 (2H, m, C(2’)ArCH), 7.86–7.92 (1H, m, ArH), 7.94–8.00 (1H, m, ArH), 8.33 
(1H, d, J 15.6, C(2’)H). 
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(E)-3-(4-Methoxystyryl)benzo[d]isothiazole 1,1-dioxide (341) 
 
Following general procedure B, imine 337 (301 mg, 1.66 mmol, 1 eq.), 4-
methoxybenzaldehyde (0.20 mL, 1.66 mmol, 1 eq.), acetic acid (10 μL, 0.17 mmol, 10 mol%) 
and piperidine (17 μL, 0.17 mmol, 10 mol%) gave the titled compound as an orange solid (267 
mg, 53%). Spectroscopic data were in accordance with the literature.17 mp 224-226 °C {Lit.17 
218-220 °C}; 1H NMR (500 MHz, CDCl3) δH: 3.86 (3H, s, OCH3), 7.75 (2H, d, J 8.8, C(3)ArC(3,5)H), 
7.75 (1H, d, J 15.6, C(2)H), 7.88–7.97 (2H, m, ArH), 8.00 (2H, d, J 8.8, C(3)ArC(2,6)H), 8.17 (1H, 
d, J 7.8, ArH), 8.26 (1H, d, J 15.6, C(3)H), 8.49 (1H, d, J 7.0, ArH). 
 
(E)-3-(4-Bromostyryl)benzo[d]isothiazole 1,1-dioxide (340) 
 
Following general procedure B, imine 337 (498 mg, 2.75 mmol, 1 eq.), 4-bromobenzaldehyde 
(509 mg, 2.75 mmol, 1 eq.), acetic acid (16 μL, 0.28 mmol, 10 mol%) and piperidine (28 μL, 
0.28 mmol, 10 mol%) gave the titled compound as an orange solid (628 mg, 66%). 
Spectroscopic data were in accordance with the literature.17 mp 258-261 °C {Lit.17 256-260 °C}; 
1H NMR (500 MHz, d6-DMSO) δH: 7.75 (2H, d, J 8.3, C(3)ArC(3,5)H), 7.89–8.00 (5H, m, 
C(3)ArC(2,6)H + C(2)H + ArH), 8.17–8.21 (1H, m, ArH), 8.25 (1H, d, J 15.8, C(3)H), 8.51 (1H, dd, 
J 1.3, 6.4, ArH). 
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(E)-3-(2-(Furan-2-yl)vinyl)benzo[d]isothiazole 1,1-dioxide (342) 
 
Following general procedure B, imine 337 (498 mg, 2.75 mmol, 1 eq.), furfural (0.23 mL, 2.75 
mmol, 1 eq.), acetic acid (16 μL, 0.28 mmol, 10 mol%) and piperidine (28 μL, 0.28 mmol, 10 
mol%) gave the titled compound as a dark-yellow solid (430 mg, 60%). Spectroscopic data 
were in accordance with the literature.17 mp 226-228 °C {Lit.17 230-233 °C (dec.)}; 1H NMR (400 
MHz, CDCl3) δH: 6.62 (1 H, dd, J 3.3, 1.7, FurC(4)H), 6.90 (1 H, d, J 3.4, FurC(3)H), 7.19 (1 H, d, J 
15.2, C(2)H), 7.66 (1H, s, FurC(5)H), 7.87–8.01 (2H, m, ArH), 7.75–7.80 (2H, m, ArH), 8.07 (1H, 
d, J 15.2, C(3)H). 
 
(E)-3-(2-(Naphthalen-1-yl)vinyl)benzo[d]isothiazole 1,1-dioxide (343) 
 
Following general procedure B, imine 337 (498 mg, 2.75 mmol, 1 eq.), 1-naphthaldehyde (0.37 
mL, 2.75 mmol, 1 eq.), acetic acid (16 μL, 0.28 mmol, 10 mol%) and piperidine (28 μL, 0.28 
mmol, 10 mol%) gave the titled compound as a yellow solid (585 mg, 67%). Spectroscopic data 
were in accordance with the literature.17 mp 275-278 °C {Lit.17 277-279 °C}; 1H NMR (500 MHz, 
d6-DMSO) δH: 7.62–7.67 (1H, m, NapH), 7.68–7.75 (2H, m, NapH), 7.92–8.00 (2H, m, ArH), 
8.01–8.08 (2H, m, C(2)H + NapH), 8.16 (1H, d, J 8.1, NapH), 8.22 (1H, dd, J 6.2, 1.9, ArH), 8.42 
(2H, t, J 7.5, NapH), 8.51–8.58 (1H, m, ArH), 9.06 (1H, d, J 15.4, C(3)H). 
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General Procedure C: Michael addition-lactamization with chalcone derived α,β-
unsaturated ketimines 
 
2-(1H-Pyrrol-1-yl)acetic acid 155 (2 eq.) was dissolved in freshly distilled anhydrous MeCN 
(0.05 M) under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (2 eq.) and pivaloyl 
chloride (2 eq.) were added. The reaction was stirred at 0 °C for 20 min before warming up to 
room temperature. HyperBTM 93 (10 mol%), the required α,β-unsaturated ketimine (1 eq.), 
and i-Pr2NEt (2.5 eq.) were added sequentially and the reaction stirred at rt. for 72 h. After 
that, the reaction was diluted with CH2Cl2 (equal volume) and washed with 1 M HCl (×2) and 
brine (×2) before being dried over MgSO4, filtered, and concentrated under reduced pressure 




Following General Procedure C, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.), 
i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) in 
MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), ketimine 323 
(45.2 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 eq.) at rt for 72 h gave 
crude product (>95:5 dr) that was purified by column chromatography (10:90 EtOAc/petrol, Rf 
0.27) to give the titled compound 344 as a white solid (53.9 mg, 92%). mp 174-175 °C; 
[α]D
20  − 63.1 (c 0.42 in DMSO); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, 
flow rate 1 mLmin-1, 220 nm, 30 °C) tR (major): 20.7 min, tR (minor): 11.1 min, 78:22 er; vmax 
(film, cm–1) 3098 (C-H), 3036 (C-H), 1734 (C=O), 1597, 1491; 1H NMR (500 MHz, CDCl3) δH: 2.51 
(3H, s, NSO2PhCH3), 4.17 (1H, dd, J 12.7, 3.4, C(4)H), 4.75 (1H, d, J 12.7, C(3)H), 5.99 (2H, t, J 
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2.1, C(3)Ar(3,4)H), 6.03 (1H, d, J 3.4, C(5)H), 6.24 (2H, t, J 2.2, C(3)Ar(2,5)H), 7.08 (2H, dd, J 6.6, 
2.9, ArH), 7.22–7.24 (3H, m, ArH), 7.35 (2H, d, J 8.1, NSO2ArC(3,5)H), 7.39–7.48 (5H, m, ArH), 
7.92 (2H, d, J 8.2, NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 21.8 (NSO2PhCH3), 45.2 
(C(4)), 67.3 (C(3)), 109.0 (C(3)ArC(3,4)H), 120.2 (C(3)ArC(2,5)H), 121.6 (C(5)), 126.0 (ArCH), 
127.3 (ArCH), 127.8 (ArCH), 128.6 (ArCH), 128.8 (ArCH), 128.9 (ArCH), 129.3 (NSO2ArC(3,5)H), 
129.5 (NSO2ArC(2,6)H), 135.9 (NSO2ArC(4)), 136.5 (C(4)ArC(1)), 137.9 (C(6)), 140.0 (C(6)ArC(1)), 
145.6 (NSO2ArC(1)), 169.4 (C(2)); HRMS (ASAP+) C28H25N2O3S [M+H]+ found 469.1583, requires 





Following General Procedure C, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.), 
i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) in 
MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), ketimine 324 
(49.5 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 eq.) at rt for 72 h gave 
crude product (>95:5 dr) that was purified by column chromatography (15:85 EtOAc/petrol) 
to give the titled compound 345 as a white solid (59.7 mg, 95%). mp 160-162 °C; [α]D
20  +
27.0 (c 0.1 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 
mLmin-1, 211 nm, 30 °C) tR (major): 25.9 min, tR (minor): 12.8 min, 83:17 er; vmax (film, cm–1) 
3028, 1734 (C=O), 1491, 1356, 1159; 1H NMR (500 MHz, CDCl3) δH: 2.50 (3H, s, NSO2PhCH3), 
4.17 (1H, dd, J 12.7, 3.4, C(4)H), 4.69 (1H, d, J 12.7, C(3)H), 5.96 (1H, d, J 3.4, C(5)H), 6.01 (2H, 
t, J 2.1, C(3)Ar(3,4)H), 6.24 (2H, t, J 2.1, C(3)Ar(2,5)H), 7.01–7.03 (2H, m, C(4)ArC(2,6)H), 7.19–
7.21 (2H, m, C(4)ArC(3,5)H), 7.35 (2H, app. d, J 8.2, NSO2ArC(3,5)H), 7.41–7.44 (5H, m, 
C(6)ArCH), 7.90–7.91 (2H, m, NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 21.8 
(NSO2PhCH3), 44.7 (C(4)), 67.1 (C(3)), 109.2 (C(3)ArC(3,4)H), 120.2 (C(3)ArC(2,5)H), 120.9 (C(5)), 
126.0 (C(6)ArCH), 128.6 (C(6)ArCH), 128.7 (C(6)ArCH), 129.0 (C(4)ArC(2,6)H), 129.0 
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(C(4)ArC(3,5)H), 129.3 (NSO2ArC(3,5)H), 129.5 (NSO2ArC(2,6)H), 133.7 (C(4)ArC(1)), 135.8 
(NSO2ArC(4)), 136.3 (C(6)), 136.4 (C(4)ArC(4)), 140.3 (C(6)ArC(1)), 145.7 (NSO2ArC(1)), 169.1 





Following General Procedure C, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.), 
i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) in 
MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), ketimine 325 
(47.4 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 eq.) at rt for 72 h gave 
crude product (>95:5 dr) that was purified by column chromatography (15:85 EtOAc/petrol) 
to give the titled compound 346 as a light yellow solid (36.5 mg, 60%). mp 152-155 °C; 
[α]D
20  + 33.4 (c 0.4 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, 
flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 24.6 min, tR (minor): 12.3 min, 76:24 er; vmax 
(film, cm–1) 3028 (C-H), 1742 (C=O); 1H NMR (500 MHz, CDCl3) δH: 2.51 (3H, s, NSO2PhCH3), 
4.17 (1H, dd, J 12.7, 3.4, C(4)H), 4.69 (1H, d, J 12.7, C(3)H), 5.99 (1H, d, J 3.4, C(5)H), 6.01 (2H, 
t, J 2.1, C(3)Ar(3,4)H), 6.23 (2H, t, J 2.1, C(3)Ar(2,5)H), 6.90–6.93 (2H, m, C(4)ArC(2,6)H), 7.03–
7.07 (2H, m, C(4)ArC(3,5)H), 7.35 (2H, d, J 8.1, NSO2ArC(3,5)H), 7.40–7.46 (5H, m, C(6)ArCH), 
7.90–7.92 (2H, m, NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 21.8 (NSO2PhCH3), 44.6 
(C(4)), 67.4 (C(3)), 109.2 (C(3)ArC(3,4)H), 115.8 (d, 3JCF 21.7, C(4)ArC(2,6)H), 120.2 
(C(3)ArC(2,5)H), 121.3 (C(5)), 126.0 (C(6)ArCH), 128.6 (C(6)ArCH), 128.9 (d, 2JCF 8.2, 
C(4)ArC(3,5)H), 129.0 (C(6)ArCH), 129.3 (NSO2ArC(3,5)H), 129.5 (NSO2ArC(2,6)H), 133.6 (d, 4JCF 
3.2, C(4)ArC(1)), 135.9 (NSO2ArC(4)), 136.4 (C(6)), 140.2 (C(6)ArC(1)), 145.7 (NSO2ArC(1)), 
162.1 (d, 1JCF 246.8, C(4)ArC(4)), 169.3 (C(2)); 19F NMR (471 MHz, CDCl3) δF: -114.0 ; HRMS (NSI+) 
C28H24N2O3SF [M+H]+ found 478.1481, requires 478.1486 (-1.1 ppm). 
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Following General Procedure C, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.), 
i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) in 
MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), ketimine 326 
(48.9 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 eq.) at rt for 72 h gave 
crude product (>95:5 dr) that was purified by column chromatography (15:85 EtOAc/petrol) 
to give the titled compound 347 as a yellow oil (41.8 mg, 67%). [α]D
20  + 18.4 (c 1.2 in CHCl3); 
Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) 
tR (major): 29.3 min, tR (minor): 18.1 min, 77:23 er; vmax (film, cm–1) 2972 (C-H), 2934 (C-H), 
1732 (C=O), 1597, 1514; 1H NMR (500 MHz, CDCl3) δH: 2.50 (3H, s, NSO2PhCH3), 3.76 (3H, s, 
OCH3), 4.12 (1H, dd, J 12.6, 3.5, C(4)H), 4.69 (1H, d, J 12.6, C(3)H), 6.00–6.01 (3H, m, C(5)H + 
C(3)Ar(3,4)H), 6.24 (2H, t, J 2.2, C(3)Ar(2,5)H), 6.74–6.77 (2H, m, C(4)ArC(3,5)H), 6.98–7.00 (2H, 
m, C(4)ArC(2,6)H), 7.35 (2H, d, J 8.1, NSO2ArC(3,5)H), 7.39–7.46 (5H, m, C(6)ArCH), 7.90–7.92 
(2H, m, NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 21.8 (NSO2PhCH3), 44.4 (C(4)), 55.2 
(OCH3), 67.4 (C(3)), 108.9 (C(3)ArC(3,4)H), 114.1 (C(4)ArC(3,5)H) , 120.3 (C(3)ArC(2,5)H), 122.1 
(C(5)) , 126.0 (C(6)ArCH), 128.4 (C(4)ArC(2,6)H), 128.6 (C(6)ArCH), 128.9 (C(6)ArCH), 129.3 
(NSO2ArC(3,5)H), 129.5 (NSO2ArC(2,6)H), 129.8 (C(4)ArC(1)), 135.9 (NSO2ArC(4)), 136.5 (C(6)), 
139.8 (C(6)ArC(1)), 145.6 (NSO2ArC(1)), 159.0 (C(4)ArC(4)), 169.6 (C(2)); HRMS (NSI+) 
C29H27N2O4S [M+H]+ found 499.1681, requires 499.1686 (-1.0 ppm). 
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Following General Procedure C, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.), 
i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) in 
MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), ketimine 329 
(51.4 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 eq.) at rt for 72 h gave 
crude product (>95:5 dr) that was purified by column chromatography (15:85 EtOAc/petrol) 
to give the titled compound 348 as a yellow solid (51.2 mg, 79%). mp 190-192 °C; [α]D
20  +
61.5 (c 0.5 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 
mLmin-1, 211 nm, 30 °C) tR (major): 32.8 min, tR (minor): 17.2 min, 78:22 er; vmax (film, cm–1) 
3067 (C-H), 3036 (C-H), 2959 (C-H), 2926 (C-H), 2874 (C-H), 1730 (C=O), 1358, 1161; 1H NMR 
(500 MHz, CDCl3) δH: 2.48 (3H, s, NSO2PhCH3), 4.33 (1H, dd, J 12.5, 3.4, C(4)H), 4.85 (1H, d, J 
12.5, C(3)H), 5.92 (2H, t, J 2.1, C(3)Ar(3,4)H), 6.09 (1H, d, J 3.5, C(5)H), 6.24 (2H, t, J 2.2, 
C(3)Ar(2,5)H), 7.16 (1H, dd, J 8.5, 1.9, C(4)ArCH), 7.32–7.33 (2H, m, NSO2ArC(3,5)H), 7.40–7.47 
(7H, m, C(6)ArCH + C(4)ArCH), 7.53–7.55 (1H, m, C(4)ArCH), 7.68–7.71 (2H, m, C(4)ArCH), 
7.74–7.77 (1H, m, C(4)ArCH), 7.89–7.92 (2H, m, NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) 
δC: 21.9 (NSO2PhCH3), 45.3 (C(4)), 67.2 (C(3)), 109.2 (C(3)ArC(3,4)H), 120.4 (C(3)ArC(2,5)H), 
121.6 (C(5)), 124.9 (ArCH), 126.1 (ArCH), 126.3 (ArCH), 126.5 (ArCH), 126.8 (ArCH), 127.8 
(ArCH), 127.8 (ArCH), 128.7 (ArCH), 128.9 (ArCH), 129.1 (ArCH), 129.5 (NSO2ArC(3,5)H), 129.7 
(NSO2ArC(2,6)H), 132.8 (ArC), 133.4 (ArC), 135.4 (NSO2ArC(4)), 136.0 (C(6)ArC(1)), 136.7 
(C(4)ArC(1)), 140.2 (C(6)), 145.7 (NSO2ArC(1)), 169.6 (C(2)); HRMS (NSI-) C32H27N2O4S [M+OH]- 
found 535.1700, requires 535.1697 (+0.6 ppm). 
  
Chapter 8: Experimentals 




Following General Procedure C, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.), 
i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) in 
MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), ketimine 328 
(51.4 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 eq.) at rt for 72 h gave 
crude product (>95:5 dr) that was purified by column chromatography (15:85 EtOAc/petrol) 
to give the titled compound 349 as a yellow gum (53.8 mg, 83%). [α]D
20  + 49.7 (c 0.8 in 
CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 mLmin-1, 211 
nm, 30 °C) tR (major): 23.0 min, tR (minor): 14.8 min, 85:15 er; vmax (film, cm–1) 3066 (C-H), 3036 
(C-H), 1732 (C=O); 1H NMR (500 MHz, CDCl3) δH: 2.50 (3H, s, NSO2PhCH3), 4.97 (1H, dd, J 11.0, 
4.2, C(4)H), 5.21 (1H, d, J 11.0, C(3)H), 5.96 (2H, t, J 2.2, C(3)Ar(3,4)H), 6.04 (1H, d, J 4.2, C(5)H), 
6.36 (2H, t, J 2.2, C(3)Ar(2,5)H), 7.34–7.37 (4H, m, C(4)ArCH + NSO2ArC(3,5)H), 7.40–7.47 (5H, 
m, C(6)ArCH), 7.52–7.60 (2H, m, C(4)ArCH), 7.74–7.79 (1H, m, C(4)ArCH), 7.87–7.90 (1H, m, 
C(4)ArCH), 7.92–7.98 (3H, m, C(4)ArCH + NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 
21.8 (NSO2PhCH3), 40.6 (C(4)), 65.3 (C(3)), 109.1 (C(3)ArC(3,4)H), 120.3 (C(3)ArC(2,5)H), 121.7 
(C(5)), 122.5 (ArCH), 125.0 (ArCH), 125.3 (ArCH), 125.9 (ArCH), 126.1 (ArCH), 126.7 (ArCH), 
128.6 (ArCH), 128.7 (ArCH), 128.9 (ArCH), 129.3 (ArCH), 129.5 (NSO2ArC(3,5)H), 129.6 
(NSO2ArC(2,6)H), 130.9 (ArC), 132.8 (ArC), 134.1 (NSO2ArC(1)), 135.9 (C(6)ArC(1)), 136.4 
(C(4)ArC(1)), 139.9 (C(6)), 145.7 (NSO2ArC(4)), 169.6 (C(2)); HRMS (NSI+) C32H27N2O3S [M+H]+ 
found 519.1731, requires 519.1737 (-1.1 ppm). 
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Following General Procedure C, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.), 
i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) in 
MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), ketimine 327 
(54.7 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 eq.) at rt for 72 h gave 
crude product (>95:5 dr) that was purified by column chromatography (15:85 EtOAc/petrol) 
to give the titled compound 350 as a yellow solid (53.8 mg, 70%). mp 177-179 °C; [α]D
20  +
10.8 (c 0.2 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 
mLmin-1, 211 nm, 30 °C) tR (major): 51.4 min, tR (minor): 31.1 min, 80:20 er; vmax (film, cm–1) 
2980 (C-H), 1730 (C=O), 1508, 1358; 1H NMR (500 MHz, CDCl3) δH: 2.51 (3H, s, NSO2PhCH3), 
4.23 (1H, dd, J 12.6, 3.4, C(4)H), 4.79 (1H, d, J 12.6, C(3)H), 6.01 (2H, t, J 2.1, C(3)Ar(3,4)H), 6.05 
(1H, d, J 3.3, C(5)H), 6.29 (2H, t, J 2.1, C(3)Ar(2,5)H), 7.14–7.17 (2H, m, C(4)ArC(2,6)H), 7.33–
7.37 (3H, m, NSO2ArC(3,5)H + C(4)ArC(4)PhH), 7.40–7.49 (9H, m, C(4)ArC(4)PhH + C(6)ArH), 
7.53–7.55 (2H, m, C(4)ArC(3,5)H), 7.91–7.94 (2H, m, NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, 
CDCl3) δC: 21.8 (NSO2PhCH3), 44.8 (C(4)), 67.2 (C(3)), 109.1 (C(3)ArC(3,4)H), 120.3 
(C(3)ArC(2,5)H), 121.5 (C(5)), 126.0 (ArCH), 127.0 (C(4)ArC(3,5)H), 127.5 (ArCH), 127.5 (ArCH), 
127.8 (C(4)ArC(2,6)H), 128.6 (ArCH), 128.8 (ArCH), 129.0 (ArCH), 129.3 (NSO2ArC(3,5)H), 129.6 
(NSO2ArC(2,6)H), 135.9 (NSO2ArC(1)), 136.5 (C(6)ArC(1)), 136.9 (C(4)ArC(4)PhC(1)), 140.1 
(C(6)), 140.3 (C(4)ArC(4)), 140.6 (C(4)ArC(1)), 145.6 (NSO2ArC(4)), 169.5 (C(2)); HRMS (NSI+) 
C34H29N2O3S [M+H]+ found 545.1889, requires 545.1893 (-0.8 ppm). 
  
Chapter 8: Experimentals 




Following General Procedure C, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.), 
i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) in 
MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), ketimine 330 
(48.4 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 eq.) at rt for 72 h gave 
crude product (70:30 dr) that was purified by column chromatography (15:85 EtOAc/petrol) 
to the combined anti and syn diastereoisomers (78:22 dr) (24.7 mg, 40%) as a light yellow oil. 
vmax (film, cm–1) 1732 (C=O), 1717 (C=O); HRMS (ESI+) C30H26N2O3SNa [M+Na]+ found 517.1555, 
requires 517.1556 (-0.3 ppm). 
(3S,4R)-351: Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 mLmin-1, 
211 nm, 30 °C) tR (3S,4R): 34.6 min, tR (3R,4S): 20.8 min, 66:34 er; 1H NMR (500 MHz, CDCl3) δH: 
2.48 (3H, s, NSO2PhCH3), 3.79 (1H, dddd, J 11.6, 7.7, 3.7, 1.2, C(4)H), 4.57 (1H, d, J 11.7, C(3)H), 
5.88 (1H, dd, J 15.8, 7.8, C(4)CH), 5.96 (1H, d, J 3.7, C(5)H), 6.15 (2H, t, J 2.1, C(3)Ar(3,4)H), 6.41 
(1H, d, J 16.0, C(4)CH=CHPh), 6.46 (2H, t, J 2.2, C(3)Ar(2,5)H), 7.14–7.39 (8H, m, NSO2ArC(3,5)H 
+ ArH), 7.41–7.54 (4H, m, ArH), 7.88–7.89 (2H, m, NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, 
CDCl3) δC (selected): 21.8 (NSO2PhCH3), 41.6 (C(4)), 65.6 (C(3)), 109.3 (C(3)ArC(3,4)H), 119.9 
(C(5)), 120.3 (C(3)ArC(2,5)H), 124.6 (C(4)CH), 133.8 (C(4)CH=CHPh),169.3 (C(2)). 
(3R,4R)-351: 1H NMR (500 MHz, CDCl3) δH: 2.44 (3H, s, NSO2PhCH3), 3.62 (1H, dddd, J 8.5, 7.4, 
5.3, 1.1, C(4)H), 5.05 (1H, d, J 5.3, C(3)H), 6.04–6.09 (1H, m, C(4)CH), 6.10 (1H, d, J 7.3, C(5)H), 
6.17 (2H, t, J 2.2, C(3)Ar(3,4)H), 6.54 (1H, d, J 15.7, C(4)CH=CHPh), 6.63 (2H, t, J 2.2, 
C(3)Ar(2,5)H), 7.14–7.39 (8H, m, NSO2ArC(3,5)H + ArH), 7.41–7.54 (4H, m, ArH), 7.88 (2H, dd, 
J 7.9, 6.0, NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) δC (selected): 21.8 (NSO2PhCH3), 42.8 
(C(4)), 64.3 (C(3)), 108.8 (C(3)ArC(3,4)H), 119.4 (C(5)), 121.5 (C(3)ArC(2,5)H), 122.5 (C(4)CH), 
135.4 (C(4)CH=CHPh), 168.7 (C(2)). 
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Following General Procedure C, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.), 
i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) in 
MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), ketimine 336 
(55.1 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 eq.) at rt for 72 h gave 
crude product (>95:5 dr) that was purified by column chromatography (15:85 EtOAc/petrol) 
to give the titled compound 352 as a yellow solid (53.4 mg, 78%). mp 104-106 °C; [α]D
20  +
37.5 (c 0.4 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 
mLmin-1, 220 nm, 30 °C) tR (major): 26.6 min, tR (minor): 9.4 min, 80:20 er; vmax (film, cm–1) 
2995 (C-H), 1743 (C=O); 1H NMR (500 MHz, CDCl3) δH: 2.51 (3H, s, NSO2PhCH3), 4.22 (1H, dd, J 
12.7, 3.4, C(4)H), 4.74 (1H, d, J 12.7, C(3)H), 6.01 (2H, t, J 2.2, C(3)Ar(3,4)H), 6.05 (1H, d, J 3.4, 
C(5)H), 6.29 (2H, t, J 2.1, C(3)Ar(2,5)H), 7.06–7.10 (2H, m, C(4)ArC(2,6)H), 7.22–7.26 (3H, m, 
C(4)ArC(3,4,5)H), 7.31 (1H, t, J 7.9, C(6)ArC(4)H), 7.36–7.39 (2H, m, NSO2ArC(3,5)H), 7.40–7.42 
(1H, m, C(6)ArC(6)H), 7.45 (1H, t, J 1.8, C(6)ArC(2)H), 7.55 (1H, ddd, J 8.0, 2.0, 1.0, C(6)ArC(5)H), 
7.89–7.93 (2H, m, NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 21.8 (NSO2PhCH3), 45.1 
(C(4)), 67.2 (C(3)), 109.1 (C(3)ArC(3,4)H), 120.3 (C(3)ArC(2,5)H), 122.5 (C(4)ArC(4)H), 122.9 
(C(5)), 124.8 (C(6)ArC(6)H), 127.3  (C(4)ArC(2,6)H), 127.9 (C(4)ArC(3,5)H), 128.9 
(C(6)ArC(2)H), 129.5 (NSO2ArC(3,5)H), 129.6 (NSO2ArC(2,6)H), 130.3 (C(6)ArC(4)H), 131.9 
(C(6)ArC(5)H), 135.7 (NSO2ArC(4)), 137.6 (C(4)ArC(1)), 138.4 (C(6)), 138.6 (C(6)ArC(1,3)), 145.8 
(NSO2ArC(1)), 169.3 (C(2)); HRMS (NSI+) C28H24N2O3S79Br [M+H]+ found 547.0681, requires 
547.0686 (-0.8 ppm). 
  
Chapter 8: Experimentals 




Following General Procedure C, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.), 
i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) in 
MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), ketimine 331 
(49.5 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 eq.) at rt for 72 h gave 
crude product (>95:5 dr) that was purified by column chromatography (15:85 EtOAc/petrol) 
to give the titled compound 353 as a white solid (50.3 mg, 80%). mp 118-120 °C; [α]D
20  +
16.6 (c 1.1 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 
mLmin-1, 211 nm, 30 °C) tR (major): 31.4 min, tR (minor): 10.4 min, 77:23 er; vmax (film, cm–1) 
3025 (C-H), 1732 (C=O); 1H NMR (500 MHz, CDCl3) δH: 2.51 (3H, s, NSO2PhCH3), 4.14 (1H, dd, J 
12.7, 3.4, C(4)H), 4.74 (1H, d, J 12.7, C(3)H), 5.98 (2H, t, J 2.1, C(3)Ar(3,4)H), 6.02 (1H, d, J 3.4, 
C(5)H), 6.21 (2H, t, J 2.2, C(3)Ar(2,5)H), 7.06–7.08 (2H, m, C(4)ArC(2,6)H), 7.22–7.25 (3H, m, 
C(4)ArC(3,4,5)H), 7.36–7.40 (6H, m, NSO2ArC(3,5)H + C(6)ArC(2,3,5,6)H), 7.91–7.95 (2H, m, 
NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 21.8 (NSO2PhCH3), 45.2 (C(4)), 67.1 (C(3)), 
109.0 (C(3)ArC(3,4)H), 120.2 (C(3)ArC(2,5)H), 122.0 (C(5)), 127.2 (C(4)ArC(2,6)H), 127.3 
(C(6)ArC(2,6)H), 127.9 (C(6)ArC(3,5)H), 128.9 (C(4)ArC(4)H), 129.4 (C(4)ArC(3,5)H), 
129.5(NSO2ArC(3,5)H + NSO2ArC(2,6)H), 134.8 (C(4)ArC(1)), 135.0 (NSO2ArC(4)), 135.8 
(C(6)ArC(1)), 137.7 (C(6)) , 139.0 (C(6)ArC(4)), 145.8 (NSO2ArC(1)), 169.3 (C(2)); HRMS (NSI+) 
C28H24N2O3S35Cl [M+H]+ found 503.1186, requires 503.1191 (-0.9 ppm). 
  
Chapter 8: Experimentals 




Following General Procedure C, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.), 
i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) in 
MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), ketimine 332 
(47.4 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 eq.) at rt for 72 h gave 
crude product (>95:5 dr) that was purified by column chromatography (15:85 EtOAc/petrol) 
to give the titled compound 354 as a light yellow solid (46.2 mg, 76%). mp 106-108 °C; 
[α]D
20  + 13.9 (c 0.6 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, 
flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 26.0 min, tR (minor): 10.0 min, 78:22 er; vmax 
(film, cm–1) 3020 (C-H), 1745 (C=O); 1H NMR (500 MHz, CDCl3) δH: 2.51 (3H, s, NSO2PhCH3), 4.15 
(1H, dd, J 12.7, 3.4, C(4)H), 4.74 (1H, d, J 12.7, C(3)H), 5.98–5.99 (3H, m, C(5)H + C(3)Ar(3,4)H), 
6.22 (2H, t, J 2.1, C(3)Ar(2,5)H), 7.07–7.13 (4H, m, C(4)ArC(2,6)H + C(6)ArC(2,6)H), 7.21–7.25 
(3H, m, C(4)ArC(3,4,5)H), 7.35–7.38 (2H, m, NSO2ArC(3,5)H), 7.40–7.44 (2H, m, C(6)ArC(3,5)H), 
7.90–7.93 (2H, m, NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 21.8 (NSO2PhCH3), 45.2 
(C(4)), 67.2 (C(3)), 109.0 (C(3)ArC(3,4)H), 115.7 (d, 3JCF 21.8, C(6)ArC(2,6)H), 120.2 
(C(3)ArC(2,5)H), 121.5 (C(5)), 127.3 (C(4)ArC(2,6)H), 127.8 (d, 2JCF 8.2, C(6)ArC(3,5)H), 127.9 
(C(4)ArC(3,5)H), 128.9 (C(4)ArC(4)H), 129.4 (NSO2ArC(3,5)H), 129.4 (NSO2ArC(2,6)H), 132.6 (d, 
4JCF 3.4, C(6)ArC(1)), 135.9 (NSO2ArC(4)), 137.8 (C(4)ArC(1)), 139.1 (C(6)), 145.8 (NSO2ArC(1)), 
163.0 (d, 1JCF 248.8, C(6)ArC(4)), 169.3 (C(2)); 19F NMR (471 MHz, CDCl3) δF: -112.1; HRMS (NSI+) 
C28H24N2O3SF [M+H]+ found 478.1481, requires 478.1486 (-1.1 ppm). 
  
Chapter 8: Experimentals 




Following General Procedure C, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.), 
i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) in 
MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), ketimine 333 
(55.1 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 eq.) at rt for 72 h gave 
crude product (>95:5 dr) that was purified by column chromatography (15:85 EtOAc/petrol) 
to give the titled compound 355 as a yellow solid (65.7 mg, 96%). mp 118-120 °C; [α]D
20  +
44.7 (c 0.7 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 
mLmin-1, 220 nm, 30 °C) tR (major): 33.9 min, tR (minor): 10.5 min, 75:25 er; vmax (film, cm–1) 
3011 (C-H), 1740 (C=O); 1H NMR (500 MHz, CDCl3) δH: 2.51 (3H, s, NSO2PhCH3), 4.13 (1H, dd, J 
12.7, 3.4, C(4)H), 4.73 (1H, d, J 12.7, C(3)H), 5.98 (2H, t, J 2.1, C(3)Ar(3,4)H), 6.03 (1H, d, J 3.4, 
C(5)H), 6.21 (2H, t, J 2.1, C(3)Ar(2,5)H), 7.06–7.08 (2H, m, C(4)ArC(2,6)H), 7.22–7.25 (3H, m, 
C(4)ArC(3,4,5)H), 7.31–7.34 (2H, m, C(6)ArC(2,6)H), 7.36–7.39 (2H, m, NSO2ArC(3,5)H), 7.54–
7.57 (2H, m, C(6)ArC(3,5)H), 7.91–7.96 (2H, m, NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) 
δC: 21.8 (NSO2PhCH3), 45.2 (C(4)), 67.1 (C(3)), 109.0 (C(3)ArC(3,4)H), 120.2 (C(3)ArC(2,5)H), 
122.1 (C(5)), 127.3 (C(4)ArC(2,6)H), 127.5 (C(6)ArC(2,6)H), 127.9 (NSO2ArC(2,6)H), 128.9 
(C(4)ArC(4)H), 129.4 (C(4)ArC(3,5)H), 129.5 (NSO2ArC(3,5)H), 131.8 (C(6)ArC(3,5)H), 135.5 
(C(4)ArC(1)), 135.8 (C(6)ArC(1) + NSO2ArC(4)), 137.6 (C(6)), 139.1 (C(6)ArC(4)), 145.8 
(NSO2ArC(1)), 169.3 (C(2)); HRMS (NSI+) C28H24N2O3S79Br [M+H]+ found 547.0680, requires 
547.0686 (-1.0 ppm). 
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(3S,4S)-4-Phenyl-3-(1H-pyrrol-1-yl)-6-(p-tolyl)-1-tosyl-3,4-dihydropyridin-2(1H)-one (356) 
 
Following General Procedure C, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.), 
i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) in 
MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), ketimine 334 
(46.9 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 eq.) at rt for 72 h gave 
crude product (>95:5 dr) that was purified by column chromatography (15:85 EtOAc/petrol) 
to give the titled compound 356 as a white solid (65.7 mg, 70%). mp 136-138 °C; [α]D
20  +
18.7 (c 0.2 in CHCl3); Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 
mLmin-1, 254 nm, 30 °C) tR (major): 20.7 min, tR (minor): 8.9 min, 75:25 er; vmax (film, cm–1) 2988 
(C-H), 1738 (C=O); 1H NMR (500 MHz, CDCl3) δH: 2.43 (3H, s, C(6)ArC(4)CH3), 2.51 (3H, s, 
NSO2PhCH3), 4.14 (1H, dd, J 12.7, 3.4, C(4)H), 4.73 (1H, d, J 12.7, C(3)H), 5.97 (2H, t, J 2.1, 
C(3)Ar(3,4)H), 5.99 (1H, d, J 3.4, C(5)H), 6.21 (2H, t, J 2.1, C(3)Ar(2,5)H), 7.05–7.10 (2H, m, 
C(4)ArC(2,6)H), 7.21–7.24 (5H, m, C(4)ArC(3,4,5)H + C(6)ArC(3,5)H), 7.34–7.38 (4H, m, 
C(6)ArC(2,4)H + NSO2ArC(3,5)H), 7.93–7.96 (2H, m, NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, 
CDCl3) δC: 21.4 (C(6)ArC(4)CH3), 21.8 (NSO2PhCH3), 45.2 (C(4)) , 67.3 (C(3)), 108.9 
(C(3)ArC(3,4)H), 120.2 (C(3)ArC(2,5)H), 120.8 (C(5)), 125.8 (C(4)ArC(2,6)H), 127.3 
(C(6)ArC(2,6)H), 127.8 (NSO2ArC(2,6)H), 128.8 (C(4)ArC(4)H), 129.3 (C(4)ArC(3,5)H), 129.6 
(NSO2ArC(3,5)H + C(6)ArC(3,5)H), 133.7 (C(4)ArC(1)), 136.0 (C(6)ArC(4)), 138.0 (C(6)), 139.0 
(C(6)ArC(1)), 140.0 (NSO2ArC(4)), 145.5 (NSO2ArC(1)), 169.5 (C(2)); HRMS (NSI+) C29H27N2O3S 
[M+H]+ found 483.1732, requires 483.1737 (-1.0 ppm). 
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Following General Procedure C, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.), 
i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) in 
MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), ketimine 335 
(48.9 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 eq.) at rt for 72 h gave 
crude product (>95:5 dr) that was purified by column chromatography (15:85 EtOAc/petrol) 
to give the titled compound 357 as a yellow oil (37.4 mg, 60%); [α]D
20  + 8.0 (c 0.2 in CHCl3); 
Chiral HPLC analysis, Chiralpak OD-H (80:20 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) 
tR (major): 35.2 min, tR (minor): 13.8 min, 72:28 er; vmax (film, cm–1) 2965 (C-H), 2925 (C-H), 
1734 (C=O); 1H NMR (500 MHz, CDCl3) δH: 2.50 (3H, s, NSO2PhCH3), 3.88 (3H, s, 
C(6)ArC(4)OCH3), 4.13 (1H, dd, J 12.7, 3.5, C(4)H), 4.73 (1H, d, J 12.7, C(3)H), 5.94 (1H, d, J 3.4, 
C(5)H), 5.97 (2H, t, J 2.1, C(3)Ar(3,4)H), 6.20 (2H, t, J 2.2, C(3)Ar(2,5)H), 6.92–6.96 (2H, m, 
C(6)ArC(3,5)H), 7.07–7.09 (2H, m, C(4)ArC(2,6)H), 7.20–7.24 (3H, m, C(4)ArC(3,4,5)H), 7.32–
7.42 (4H, m, C(6)ArC(2.6)H + NSO2ArC(3,5)H), 7.92–7.94 (2H, m, NSO2ArC(2,6)H); 13C{1H} NMR 
(126 MHz, CDCl3) δC: 21.8 (NSO2PhCH3), 45.2 (C(4)), 55.4 (C(6)ArC(4)OCH3), 67.4 (C(3)), 108.9 
(C(3)ArC(3,4)H), 114.0 (C(6)ArC(3,5)H), 120.1 (C(3)ArC(2,5)H), 120.2 (C(5)), 127.3 
(C(4)ArC(2,6)H), 127.4 (C(6)ArC(2,6)H), 127.8 (NSO2ArC(2,6)H), 128.8 (C(4)ArC(4)H), 129.0 
(C(4)ArC(3)H), 129.3 (NSO2ArC(3,5)H), 129.5 (C(4)ArC(5)H), 136.1 (C(4)ArC(1) + C(6)ArC(1)), 
138.0(C(6)), 139.7 (NSO2ArC(4)), 145.6 (NSO2ArC(1)), 160.1 (C(6)ArC(4)), 169.6 (C(2)); HRMS 
(NSI+) C29H27N2O4S [M+H]+ found 499.1681, requires 499.1686 (-1.0 ppm). 
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General Procedure D: Michael addition-lactamization with saccharin derived α,β-
unsaturated ketimines and 2-(1H-Pyrrol-1-yl)acetic acid 155 
 
2-(1H-Pyrrol-1-yl)acetic acid 155 (2 eq.) was dissolved in anhydrous MeCN (0.05 M) under an 
atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (2 eq.) and pivaloyl chloride (2 eq.) were 
added. The reaction was stirred at 0 °C for 20 min before cooling to –20 °C. HyperBTM 93 (10 
mol%), the required saccharin-derived ketimine (1 eq.), and i-Pr2NEt (2.5 eq.) were added 
sequentially and the reaction stirred at – 20 ° C for 48 h. After that, the solvent was 
concentrated under reduced pressure to give the crude product, which was purified by flash 
silica column chromatography 
 
(8S,9S)-9-Phenyl-8-(1H-pyrrol-1-yl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-
one 5,5-dioxide (358) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 
eq.), i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) 
in MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), saccharin-
derived ketimine 339 (33.7 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 
eq.) at rt for 72 h gave crude product (>95:5 dr) that was purified by column chromatography 
(30:70 to 50:50 EtOAc/petrol) to give the titled compound as a white solid (32.9 mg, 70%). mp 
250–252 °C; [α]D
20  − 95.0  (c 0.2 in DMSO); Chiral HPLC analysis, Chiralpak AD-H (70:30 
hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 21.0 min, tR (minor): 17.5 min, 
99:1 er; vmax (film, cm–1) 3063 (C-H), 3030 (C-H), 1736 (C=O), 1462, 1314; 1H NMR (500 MHz, 
CDCl3) δH: 4.37 (1H, dd, J 11.6, 3.0, C(9)H), 4.93 (1H, d, J 11.5, C(8)H), 6.09–6.14 (3H, m, C(10)H 
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+ C(8)Ar(3,4)H), 6.52 (2H, t, J 2.2, C(8)Ar(2,5)H), 7.05–7.08 (2H, m, C(9)ArC(2,6)H), 7.28–7.31 
(3H, m, C(9)ArC(3,4,5)H), 7.70 (1H, dq, J 8.2, 4.3, ArCH), 7.78 (2H, d, J 4.1, ArCH), 7.90 (1H, d, J 
7.9, ArCH); 13C{1H} NMR (126 MHz, CDCl3) δC: 47.3 (C(9)), 65.7 (C(8)), 105.1 (C(10)), 109.5 
(C(8)ArC(3,4)H), 120.5 (C(8)ArC(2,5)H), 121.9 (ArCH), 122.0 (ArCH), 126.2 (ArC(10b)), 127.5 
(C(9)ArC(2,6)H), 128.4 (C(9)ArC(4)H), 129.3 (C(9)ArC(3,5)H), 129.9 (ArC(10a)), 131.5 (ArCH), 
132.9 (C(4a)), 134.5 (ArCH), 138.9 (C(9)ArC(1)), 163.0 (C(7)); HRMS (ESI+) C21H16N2O3SNa 
[M+Na]+ found 399.0773, requires 399.0774 (-0.2 ppm). 
 
(8S,9S)-9-(4-Bromophenyl)-8-(1H-pyrrol-1-yl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-
a]pyridin-7-one 5,5-dioxide (361) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 
eq.), i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) 
in MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), saccharin-
derived ketimine 340 (43.5 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 
eq.) at rt for 72 h gave crude product (>95:5 dr) that was purified by column chromatography 
(30:70 to 50:50 EtOAc/petrol) to give the titled compound as a light yellow solid (37.6 mg, 
66%). mp 258–260 °C; [α]D
20  − 82.6 (c 0.5 in DMSO); Chiral HPLC analysis, Chiralpak AS-H 
(70:30 hexane/i-PrOH, flow rate 0.7 mLmin-1, 211 nm, 40 °C) tR (major): 60.6 min, tR (minor): 
40.9 min, 98:2 er; vmax (film, cm–1) 3084 (C-H), 1719 (C=O), 1489, 1342; 1H NMR (500 MHz, 
CDCl3) δH: 4.35 (1H, dd, J 12.0, 2.8, C(9)H), 4.86 (1H, d, J 12.0, C(8)H), 6.04 (1H, d, J 2.8, C(10)H), 
6.13 (2H, t, J 2.1, C(8)Ar(3,4)H), 6.50 (2H, t, J 2.1, C(8)Ar(2,5)H), 6.91–6.94 (2H, m, 
C(9)ArC(2,6)H), 7.40–7.43 (2H, m, C(9)ArC(3,5)H), 7.68–7.74 (1H, m, ArCH), 7.77–7.81 (2H, m, 
ArCH), 7.90–7.92 (1H, m, ArCH); 13C{1H} NMR (126 MHz, CDCl3) δC: 46.8 (C(9)), 65.5 (C(8)), 
104.2 (C(10)), 109.8 (C(8)ArC(3,4)H), 120.5 (C(8)ArC(2,5)H), 121.9 (ArCH), 122.1 (ArCH), 122.4 
(C(9)ArC(4)), 126.0 (ArC(10b)), 129.2 (C(9)ArC(2,6)H), 130.3 (ArC(10a)), 131.7 (ArCH), 132.4 
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(C(9)ArC(3,5)H), 133.0 (C(4a)), 134.5 (ArCH), 137.9 (C(9)ArC(1)), 162.8 (C(7)); HRMS (ESI+) 
C21H15N2O3S79BrNa [M+Na]+ found 476.9882, requires 476.9879 (+0.6 ppm). 
 
(8S,9S)-9-(4-Methoxyphenyl)-8-(1H-pyrrol-1-yl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-
a]pyridin-7-one 5,5-dioxide (362) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 
eq.), i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) 
in MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), saccharin-
derived ketimine 341 (37.4 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 
eq.) at rt for 72 h gave crude product (>95:5 dr) that was purified by column chromatography 
(30:70 to 50:50 EtOAc/petrol) to give the titled compound as a light yellow solid (45.7 mg, 
90%). mp 208–210 °C; [α]D
20  − 58.5 (c 1.2 in DMSO); Chiral HPLC analysis, Chiralpak AD-H 
(60:40 hexane/i-PrOH, flow rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 20.5 min, tR (minor): 15.5 
min, 97:3 er; vmax (film, cm–1) 3052 (C-H), 1732 (C=O), 1611, 1514; 1H NMR (500 MHz, CDCl3) 
δH: 3.78 (3H, s, CH3), 4.32 (1H, dd, J 11.5, 3.0, C(9)H), 4.87 (1H, d, J 11.5, C(8)H), 6.09 (1H, d, J 
3.0, C(10)H), 6.12 (2H, t, J 2.1, C(8)Ar(3,4)H), 6.52 (2H, t, J 2.1, C(8)Ar(2,5)H), 6.79–6.83 (2H, m, 
C(9)ArC(3,5)H), 6.95–6.98 (2H, m, C(9)ArC(2,6)H), 7.70 (1H, dq, J 8.2, 4.2, ArCH), 7.77–7.78 (2H, 
m, ArCH), 7.89–7.91 (1H, m, ArCH); 13C{1H} NMR (126 MHz, CDCl3) δC: 46.5 (C(9)), 55.4 (CH3), 
65.9 (C(8)), 105.5 (C(10)), 109.5 (C(8)ArC(3,4)H), 114.6 (C(9)ArC(3,5)H), 120.5 (C(8)ArC(2,5)H), 
121.8 (ArCH), 122.0 (ArCH), 126.2 (ArC(10b)), 128.6 (C(9)ArC(2,6)H), 129.7 (ArC(10a)), 130.8 
(C(9)ArC(1)), 131.5 (ArCH), 132.9 (C(4a)), 134.5 (ArCH), 159.5 (C(9)ArC(4)), 163.1 (C(7)); HRMS 
(ESI+) C22H18N2O4SNa [M+Na]+ found 429.0881, requires 429.0879 (+0.4 ppm). 
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(8S,9S)-9-(Naphthalen-1-yl)-8-(1H-pyrrol-1-yl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-
a]pyridin-7-one 5,5-dioxide (363) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 
eq.), i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) 
in MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), saccharin-
derived ketimine 343 (79.8 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 
eq.) at rt for 72 h gave crude product (>95:5 dr) that was purified by column chromatography 
(30:70 to 50:50 EtOAc/petrol) to give the titled compound as a white solid (51.7 mg, 97%). mp 
226–228 °C; [α]D
20  − 57.8  (c 1.0 in DMSO); Chiral HPLC analysis, Chiralpak AD-H (60:40 
hexane/i-PrOH, flow rate 1 mLmin-1, 254 nm, 30 °C) tR (major): 13.6 min, tR (minor): 16.6 min, 
98:2 er; vmax (film, cm–1) 3057 (C-H), 1736 (C=O), 1491, 1470, 1329; 1H NMR (500 MHz, CDCl3) 
δH: 5.09 (1H, app. s, C(9)H), 5.30 (1H, app. s, C(8)H), 6.06 (2H, t, J 2.1, C(8)Ar(3,4)H), 6.24 (1H, 
d, J 3.8, C(10)H), 6.58 (2H, app. s, C(8)Ar(2,5)H), 7.27–7.43 (2H, m, ArCH), 7.54 (2H, dt, J 6.4, 
3.5, ArCH), 7.68–8.00 (7H, m, ArCH); 13C{1H} NMR (126 MHz, CDCl3) δC (selected): 63.8 (C(8)), 
105.2 (C(10)), 109.6 (C(8)ArC(3,4)H), 120.1 (C(8)ArC(2,5)H), 121.9 (ArCH), 122.0 (ArCH), 122.3 
(ArCH), 125.5 (ArCH), 126.1 (ArCH), 126.9 (ArC(10b)), 129.2 (ArCH), 129.6 (ArCH), 130.6 
(ArC(10a)), 131.5 (ArCH), 132.7 (C(4a)), 133.3 (C(9)ArC), 134.3 (ArCH), 134.4 (C(9)ArC), 162.7 
(C(7)); HRMS (ESI+) C25H18N2O3SNa [M+Na]+ found 449.0938, requires 449.0930 (+1.7 ppm). 
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(8S,9R)-9-(Furan-2-yl)-8-(1H-pyrrol-1-yl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-
a]pyridin-7-one 5,5-dioxide (364) 
 
Following General Procedure D, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 
eq.), i-Pr2NEt (0.044 mL, 0.25 mmol, 2.0 eq.), pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) 
in MeCN (2.5 mL) at 0 °C for 20 min followed by HyperBTM 93 (3.9 mg, 10 mol%), saccharin-
derived ketimine 342 (32.4 mg, 0.125 mmol, 1.0 eq.) and i-Pr2NEt (0.055 mL, 0.32 mmol, 2.5 
eq.) at rt for 72 h gave crude product (>95:5 dr) that was purified by column chromatography 
(30:70 to 50:50 EtOAc/petrol) to give the titled compound as a dark brown solid (23.8 mg, 
52%). mp 222–224 °C; [α]D
20  − 64.9 (c 0.8 in DMSO); Chiral HPLC analysis, Chiralpak AD-H 
(60:40 hexane/i-PrOH, flow rate 1 mLmin-1, 254 nm, 30 °C) tR (major): 15.9 min, tR (minor): 12.5 
min, 96:4 er; vmax (film, cm–1) 2972 (C-H), 1732 (C=O), 1493, 1470, 1339; 1H NMR (500 MHz, 
CDCl3) δH: 4.51 (1H, dd, J 10.6, 3.4, C(9)H), 5.15 (1H, d, J 10.5, C(8)H), 5.99 (1H, d, J 3.3, 
C(9)ArC(3)H), 6.13 (1H, d, J 3.4, C(10)H), 6.17 (2H, t, J 2.1, C(8)Ar(3,4)H), 6.28 (1H, dd, J 3.3, 
1.9, C(9)ArC(4)H), 6.62 (2H, t, J 2.1, C(8)Ar(2,5)H), 7.38 (1H, d, J 1.7, C(9)ArC(5)H), 7.68–7.73 
(1H, m, ArCH), 7.76–7.80 (2H, m, ArCH), 7.88–7.91 (1H, m, ArCH); 13C{1H} NMR (126 MHz, CDCl3) 
δC: 40.7 (C(9)), 62.5 (C(8)), 102.3 (C(10)), 108.4 (C(9)ArC(3)H), 109.7 (C(8)ArC(3,4)H), 111.0 
(C(9)ArC(4)H), 120.4 (C(8)ArC(2,5)H), 122.0 (ArCH), 122.0 (ArCH), 126.1 (ArC(10b)), 129.9 
(ArC(10a)), 131.7 (ArCH), 133.0 (C(4a)), 134.5 (ArCH), 143.0 (C(9)ArC(5)H), 149.9 (C(9)ArC(1)), 
162.8 (C(7)); HRMS (ESI+) C19H14N2O4SNa [M+Na]+ found 389.0568, requires 389.0566 (+0.4 
ppm). 
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(8S,9S)-8-(1H-Indol-1-yl)-9-phenyl-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-
one 5,5-dioxide (365) (by Lucas) 
 
2-(1H-Indol-1-yl)acetic acid 223 (46.0 mg, 0.25 mmol, 1.5 eq.) was dissolved in anhydrous 
MeCN (2.5 mL, 0.07 M) under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (58 μL, 
0.34 mmol, 2 eq.) and pivaloyl chloride (42 μL, 0.34 mmol, 2 eq.) were added. The reaction 
was stirred at 0 °C for 20 min before cooled to –40 °C. HyperBTM 93 (10.0 mg, 0.03 mmol, 
20 mol%), saccharin-derived ketimine 339 (45.8 mg, 0.17 mmol, 1 eq.), and i-Pr2NEt (73 μL, 
0.43 mmol, 2.5 eq.) were added sequentially and the reaction stirred at –40 °C for 2 h. The 
reaction mixture was quenched with aq. HCl (10 mL, 0.1 M) and extracted with CH2Cl2 (3 x 10 
mL). The combined organics were dried over MgSO4, filtered and concentrated under reduced 
pressure to give the crude product (>95:5 dr) that was purified by column chromatography 
(30:70 EtOAc/petrol) to give the titled compound as a white solid (55.9 mg, 77%). mp 248 °C; 
[α]D
20 + 3.4 (c 1.4 in CHCl3); Chiral HPLC analysis, Chiralpak AD-H (60:40 hexane/i-PrOH, flow 
rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 11.2 min, tR (minor): 12.8 min, 98:2 er; vmax (film, cm–
1) 2922 (C-H), 1722 (C=O); 1H NMR (500 MHz, DMSO) δH: 5.05 (1H, dd, J 13.4, 2.3, C(9)H), 6.34 
(1H, d, J 13.5, C(8)H), 6.45 (1H, d, J 3.2, C(8)indolylC(3)H), 6.61 (1H, d, J 3.2, C(10)H), 6.92 (1H, 
m, C(8)indolylC(5)H), 6.97 (1H, m, C(8)indolylC(6)H), 7.04 (1H, m, C(9)Ar(4)H), 7.16 (2H, m, 
C(9)Ar(3,5)H), 7.26 (2H, m, C(9)Ar(2,6)H), 7.39 (1H, m, C(8)indolylC(7)H), 7.42 (1H, m, 
C(8)indolylC(4)H), 7.63 (1H, d, J 3.2, C(8)indolylC(2)H), 7.80 (1H, m, C(3)H), 7.92 (1H, m, C(2)H), 
8.18 (1H, m, C(4)H), 8.30 (1H, m, C(1)H); 13C{1H} NMR (126 MHz, DMSO) δC: 44.3 (C(9)H), 60.1 
(C(8)H), 102.5 (C(8)indolylC(3)H), 108.4 (C(10)), 109.7 (C(8)indolylC(7)H), 119.2 
(C(8)indolylC(5)H), 120.2 (C(8)indolylC(4)H), 112.1 (C(8)indolylC(6)H), 121.7 (C(4)H), 122.8 
(C(1)H), 126.1 (C(10b)), 126.9 (C(8)indolylC(2)H), 127.4 (C(9)ArC(4)H), 127.6 (C(8)indolylC(3a)), 
127.9 (C(10a)), 128.0 (C(9)ArC(2,6)H), 128.5 ((C(9)ArC(3,5)H), 131.6 (C(3)H), 131.9 (C(4a)), 
135.0 (C(2)H), 137.2 (C(8)indolylC(7a)), 139.8 (C(9)ArC(1)), 164.6 (C(7)); HRMS (ESI+) 
C25H18N2NaO3S [M+Na]+ found 449.0925, requires 449.0936 (-2.4 ppm). 
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(8S,9S)-9-(4-Bromophenyl)-8-(1H-indol-1-yl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-
a]pyridin-7-one 5,5-dioxide (366) (by Lucas) 
 
2-(1H-Indol-1-yl)acetic acid 223 (48.0 mg, 0.22 mmol, 1.5 eq.) was dissolved in anhydrous 
MeCN (2.2 mL, 0.07 M) under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (49 μL, 
0.29 mmol, 2 eq.) and pivaloyl chloride (35 μL, 0.29 mmol, 2 eq.) were added. The reaction 
was stirred at 0 °C for 20 min before cooled to –40 °C. HyperBTM 93 (10.0 mg, 0.03 mmol, 
20 mol%), saccharin-derived ketimine 340 (50 mg, 0.14 mmol, 1 eq.), and i-Pr2NEt (61 μL, 0.36 
mmol, 2.5 eq.) were added sequentially and the reaction stirred at –40 °C for 48 h. The 
reaction mixture was quenched with aq. HCl (10 mL, 0.1 M) and extracted with CH2Cl2 (3 x 10 
mL). The combined organics were dried over MgSO4, filtered and concentrated under reduced 
pressure to give the crude product (>95:5 dr) that was purified by column chromatography 
(30:70 EtOAc/petrol) to give the titled compound as a yellow solid (19.2 mg, 26%). mp 230 °C; 
[α]D
20 + 6.5 (c 1.4 in CHCl3); Chiral HPLC analysis, Chiralpak IB (80:20 hexane/i-PrOH, flow rate 
1 mLmin-1, 211 nm, 30 °C) tR (major): 59.4 min, tR (minor): 72.1 min, 97:3 er; vmax (film, cm–1) 
2924 (C-H), 1718 (C=O); 1H NMR (500 MHz, DMSO) δH: 5.08 (1H, dd, J 13.4, 2.2, C(9)H), 6.35 
(1H, d, J 13.4, C(8)H), 6.48 (1H, d, J 3.2, C(8)indolylC(3)H), 6.50 (1H, d, J 3.2, C(10)H), 6.92–6.98 
(1H, m, C(8)indolylC(5)H), 6.98–7.03 (1H, m, C(8)indolylC(6)H), 7.20–7.24 (2H, m, C(9)Ar(2,6)H), 
7.36–7.39 (2H, m, C(9)Ar(3,5)H), 7.38–7.42 (1H, m, C(8)indolylC(4)H), 7.44–7.47 (1H, m, 
C(8)indolylC(7)H), 7.64 (1H, d, J 3.2, C(8)indolylC(2)H), 7.81 (1H, t, J 7.7, ArC(3)H), 7.91–7.96 
(1H, m, ArC(2)H), 8.20 (1H, d, J 7.9, ArC(4)H), 8.29 (1H, d, J 7.9 ArC(1)H); 13C{1H} NMR (126 MHz, 
DMSO) δC: 43.8 (C(9)H), 59.8 (C(8)H), 102.7 (C(8)indolylC(3)H), 107.7 (C(10)H), 109.6 
(C(8)indolylC(7)H), 119.3 (C(8)indolylC(5)H), 120.3 (C(8)indolylC(4)H), 120.6 (C(9)ArC(4)), 
121.2 (C(8)indolylC(6)H), 121.7 (ArC(4)H), 122.8 (ArC(1)H), 126.0 (C(10b)), 126.9 
(C(8)indolylC(2)H), 127.6 (C(8)indolylC(3a)H), 128.2 (C(10a)), 130.3 (C(9)ArC(2,6)), 131.4 
(C(9)ArC(3,5)), 131.7 (ArC(3)H), 131.9 (ArC(4a)H), 135.0 (ArC(2)H), 137.2 (C(8)indolylC(7a)), 
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139.7 (C(9)ArC(1)), 164.4 (C(7)); HRMS (ESI+) C25H17N2NaO3S79Br [M+Na]+, found 527.0026, 
requires 527.0041 (-2.8 ppm). 
 
(8S,9S)-8-(1H-Indol-1-yl)-9-(4-methoxyphenyl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-
a]pyridin-7-one 5,5-dioxide (367) (by Lucas) 
 
2-(1H-Indol-1-yl)acetic acid 223 (46.0 mg, 0.25 mmol, 1.5 eq.) was dissolved in anhydrous 
MeCN (2.5 mL, 0.07 M) under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (58 μL, 
0.34 mmol, 2 eq.) and pivaloyl chloride (42 μL, 0.34 mmol, 2 eq.) were added. The reaction 
was stirred at 0 °C for 20 min before cooled to –40 °C. HyperBTM 93 (10 mg, 0.03 mmol, 20 
mol%), saccharin-derived ketimine 341 (50.0 mg, 0.17 mmol, 1 eq.), and i-Pr2NEt (73 μL, 0.43 
mmol, 2.5 eq.) were added sequentially and the reaction stirred at –40 °C for 48 h. The 
reaction mixture was quenched with aq. HCl (10 mL, 0.1 M) and extracted with CH2Cl2 (3 x 10 
mL). The combined organics were dried over MgSO4, filtered and concentrated under reduced 
pressure to give the crude product (>95:5 dr) that was purified by column chromatography 
(30:70 EtOAc/petrol) to give the titled compound as a yellow solid (47.2 mg, 62%). mp 210 °C; 
[α]D
20 + 6.2 (c 1.4 in CHCl3); Chiral HPLC analysis, Chiralpak AD-H (60:40 hexane/i-PrOH, flow 
rate 1 mLmin-1, 254 nm, 30 °C) tR (major): 14.9 min, tR (minor): 17.7 min, 95:5 er; vmax (film, cm–
1) 2926 (C-H), 1722 (C=O); 1H NMR (500 MHz, DMSO) δH: 3.61 (3H, s, OCH3), 5.00 (1H, dd, J  
13.4, 2.1, C(9)H), 6.29 (1H, d, J 13.5, C(8)H), 6.45 (1H, d, J 3.2, C(8)indolylC(3)H), 6.56 (1H, d, J 
2.3, C(10)H), 6.71–6.75 (2H, m, C(9)Ar(3,5)H), 6.92–6.97 (1H, m, C(8)indolylC(5)H), 7.00 (1H, t, 
J 7.5, C(8)indolylC(6)H), 7.19 (2H, d, J 8.7, C(9)Ar(2,6)H), 7.41 (1H, d, J 8.4, C(8)indolylC(7)H), 
7.44 (1H, d, J 7.8, C(8)indolylC(4)H), 7.62 (1H, d, J 3.2, C(8)indolylC(2)H), 7.79 (1H, t, J 7.7, 
ArC(3)H), 7.98–7.95 (1H, m, ArC(2)H), 8.18 (1H, d, J 7.9, ArC(4)H), 8.28 (1H, d, J 8.0, ArC(1)H); 
13C{1H} NMR (126 MHz, DMSO) δC: 43.5 (C(9)), 54.9 (OCH3), 60.2 (C(8)H), 102.4 
(C(8)indolylC(3)H), 108.9 (C(10)), 109.7 (C(8)indolylC(7)H), 113.9 (C(9)ArC(3,5)H), 119.2 
(C(8)indolylC(5)H), 120.2 (C(8)indolylC(4)H), 121.1 (C(8)indolylC(6)H), 121.7 (ArC(4)H), 122.8 
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(ArC(1)H), 126.1 (ArC(10b)), 126.9 (C(8)indolylC(2)H), 127.6 (C(8)indolylC(3a)), 127.7 (C(10a)), 
129.1 (C(9)ArC(2,6)H), 131.5 (ArC(3)H), 131.6 (C(8)indolylC(7a)), 131.9 (C(9)ArC(1)), 135.0 
(ArC(2)H), 137.2 (ArC(4a)), 158.4 (C(9)ArC(4)), 164.6 (C(7)); HRMS (ESI+) C26H20N2NaO4S 
[M+Na]+, found 479.1024, requires 479.1041 (-3.5 ppm). 
 
(8S,9R)-9-(Furan-2-yl)-8-(1H-indol-1-yl)-8,9-dihydro-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-
7-one 5,5-dioxide (368) (by Lucas) 
 
2-(1H-Indol-1-yl)acetic acid 223 (50.0 mg, 0.29 mmol, 1.5 eq.) was dissolved in anhydrous 
MeCN (2.9 mL, 0.07 M) under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (65 μL, 
0.39 mmol, 2 eq.) and pivaloyl chloride (47 μL, 0.39 mmol, 2 eq.) were added. The reaction 
was stirred at 0 °C for 20 min before cooled to –40 °C. HyperBTM 93 (11.9 mg, 0.04 mmol, 
20 mol%), saccharin-derived ketimine 342 (50.0 mg, 0.19 mmol, 1 eq.), and i-Pr2NEt (81 μL, 
0.48 mmol, 2.5 eq.) were added sequentially and the reaction stirred at –40 °C for 2 h. The 
reaction mixture was quenched with aq. HCl (10 mL, 0.1 M) and extracted with CH2Cl2 (3 x 10 
mL). The combined organics were dried over MgSO4, filtered and concentrated under reduced 
pressure to give the crude product (>95:5 dr) that was purified by column chromatography 
(30:70 EtOAc/petrol) to give the titled compound as a brown solid (60.1 mg, 76%). mp 220 °C; 
[α]D
20 + 6.2 (c 1.4 in CHCl3); Chiral HPLC analysis, Chiralpak AD-H (60:40 hexane/i-PrOH, flow 
rate 1 mLmin-1, 211 nm, 30 °C) tR (major): 13.5 min, tR (minor): 14.8 min, >99:1 er; vmax (film, 
cm–1) 3078 (C-H), 1736 (C=O); 1H NMR (500 MHz, DMSO) δH: 5.23 (1H, dd, J 13.4, 2.4, C(9)H), 
6.02–6.04 (1H, m, C(9)furanC(3)H), 6.18 (1H, dd, J 3.2, 1.9 (C(9)furanC(4)H), 6.32 (1H, d, J 13.4 
C(8)H), 6.49 (1H, d, J 3.3, C(8)indolylC(3)H), 6.65 (1H, d, J 2.5, C(10)H), 6.96–7.01 (1H, m, 
C(8)indolylC(5)H), 7.03–7.08 (1H, m, C(8)indolylC(6)H), 7.45 (1H, dd, J 3.3, 1.7, C(9)furanC(5)H), 
7.47–7.50 (1H, m, C(8)indolylC(7)H), 7.48–7.50 (1H, m, C(8)indolylC(4)H), 7.61 (1H, d, J 3.3, 
C(8)indolylC(2)H), 7.78–7.84 (1H, m, ArC(3)H), 7.91–7.96 (1H, m, ArC(2)H), 8.17–8.20 (1H, m, 
ArC(4)H), 8.30–8.35 (1H, m, ArC(1)H); 13C{1H} NMR (126 MHz, DMSO) δC: 35.4 (C(9)H), 58.1 
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(C(8)H), 102.6 (C(8)indolylC(3)H), 105.6 (C(10)H), 107.3 (C(9)furanC(3)H), 109.7 
(C(8)indolylC(7)H), 110.5 (C(9)furanC(4)H), 119.3 (C(8)indolylC(5)H), 120.31 (C(8)indolylC(4)H), 
121.7 (C(8)indolylC(6)H), 122.9 (ArC(4)H), 126.0 (ArC(1)H), 127.0 (C(8)indolylC(2)H), 127.7 
(C(8)indolylC(3a)), 128.2 (C(10a)), 131.7 (ArC(3)H),  131.9 (C(4a)), 135.0 (ArC(2)H), 137.1 
(C(8)indolylC(7a)), 142.6 (C(9)furanC(5)H), 151.6 (C(9)furanC(2)), 164.2 (ArC(7)); HRMS (ESI+) 
C23H16N2NaO3S [M+Na]+, found 439.0713, requires 439.0728 (-3.4 ppm). 
 
9-Phenyl-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-one 5,5-dioxide (360) 
 
2-(1H-Pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.) was dissolved in anhydrous 
MeCN (2.5 mL, 0.1 M) under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (0.044 
mL, 0.25 mmol, 2.0 eq.) and pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) were added. The 
reaction was stirred at 0 °C for 20 min before warmed up to rt. HyperBTM 93 (3.9 mg, 10 mol%), 
saccharin-derived ketimine 339 (33.7 mg, 0.125 mmol, 1.0 eq.), and i-Pr2NEt (0.044 mL, 0.25 
mmol, 2.0 eq.) were added sequentially and the reaction stirred at rt. for 24 h. The reaction 
mixture was concentrated under reduced pressure to give the crude product that was purified 
by column chromatography (50:50 EtOAc/petrol) to give the titled compound as a yellow solid 
(25.1 mg, 65%). Spectroscopic data were in accordance with the literature.18 mp >300 °C 
{Lit.18 >300 °C}; 1H NMR (500 MHz, DMSO) δH: 6.94 (1H, d, J 1.4, C(8)H), 7.54–7.61 (3H, m, 
C(9)PhC(2,6)H+C(9)PhC(4)H), 7.77 (1H, d, J 1.5, C(10)H), 7.85–7.90 (1H, m, ArC(3)H), 7.91–7.94 
(2H, m, C(9)PhC(3,5)H), 7.99–8.03 (1H, m, ArC(2)H), 8.29 (1H, d, J 7.8, ArC(1)H), 8.50 (1H, d, J 
7.9, ArC(4)H). 
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9-(Furan-2-yl)-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-one 5,5-dioxide (372) 
 
2-(1H-Indol-1-yl)acetic acid 223 (50.0 mg, 0.29 mmol, 1.5 eq.) was dissolved in anhydrous 
MeCN (2.9 mL, 0.07 M) under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (65 μL, 
0.39 mmol, 2 eq.) and pivaloyl chloride (47 μL, 0.39 mmol, 2 eq.) were added. The reaction 
was stirred at 0 °C for 20 min before warmed to rt. rac. HyperBTM 93 (11.9 mg, 0.04 mmol, 20 
mol%), saccharin-derived ketimine 342 (50.0 mg, 0.19 mmol, 1 eq.), and i-Pr2NEt (81 μL, 0.48 
mmol, 2.5 eq.) were added sequentially and the reaction stirred at rt. for 24 h. The reaction 
mixture was concentrated under reduced pressure to give the crude product that was purified 
by recrystallization in EtOAc to give the titled compound as a brown solid (10 mg, 17%). mp 
284 °C; vmax (film, cm–1) 1661 (C=O), 1624 (C=C), 1578 (S=O); 1H NMR (500 MHz, DMSO) δH: 
6.73 (1H, s, C(8)H), 6.79–6.82 (1H, m, C(9)furanC(5)H), 7.53 (1H, d, J 3.4, C(9)furanC(4)H), 7.73 
(1H, s, C(10)H), 7.87 (1H, t, J 7.6, ArC(3)H), 7.98–7.03 (1H, m, ArC(2)H), 8.02–8.05 (1H, m, 
C(9)furanC(5)H), 8.27 (1H, d, J 7.8, ArC(1)H), 8.41 (1H, d, J 7.8, ArC(4)H); 13C{1H} NMR (126 MHz, 
DMSO) δC: 98.9 (C(10)H), 112.3 (C(8)H), 113.3 (C(9)furanC(3)H), 114.5 (C(9)furanC(4)H), 122.3 
(ArC(1)H), 123.7 (ArC(4)H), 124.9 (ArC(10b)H), 131.7 (ArC(4a)H), 133.1 (ArC(3)H), 135.5 
(ArC(2)H), 135.9 (C(10a)), 141.7 (C(9)furanC(2)H), 147.0 (C(9)furanC(5)H), 149.1 (C(9)), 158.4 
(C(7)); HRMS (ESI+) C15H9NO4SNa [M+Na]+ found 322.0134, requires 322.0145 (-3.4 ppm). 
 
9-(4-Bromophenyl)-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-one 5,5-dioxide (370) 
 
2-(1H-Pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.) was dissolved in anhydrous 
MeCN (2.5 mL, 0.1 M) under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (0.044 
mL, 0.25 mmol, 2.0 eq.) and pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) were added. The 
reaction was stirred at 0 °C for 20 min before warmed up to rt. HyperBTM 93 (3.9 mg, 10 mol%), 
saccharin-derived ketimine 340 (43.5 mg, 0.125 mmol, 1.0 eq.), and i-Pr2NEt (0.044 mL, 0.25 
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mmol, 2.0 eq.) were added sequentially and the reaction stirred at rt. for 24 h. The reaction 
mixture was concentrated under reduced pressure to give the crude product that purified by 
recrystallization in Et2O/pentane to give the titled compound as a yellow solid (9.7 mg, 20%). 
Spectroscopic data were in accordance with the literature.18 mp >300 °C {Lit.18 >300 °C}; 1H 
NMR (500 MHz, DMSO) δH: 6.97 (1H, d, J 1.5, C(8)H), 7.73–7.79 (3H, m C(9)ArC(2,6)H + C(10)H), 
7.85–7.88 (3H, m, ArH), 8.00 (1H, t, J 7.7, ArH), 8.28 (1H, d, J 7.8, ArH), 8.47 (1H, d, J 7.9, ArH). 
 
9-(4-Methoxyphenyl)-7H-benzo[4,5]isothiazolo[2,3-a]pyridin-7-one 5,5-dioxide (371) 
 
2-(1H-Pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 2.0 eq.) was dissolved in anhydrous 
MeCN (2.5 mL, 0.1 M) under an atmosphere of N2 and cooled to 0 °C before i-Pr2NEt (0.044 
mL, 0.25 mmol, 2.0 eq.) and pivaloyl chloride (0.031 mL, 0.25 mmol, 2.0 eq.) were added. The 
reaction was stirred at 0 °C for 20 min before warmed up to rt. HyperBTM 93 (3.9 mg, 10 mol%), 
saccharin-derived ketimine 341 (37.4 mg, 0.125 mmol, 1.0 eq.), and i-Pr2NEt (0.044 mL, 0.25 
mmol, 2.0 eq.) were added sequentially and the reaction stirred at rt. for 24 h. The reaction 
mixture was concentrated under reduced pressure to give the crude product that purified by 
recrystallization in Et2O/pentane to give the titled compound as a yellow solid (6.4 mg, 15%). 
Spectroscopic data were in accordance with the literature.18 mp >300 °C {Lit.18 >300 °C}; 1H 
NMR (400 MHz, CDCl3) δH: 3.91 (3H, s, OCH3), 6.78 (1H, d, J 1.5, C(8)H), 6.97 (1H, d, J 1.5, 
C(10)H), 7.02–7.07 (2H, m, C(9)ArC(3,5)H), 7.59–7.63 (2H, m, C(9)ArC(2,6)H), 7.75 (1H, td, J 
7.6, 1.1, ArCH), 7.83 (1H, td, J 7.6, 1.2, ArCH), 7.91–7.97 (2H, m, ArCH). 
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8.6. Experimentals for Chapter 6 
General Procedure A: Synthesis of unsaturated ketimines 
 
To a solution of the corresponding unsaturated ketone (1.0 eq.) and ArSO2NH2 (1.0-1.1 eq.) in 
dry CH2Cl2 (0.2 M) was added NEt3 (2.0 eq.) followed by titanium tetrachloride (1.0 eq., 
dropwise) at 0 °C under an atmosphere of N2. The reaction mixture was further stirred at rt. 
for 16 h. Then it was quenched with H2O (20 mL). The aqueous phase was extracted with EtOAc 
(3 x 30 mL) and the combined organic layers were dried with MgSO4 and concentrated under 
reduced pressure to give the crude mixture. 
 
Generally, ketimines within the ester series were troublesome to purify, unless a solid was 
obtained. These were judged to be >90% pure by 1H NMR and suitable for use in this protocol. 
 
(1E)-3-Phenyl-3-(tosylimino)prop-1-en-1-yl acetate (402) 
 
Following general procedure A: methyl (E)-4-oxo-4-phenylbut-2-enoate19 (4.70 g, 24.7 mmol), 
TsNH2 (4.23 g, 24.7 mmol, 1.0 eq.), Et3N (6.89 mL, 49.4 mmol, 2.0 eq.) and TiCl4 (2.71 mL, 24.8 
mmol) in CH2Cl2 (100 mL) gave crude 402 as a yellow oil which was used as a crude without 
further purification. Spectroscopic data were in accordance with the literature.19 1H NMR (400 
MHz, CDCl3) δH: 2.43 (3 H, s, CH3), 3.83 (3 H, s, OCH3), 6.21 (1 H, d, J 16.0, PhCCH), 7.19–7.60 
(7 H, m, ArH), 7.86–7.92 (2 H, m, ArH), 8.22 (1 H, d, J 15.9, PhCH=CH). 
 
Methyl (3E)-4-phenyl-2-(tosylimino)but-3-enoate (412) 
 
Following general procedure A: methyl (E)-2-oxo-4-phenylbut-3-enoate 132 (1.18 g, 6.18 
mmol), TsNH2 (1.06 g, 6.18 mmol, 1.0 eq.), Et3N (1.72 mL, 12.4 mmol, 2.0 eq.) and TiCl4 (0.68 
mL, 6.18 mmol) in CH2Cl2 (30 mL) gave, after chromatographic purification (20:80 
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EtOAc/petrol), the titled compound as a sticky yellow oil (850 mg, 40%). Spectroscopic data 
were in accordance with the literature.19 1H NMR (400 MHz, CDCl3) δH: 2.44 (3 H, s, CH3), 4.12 
(3 H, s, OCH3), 6.88 (1 H, d, J 16.1, C(3)H), 7.34-7.58 (8 H, m, ArH and C(4)H), 7.94 (2 H, d, J 8.1, 
NSO2ArC(2,6)H). 
 
Methyl (2E)-4-phenyl-4-(((2,4,6-triisopropylphenyl)sulfonyl)imino)but-2-enoate (425) 
 
Following general procedure A: methyl (E)-4-oxo-4-phenylbut-2-enoate19 (1.18 g, 6.18 mmol), 
2,4,6-triisopropylbenzenesulfonamide (1.93 g, 6.80 mmol, 1.1 eq.), Et3N (1.72 mL, 12.4 mmol, 
2.0 eq.) and TiCl4 (0.68 mL, 6.18 mmol) in CH2Cl2 (30 mL) gave, after chromatographic 
purification (30:70 Et2O/petrol) and recrystallization in EtOAc/petrol, the titled compound as 
a white crystalline solid (1.75 g, 62 %). mp 112–114 °C; vmax (film, cm–1) 2957 (C-H), 2928 (C-H), 
1730 (C=O), 1721 (C=C), 1626, 1599, 1531, 1244; 1H NMR (500 MHz, CDCl3) δH: 1.25 (18H, J 6.7, 
CH3), 2.90 (1H, hept, J 6.9, CH), 3.79 (3H, s, OCH3), 4.14–4.25 (2H, m, 2 x CH), 6.09 (1H, d, J 
16.3, C(2)H), 7.16 (2H, s, ArCH), 7.42 (2H, t, J 7.7, C(4)ArCH), 7.55 (1H, t, J 7.6, C(4)ArCH), 7.74–
7.78 (2H, m, C(4)ArCH), 8.05 (1H, d, J 16.3, C(3)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 23.7 (CH3), 
24.8 (CH3), 30.2 (CH), 34.4 (CH), 52.5 (OCH3), 123.7 (ArCH), 128.8 (ArCH), 130.3 (ArCH), 131.8 
(ArC), 133.4 (ArC), 134.1 (ArC), 136.1 (ArC), 137.0 (ArC), 150.0 (ArC), 153.4 (ArC), 165.1 (C=N), 
173.7 (CO2Me); HRMS (ESI+) C26H33NO4SNa [M+Na]+ found 478.2009, requires 478.2023 (-2.8 
ppm). 
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Following general procedure A: methyl (E)-4-(4-methoxyphenyl)-4-oxobut-2-enoate20 (1.36 g, 
6.18 mmol), 2,4,6-triisopropylbenzenesulfonamide (1.93 g, 6.80 mmol, 1.1 eq.), Et3N (1.72 mL, 
12.4 mmol, 2.0 eq.) and TiCl4 (0.68 mL, 6.18 mmol) in CH2Cl2 (30 mL) gave, after filtering 
through a pad of silica (30:70 Et2O/petrol), the titled compound as a viscous yellow oil (>90% 
purity, 13:87 mixture of isomers) which was used as crude without further purification. 1H 
NMR (500 MHz, CDCl3) δH: 1.24 (9H, d, J 6.7, CH3), 1.24 (9H, d, J 6.7, CH3), 2.81–2.96 (1H, m, 
CH), 3.77 (3H, s, OCH3), 3.85 (3H, s, OCH3), 4.22 (2H, hept, J 6.8, CH), 6.00 (1H, d, J 16.4, C(2)H), 
6.87–6.92 (2H, m, C(1)ArC(3,5)H), 7.14 (2H, s, SO2ArCH), 7.74–7.83 (2H, m, C(1)ArC(2,4)H), 
7.90 (1H, d, J 16.3, C(3)H). Selected data for the minor isomer: 1H NMR (500 MHz, CDCl3) δH 





Following general procedure A: methyl (E)-4-(2-fluorophenyl)-4-oxobut-2-enoate19 (1.29 g, 
6.18 mmol), 2,4,6-triisopropylbenzenesulfonamide (1.93 g, 6.80 mmol, 1.1 eq.), Et3N (1.72 mL, 
12.4 mmol, 2.0 eq.) and TiCl4 (0.68 mL, 6.18 mmol) in CH2Cl2 (30 mL) gave, after filtering 
through a pad of silica (30:70 Et2O/petrol), the titled compound as a viscous deep red oil (>85% 
purity) which was used as crude without further purification. 1H NMR (400 MHz, CDCl3) δH: 
1.23 (9H, d, J 6.7, CH3), 1.27 (9H, d, J 6.9, CH3), 2.91 (1H, h, J 6.9, CH), 3.79 (3H, s, OCH3), 4.03 
(1H, p, J 6.8, CH), 4.15–4.24 (1H, m, CH), 6.08–6.20 (1H, m, C(2)H), 7.09–7.26 (4H, m, ArCH), 
7.43–7.52 (3H, m, ArCH + C(3)H); 19F{1H} NMR (377 MHz, CDCl3) δF: -111.5. 
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Methyl (2E)-4-(p-tolyl)-4-(((2,4,6-triisopropylphenyl)sulfonyl)imino)but-2-enoate (498) 
 
Following general procedure A: methyl (E)-4-oxo-4-(p-tolyl)but-2-enoate19 (1.26 g, 6.18 mmol), 
2,4,6-triisopropylbenzenesulfonamide (1.93 g, 6.80 mmol, 1.1 eq.), Et3N (1.72 mL, 12.4 mmol, 
2.0 eq.) and TiCl4 (0.68 mL, 6.18 mmol) in CH2Cl2 (30 mL) gave, after filtering through a pad of 
silica (30:70 Et2O/petrol), the titled compound as a yellow oil (>90% purity) which was used as 
crude without further purification. 1H NMR δH (500 MHz, CDCl3): 1.13–1.16 (18H, d J 6.7, CH3), 
2.31 (3H, s, C(4)ArC(4)CH3), 2.79 (1H, hept, J 6.9, CH), 3.68 (3H, s, OCH3), 4.10 (2H, s, CH), 5.94 
(1H, d, J 16.3, C(2)H), 7.05 (2H, s, NSO2ArCH), 7.12 (2H, d, J 7.9, C(4)ArC(3,5)H), 7.58 (2H, d, J 





Following general procedure A: methyl (E)-4-(4-chlorophenyl)-4-oxobut-2-enoate19 (1.39 g, 
6.18 mmol), 2,4,6-triisopropylbenzenesulfonamide (1.93 g, 6.80 mmol, 1.1 eq.), Et3N (1.72 mL, 
12.4 mmol, 2.0 eq.) and TiCl4 (0.68 mL, 6.18 mmol) in CH2Cl2 (30 mL) gave, after filtering 
through a pad of silica (30:70 Et2O/petrol), the titled compound as a yellow oil (>90% purity) 
which was used as crude without further purification. 1H NMR (400 MHz, CDCl3) δH: 1.24 (9H, 
d, J 6.9, CH3), 1.25 (9H, d, J 6.9, CH3), 2.90 (1H, hept, J 6.9, CH), 3.79 (3H, s, OCH3), 4.10–4.24 
(2H, m, CH), 6.07 (1H, d, J 16.4, C(2)H), 7.16 (2H, s, NSO2ArCH), 7.40 (2H, d, J 8.3, C(4)ArC(2,6)H), 
7.72 (2H, d, J 8.3, C(4)ArC(3,5)H), 8.00 (1H, d, J 16.4, C(3)H). 
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Methyl (3E)-4-phenyl-2-(((2,4,6-triisopropylphenyl)sulfonyl)imino)but-3-enoate (424) 
 
Following general procedure A: methyl (E)-2-oxo-4-phenylbut-3-enoate 132 (1.18 g, 6.18 
mmol), 2,4,6-triisopropylbenzenesulfonamide (1.93 g, 6.80 mmol, 1.1 eq.), Et3N (1.72 mL, 12.4 
mmol, 2.0 eq.) and TiCl4 (0.68 mL, 6.18 mmol) in CH2Cl2 (30 mL) gave, after chromatographic 
purification (30:70 Et2O/petrol), the titled compound as a white crystalline solid (62:38 
mixture of isomers, 2.11 g, 75%). Spectroscopic data were in accordance with the literature.21 
mp 98–99 °C; 1H NMR (500 MHz, CDCl3) δH: 1.31 (18H, d, J 6.7, major + minor CH3), 2.88–2.94 
(1H, m, major + minor CH), 3.92 (3H, s, minor OCH3), 4.02 (3H, s, major OCH3), 4.11–4.26 (2H, 
m, major + minor CH), 6.82 (1H, d, J 16.4, C(2)H), 7.19 (2H, s, major + minor NSO2ArCH), 7.32–
7.59 (6H, m, major + minor ArH + C(3)H), 7.73 (1H, d, J 16.2, minor C(3)H). 
 
Methyl (3E)-4-(p-tolyl)-2-(((2,4,6-triisopropylphenyl)sulfonyl)imino)but-3-enoate (500) 
 
Following general procedure A: methyl (E)-2-oxo-4-(p-tolyl)but-3-enoate 488 (1.26 g, 6.18 
mmol), 2,4,6-triisopropylbenzenesulfonamide (1.93 g, 6.80 mmol, 1.1 eq.), Et3N (1.72 mL, 12.4 
mmol, 2.0 eq.) and TiCl4 (0.68 mL, 6.18 mmol) in CH2Cl2 (30 mL) gave, after chromatographic 
purification (30:70 Et2O/petrol), the titled compound as a yellow solid (62:38 mixture of 
isomers, 1.68 g, 58%). Spectroscopic data were in accordance with the literature.21 mp 87–
89 °C; 1H NMR (500 MHz, CDCl3) δH: 1.31 (18H, d, J 6.7, major + minor CH3), 2.37 (3H, s, major 
+ minor CH3), 2.87–2.93 (1H, m, major + minor CH), 3.91 (3H, s, minor OCH3), 4.01 (3H, s, major 
OCH3), 4.14–4.32 (2H, m, major + minor CH), 6.79 (1H, d, J 16.3, major C(2)H), 7.19 (2H, s, 
major + minor NSO2ArCH), 7.30–7.48 (5H, m, major + minor, ArH + C(3)H), 7.68 (1H, J 16.2, 
minor C(3)H). 
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Following general procedure A: methyl (3E,5E)-2-oxo-6-phenylhexa-3,5-dienoate 285 (1.34 g, 
6.18 mmol), 2,4,6-triisopropylbenzenesulfonamide (1.93 g, 6.80 mmol, 1.1 eq.), Et3N (1.72 mL, 
12.4 mmol, 2.0 eq.) and TiCl4 (0.68 mL, 6.18 mmol) in CH2Cl2 (30 mL) gave, after 
chromatographic purification (30:70 Et2O/petrol), the titled compound as a yellow solid (56:44 
mixture of isomers, 2.14 g, 62%). Spectroscopic data were in accordance with the literature.21 
mp 63–65 °C; 1H NMR (500 MHz, CDCl3) δH: 1.31 (18H, d, J 6.7, major + minor CH3), 2.87–2.94 
(1H, m, major + minor CH), 3.90 (3H, s, minor OCH3), 4.01 (3H, s, major OCH3), 4.07–4.32 (2H, 
m, major + minor CH), 6.38 (1H, d, J 15.6, major C(2)H), 6.91–7.52 (10H, m, major + minor 
ArCH and CHA=CHB). 
 
Methyl (3E)-4-(furan-2-yl)-2-(((2,4,6-triisopropylphenyl)sulfonyl)imino)but-3-enoate (502) 
 
Following general procedure A: methyl (E)-4-(furan-2-yl)-2-oxobut-3-enoate 495 (1.11 g, 6.18 
mmol), 2,4,6-triisopropylbenzenesulfonamide (1.93 g, 6.80 mmol, 1.1 eq.), Et3N (1.72 mL, 12.4 
mmol, 2.0 eq.) and TiCl4 (0.68 mL, 6.18 mmol) in CH2Cl2 (30 mL) gave, after chromatographic 
purification (30:70 Et2O/petrol), the titled compound as a yellow solid (61:39 mixture of 
isomers, 1.35 g, 49%). Spectroscopic data were in accordance with the literature.21 mp 56–
58 °C; 1H NMR (500 MHz, CDCl3) δH: 1.17–1.43 (18H, m, major + minor CH3), 2.87–2.96 (1H, m, 
major + minor CH), 3.90 (3H, s, minor OCH3), 4.01 (3H, s, major OCH3), 4.09–4.31 (2H, m, major 
+ minor CH), 6.54–7.61 (7H, major + minor ArCH and CH=CH). 
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General Procedure B: Synthesis of pyridines 
 
Acid (1.0 eq.) was dissolved in anhydrous MeCN or DMF (0.1 M) under an atmosphere of N2 
and cooled to 0 °C before i-Pr2NEt (2 eq.) and pivaloyl chloride (2 eq.) were added. The 
reaction was stirred at 0 °C for 20 min before heating to 50 or 60 °C. DHPB 114 (10 mol%), the 
required unsaturated ketimine (1 eq.), and i-Pr2NEt (2.5 eq.) were added sequentially and the 
reaction stirred at 50 or 60 °C for 18 h. After that, the reaction mixture was concentrated 






Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1.0 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol, 2.0 eq.), pivaloyl chloride (0.062 mL, 0.5 mmol, 2.0 eq.) in MeCN 
(2.5 mL) at 0 °C for 20 min followed by DHPB 114 (4.8 mg, 10 mol%), ketimine 412 (85.9 mg, 
0.25 mmol, 1.0 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) at 60 °C for 4 h gave crude 
product that was purified by column chromatography (30:70 Et2O/petrol, Rf 0.40) to give the 
titled compound as a yellow oil (30 mg, 27%). vmax (film, cm–1) 2961 (C-H), 1744 (C=O), 1692 
(C=O), 1597 (C=C), 1352; 1H NMR (500 MHz, CDCl3) δH: 2.43 (3H, s, NSO2PhCH3), 3.42 (1H, dd, 
J 17.9, 5.7, C(3)HAHB), 3.49 (1H, dd, J 17.9, 2.6, C(3)HAHB), 3.70 (3H, s, OCH3), 5.56 (1H, dd, J 
5.7, 2.5, C(2)H), 6.04 (2H, t, J 2.2, C(5)Ar(3,4)H), 6.34 (2H, t, J 2.2, C(5)Ar(2,5)H), 6.90–6.93 (2H, 
m, C(4)ArC(2,6)H), 7.21–7.32 (5H, m, NSO2ArC(3,5)H + C(4)ArC(3,4,5)H), 8.00–8.03 (2H, m, 
NSO2ArC(2,6)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 21.9 (NSO2PhCH3), 33.4 (C(3)), 53.4 (OCH3), 
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55.7 (C(2)), 109.5 (C(5)ArC(3,4)H), 122.5 (C(5)ArC(2,5)H), 127.4 (C(4)ArC(2,6)H), 128.4 
(C(4)ArC(4)H), 128.7 (C(4)ArC(3,5)H), 129.2 (NSO2ArC(3,5)H), 129.9 (NSO2ArC(1)), 130.1 
(NSO2ArC(2,6)H), 135.0 (NSO2ArC(4)), 135.2 (C(4)ArC(1)), 144.6 (C(4)), 145.4 (C(5)), 160.4 
(C(6)), 170.2 (C(2)CO2Me); HRMS (ESI+) C24H23N2O5S [M+H]+ found 451.1322, requires 451.1322 
(-0.1 ppm). 
 
Methyl 4-phenyl-6-(pivaloyloxy)-5-(1H-pyrrol-1-yl)picolinate (413) 
 
Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1.0 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol, 2.0 eq.), pivaloyl chloride (0.062 mL, 0.5 mmol, 2.0 eq.) in DMF 
(2.5 mL) at 0 °C for 20 min followed by DHPB 114 (4.8 mg, 10 mol%), ketimine 424 (113.9 mg, 
0.25 mmol, 1.0 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) at 60 °C for 18 h gave crude 
product that was purified by column chromatography (15:85 to 20:80 Et2O/petrol) to give the 
titled compound as a yellow solid (62.4 mg, 66%). mp 108–110 °C; vmax (film, cm–1) 2968 (C-H), 
2955 (C-H), 2928 (C-H), 1763 (C=O), 1724 (C=O), 1489 (ArC=C), 1362, 1263; 1H NMR (500 MHz, 
CDCl3) δH: 1.16 (9H, s, 3 x CH3), 4.02 (3H, s, OCH3), 6.16 (2H, t, J 2.1, C(5)Ar(3,4)H), 6.48 (2H, t, 
J 2.1, C(5)Ar(2,5)H), 7.08–7.10 (2H, m, C(4)ArC(2,6)H), 7.29–7.37 (3H, m, C(4)ArC(3,4,5)H), 8.23 
(1H, s, C(3)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 27.0 (CH3), 39.2 (C(CH3)3), 53.4 (OCH3), 110.2 
(C(5)ArC(3,4)H), 122.5 (C(5)ArC(2,5)H), 126.0 (C(3)), 127.9 (C(4)ArC(2,6)H), 128.8 
(C(4)ArC(3,5)H), 129.5 (C(4)ArC(4)H), 131.0 (C(4)), 134.8 (C(4)ArC(1)), 145.3 (C(6)), 150.8 (C(5)), 
155.2 (C(2)), 164.6 (C(2)CO2Me), 176.4 (C(6)OCO); HRMS (ESI+) C22H23N2O4 [M+H]+ found 
379.1644, requires 379.1652 (-2.2 ppm). 
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Methyl 5-(1H-indol-1-yl)-4-phenyl-6-(pivaloyloxy)picolinate (432) 
 
Following General Procedure B, 2-(1H-indol-1-yl)acetic acid 223 (43.8 mg, 0.25 mmol, 1.0 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol, 2.0 eq.), pivaloyl chloride (0.062 mL, 0.5 mmol, 2.0 eq.) in DMF 
(2.5 mL) at 0 °C for 20 min followed by DHPB 114 (4.8 mg, 10 mol%), ketimine 424 (113.9 mg, 
0.25 mmol, 1.0 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) at 60 °C for 18 h gave crude 
product that was purified by column chromatography (15:85 to 20:80 Et2O/petrol) to give the 
titled compound as a yellow oil (50.3 mg, 47%). vmax (film, cm–1) 2958 (C-H), 1734 (C=O), 1645 
(C=O); 1H NMR (500 MHz, CDCl3) δH: 1.26 (9H, s, 3 x CH3), 4.05 (3H, s, OCH3), 6.47 (1H, dd, J 3.3, 
0.9, C(5)ArH), 6.65 (1H, d, J 3.3, C(5)ArH), 6.98–7.00 (2H, m, C(5)ArH), 7.04–7.21 (6H, m, 
C(5)ArH + C(4)ArCH), 7.58 (1H, dt, J 7.6, 1.0, C(5)ArH), 8.32 (1H, s, C(3)H); 13C{1H} NMR (126 
MHz, CDCl3) δC: 26.6 (CH3), 38.9 (C(CH3)3), 53.4 (OCH3), 104.7 (ArCH), 110.7 (ArCH), 120.8 
(ArCH), 121.1 (ArCH), 122.9 (ArCH), 123.8 (ArCH), 126.2 (C(3)), 127.9 (ArCH), 128.3 (ArCH), 
128.6 (ArCH), 128.9 (C(5)ArC), 129.6 (C(4)), 134.7 (C(4)ArC(1)), 136.7 (C(5)ArC), 145.9 (C(6)), 
152.1 (C(5)), 156.3 (C(2)), 164.7 (C(2)CO2Me), 176.2 (C(6)OCO); HRMS (ESI+) C26H25N2O4 [M+H]+ 
found 429.1804, requires 429.1809 (-1.1 ppm). 
 
Methyl 6-(pivaloyloxy)-5-(1H-pyrrol-1-yl)-4-(p-tolyl)picolinate (433) 
 
Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1.0 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol, 2.0 eq.), pivaloyl chloride (0.062 mL, 0.5 mmol, 2.0 eq.) in DMF 
(2.5 mL) at 0 °C for 20 min followed by DHPB 114 (4.8 mg, 10 mol%), ketimine 500 (117.4 mg, 
0.25 mmol, 1.0 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) at 60 °C for 18 h gave crude 
product that was purified by column chromatography (15:85 to 20:80 Et2O/petrol) to give the 
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titled compound as a yellow oil (62.4 mg, 59%). vmax (film, cm–1) 2959 (C-H), 1732 (C=O), 1695 
(C=O); 1H NMR (500 MHz, CDCl3) δH: 1.24 (9H, s, 3 x CH3), 2.33 (3H, s, CH3), 4.02 (3H, s, OCH3), 
6.18 (2H, t, J 2.1, C(5)Ar(3,4)H), 6.48 (2H, t, J 2.1, C(5)Ar(2,5)H), 6.95–6.98 (2H, m, 
C(4)ArC(3,5)H), 7.11 (2H, d, J 8.0, C(4)ArC(2,6)H), 8.22 (1H, s, C(3)H); 13C{1H} NMR (126 MHz, 
CDCl3) δC: 21.4 (CH3), 27.2 (CH3), 39.2 (C(CH3)3), 53.3 (OCH3), 110.2 (C(5)ArC(3,4)H), 122.5 
(C(5)ArC(2,5)H), 125.9 (C(3)), 127.8 (C(4)ArC(3,5)H), 129.6 (C(4)ArC(2,6)H), 130.9 (C(4)), 131.9 
(C(4)ArC(1)), 139.8 (C(4)ArC(4)), 145.3 (C(6)), 150.8 (C(5)), 155.3 (C(2)), 164.7 (C(2)CO2Me), 
176.5 (C(6)OCO); HRMS (ESI+) C23H24N2O4Na [M+Na]+ found 415.1624, requires 415.1628 (-1.0 
ppm). 
 
Methyl (E)-6-(pivaloyloxy)-5-(1H-pyrrol-1-yl)-4-styrylpicolinate (435) 
 
Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1.0 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol, 2.0 eq.), pivaloyl chloride (0.062 mL, 0.5 mmol, 2.0 eq.) in DMF 
(2.5 mL) at 0 °C for 20 min followed by DHPB 114 (4.8 mg, 10 mol%), ketimine 501 (120.4 mg, 
0.25 mmol, 1.0 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) at 60 °C for 18 h gave crude 
product that was purified by column chromatography (15:85 to 20:80 Et2O/petrol) to give the 
titled compound as a yellow oil (57.6 mg, 57%). vmax (film, cm–1) 2958 (C-H), 1732 (C=O); 1H 
NMR (500 MHz, CDCl3) δH: 1.23 (9H, s, 3 x CH3), 4.04 (3H, s, OCH3), 6.36 (2H, t, J 2.1, 
C(5)Ar(3,4)H), 6.51 (1H, d, J 16.4, C(4)CH=CHPh), 6.68 (2H, t, J 2.1, C(5)Ar(2,5)H), 7.30–7.45 
(6H, m, ArCH + C(4)CH=CHPh), 8.45 (1H, s, C(3));13C{1H} NMR (126 MHz, CDCl3) δC: 27.1 (CH3), 
39.0 (C(CH3)3), 53.3 (OCH3), 110.2 (C(5)ArC(2,6)H), 119.7(C(4)CH=CHPh), 120.4 (C(3)), 123.0 
(C(5)ArC(3,5)H), 127.5 (PhC(2,6)H), 128.9 (PhC(3,5)H), 129.6 (PhC(4)H), 130.9 (C(4)), 135.5 
(PhC(1)), 137.1 (C(4)CH=CHPh), 145.3 (C(6)), 147.4 (C(5)), 155.6 (C(2)), 164.8 (C(2)CO2Me), 
176.4 (C(6)OCO); HRMS (ESI+) C24H24N2O4Na [M+Na]+ found 427.1622, requires 427.1628 (-1.5 
ppm). 
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Methyl (E)-5-(1H-indol-1-yl)-6-(pivaloyloxy)-4-styrylpicolinate (436) 
 
Following General Procedure B, 2-(1H-indol-1-yl)acetic acid 223 (43.8 mg, 0.25 mmol, 1.0 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol, 2.0 eq.), pivaloyl chloride (0.062 mL, 0.5 mmol, 2.0 eq.) in DMF 
(2.5 mL) at 0 °C for 20 min followed by DHPB 114 (4.8 mg, 10 mol%), ketimine 501 (120.4 mg, 
0.25 mmol, 1.0 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) at 60 °C for 18 h gave crude 
product that was purified by column chromatography (15:85 to 20:80 Et2O/petrol) to give the 
titled compound as a red oil (62.5 mg, 55%). vmax (film, cm–1) 2961 (C-H), 1734 (C=O), 1634 
(C=O); 1H NMR (500 MHz, CDCl3) δH: 1.24 (9H, s, 3 x CH3), 4.07 (3H, s, OCH3), 6.52 (1H, d, J 16.3, 
C(4)CH=CHPh), 6.74 (1H, dd, J 3.2, 0.9, C(5)ArH), 6.97–7.00 (1H, m, C(5)ArH), 7.07 (1H, d, J 3.2, 
C(5)ArH), 7.15–7.21 (3H, m, C(5)ArH + PhH), 7.25–7.28 (4H, m, PhH), 7.40 (1H, d, J 16.3, 
C(4)CH=CHPh), 7.67–7.70 (1H, m, C(5)ArH), 8.55 (1H, s, C(3)H); 13C{1H} NMR (126 MHz, CDCl3) 
δC: 26.6 (CH3), 38.9 (C(CH3)3), 53.5 (OCH3), 104.7 (ArCH), 110.8 (ArCH), 119.8 (C(4)CH=CHPh), 
120.7 (C(3)), 121.0 (ArCH), 121.1 (ArCH), 123.1 (ArCH), 127.6 (ArCH), 129.0 (C(5)ArC), 129.7 
(C(4)), 135.4 (PhC(1)), 137.1 (C(4)CH=CHPh), 137.4 (C(5)ArC), 145.8 (C(6)), 148.1 (C(5)), 156.6 
(C(2)), 165.0 (C(2)CO2Me), 176.2 (C(6)OCO); HRMS (ESI+) C28H26N2O4Na [M+Na]+ found 
477.1779, requires 477.1785 (-1.2 ppm). 
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Methyl 4-(furan-2-yl)-6-(pivaloyloxy)-5-(1H-pyrrol-1-yl)picolinate (434) 
 
Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1.0 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol, 2.0 eq.), pivaloyl chloride (0.062 mL, 0.5 mmol, 2.0 eq.) in DMF 
(2.5 mL) at 0 °C for 20 min followed by DHPB 114 (4.8 mg, 10 mol%), ketimine 502 (111.4 mg, 
0.25 mmol, 1.0 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) at 60 °C for 18 h gave crude 
product that was purified by column chromatography (15:85 to 20:80 Et2O/petrol) to give the 
titled compound as a yellow oil (48.8 mg, 53%). vmax (film, cm–1) 2959 (C-H), 1732 (C=O); 1H 
NMR (500 MHz, CDCl3) δH: 1.26 (9H, s, 3 x CH3), 4.06 (3H, s, OCH3), 5.25 (1H, d, J 3.6, 
C(4)ArC(3)H), 6.37–6.38 (1H, m, C(3)ArC(4)H), 6.40 (2H, t, J 2.1, C(5)Ar(3,4)H), 6.57 (2H, t, J 2.1, 
C(5)Ar(2,5)H), 7.57 (1H, d, J 1.7, C(3)ArC(5)H), 8.66 (1H, s, C(3)); 13C{1H} NMR (126 MHz, CDCl3) 
δC: 27.0 (CH3), 39.0 (C(CH3)3), 53.3 (OCH3), 110.7 (C(5)ArC(2,6)H), 113.3 (C(4)ArC(4)H), 114.4 
(C(4)ArC(3)H), 120.3 (C(3)), 120.5 (C(5)ArC(3,5)H), 126.8 (C(4)), 144.7 (C(4)ArC(5)H), 146.0 
(C(6)), 149.2 (C(5)), 152.8 (C(4)ArC(2)) 156.6 (C(2)), 164.5 (C(2)CO2Me), 176.5 (C(6)OCO); 
HRMS (ESI+) C20H20N2O5Na [M+Na]+ found 391.1260, requires 391.1264 (-1.1 ppm). 
 
Methyl 6-phenyl-2-(pivaloyloxy)-3-(1H-pyrrol-1-yl)isonicotinate (403) 
 
Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1.0 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol, 2.0 eq.), pivaloyl chloride (0.062 mL, 0.5 mmol, 2.0 eq.) in MeCN 
(2.5 mL) at 0 °C for 20 min followed by DHPB 114 (4.8 mg, 10 mol%), ketimine 425 (113.9 mg, 
0.25 mmol, 1.0 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) at 50 °C for 18 h gave crude 
product that was purified by column chromatography (15:85 to 20:80 Et2O/petrol) to give the 
titled compound as a yellow solid (60.5 mg, 64%). mp 106–109 °C; vmax (film, cm–1) 2959 (C-H), 
2932 (C-H), 2870 (C-H), 1765 (C=O), 1720 (C=O), 1487 (Ar C=C), 1441 (Ar C=C), 1356, 1258, 
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1233, 1098, 1070, 1059; 1H NMR (500 MHz, CDCl3) δH: 1.19 (9H, s, 3 x CH3), 3.73 (3H, s, OCH3), 
6.28 (2H, t, J 2.1, C(3)Ar(3,4)H), 6.68 (2H, t, J 2.1, C(3)Ar(2,5)H), 7.44–7.52 (3H, m, 
C(6)ArC(3,4,5)H), 8.04–8.06 (3H, m, C(6)ArC(2,6)H + C(5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 
26.9 (CH3), 39.2 (C(CH3)3), 53.2 (OCH3), 109.7 (C(3)ArC(3,4)H), 118.7 (C(5)), 123.0 
(C(3)ArC(2,5)H), 126.7 (C(6)), 127.4 (C(6)ArC(2,6)H), 129.0 (C(6)ArC(4)H), 130.2 (C(6)ArC(3,5)H), 
136.8 (C(6)ArC(1)), 140.7 (C(2)), 155.3 (C(4)), 156.4 (C(3)), 165.0 (C(4)CO2Me), 176.5 (C(2)OCO); 
HRMS (ESI+) C22H22N2O4Na [M+Na]+ found 401.1460, requires 401.1472 (-2.9 ppm). 
 
Methyl 3-(1H-indol-1-yl)-6-phenyl-2-(pivaloyloxy)isonicotinate (427) 
 
Following General Procedure B, 2-(1H-indol-1-yl)acetic acid 223 (43.8 mg, 0.25 mmol, 1.0 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol, 2.0 eq.), pivaloyl chloride (0.062 mL, 0.5 mmol, 2.0 eq.) in MeCN 
(2.5 mL) at 0 °C for 20 min followed by DHPB 114 (4.8 mg, 10 mol%), ketimine 425 (113.9 mg, 
0.25 mmol, 1.0 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) at 50 °C for 18 h gave crude 
product that was purified by column chromatography (15:85 to 20:80 Et2O/petrol) to give the 
titled compound as a light yellow solid (57.8 mg, 54%). mp 128–130 °C; vmax (film, cm–1) 2967 
(C-H), 2955 (C-H), 1761 (C=O), 1721 (C=O); 1H NMR (500 MHz, CDCl3) δH: 0.90 (9H, s, 3 x CH3), 
3.53 (3H, s, OCH3), 6.66 (1H, dd, J 3.3, 0.9, C(3)ArH), 7.00–7.03 (1H, m, C(3)ArH), 7.08 (1H, d, J 
3.3, C(3)ArH), 7.11–7.19 (2H, m, C(6)ArCH), 7.48–7.54 (3H, m, C(6)ArCH), 7.63 (1H, dt, J 7.7, 
0.9, C(3)ArH), 8.08–8.11 (2H, m, C(3)ArH), 8.18 (1H, s, C(5)H); 13C{1H} NMR (126 MHz, CDCl3) 
δC: 26.6 (CH3), 39.0 (C(CH3)3), 53.1 (OCH3), 103.9 (ArCH), 110.2 (ArCH), 119.3 (C(5)), 120.5 
(ArCH), 121.0(ArCH), 122.7 (ArCH), 124.7 (ArCH), 127.4 (ArCH), 128.6 (C(3)ArC), 129.1 (ArCH), 
129.3 (ArCH), 130.3 (C(2)), 136.9 (C(6)ArC(1)), 137.6 (C(3)ArC), 141.2(C(6)), 156.4 (C(3)), 156.9 
(C(4)), 164.7 (C(2)CO2Me), 176.2 (C(2)OCO); HRMS (ESI+) C26H25N2O4 [M+H]+ found 429.1803, 
requires 429.1809 (-1.4 ppm). 
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Methyl 6-(4-methoxyphenyl)-2-(pivaloyloxy)-3-(1H-pyrrol-1-yl)isonicotinate (428) 
 
Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1.0 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol, 2.0 eq.), pivaloyl chloride (0.062 mL, 0.5 mmol, 2.0 eq.) in MeCN 
(2.5 mL) at 0 °C for 20 min followed by DHPB 114 (4.8 mg, 10 mol%), ketimine 496 (121.4 mg, 
0.25 mmol, 1.0 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) at 50 °C for 18 h gave crude 
product that was purified by column chromatography (15:85 to 20:80 Et2O/petrol) to give the 
titled compound as a yellow solid (38.8 mg, 38%). mp 74–78 °C; vmax (film, cm–1) 2961 (C-H), 
1763 (C=O), 1721 (C=O); 1H NMR (500 MHz, CDCl3) δH: 1.17 (9H, s, 3 x CH3), 3.72 (3H, s, 
COOCH3), 3.88 (3H, s, OCH3), 6.26 (2H, t, J 2.1, C(3)Ar(3,4)H), 6.66 (2H, t, J 2.1, C(3)Ar(2,5)H), 
6.98–7.01 (2H, m, C(6)ArC(3,5)H), 7.97 (1H, s, C(5)H), 7.99–8.02 (2H, m, C(6)ArC(2,6)H); 13C{1H} 
NMR (126 MHz, CDCl3) δC: 26.9 (CH3), 39.1 (C(CH3)3), 53.1 (COOCH3), 55.6 (OCH3), 109.6 
(C(3)ArC(3,4)H), 114.4 (C(6)ArC(3,5)H), 117.8 (C(5)), 123.1 (C(3)ArC(2,5)H), 125.8 (C(6)), 128.8 
(C(6)ArC(2,6)H), 129.4 (C(6)ArC(1)), 140.6 (C(2)), 155.2 (C(4)), 156.2 (C(3)), 161.4 (C(6)ArC(4)), 
165.1 (C(4)CO2Me), 176.6 (C(2)OCO); HRMS (ESI+) C23H24N2O5Na [M+Na]+ found 431.1570, 
requires 431.1577 (-1.7 ppm). 
 
Methyl 2-(pivaloyloxy)-3-(1H-pyrrol-1-yl)-6-(p-tolyl)isonicotinate (429) 
 
Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1.0 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol, 2.0 eq.), pivaloyl chloride (0.062 mL, 0.5 mmol, 2.0 eq.) in MeCN 
(2.5 mL) at 0 °C for 20 min followed by DHPB 114 (4.8 mg, 10 mol%), ketimine 498 (117.4 mg, 
0.25 mmol, 1.0 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) at 50 °C for 18 h gave crude 
product that was purified by column chromatography (15:85 to 20:80 Et2O/petrol) to give the 
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titled compound as a yellow solid (56.9 mg, 58%). mp 96–100 °C; vmax (film, cm–1) 2968 (C-H), 
1765 (C=O), 1719 (C=O); 1H NMR (500 MHz, CDCl3) δH: 1.18 (9H, s, 3 x CH3), 2.42 (3H, s, CH3), 
3.73 (3H, s, COOCH3), 6.27 (2H, t, J 2.2, C(3)Ar(3,4)H), 6.67 (2H, t, J 2.1, C(3)Ar(2,5)H), 7.27–
7.31 (2H, m, C(6)ArC(3,5)H), 7.92–7.96 (2H, m, C(6)ArC(2,6)H), 8.00 (1H, s, C(5)H); 13C{1H} NMR 
(126 MHz, CDCl3) δC: 21.5 (CH3), 26.9 (CH3), 39.1 (C(CH3)3), 53.1 (OCH3), 109.6 (C(3)ArC(3,4)H), 
118.3 (C(5)), 123.1 (C(3)ArC(2,5)H), 126.3  (C(6)), 127.2 (C(6)ArC(3,5)H), 129.8 
(C(6)ArC(2,6)H), 134.1 (C(6)ArC(1)), 140.5 (C(2)), 140.6 (C(6)ArC(4)), 155.3 (C(4)), 156.5 (C(3)), 
165.0 (C(4)CO2Me), 176.5 (C(2)OCO); HRMS (ESI+) C23H24N2O4Na [M+Na]+ found 415.1619, 
requires 415.1628 (-2.2 ppm). 
 
Methyl 6-(4-chlorophenyl)-2-(pivaloyloxy)-3-(1H-pyrrol-1-yl)isonicotinate (430) 
 
Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1.0 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol, 2.0 eq.), pivaloyl chloride (0.062 mL, 0.5 mmol, 2.0 eq.) in MeCN 
(2.5 mL) at 0 °C for 20 min followed by DHPB 114 (4.8 mg, 10 mol%), ketimine 499 (122.5 mg, 
0.25 mmol, 1.0 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) at 50 °C for 18 h gave crude 
product that was purified by column chromatography (15:85 to 20:80 Et2O/petrol) to give the 
titled compound as a yellow solid (64.0 mg, 62%). mp 88–90 °C; vmax (film, cm–1) 2972 (C-H), 
1761 (C=O), 1721 (C=O); 1H NMR (500 MHz, CDCl3) δH: 1.18 (9H, s, 3 x CH3), 3.73 (3H, s, CH3), 
6.28 (2H, t, J 2.1, C(3)Ar(3,4)H), 6.67 (2H, t, J 2.1, C(3)Ar(2,5)H), 7.44–7.47 (2H, m, 
C(6)ArC(2,6)H), 7.98–8.01 (3H, m, C(6)ArC(3,5)H + C(5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 
26.9 (CH3), 39.2 (C(CH3)3), 53.2 (OCH3), 109.8 (C(3)ArC(3,4)H), 118.5 (C(5)), 123.0 
(C(3)ArC(2,5)H), 127.0 (C(6)), 128.6(C(6)ArC(3,5)H), 129.3(C(6)ArC(2,6)H), 135.2 (C(6)ArC(4)), 
136.5 (C(6)ArC(1)), 140.8 (C(2)), 155.1 (C(4)), 155.4 (C(3)), 164.8 (C(4)CO2Me), 176.5 (C(2)OCO); 
HRMS (ESI+) C22H21N2O4Na35Cl [M+Na]+ found 435.1075, requires 435.1082 (-1.6 ppm). 
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Methyl 6-(2-fluorophenyl)-2-(pivaloyloxy)-3-(1H-pyrrol-1-yl)isonicotinate (431) 
 
Following General Procedure B, 2-(1H-pyrrol-1-yl)acetic acid 155 (31.3 mg, 0.25 mmol, 1.0 eq.), 
i-Pr2NEt (0.087 mL, 0.5 mmol, 2.0 eq.), pivaloyl chloride (0.062 mL, 0.5 mmol, 2.0 eq.) in MeCN 
(2.5 mL) at 0 °C for 20 min followed by DHPB 114 (4.8 mg, 10 mol%), ketimine 497 (118.4 mg, 
0.25 mmol, 1.0 eq.) and i-Pr2NEt (0.11 mL, 0.63 mmol, 2.5 eq.) at 50 °C for 18 h gave crude 
product that was purified by column chromatography (15:85 to 20:80 Et2O/petrol) to give the 
titled compound as an orange solid (46.6 mg, 47%). mp 112–114 °C; vmax (film, cm–1) 2974 (C-
H), 1757 (C=O), 1719 (C=O); 1H NMR (500 MHz, CDCl3) δH: 1.18 (9H, s, 3 x CH3), 3.74 (3H, s, 
CH3), 6.28 (2H, t, J 2.1, C(3)Ar(3,4)H), 6.69 (2H, t, J 2.1, C(3)Ar(2,5)H), 7.19 (1H, ddd, J 11.5, 8.2, 
1.1, C(6)ArC(6)H), 7.28 (1H, td, J 7.6, 1.2, C(6)ArC(4)H), 7.40–7.45 (1H, m, C(6)ArC(5)H), 8.07 
(1H, td, J 7.9, 1.9, C(6)ArC(3)H), 8.14 (1H, d, J 1.2, C(5)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 
26.9 (CH3), 39.2 (C(CH3)3), 53.2 (OCH3), 109.8 (C(3)ArC(3,4)H), 116.5 (d, J 22.7, C(6)ArC(3)H), 
122.8 (d, J 11.7, C(5)), 123.0 (C(3)ArC(2,5)H), 124.9 (d, J 3.6, C(6)ArC(5)H), 125.0 (d, J 10.7, 
C(6)ArC(1)), 127.0 (C(6)), 131.4 (d, J 2.2, C(6)ArC(6)), 131.8 (d, J 8.6, C(6)ArC(4)H), 140.6 (C(2)), 
152.0 (d, J 1.9, C(4)), 155.2 (C(3)), 160.8 (d, J 251.4, C(6)ArC(2)), 164.8 (C(4)CO2Me), 176.5 
(C(2)OCO); 19F NMR (471 MHz, CDCl3) δF: –115.8; HRMS (ESI+) C22H21N2O4FNa [M+Na]+ found 
419.1369, requires 435.1378 (-2.0 ppm). 
 
Methyl 2-hydroxy-6-phenyl-3-(1H-pyrrol-1-yl)isonicotinate (439) 
 
Following the procedure by Volochnyuk,22 a solution of 403 (90.8 mg, 0.24 mmol), morpholine 
(0.21 mL, 2.4 mmol, 10 eq.), Et3N (67 μL, 0.48 mmol, 2 eq.) were stirred in toluene (2 mL) in a 
sealed vial at 110 °C for 16 h. Once cooled, the resulting solid was collected by filtration and 
washed with petrol to give the titled compound as a yellow solid (41.0 mg, 58%). mp 76–78 °C; 
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vmax (film, cm–1) 2951 (C-H), 2911 (C-H), 1719 (C=O), 1638 (Ar C=C), 1612 (Ar C=C), 1487, 1454; 
1H NMR (500 MHz, CDCl3) δH: 3.73 (3H, s, CH3), 6.33 (2H, t, J 2.1, C(3)Ar(3,4)H), 6.72 (1H, s, 
C(5)H), 6.87 (2H, t, J 2.1, C(3)Ar(2,5)H), 7.46–7.51 (3H, m, C(6)ArC(3,4,5)H), 7.73–7.76 (2H, m, 
C(6)ArC(2,6)H), 11.79 (1H, s, OH); 13C{1H} NMR (126 MHz, CDCl3) δC: 52.9 (OCH3), 103.0 (C(5)), 
109.6 (C(3)ArC(3,4)H), 122.2 (C(3)ArC(2,5)H), 126.4 (C(6)ArC(2,6)H), 128.1 (C(6)), 129.5 
(C(6)ArC(3,5)H), 130.7 (C(6)ArC(4)H), 132.1 (C(4)), 137.8 (C(2)), 144.8 (C(6)ArC(1)), 161.0 (C(3)), 





Following the procedure by Volochnyuk,22 a solution of 413 (90.8 mg, 0.24 mmol), morpholine 
(0.21 mL, 2.4 mmol, 10 eq.), Et3N (67 μL, 0.48 mmol, 2 eq.) were stirred in toluene (2 mL) in a 
sealed vial at 110 °C for 16 h. Once cooled, the resulting solid was collected by filtration and 
washed with petrol to give the titled compound as a white solid (42.8 mg, 51%). mp 241–
242 °C; vmax (film, cm–1) 3117 (C-H), 1639 (C=O), 1589 (C=O); 1H NMR (500 MHz, CDCl3) δH: 3.22 
(4H, t, J 4.8, morpholineC-H), 3.90 (4H, t, J 4.8, morpholineC-H), 6.13 (2H, t, J 2.1, C(5)Ar(3,4)H), 
6.56 (2H, t, J 2.2, C(5)Ar(2,5)H), 7.11–7.14 (2H, m, C(4)ArC(2,6)H), 7.23 (1H, s, C(3)H), 7.27–
7.31 (3H, m, C(4)ArC(3,4,5)H), 12.57 (1H, s, OH); 13C{1H} NMR (126 MHz, CDCl3) δC: 43.0 (2 x 
CH2), 64.3 (2 x CH2), 108.9 (C(5)ArC(3,4)H), 110.7 (C(3)), 122.4 (C(5)ArC(2,5)H), 127.9 
(C(4)ArC(2,6)H), 128.6 (C(4)ArC(3,5)H), 129.0 (C(4)ArC(4)H), 129.4 (C(6)), 136.5(C(4)ArC(1)), 
136.7 (C(4)), 140.9 (C(5))147.9 (C(2)), 161.0 (C(2)CO); Characterization was not carried out 
further due to low solubility. 
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Methyl 6-phenyl-3-(1H-pyrrol-1-yl)-2-(tosyloxy)isonicotinate (442) 
 
Stirred solution of 439 (30 mg, 0.10 mmol, 1 eq.) in anhydrous THF (1.5 mL) at –78 °C under 
an N2 atmosphere was treated with NaH (6 mg, 60% wt, 0.15 mmol, 1.5 eq) followed by a 
solution of tosyl chloride (29.2 mg, 0.153 mmol, 1.5 eq) in anhydrous THF (1.5 mL). After 1 h, 
the reaction mixture was allowed to warm to rt, then heated to 60 °C for 3 h. The reaction was 
then poured into ice water (10 mL), neutralized with K2CO3 and extracted with CHCl3 (3 x 10 
mL). The crude material was purified by flash chromatography (15:85 EtOAc/petrol) to afford 
the titled compound as a yellow solid (39.3 mg, 86%). mp 98–102 °C; vmax (film, cm–1) 2926 (C-
H), 2851 (C-H), 1734 (C=O), 1491 (Ar C=C); 1H NMR (500 MHz, CDCl3) δH: 2.50 (3H, s, CH3), 3.75 
(3H, s, OCH3), 6.37 (2H, t, J 2.1, C(3)Ar(3,4)H), 6.81 (2H, t, J 2.2, C(3)Ar(2,5)H), 7.32–7.37 (2H, 
m, ArCH), 7.44–7.50 (3H, m, ArCH), 7.81–7.87 (4H, m, ArCH), 7.99 (1H, s, C(5)H); 13C{1H} NMR 
(126 MHz, CDCl3) δC: 21.9 (CH3), 53.3 (OCH3), 110.5 (C(3)ArC(3,4)H), 118.5 (C(5)), 122.9 
(C(3)ArC(2,5)H), 125.3 (C(6)), 127.2 (ArCH), 128.9 (ArCH), 129.0 (ArCH), 129.8 (ArCH), 130.4 
(ArCH), 134.5 (C(6)ArC(1)), 136.1 (C(2)), 141.0 (ArC), 145.4 (ArC), 152.4 (C(3)), 154.8 (C(4)), 
165.2 (C(4)CO2Me); HRMS (ESI+) C24H20N2O5NaS [M+Na]+ found 471.0978, requires 471.0985 (-
1.5 ppm). 
 
Methyl 2-phenyl-5-(1H-pyrrol-1-yl)isonicotinate (445) 
 
Following the procedure of Yoshida,23 to a solution of 442 (52 mg, 0.12 mmol), Pd(OAc)2 (1.3 
mg, 0.006 mmol, 5 mol%), DPPP (2.4 mg, 0.006 mmol, 5 mol%) and Et3N (0.081 mL, 0.6 mmol, 
5.0 eq.) in DMF (1.2 mL) was added formic acid (13 μL, 0.36 mmol, 3.0 eq.). The reaction was 
heated in a sealed vial for 1 h at 60 °C under N2. Once cooled, the reaction mixture was 
quenched with brine (5 mL) and extracted with EtOAc (3 x 10 mL). The combined organics were 
dried over MgSO4, filtered and concentrated under reduced pressure. Chromatographic 
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purification (5:95 EtOAc/Petrol) gave the title compound as a yellow gum (26.0 mg, 78%). vmax 
(film, cm–1) 3103 (C-H), 2953 (C-H), 1721 (C=O), 1487; 1H NMR (500 MHz, CDCl3) δH: 3.80 (3H, 
s, CH3), 6.39 (2H, t, J 2.2, C(5)Ar(3,4)H), 6.87 (2H, t, J 2.1, C(5)Ar(2,5)H), 7.44–7.54 (3H, m, 
C(2)ArC(3,4,5)H), 8.03–8.06 (3H, m, C(2)ArC(2,6)H + C(3)H), 8.78 (1H, s, C(6)H); 13C{1H} NMR 
(126 MHz, CDCl3) δC: 53.1 (CH3), 110.7 (C(5)ArC(3,4)H), 120.0 (C(3)), 122.2 (C(5)ArC(2,5)H), 
127.1 (C(2)ArC(3,5)H), 129.1 (C(2)ArC(2,6)H), 129.8 (C(2)ArC(4)H), 133.8 (C(5)), 135.2 (C(2)), 
137.7 (C(2)ArC(1)), 147.7 (C(6)), 156.6 (C(4)), 166.1 (C(4)COOMe); HRMS (ESI+) C17H15N2O2 
[M+H]+ found 279.1119, requires 279.1128 (-3.2 ppm). 
 
Methyl 2-(4-methoxyphenyl)-6-phenyl-3-(1H-pyrrol-1-yl)isonicotinate (446) 
 
To a screw cap vial was charged Pd(dba)2 (1.6 mg, 0.003 mmol, 2.5 mol%), 4,4,5,5-tetramethyl-
1,3,2-dioxaphospholane 2-oxide (1.0 mg, 0.006 mmol, 5 mol%) and anhydrous 1,4-dioxane (1 
mL). The reaction mixture was stirred at rt for 5 mins. 4-Methoxylphenylmagnesium bromide 
solution (0.5 M in THF, 0.17 mL, 0.17 mmol, 1.5 eq.) was added and the reaction mixture was 
stirred at rt for 5 minutes. 442 (50 mg, 0.11 mmol, 1.0 eq.) was added and the reaction was 
heated at 80 °C for 16 h before being cooled to rt. Then the reaction mixture was quenched 
with 1 M aq. HCl and extracted with Et2O (3 x 10 mL). The combined organic layers were dried 
(MgSO4), filtered and concentrated in vacuo. Chromatographic purification (Et2O/petrol 10:90) 
gave the titled compound as a light yellow oil (8.5 mg, 20%). vmax (film, cm–1) 2953 (C-H), 1724 
(C=O), 1609 (Ar C=C); 1H NMR (500 MHz, CDCl3) δH: 3.73 (3H, s, OCH3), 3.81 (3H, s, OCH3), 6.27 
(2H, t, J 2.1, C(3)Ar(3,4)H), 6.62 (2H, t, J 2.1, C(3)Ar(2,5)H), 6.80–6.84 (2H, m, C(2)ArC(3,5)H), 
7.30–7.34 (2H, m, C(6)ArC(2,6)H), 7.44–7.53 (3H, m, C(6)ArC(3,4,5)H), 7.92 (1H, s, C(5)H), 
8.12–8.16 (2H, m, C(2)ArC(2,4)H); 13C{1H} NMR (126 MHz, CDCl3) δC: 53.1 (CH3), 55.4 (CH3), 
110.2 (C(3)ArC(3,4)H), 113.7 (C(2)ArC(3,5)H), 117.4 (C(5)), 122.6 (C(3)ArC(2,5)H), 127.2 
(C(2)ArC(2,4)H), 129.0 (C(2)ArC(3,5)H), 129.8 (C(6)ArC(3,5)H), 129.9 (C(6)ArC(4)H), 130.1 
(C(6)ArC(2,6)H), 130.7 (C(3)), 138.0 (C(6)), 139.8 (C(6)ArC(1)), 155.6 (C(2)), 156.5 (C(2)ArC(4)), 
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160.4 (C(4)), 166.5 (C(4)COOMe); HRMS (ESI+) C24H21N2O3 [M+H]+ found 385.1538, requires 





To a screw cap vial was charged Pd(dba)2 (1.6 mg, 0.003 mmol, 2.5 mol%), 4,4,5,5-tetramethyl-
1,3,2-dioxaphospholane 2-oxide (1.0 mg, 0.006 mmol, 5 mol%) and anhydrous 1,4-dioxane (1 
mL). The reaction mixture was stirred at rt for 5 mins. 4-Methoxylphenylmagnesium bromide 
solution (0.5 M in THF, 0.17 mL, 0.17 mmol, 1.5 eq.) was added and the reaction mixture was 
stirred at rt for 5 minutes. 442 (50 mg, 0.11 mmol, 1.0 eq.) was added and the reaction was 
heated at 80 °C for 16 h before being cooled to rt. Then the reaction mixture was quenched 
with 1 M aq. HCl and extracted with Et2O (3 x 10 mL). The combined organic layers were dried 
(MgSO4), filtered and concentrated in vacuo. Chromatographic purification (Et2O/petrol 10:90) 
gave the titled compound as a white solid (31.2 mg, 54%). mp 164–166 °C; vmax (film, cm–1) 
3157 (C-H), 1661 (C=O), 1603 (Ar C=C), 1576 (S=O), 1489; 1H NMR (500 MHz, CDCl3) δH: 2.48 
(3H, s, CH3), 3.83 (3H, s, OCH3), 6.07 (2H, t, J 2.2, C(3)Ar(3,4)H), 6.72 (2H, t, J 2.1, C(3)Ar(2,5)H), 
6.80–6.84 (2H, m, ArH), 7.31–7.35 (2H, m, ArH), 7.40–7.46 (3H, m, ArH), 7.60–7.64 (2H, m, 
ArH), 7.71 (1H, s, C(5)H), 7.78–7.81 (2H, m, ArH), 7.83–7.88 (2H, m, ArH); 13C{1H} NMR (126 
MHz, CDCl3) δC: 21.9 (CH3), 55.7 (OCH3), 110.8 (C(3)ArC(3,4)H), 114.0 (ArCH), 117.8 (C(5)), 
123.0 (C(3)ArC(2,5)H), 124.2 (ArC), 127.2 (ArCH), 128.0 (ArC), 128.9 (ArCH), 129.0 (ArCH), 
129.8 (ArCH), 130.3 (ArC), 131.9 (ArCH), 134.6 (C(2)), 136.3 (ArC), 145.4 (C(6)), 148.4 (C(3)), 
151.3 (ArC), 154.3 (C(4)), 164.6 (C(4)COArC(4)), 191.9 (C(4)CO); HRMS (ESI+) C30H25N2O5S 
[M+H]+ found 525.1473, requires 525.1479 (-1.1 ppm). 
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